Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"35,014",535,DB00759,Tetracycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"41,851",536,DB00759,Tetracycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"18,866",537,DB00759,Tetracycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"17,817",538,DB00759,Tetracycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.56,539,DB00759,Tetracycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.60,540,DB00759,Tetracycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.25,541,DB00759,Tetracycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.29,542,DB00759,Tetracycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.56,543,DB00759,Tetracycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.60,544,DB00759,Tetracycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.25,545,DB00759,Tetracycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.29,546,DB00759,Tetracycline
,32988509,bioavailability,"In turn, after PO administration, TIG was absorbed in only 1.55% ± 0.82, and CTC in 30.54% ± 6.99, whereas the bioavailability of MIN and TET was relatively high at 52.33% ± 3.92 and 56.45% ± 9.71, respectively.","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),%,52.33,547,DB00759,Tetracycline
,32988509,bioavailability,"In turn, after PO administration, TIG was absorbed in only 1.55% ± 0.82, and CTC in 30.54% ± 6.99, whereas the bioavailability of MIN and TET was relatively high at 52.33% ± 3.92 and 56.45% ± 9.71, respectively.","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),%,56.45,548,DB00759,Tetracycline
,14987868,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) of CAP was 10.04 h, the elimination half-life (t(1/2)) of SMZ was 5.68 h and that of OTC was 16.12 h.","Elimination of chloramphenicol, sulphamethoxazole and oxytetracycline in shrimp, Penaeus chinensis following medicated-feed treatment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987868/),h,10.04,1337,DB00759,Tetracycline
,14987868,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) of CAP was 10.04 h, the elimination half-life (t(1/2)) of SMZ was 5.68 h and that of OTC was 16.12 h.","Elimination of chloramphenicol, sulphamethoxazole and oxytetracycline in shrimp, Penaeus chinensis following medicated-feed treatment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987868/),h,5.68,1338,DB00759,Tetracycline
,14987868,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) of CAP was 10.04 h, the elimination half-life (t(1/2)) of SMZ was 5.68 h and that of OTC was 16.12 h.","Elimination of chloramphenicol, sulphamethoxazole and oxytetracycline in shrimp, Penaeus chinensis following medicated-feed treatment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987868/),h,16.12,1339,DB00759,Tetracycline
,14987868,MRPL,"If the EU MRPL value of 0.3 ng/g for CAP and MRL value of 0.1 microg/g for SMZ and OTC quoted for muscle from finfish is extended to shrimp muscle, extrapolation of the data indicates that it would be passed after a 139.7 h (95% CI=132.0-144.4 h), 30.6 h (95% CI=27.2-33.1 h), 90.3 h (95% CI=87.9-92.5 h) withdrawal period for CAP, SMZ and OTC in shrimp muscle, respectively.","Elimination of chloramphenicol, sulphamethoxazole and oxytetracycline in shrimp, Penaeus chinensis following medicated-feed treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987868/),[ng] / [g],0.3,1340,DB00759,Tetracycline
,14987868,MRL,"If the EU MRPL value of 0.3 ng/g for CAP and MRL value of 0.1 microg/g for SMZ and OTC quoted for muscle from finfish is extended to shrimp muscle, extrapolation of the data indicates that it would be passed after a 139.7 h (95% CI=132.0-144.4 h), 30.6 h (95% CI=27.2-33.1 h), 90.3 h (95% CI=87.9-92.5 h) withdrawal period for CAP, SMZ and OTC in shrimp muscle, respectively.","Elimination of chloramphenicol, sulphamethoxazole and oxytetracycline in shrimp, Penaeus chinensis following medicated-feed treatment. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14987868/),[μg] / [g],0.1,1341,DB00759,Tetracycline
,27245381,m,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,58,1722,DB00759,Tetracycline
,27245381,m,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,513.2,1723,DB00759,Tetracycline
,27245381,m/z,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,59,1724,DB00759,Tetracycline
,27245381,m/z,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,514.3,1725,DB00759,Tetracycline
,27245381,AUC0-12,"The AUC0-12 in plasma and CSF calculated according to our noncompartment model were 4713 and 23,0238 h ng/mL, respectively.",Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),[h·ng] / [ml],4713,1726,DB00759,Tetracycline
,27245381,AUC0-12,"The AUC0-12 in plasma and CSF calculated according to our noncompartment model were 4713 and 23,0238 h ng/mL, respectively.",Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),[h·ng] / [ml],"23,0238",1727,DB00759,Tetracycline
,10423658,elimination half-lives at beta-phase,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),h,25.0,2796,DB00759,Tetracycline
,10423658,volume of distribution,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),l,32.9,2797,DB00759,Tetracycline
,10423658,total clearance,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),[l] / [h],1.14,2798,DB00759,Tetracycline
,28264853,MIC,"Specifically, we investigated the relationship between minocycline exposure and bactericidal activity using five A. baumannii isolates with a broad range of susceptibility (MIC ranged from 0.25 mg/liter to 16 mg/liter).",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),[mg] / [l],0.25,3730,DB00759,Tetracycline
,28264853,MIC,"Specifically, we investigated the relationship between minocycline exposure and bactericidal activity using five A. baumannii isolates with a broad range of susceptibility (MIC ranged from 0.25 mg/liter to 16 mg/liter).",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),[mg] / [l],16,3731,DB00759,Tetracycline
,28264853,AUCELF,"The required AUCELF,0-24/MIC for maintaining stasis and achieving 1-log-unit reduction were 140 and 410, respectively.",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),,140,3732,DB00759,Tetracycline
,28264853,0-24/MIC,"The required AUCELF,0-24/MIC for maintaining stasis and achieving 1-log-unit reduction were 140 and 410, respectively.",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),,410,3733,DB00759,Tetracycline
,8345571,half-life,It was demonstrated that a very slow terminal elimination phase was present both after i.v. and i.m. administration with a half-life of approximately 95 h.,Three phase elimination of oxytetracycline in veal calves; the presence of an extended terminal elimination phase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345571/),h,95,7244,DB00759,Tetracycline
,27556265,peak doxycycline concentrations,"Median peak doxycycline concentrations for the 5 mg/kg and 10 mg/kg doses were 2.19 ng/mL on day 3 and 4.32 ng/mL on day 4, respectively.",Tear film concentrations of doxycycline following oral administration in ophthalmologically normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27556265/),[ng] / [ml],2.19,7245,DB00759,Tetracycline
,27556265,peak doxycycline concentrations,"Median peak doxycycline concentrations for the 5 mg/kg and 10 mg/kg doses were 2.19 ng/mL on day 3 and 4.32 ng/mL on day 4, respectively.",Tear film concentrations of doxycycline following oral administration in ophthalmologically normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27556265/),[ng] / [ml],4.32,7246,DB00759,Tetracycline
,22533405,maximum plasma concentration,"Mean ± SD values for pharmacokinetic parameters included maximum plasma concentration (2.792 ± 0.791 μg/mL), time to reach maximum plasma concentration (0.856 ± 0.472 hours), mean residence time (91.1 ± 40.78 hours), elimination half-life (77.88 ± 28.45 hours), and area under the curve (65.67 ± 9.877 μg•h/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),[μg] / [ml],2.792,7356,DB00759,Tetracycline
,22533405,time to reach maximum plasma concentration,"Mean ± SD values for pharmacokinetic parameters included maximum plasma concentration (2.792 ± 0.791 μg/mL), time to reach maximum plasma concentration (0.856 ± 0.472 hours), mean residence time (91.1 ± 40.78 hours), elimination half-life (77.88 ± 28.45 hours), and area under the curve (65.67 ± 9.877 μg•h/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),h,0.856,7357,DB00759,Tetracycline
,22533405,mean residence time,"Mean ± SD values for pharmacokinetic parameters included maximum plasma concentration (2.792 ± 0.791 μg/mL), time to reach maximum plasma concentration (0.856 ± 0.472 hours), mean residence time (91.1 ± 40.78 hours), elimination half-life (77.88 ± 28.45 hours), and area under the curve (65.67 ± 9.877 μg•h/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),h,91.1,7358,DB00759,Tetracycline
,22533405,elimination half-life,"Mean ± SD values for pharmacokinetic parameters included maximum plasma concentration (2.792 ± 0.791 μg/mL), time to reach maximum plasma concentration (0.856 ± 0.472 hours), mean residence time (91.1 ± 40.78 hours), elimination half-life (77.88 ± 28.45 hours), and area under the curve (65.67 ± 9.877 μg•h/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),h,77.88,7359,DB00759,Tetracycline
,22533405,area under the curve,"Mean ± SD values for pharmacokinetic parameters included maximum plasma concentration (2.792 ± 0.791 μg/mL), time to reach maximum plasma concentration (0.856 ± 0.472 hours), mean residence time (91.1 ± 40.78 hours), elimination half-life (77.88 ± 28.45 hours), and area under the curve (65.67 ± 9.877 μg•h/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),[h·μg] / [ml],65.67,7360,DB00759,Tetracycline
,22533405,minimum inhibitory concentration,"A daily dose of 20 mg/kg would be sufficient to reach effective plasma concentrations against Chlamydia spp (minimum inhibitory concentration, 0.008 to 0.031 μg/mL) and Staphylococcus aureus (minimum inhibitory concentration, 0.12 μg/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),[μg] / [ml],0.008 to 0.031,7361,DB00759,Tetracycline
,22533405,minimum inhibitory concentration,"A daily dose of 20 mg/kg would be sufficient to reach effective plasma concentrations against Chlamydia spp (minimum inhibitory concentration, 0.008 to 0.031 μg/mL) and Staphylococcus aureus (minimum inhibitory concentration, 0.12 μg/mL).",Pharmacokinetic behavior of doxycycline after intramuscular injection in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533405/),[μg] / [ml],0.12,7362,DB00759,Tetracycline
,23883872,urine recovery,"The serum concentration-time profiles and exposures were similar in the obese-C3 and NW adults, with a mean urine recovery of 15.8% and 13.4%, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),%,15.8,8334,DB00759,Tetracycline
,23883872,urine recovery,"The serum concentration-time profiles and exposures were similar in the obese-C3 and NW adults, with a mean urine recovery of 15.8% and 13.4%, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),%,13.4,8335,DB00759,Tetracycline
,23883872,AUC0-∞,"The median (range) AUC0-∞ was 8.19 (6.12, 11.2) and 7.50 (6.78, 9.13) mg · h/L in the obese-C3 and NW groups, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),[h·mg] / [l],8.19,8336,DB00759,Tetracycline
,23883872,AUC0-∞,"The median (range) AUC0-∞ was 8.19 (6.12, 11.2) and 7.50 (6.78, 9.13) mg · h/L in the obese-C3 and NW groups, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),[h·mg] / [l],7.50,8337,DB00759,Tetracycline
≥,23883872,AUC0-∞ : MIC target,"The CFR was calculated to be <90% against Acinetobacter baumannii, Enterobacter cloacae and Klebsiella pneumoniae for an AUC0-∞ : MIC target ≥ 6.96.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),,6.96,8338,DB00759,Tetracycline
,31773505,oral bioavailability,The oral bioavailability of omadacycline was 34.5% under fasted conditions (no food intake 6 h before and 4 h after dosing).,Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31773505/),%,34.5,9632,DB00759,Tetracycline
,31773505,volume of distribution,Omadacycline has a large volume of distribution (190 L) and low plasma protein binding (21.3%) that was concentration independent.,Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31773505/),l,190,9633,DB00759,Tetracycline
,31773505,plasma protein binding,Omadacycline has a large volume of distribution (190 L) and low plasma protein binding (21.3%) that was concentration independent.,Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31773505/),%,21.3,9634,DB00759,Tetracycline
,17139544,maximum concentrations (C (max)),"The mean maximum concentrations (C (max)) was 8.00 +/- 2.05 microg/ml and 8.61 +/- 1.42 micro/ml, respectively.",Bioequivalence study of two long-acting oxytetracycline formulations in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139544/),[μg] / [ml],8.00,9705,DB00759,Tetracycline
,17139544,maximum concentrations (C (max)),"The mean maximum concentrations (C (max)) was 8.00 +/- 2.05 microg/ml and 8.61 +/- 1.42 micro/ml, respectively.",Bioequivalence study of two long-acting oxytetracycline formulations in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139544/),[μ] / [ml],8.61,9706,DB00759,Tetracycline
,17139544,area under the concentration time curve (AUC),"The mean area under the concentration time curve (AUC) values were 154.95 +/- 50.37(microg h)/ml and 161.70 +/- 47.02(microg h)/ml, respectively.",Bioequivalence study of two long-acting oxytetracycline formulations in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139544/),,154.95,9707,DB00759,Tetracycline
,17139544,area under the concentration time curve (AUC),"The mean area under the concentration time curve (AUC) values were 154.95 +/- 50.37(microg h)/ml and 161.70 +/- 47.02(microg h)/ml, respectively.",Bioequivalence study of two long-acting oxytetracycline formulations in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139544/),[h·μg] / [ml],161.70,9708,DB00759,Tetracycline
,18468050,limit of detection,The limit of detection was 0.1 microg/g.,Distribution and residue depletion of oxytetracycline in giant freshwater prawn (Macrobrachium rosenbergii). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468050/),[μg] / [g],0.1,10846,DB00759,Tetracycline
,18468050,depletion half-life,"The depletion half-life and mean residence time of oxytetracycline were 30.96 and 100.3 h, respectively.",Distribution and residue depletion of oxytetracycline in giant freshwater prawn (Macrobrachium rosenbergii). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468050/),h,30.96,10847,DB00759,Tetracycline
,18468050,mean residence time,"The depletion half-life and mean residence time of oxytetracycline were 30.96 and 100.3 h, respectively.",Distribution and residue depletion of oxytetracycline in giant freshwater prawn (Macrobrachium rosenbergii). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468050/),h,100.3,10848,DB00759,Tetracycline
,2712418,bioavailability,The bioavailability of tetracycline hydrochloride administered orally to fasted gilts was approximately 23%.,"Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712418/),%,23,11061,DB00759,Tetracycline
,2712418,half-life,"The drug had a rapid distribution phase followed by a relatively slow elimination phase, with half-life of 16 hours.","Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712418/),h,16,11062,DB00759,Tetracycline
,2712418,volume of distribution,Its large volume of distribution (4.5 +/- 1.06 L/kg) suggested that tetracycline is distributed widely in swine tissues.,"Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712418/),[l] / [kg],4.5,11063,DB00759,Tetracycline
,2712418,Total body clearance,Total body clearance was 0.185 +/- 0.24 L/kg/h.,"Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712418/),[l] / [h·kg],0.185,11064,DB00759,Tetracycline
,2712418,Plasma drug concentration,Plasma drug concentration peaked (0.6 micrograms/ml) at 72 hours after access to the medicated feed.,"Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712418/),[μg] / [ml],0.6,11065,DB00759,Tetracycline
,10722495,elimination half-lives,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),h,1.05 to 2.34,11067,DB00759,Tetracycline
,10722495,elimination half-lives,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),h,1.65 to 3.36,11068,DB00759,Tetracycline
,10722495,serum protein bindings,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),%,59,11069,DB00759,Tetracycline
,10722495,serum protein bindings,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),%,71,11070,DB00759,Tetracycline
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12.5,11415,DB00759,Tetracycline
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,23.3,11416,DB00759,Tetracycline
,33975336,fAUC/MIC,An fAUC/MIC minocycline target of 12-36 is appropriate for S. aureus.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12-36,11417,DB00759,Tetracycline
,9416381,recovery,"Multiple linear regression analysis of the spectral absorbance data demonstrated a calculated recovery of tetracycline of 100.9% and, therefore, a lack of in vitro complexation with bismuth.",Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9416381/),%,100.9,11597,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,79.88,13278,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,90.71,13279,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,85.72,13280,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,93.17,13281,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,94.38,13282,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,101.00,13283,DB00759,Tetracycline
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,99.87,13284,DB00759,Tetracycline
,30947125,run time,"Separation of all analytes was performed on a Xselect CSH™ C18 HPLC column (Waters, 3.0 x 150 mm, 3.5 μm particle size) with gradient elution employing a mobile phase consisting of 0.1% v/v formic acid in water and methanol with a run time of 20 min.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),min,20,13285,DB00759,Tetracycline
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,445.4,13286,DB00759,Tetracycline
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,200.2,13287,DB00759,Tetracycline
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,282.3,13288,DB00759,Tetracycline
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,298.3,13289,DB00759,Tetracycline
,7040708,Bioavailability,"Bioavailability of doxycycline was significantly reduced by 37% and 51%, respectively, when subsalicylate bismuth was given simultaneously and as a multiple-dose regimen before doxycycline.",Influence of subsalicylate bismuth on absorption of doxycycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7040708/),%,37,14827,DB00759,Tetracycline
,7040708,Bioavailability,"Bioavailability of doxycycline was significantly reduced by 37% and 51%, respectively, when subsalicylate bismuth was given simultaneously and as a multiple-dose regimen before doxycycline.",Influence of subsalicylate bismuth on absorption of doxycycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7040708/),%,51,14828,DB00759,Tetracycline
,19000273,Peak muscle concentrations (C(max)),"Peak muscle concentrations (C(max)) were 3.47 and 1.73 microg/g after i.m. and p.o. administration at a single dose of 11 mg/kg b.w. whereas they were 6.03 and 2.51 microg/g at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),[μg] / [g],3.47,15114,DB00759,Tetracycline
,19000273,Peak muscle concentrations (C(max)),"Peak muscle concentrations (C(max)) were 3.47 and 1.73 microg/g after i.m. and p.o. administration at a single dose of 11 mg/kg b.w. whereas they were 6.03 and 2.51 microg/g at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),[μg] / [g],1.73,15115,DB00759,Tetracycline
,19000273,Peak muscle concentrations (C(max)),"Peak muscle concentrations (C(max)) were 3.47 and 1.73 microg/g after i.m. and p.o. administration at a single dose of 11 mg/kg b.w. whereas they were 6.03 and 2.51 microg/g at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),[μg] / [g],6.03,15116,DB00759,Tetracycline
,19000273,Peak muscle concentrations (C(max)),"Peak muscle concentrations (C(max)) were 3.47 and 1.73 microg/g after i.m. and p.o. administration at a single dose of 11 mg/kg b.w. whereas they were 6.03 and 2.51 microg/g at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),[μg] / [g],2.51,15117,DB00759,Tetracycline
,19000273,terminal half-lives,"The terminal half-lives of OTC were 28.68 and 28.09 h after i.m. and p.o. administration at a single dose of 11 mg/kg b.w., but 29.95 and 27.03 h at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),h,28.68,15118,DB00759,Tetracycline
,19000273,terminal half-lives,"The terminal half-lives of OTC were 28.68 and 28.09 h after i.m. and p.o. administration at a single dose of 11 mg/kg b.w., but 29.95 and 27.03 h at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),h,28.09,15119,DB00759,Tetracycline
,19000273,terminal half-lives,"The terminal half-lives of OTC were 28.68 and 28.09 h after i.m. and p.o. administration at a single dose of 11 mg/kg b.w., but 29.95 and 27.03 h at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),h,29.95,15120,DB00759,Tetracycline
,19000273,terminal half-lives,"The terminal half-lives of OTC were 28.68 and 28.09 h after i.m. and p.o. administration at a single dose of 11 mg/kg b.w., but 29.95 and 27.03 h at a single dose of 22 mg/kg b.w., respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),h,27.03,15121,DB00759,Tetracycline
,19000273,relative bioavailability,"The relative bioavailability was 82.32 and 64.67% following i.m. and p.o. administration, respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),%,82.32,15122,DB00759,Tetracycline
,19000273,relative bioavailability,"The relative bioavailability was 82.32 and 64.67% following i.m. and p.o. administration, respectively.",Muscle tissue kinetics of oxytetracycline following intramuscular and oral administration at two dosages to giant freshwater shrimp (Macrobrachium rosenbergii). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000273/),%,64.67,15123,DB00759,Tetracycline
,4028871,serum half-life,"The serum half-life for lymecycline was close to 10 h, for doxycycline 12 h.",Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028871/),h,10,15716,DB00759,Tetracycline
,4028871,serum half-life,"The serum half-life for lymecycline was close to 10 h, for doxycycline 12 h.",Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028871/),h,12,15717,DB00759,Tetracycline
,2729939,half-life,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),h,16.2,17056,DB00759,Tetracycline
,2729939,half-life,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),h,11.2,17057,DB00759,Tetracycline
,2729939,total body clearance,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),[ml] / [min],37.4,17058,DB00759,Tetracycline
,2729939,total body clearance,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),[ml] / [min],54.1,17059,DB00759,Tetracycline
,7356903,bioavailability,The bioavailability of tetracycline from tablets and suspension was found to be similar (31.2% and 36.9% of the dose excreted in the urine over 72 h).,Effect of cimetidine on the absorption of orally administered tetracycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),%,31.2,18670,DB00759,Tetracycline
,7356903,bioavailability,The bioavailability of tetracycline from tablets and suspension was found to be similar (31.2% and 36.9% of the dose excreted in the urine over 72 h).,Effect of cimetidine on the absorption of orally administered tetracycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),%,36.9,18671,DB00759,Tetracycline
,7356903,renal clearance,The mean renal clearance of tetracycline was 83.8 ml/min (95% confidence interval +/- 9.2 ml/min) and was unaltered by cimetidine treatment.,Effect of cimetidine on the absorption of orally administered tetracycline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7356903/),[ml] / [min],83.8,18672,DB00759,Tetracycline
,8239590,MIC,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19585,DB00759,Tetracycline
,8239590,MIC90,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19586,DB00759,Tetracycline
,8239590,MIC50,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.39,19587,DB00759,Tetracycline
,8239590,MB,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],3.13,19588,DB00759,Tetracycline
,8239590,MBC90,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],3.13,19589,DB00759,Tetracycline
,8239590,MBC50,"The MIC for 90% of strains tested (MIC90) and the MIC50 were 0.78 and 0.39 microgram/ml, respectively, and the MBC for 90% of strains tested (MBC90) and the MBC50 were 3.13 and 0.78 microgram/ml, respectively.","In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),[μg] / [ml],0.78,19590,DB00759,Tetracycline
,8239590,MBC50-to-MIC50 ratio,The MBC50-to-MIC50 ratio for Q-35 was 2.,"In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239590/),,2,19591,DB00759,Tetracycline
,30396916,Peak plasma concentrations,"The main outcomes of our study are: 1) Peak plasma concentrations ranged from 2 to10 μg/ml, superimposable to those in humans; 2) brain-to-plasma ratio was ∼0.2, comparable to the cerebrospinal fluid/serum ratios in humans; 3) brain Cmax 4-6 hours after a single dose was ∼0.5 (10 mg/kg) and ∼5 μM (100 mg/kg).",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),[μg] / [ml],2 to10,19923,DB00759,Tetracycline
,30396916,brain-to-plasma ratio,"The main outcomes of our study are: 1) Peak plasma concentrations ranged from 2 to10 μg/ml, superimposable to those in humans; 2) brain-to-plasma ratio was ∼0.2, comparable to the cerebrospinal fluid/serum ratios in humans; 3) brain Cmax 4-6 hours after a single dose was ∼0.5 (10 mg/kg) and ∼5 μM (100 mg/kg).",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),,∼0.2,19924,DB00759,Tetracycline
,30396916,brain,"The main outcomes of our study are: 1) Peak plasma concentrations ranged from 2 to10 μg/ml, superimposable to those in humans; 2) brain-to-plasma ratio was ∼0.2, comparable to the cerebrospinal fluid/serum ratios in humans; 3) brain Cmax 4-6 hours after a single dose was ∼0.5 (10 mg/kg) and ∼5 μM (100 mg/kg).",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),μM,∼0.5,19925,DB00759,Tetracycline
,30396916,Cmax,"The main outcomes of our study are: 1) Peak plasma concentrations ranged from 2 to10 μg/ml, superimposable to those in humans; 2) brain-to-plasma ratio was ∼0.2, comparable to the cerebrospinal fluid/serum ratios in humans; 3) brain Cmax 4-6 hours after a single dose was ∼0.5 (10 mg/kg) and ∼5 μM (100 mg/kg).",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),μM,∼0.5,19926,DB00759,Tetracycline
,30396916,Cmax,"The main outcomes of our study are: 1) Peak plasma concentrations ranged from 2 to10 μg/ml, superimposable to those in humans; 2) brain-to-plasma ratio was ∼0.2, comparable to the cerebrospinal fluid/serum ratios in humans; 3) brain Cmax 4-6 hours after a single dose was ∼0.5 (10 mg/kg) and ∼5 μM (100 mg/kg).",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),μM,∼5,19927,DB00759,Tetracycline
,30396916,elimination half-life,"Notably, these concentrations are lower than those required for the drug's antiaggregating properties as observed in cell-free studies, suggesting that other features underlie the positive cognitive effects in AD mice; 4) elimination half-life was shorter than in humans (3-6 vs. 15-30 hours), therefore no significant accumulation was observed in mouse brain following repeated treatments; and 5) there were no differences between doxycycline concentrations in brain areas of age-matched wild-type and APP23 mice.",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),h,3-6,19928,DB00759,Tetracycline
,30396916,elimination half-life,"Notably, these concentrations are lower than those required for the drug's antiaggregating properties as observed in cell-free studies, suggesting that other features underlie the positive cognitive effects in AD mice; 4) elimination half-life was shorter than in humans (3-6 vs. 15-30 hours), therefore no significant accumulation was observed in mouse brain following repeated treatments; and 5) there were no differences between doxycycline concentrations in brain areas of age-matched wild-type and APP23 mice.",Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396916/),h,15-30,19929,DB00759,Tetracycline
,27597645,Cmax,"The Cmax values of OTC were 12.11 ± 1.87 μg/mL and 12.27 ± 1.92 μg/mL at doses of 20 and 30 mg/kg, respectively.",Disposition of a long-acting oxytetracycline formulation in Thai swamp buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597645/),[μg] / [ml],12.11,20880,DB00759,Tetracycline
,27597645,Cmax,"The Cmax values of OTC were 12.11 ± 1.87 μg/mL and 12.27 ± 1.92 μg/mL at doses of 20 and 30 mg/kg, respectively.",Disposition of a long-acting oxytetracycline formulation in Thai swamp buffaloes (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597645/),[μg] / [ml],12.27,20881,DB00759,Tetracycline
,27597645,half-life,"The half-life values were 52.00 ± 14.26 h and 66.80 ± 10.91 h at doses of 20 and 30 mg/kg b.w, respectively.",Disposition of a long-acting oxytetracycline formulation in Thai swamp buffaloes (Bubalus bubalis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597645/),h,52.00,20882,DB00759,Tetracycline
,27597645,half-life,"The half-life values were 52.00 ± 14.26 h and 66.80 ± 10.91 h at doses of 20 and 30 mg/kg b.w, respectively.",Disposition of a long-acting oxytetracycline formulation in Thai swamp buffaloes (Bubalus bubalis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597645/),h,66.80,20883,DB00759,Tetracycline
,2080940,maximum plasma concentration (cmax,"Mean maximum plasma concentration (cmax +/- standard deviation) of doxycycline were 1.57 +/- 0.40 micrograms/ml (test) and 1.59 +/- 0.38 micrograms/ml (reference), respectively, and were reached 1.47 +/- 0.55 h and 1.66 +/- 0.57 h after administration.",[The bioavailability of doxycycline]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),[μg] / [ml],1.57,21621,DB00759,Tetracycline
,2080940,maximum plasma concentration (cmax,"Mean maximum plasma concentration (cmax +/- standard deviation) of doxycycline were 1.57 +/- 0.40 micrograms/ml (test) and 1.59 +/- 0.38 micrograms/ml (reference), respectively, and were reached 1.47 +/- 0.55 h and 1.66 +/- 0.57 h after administration.",[The bioavailability of doxycycline]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),[μg] / [ml],1.59,21622,DB00759,Tetracycline
,2080940,Plasma half-lives,"Plasma half-lives were 16.6 +/- 2.9 h and 16.8 +/- 3.0 h, the areas under the plasma concentration-time curves (AUC0-00) 29.3 +/- 4.5 mg/l.h and 29.7 +/- 4.4 mg/l.h.",[The bioavailability of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),h,16.6,21623,DB00759,Tetracycline
,2080940,Plasma half-lives,"Plasma half-lives were 16.6 +/- 2.9 h and 16.8 +/- 3.0 h, the areas under the plasma concentration-time curves (AUC0-00) 29.3 +/- 4.5 mg/l.h and 29.7 +/- 4.4 mg/l.h.",[The bioavailability of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),h,16.8,21624,DB00759,Tetracycline
,2080940,areas under the plasma concentration-time curves (AUC0-00),"Plasma half-lives were 16.6 +/- 2.9 h and 16.8 +/- 3.0 h, the areas under the plasma concentration-time curves (AUC0-00) 29.3 +/- 4.5 mg/l.h and 29.7 +/- 4.4 mg/l.h.",[The bioavailability of doxycycline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),[mg] / [h·l],29.3,21625,DB00759,Tetracycline
,2080940,areas under the plasma concentration-time curves (AUC0-00),"Plasma half-lives were 16.6 +/- 2.9 h and 16.8 +/- 3.0 h, the areas under the plasma concentration-time curves (AUC0-00) 29.3 +/- 4.5 mg/l.h and 29.7 +/- 4.4 mg/l.h.",[The bioavailability of doxycycline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),[mg] / [h·l],29.7,21626,DB00759,Tetracycline
,2080940,maximum concentrations,"The concentration of doxycycline in saliva were low, median maximum concentrations of 50 ng/ml were measured 1-2 h after administration.",[The bioavailability of doxycycline]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080940/),[ng] / [ml],50,21627,DB00759,Tetracycline
,19738006,MICs,"Six S. aureus isolates were studied, and the TGC MICs for those isolates ranged from 0.125 to 0.5 mg/liter.",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),[mg] / [l],0.125 to 0.5,22066,DB00759,Tetracycline
,19738006,half-life,TGC displayed linear PK and had a mean half-life of 10.9 +/- 2.5 h.,Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),h,10.9,22067,DB00759,Tetracycline
,19738006,80%,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22068,DB00759,Tetracycline
,19738006,50%,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22069,DB00759,Tetracycline
,19738006,effective exposure,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22070,DB00759,Tetracycline
,19738006,stasis exposure index,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,1.84,22071,DB00759,Tetracycline
,19738006,stasis exposure index,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,1.9,22072,DB00759,Tetracycline
,29358291,elimination,"The estimated values of mean population PK parameters were 22.1 liters/h and 69.4 liters/h for elimination and intercompartmental clearance, respectively, and 162 liters and 87.9 liters for volume of the central and peripheral compartment, respectively.",Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358291/),[l] / [h],22.1,22397,DB00759,Tetracycline
,29358291,elimination,"The estimated values of mean population PK parameters were 22.1 liters/h and 69.4 liters/h for elimination and intercompartmental clearance, respectively, and 162 liters and 87.9 liters for volume of the central and peripheral compartment, respectively.",Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358291/),l,162,22398,DB00759,Tetracycline
,29358291,volume of the central,"The estimated values of mean population PK parameters were 22.1 liters/h and 69.4 liters/h for elimination and intercompartmental clearance, respectively, and 162 liters and 87.9 liters for volume of the central and peripheral compartment, respectively.",Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358291/),l,162,22399,DB00759,Tetracycline
,29358291,volume of the central,"The estimated values of mean population PK parameters were 22.1 liters/h and 69.4 liters/h for elimination and intercompartmental clearance, respectively, and 162 liters and 87.9 liters for volume of the central and peripheral compartment, respectively.",Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29358291/),l,87.9,22400,DB00759,Tetracycline
,33128251,accumulation index,"After a multiple-dosage regimen, the accumulation index was 1.88 ± 0.82.",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),,1.88,23468,DB00759,Tetracycline
,33128251,Cmaxss,"The Cmaxss and Cminss values were 5.18 ± 1.81 µg/ml and 1.91 ± 1.35 µg/ml, respectively.",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),[μg] / [ml],5.18,23469,DB00759,Tetracycline
,33128251,Cminss,"The Cmaxss and Cminss values were 5.18 ± 1.81 µg/ml and 1.91 ± 1.35 µg/ml, respectively.",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),[μg] / [ml],1.91,23470,DB00759,Tetracycline
over,33128251,Cminss,"The Cminss value was over the MIC of the principal pathogens, and Cmaxss was higher than the resistance values (>2 μg/ml).",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),,the,23471,DB00759,Tetracycline
over,33128251,Cminss,"The Cminss value was over the MIC of the principal pathogens, and Cmaxss was higher than the resistance values (>2 μg/ml).",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),,MI,23472,DB00759,Tetracycline
,33128251,MIC,"For AUC/MIC indices of 12, 25 and 40, the cumulative fraction responses (CFR) were 94.01%, 69.55% and 60.86%, respectively; for an MIC value of 2 µg/ml, the corresponding probability of target attainment (PTA) was 99.94%, 84.78% and 45.16%, respectively.",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),[μg] / [ml],2,23473,DB00759,Tetracycline
<,33128251,MIC,"For the strains with MIC < 1 μg/mL, PTA was close to 100%, even for the most demanding ones, specifically 94.98% for an index of 40% and 99.9% for an index of 25.",Pharmacokinetics of doxycycline after oral administration of multiple doses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128251/),[μg] / [ml],1,23474,DB00759,Tetracycline
,6731978,half-life,"The drug half-life was 6.7 hours, with an overall elimination constant of 0.104 hour-1.",Pharmacokinetics of tetracycline encapsulated in bovine carrier erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731978/),h,6.7,24049,DB00759,Tetracycline
,6731978,overall elimination constant,"The drug half-life was 6.7 hours, with an overall elimination constant of 0.104 hour-1.",Pharmacokinetics of tetracycline encapsulated in bovine carrier erythrocytes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731978/),1/[h],0.104,24050,DB00759,Tetracycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.65,24762,DB00759,Tetracycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.52,24763,DB00759,Tetracycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.60,24764,DB00759,Tetracycline
,20921312,steady-state tissue concentrations,"Mean steady-state tissue concentrations for the thigh and wound were similar at 0.12 ± 0.02 μg/ml, and clearance from the tissues appeared similar to that from plasma.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[μg] / [ml],0.12,24765,DB00759,Tetracycline
,20921312,Tissue penetration ratios (tissue fAUC/plasma fAUC),Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964).,Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),%,99,24766,DB00759,Tetracycline
,20921312,Tissue penetration ratios (tissue fAUC/plasma fAUC),Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964).,Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),%,100,24767,DB00759,Tetracycline
,20705929,half-life,Pharmacokinetic analysis (n=22) revealed a half-life of approximately 24 hours and linearity of parameters over doses.,Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25184,DB00759,Tetracycline
,20705929,half-life,"The half-life of minocycline is approximately 24 hours, allowing every 24-hour dosing.",Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25185,DB00759,Tetracycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],"1,308.60",27338,DB00759,Tetracycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],181.40,27339,DB00759,Tetracycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],145.00,27340,DB00759,Tetracycline
,24588058,maximal drug concentration,"We estimated that during CTC feeding to a 300-kg steer for growth promotion, the maximal drug concentration in the large intestine was 0.3 μg/mL; during disease control it was 1.7 μg/mL; and during treatment it was 31.5 μg/mL.","Use of pharmacokinetic modeling to assess antimicrobial pressure on enteric bacteria of beef cattle fed chlortetracycline for growth promotion, disease control, or treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588058/),[μg] / [ml],0.3,28698,DB00759,Tetracycline
,24588058,maximal drug concentration,"We estimated that during CTC feeding to a 300-kg steer for growth promotion, the maximal drug concentration in the large intestine was 0.3 μg/mL; during disease control it was 1.7 μg/mL; and during treatment it was 31.5 μg/mL.","Use of pharmacokinetic modeling to assess antimicrobial pressure on enteric bacteria of beef cattle fed chlortetracycline for growth promotion, disease control, or treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588058/),[μg] / [ml],1.7,28699,DB00759,Tetracycline
,24588058,maximal drug concentration,"We estimated that during CTC feeding to a 300-kg steer for growth promotion, the maximal drug concentration in the large intestine was 0.3 μg/mL; during disease control it was 1.7 μg/mL; and during treatment it was 31.5 μg/mL.","Use of pharmacokinetic modeling to assess antimicrobial pressure on enteric bacteria of beef cattle fed chlortetracycline for growth promotion, disease control, or treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588058/),[μg] / [ml],31.5,28700,DB00759,Tetracycline
,1885404,oral bioavailability,"In healthy pigs the oral bioavailability of oxytetracycline (50 mg/kg), given on an empty stomach, was 4.8% and the elimination half-life (t1/2 beta) was 5.92 h.",The influence of disease on feed and water consumption and on pharmacokinetics of orally administered oxytetracycline in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885404/),%,4.8,29839,DB00759,Tetracycline
,1885404,elimination half-life (t1/2 beta),"In healthy pigs the oral bioavailability of oxytetracycline (50 mg/kg), given on an empty stomach, was 4.8% and the elimination half-life (t1/2 beta) was 5.92 h.",The influence of disease on feed and water consumption and on pharmacokinetics of orally administered oxytetracycline in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885404/),h,5.92,29840,DB00759,Tetracycline
,1885404,maximum plasma concentrations,"In diseased pigs the mean of maximum plasma concentrations (.87 micrograms/ml) was reached after 7 h, in contrast to 1.74 h (1.87 micrograms/ml) in the healthy pigs.",The influence of disease on feed and water consumption and on pharmacokinetics of orally administered oxytetracycline in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885404/),[μg] / [ml],.87,29841,DB00759,Tetracycline
,1885404,maximum plasma concentrations,"In diseased pigs the mean of maximum plasma concentrations (.87 micrograms/ml) was reached after 7 h, in contrast to 1.74 h (1.87 micrograms/ml) in the healthy pigs.",The influence of disease on feed and water consumption and on pharmacokinetics of orally administered oxytetracycline in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885404/),[μg] / [ml],1.87,29842,DB00759,Tetracycline
,782466,serum levels,After i.v. infusion of 200 mg minocycline (during 1 h) mean serum levels fell from 3.5 mug/ml to 0.6 mug/ml (after 24 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],3.5,32218,DB00759,Tetracycline
,782466,serum levels,After i.v. infusion of 200 mg minocycline (during 1 h) mean serum levels fell from 3.5 mug/ml to 0.6 mug/ml (after 24 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.6,32219,DB00759,Tetracycline
,782466,Half-life,"Half-life was calculated as 15.7 h, urine recovery as 5.9%.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),h,15.7,32220,DB00759,Tetracycline
,782466,urine recovery,"Half-life was calculated as 15.7 h, urine recovery as 5.9%.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),%,5.9,32221,DB00759,Tetracycline
,782466,serum level peaks,"After oral application of 200 mg minocycline serum level peaks were 2.7 mug/ml, serum levels after 24 h 0.7 mug/ml.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.7,32222,DB00759,Tetracycline
,782466,serum levels,"After oral application of 200 mg minocycline serum level peaks were 2.7 mug/ml, serum levels after 24 h 0.7 mug/ml.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.7,32223,DB00759,Tetracycline
,782466,CSF,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.74,32224,DB00759,Tetracycline
,782466,CSF,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.2,32225,DB00759,Tetracycline
,782466,levels,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.74,32226,DB00759,Tetracycline
,782466,levels,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.2,32227,DB00759,Tetracycline
,782466,Half-life,Half-life of minocycline in chronic renal failure (7 adult patients) was not prolonged (15--20 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),h,15--20,32228,DB00759,Tetracycline
,20462741,minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs),"One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum beta-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25 microg/mL) were used.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[μg] / [ml],0.12,32641,DB00759,Tetracycline
,20462741,minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs),"One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum beta-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25 microg/mL) were used.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[μg] / [ml],0.25,32642,DB00759,Tetracycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,25.6,32643,DB00759,Tetracycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,53.76,32644,DB00759,Tetracycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,79.52,32645,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],120.60,32646,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],143.20,32647,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],195.80,32648,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],95.75,32649,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],172.55,32650,DB00759,Tetracycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],216.90,32651,DB00759,Tetracycline
,20462741,ABBCs,"Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75 log CFU x h/mL with standard inocula and 63.33 log CFU x h/mL with high inocula).",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],145.75,32652,DB00759,Tetracycline
,20462741,ABBCs,"Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75 log CFU x h/mL with standard inocula and 63.33 log CFU x h/mL with high inocula).",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],63.33,32653,DB00759,Tetracycline
,6869979,plasma to genital tissue ratios,"The mean plasma to genital tissue ratios for healthy and infected postpartum cows, respectively, were 1.38 and 1.31 for uterine tissue and 1.09 and 1.16 for ovarian tissue.",Distribution of oxytetracycline in the healthy and diseased postpartum genital tract of cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869979/),,1.38,35987,DB00759,Tetracycline
,6869979,plasma to genital tissue ratios,"The mean plasma to genital tissue ratios for healthy and infected postpartum cows, respectively, were 1.38 and 1.31 for uterine tissue and 1.09 and 1.16 for ovarian tissue.",Distribution of oxytetracycline in the healthy and diseased postpartum genital tract of cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869979/),,1.31,35988,DB00759,Tetracycline
,6869979,plasma to genital tissue ratios,"The mean plasma to genital tissue ratios for healthy and infected postpartum cows, respectively, were 1.38 and 1.31 for uterine tissue and 1.09 and 1.16 for ovarian tissue.",Distribution of oxytetracycline in the healthy and diseased postpartum genital tract of cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869979/),,1.09,35989,DB00759,Tetracycline
,6869979,plasma to genital tissue ratios,"The mean plasma to genital tissue ratios for healthy and infected postpartum cows, respectively, were 1.38 and 1.31 for uterine tissue and 1.09 and 1.16 for ovarian tissue.",Distribution of oxytetracycline in the healthy and diseased postpartum genital tract of cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869979/),,1.16,35990,DB00759,Tetracycline
,25233871,AUC,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),[h·μg] / [ml],7.2,36474,DB00759,Tetracycline
,25233871,AUC,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),[h·μg] / [ml],36.0,36475,DB00759,Tetracycline
,25233871,relative bioavailability,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),%,20,36476,DB00759,Tetracycline
,25233871,relative bioavailability,Delaying sucralfate suspension by 2 h after doxycycline administration resulted in no difference in doxycycline absorption as compared with doxycycline administration alone with a relative bioavailability of 74%.,The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),%,74,36477,DB00759,Tetracycline
,24479741,Cmax1,"Following oral administration, the double-peak phenomenon was observed, and the first (Cmax1 ) and second (Cmax2) peaks were 1.99 ± 0.43 μg/mL at 2.0 h and 2.27 ± 0.38 μg/mL at 24.0 h, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),[μg] / [ml],1.99,36917,DB00759,Tetracycline
,24479741,Cmax2,"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),[μg] / [ml],12.12,36918,DB00759,Tetracycline
,24479741,apparent elimination rate constant (λz),"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),1/[h],0.018,36919,DB00759,Tetracycline
,24479741,apparent elimination half-life (t1/2λz),"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),h,39.0,36920,DB00759,Tetracycline
,24479741,systemic total body clearance (Cl),"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),[ml] / [h·kg],41.28,36921,DB00759,Tetracycline
,24479741,volume of distribution (Vz),"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),[ml] / [kg],2323.21,36922,DB00759,Tetracycline
,24479741,volume of distribution at steady-state (Vss),"After the intravenous injection, a Cmax2 (12.12 ± 1.97 μg/mL) was also observed, and initial concentration of 45.76 μg/mL, apparent elimination rate constant (λz) of 0.018 per h, apparent elimination half-life (t1/2λz) of 39.0 h, systemic total body clearance (Cl) of 41.28 mL/h/kg, volume of distribution (Vz) of 2323.21 mL/kg, and volume of distribution at steady-state (Vss) of 1356.69 mL/kg were determined, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),[ml] / [kg],1356.69,36923,DB00759,Tetracycline
,24479741,λz,"While after oral administration, the λz, t1/2λz, and bioavailability of doxycycline were 0.009 per h, 77.2 h, and 23.41%, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),1/[h],0.009,36924,DB00759,Tetracycline
,24479741,t1/2λz,"While after oral administration, the λz, t1/2λz, and bioavailability of doxycycline were 0.009 per h, 77.2 h, and 23.41%, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),h,77.2,36925,DB00759,Tetracycline
,24479741,bioavailability,"While after oral administration, the λz, t1/2λz, and bioavailability of doxycycline were 0.009 per h, 77.2 h, and 23.41%, respectively.",Pharmacokinetics of doxycycline in tilapia (Oreochromis aureus × Oreochromis niloticus) after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479741/),%,23.41,36926,DB00759,Tetracycline
,32690646,area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.85,37069,DB00759,Tetracycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.77,37070,DB00759,Tetracycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,2.4,37071,DB00759,Tetracycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,140,37072,DB00759,Tetracycline
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],-,37073,DB00759,Tetracycline
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],0.119,37074,DB00759,Tetracycline
,19732498,cerebral AUC0-infinity /plasmatic AUC0-infinity ratio,"At the dose of 10 mg/kg, the cerebral AUC0-infinity /plasmatic AUC0-infinity ratio was 4.6 in mdr1a (-/-) mice and 2.4 in mdr1a (+/+) mice.",Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732498/),,4.6,37711,DB00759,Tetracycline
,19732498,cerebral AUC0-infinity /plasmatic AUC0-infinity ratio,"At the dose of 10 mg/kg, the cerebral AUC0-infinity /plasmatic AUC0-infinity ratio was 4.6 in mdr1a (-/-) mice and 2.4 in mdr1a (+/+) mice.",Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732498/),,2.4,37712,DB00759,Tetracycline
,34318509,elimination half-life,A long elimination half-life was observed (13 h).,Doxycycline pharmacokinetics in geese. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34318509/),h,13,37956,DB00759,Tetracycline
,34318509,oral bioavailability,"The area under the curve was statistically different between the two treatments, with the oral bioavailability being moderate (43%).",Doxycycline pharmacokinetics in geese. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34318509/),%,43,37957,DB00759,Tetracycline
,25815578,minimum effective serum doxycycline concentration,"Given the minimum effective serum doxycycline concentration of 0.26 μg/mL, a dose interval of 48 hours can be achieved for each tested ERF.",Pharmacokinetics of an oral extended-release formulation of doxycycline hyclate containing acrylic acid and polymethacrylate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815578/),[μg] / [ml],0.26,41004,DB00759,Tetracycline
,7183793,serum half-lives in the beta-elimination phase,"The serum half-lives in the beta-elimination phase of both 10% and 20% solutions after i.v. injection of 10 mg/kg were similar (7.07 +/- 1.36 h and 7.16 +/- 1.17 h, mean +/- SD), whereas the total body clearance and the apparent volume of distribution were higher for the 20% solution.",Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,7.07,41181,DB00759,Tetracycline
,7183793,serum half-lives in the beta-elimination phase,"The serum half-lives in the beta-elimination phase of both 10% and 20% solutions after i.v. injection of 10 mg/kg were similar (7.07 +/- 1.36 h and 7.16 +/- 1.17 h, mean +/- SD), whereas the total body clearance and the apparent volume of distribution were higher for the 20% solution.",Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,7.16,41182,DB00759,Tetracycline
,7183793,t1/2 alpha 1,"Intramuscular administration of the 20% solution gave a complete absorption with two rate constants of absorption, a faster (t1/2 alpha 1 = 0.27 h) and a slower one (t1/2 alpha 2 = 10.90 h) responsible for the delayed elimination half-life after this route of application (t1/2 beta = 9.83 +/- 1.35 h).",Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,0.27,41183,DB00759,Tetracycline
,7183793,t1/2 alpha 2,"Intramuscular administration of the 20% solution gave a complete absorption with two rate constants of absorption, a faster (t1/2 alpha 1 = 0.27 h) and a slower one (t1/2 alpha 2 = 10.90 h) responsible for the delayed elimination half-life after this route of application (t1/2 beta = 9.83 +/- 1.35 h).",Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,10.90,41184,DB00759,Tetracycline
,7183793,t1/2 beta,"Intramuscular administration of the 20% solution gave a complete absorption with two rate constants of absorption, a faster (t1/2 alpha 1 = 0.27 h) and a slower one (t1/2 alpha 2 = 10.90 h) responsible for the delayed elimination half-life after this route of application (t1/2 beta = 9.83 +/- 1.35 h).",Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,9.83,41185,DB00759,Tetracycline
,7183793,maximum level,Mean serum concentrations reached a maximum level of 3.01 +/- 0.72 micrograms/ml at 4.01 +/- 2.84 h and decreased to 0.5 microgram/ml between 12 and 24 h.,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),[μg] / [ml],3.01,41186,DB00759,Tetracycline
,7183793,bioavailability,50 mg/kg given orally with a milk replacer were found to have a mean bioavailability of 46.35%.,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),%,46.35,41187,DB00759,Tetracycline
,7183793,serum peak level,A mean serum peak level of 4.99 +/- 1.37 micrograms/ml was achieved at 9.16 +/- 1.99 h and the mean concentration was still above 0.5 microgram/ml after 48 h.,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),[μg] / [ml],4.99,41188,DB00759,Tetracycline
,7183793,elimination half-life (t1/2 beta,The elimination half-life (t1/2 beta = 10.66 +/- 3.15 h) reflected the slow absorption step (t1/2 alpha 2 = 10.15 h) following that responsible for the initial faster absorption (t1/2 alpha 1 = 1.99 h).,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,10.66,41189,DB00759,Tetracycline
,7183793,t1/2 alpha 2,The elimination half-life (t1/2 beta = 10.66 +/- 3.15 h) reflected the slow absorption step (t1/2 alpha 2 = 10.15 h) following that responsible for the initial faster absorption (t1/2 alpha 1 = 1.99 h).,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,10.15,41190,DB00759,Tetracycline
,7183793,t1/2 alpha 1,The elimination half-life (t1/2 beta = 10.66 +/- 3.15 h) reflected the slow absorption step (t1/2 alpha 2 = 10.15 h) following that responsible for the initial faster absorption (t1/2 alpha 1 = 1.99 h).,Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7183793/),h,1.99,41191,DB00759,Tetracycline
,3389959,half lives,"When expressed in the ""pharmacokinetic time"" scale the half lives were equal to 4.6-5.4, 3.5-3.7 and 5.2 h.kg-0.25 respectively.",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[h] / [(kg)^0],4.6-5.4,41366,DB00759,Tetracycline
,3389959,half lives,"When expressed in the ""pharmacokinetic time"" scale the half lives were equal to 4.6-5.4, 3.5-3.7 and 5.2 h.kg-0.25 respectively.",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[h] / [(kg)^0],3.5-3.7,41367,DB00759,Tetracycline
,3389959,half lives,"When expressed in the ""pharmacokinetic time"" scale the half lives were equal to 4.6-5.4, 3.5-3.7 and 5.2 h.kg-0.25 respectively.",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[h] / [(kg)^0],5.2,41368,DB00759,Tetracycline
,3389959,total clearance,"Therefore, with using the ""pharmacokinetic time"" 10-fold species differences in the total clearance (0.55 and 0.056 l.h-1.kg-1 in rats and humans respectively) transformed into 2-fold differences (0.37 and 0.16 l.h-1.kg-0.75 respectively).",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[l] / [h·kg],0.55,41369,DB00759,Tetracycline
,3389959,total clearance,"Therefore, with using the ""pharmacokinetic time"" 10-fold species differences in the total clearance (0.55 and 0.056 l.h-1.kg-1 in rats and humans respectively) transformed into 2-fold differences (0.37 and 0.16 l.h-1.kg-0.75 respectively).",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[l] / [h·kg],0.056,41370,DB00759,Tetracycline
,3389959,total clearance,"Therefore, with using the ""pharmacokinetic time"" 10-fold species differences in the total clearance (0.55 and 0.056 l.h-1.kg-1 in rats and humans respectively) transformed into 2-fold differences (0.37 and 0.16 l.h-1.kg-0.75 respectively).",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[l] / [(kg)^0·h],0.37,41371,DB00759,Tetracycline
,3389959,total clearance,"Therefore, with using the ""pharmacokinetic time"" 10-fold species differences in the total clearance (0.55 and 0.056 l.h-1.kg-1 in rats and humans respectively) transformed into 2-fold differences (0.37 and 0.16 l.h-1.kg-0.75 respectively).",[Prediction of the pharmacokinetic profiles of doxycycline in humans based on the results of experiments in animals]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389959/),[l] / [(kg)^0·h],0.16,41372,DB00759,Tetracycline
,1774812,t1/2 of rapid distribution,"The t1/2 of rapid distribution was 0.9 h, the t1/2 of the slow distribution was 5.9 h and the t1/2 elimination was 81.5 h.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),h,0.9,41908,DB00759,Tetracycline
,1774812,t1/2,"The t1/2 of rapid distribution was 0.9 h, the t1/2 of the slow distribution was 5.9 h and the t1/2 elimination was 81.5 h.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),h,5.9,41909,DB00759,Tetracycline
,1774812,t1/2 elimination,"The t1/2 of rapid distribution was 0.9 h, the t1/2 of the slow distribution was 5.9 h and the t1/2 elimination was 81.5 h.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),h,81.5,41910,DB00759,Tetracycline
,1774812,Clearance,Clearance was 25.4 ml/kg/h and Vd(area) 2988 ml/kg.,Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),[ml] / [h·kg],25.4,41911,DB00759,Tetracycline
,1774812,Vd(area),Clearance was 25.4 ml/kg/h and Vd(area) 2988 ml/kg.,Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),[ml] / [kg],2988,41912,DB00759,Tetracycline
,1774812,rates of decay,"Regression analysis of the serum levels for the three intervals, 0.5-2.0 h, 6.0-18.0 h, and 24-96 h, indicated that the rates of decay for each interval were 0.6151 h-1, 0.0564 h-1 and 0.0088 h-1 respectively.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),1/[h],0.6151,41913,DB00759,Tetracycline
,1774812,rates of decay,"Regression analysis of the serum levels for the three intervals, 0.5-2.0 h, 6.0-18.0 h, and 24-96 h, indicated that the rates of decay for each interval were 0.6151 h-1, 0.0564 h-1 and 0.0088 h-1 respectively.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),1/[h],0.0564,41914,DB00759,Tetracycline
,1774812,rates of decay,"Regression analysis of the serum levels for the three intervals, 0.5-2.0 h, 6.0-18.0 h, and 24-96 h, indicated that the rates of decay for each interval were 0.6151 h-1, 0.0564 h-1 and 0.0088 h-1 respectively.",Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),1/[h],0.0088,41915,DB00759,Tetracycline
,1774812,t1/2,Kidney equilibrated the fastest with t1/2 to equilibration of 1.1 h for H (anterior) kidney and 1.98 h for P (posterior) kidney.,Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),h,1.1,41916,DB00759,Tetracycline
,1774812,t1/2,Kidney equilibrated the fastest with t1/2 to equilibration of 1.1 h for H (anterior) kidney and 1.98 h for P (posterior) kidney.,Pharmacokinetic and tissue distribution study of oxytetracycline in rainbow trout following bolus intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774812/),h,1.98,41917,DB00759,Tetracycline
,24659422,recovery,The mean recovery ranged from 94.3 to 105.6% and the matrix effect from 92.1 to 97.6%.,Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24659422/),%,94.3 to 105.6,42026,DB00759,Tetracycline
,24659422,matrix effect,The mean recovery ranged from 94.3 to 105.6% and the matrix effect from 92.1 to 97.6%.,Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24659422/),%,92.1 to 97.6,42027,DB00759,Tetracycline
,29316830,susceptibility rate,"The susceptibility rate of tigecycline and minocycline were 79.9% and 41.5%, respectively.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),%,79.9,42226,DB00759,Tetracycline
,29316830,susceptibility rate,"The susceptibility rate of tigecycline and minocycline were 79.9% and 41.5%, respectively.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),%,41.5,42227,DB00759,Tetracycline
≤,29316830,MICs,"At recommended doses, an optimal PTA of 90% was obtained for treating HAP caused by CP-KP with MICs of tigecycline ≤0.5 mg/L or minocycline ≤4 mg/L.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],0.5,42228,DB00759,Tetracycline
≤,29316830,MICs,"At recommended doses, an optimal PTA of 90% was obtained for treating HAP caused by CP-KP with MICs of tigecycline ≤0.5 mg/L or minocycline ≤4 mg/L.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],4,42229,DB00759,Tetracycline
≤,29316830,MICs,minocycline (200 mg q12h) might be a potential alternative of tigecycline to against strains with MICs ≤ 8 mg/L.,Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],8,42230,DB00759,Tetracycline
,18411322,MICs,The BPR MICs of the test isolates ranged from 0.25 to 2 mug/ml.,Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18411322/),[μg] / [ml],0.25 to 2,42697,DB00759,Tetracycline
,30033542,plasma protein binding,"Correcting for plasma protein binding (~90%), dermal doxycycline exposure was approximately threefold higher than unbound plasma exposure.",Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of the food effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30033542/),%,90,43372,DB00759,Tetracycline
,31269331,absolute bioavailability (F),"The administration of feed decreased the absolute bioavailability (F) of OTC from 12.70%±4.01 to 6.40%±1.08, and this effect was more pronounced after the combined administration of OTC with feed and hard water (5.31%±0.90).",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),%,12.70,44781,DB00759,Tetracycline
,31269331,absolute bioavailability (F),"The administration of feed decreased the absolute bioavailability (F) of OTC from 12.70%±4.01 to 6.40%±1.08, and this effect was more pronounced after the combined administration of OTC with feed and hard water (5.31%±0.90).",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),%,6.40,44782,DB00759,Tetracycline
,31269331,absolute bioavailability (F),"The administration of feed decreased the absolute bioavailability (F) of OTC from 12.70%±4.01 to 6.40%±1.08, and this effect was more pronounced after the combined administration of OTC with feed and hard water (5.31%±0.90).",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),%,5.31,44783,DB00759,Tetracycline
,31269331,area under the concentration- time curve (AUC0-t),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[h·μg] / [ml],10.18,44784,DB00759,Tetracycline
,31269331,area under the concentration- time curve (AUC0-t),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[h·μg] / [ml],5.13,44785,DB00759,Tetracycline
,31269331,area under the concentration- time curve (AUC0-t),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[h·μg] / [ml],4.26,44786,DB00759,Tetracycline
,31269331,maximum plasma concentration of OTC (Cmax),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[μg] / [ml],1.22,44787,DB00759,Tetracycline
,31269331,maximum plasma concentration of OTC (Cmax),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[μg] / [ml],1.01,44788,DB00759,Tetracycline
,31269331,maximum plasma concentration of OTC (Cmax),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[μg] / [ml],0.68,44789,DB00759,Tetracycline
,31269331,maximum plasma concentration of OTC (Cmax),"A decrease in the area under the concentration- time curve (AUC0-t), (from 10.18±3.24 μg·h/ml in control to 5.13 μg·h/ml±1.26 for feed and 4.26 μg·h/ml±1.10 for feed and hard water) and the maximum plasma concentration of OTC (Cmax) (from 1.22±0.18 μg/ml in control, to 1.01 μg/ml ±0.10 for hard water, 0.68 μg/ml±0.10 for feed and 0.61 μg/ml±0.10 for feed and hard water) was observed.",Hard water may increase the inhibitory effect of feed on the oral bioavailability of oxytetracycline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269331/),[μg] / [ml],0.61,44790,DB00759,Tetracycline
,26681141,absorption half-life time,"The absorption half-life time was 1.23 ± 0.36 h, 1.19 ± 0.52 h, and 0.49 ± 0.38 h after IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,1.23,44987,DB00759,Tetracycline
,26681141,absorption half-life time,"The absorption half-life time was 1.23 ± 0.36 h, 1.19 ± 0.52 h, and 0.49 ± 0.38 h after IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,1.19,44988,DB00759,Tetracycline
,26681141,absorption half-life time,"The absorption half-life time was 1.23 ± 0.36 h, 1.19 ± 0.52 h, and 0.49 ± 0.38 h after IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,0.49,44989,DB00759,Tetracycline
,26681141,elimination half-life time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,27.41,44990,DB00759,Tetracycline
,26681141,elimination half-life time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,10.23,44991,DB00759,Tetracycline
,26681141,elimination half-life time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,7.83,44992,DB00759,Tetracycline
,26681141,elimination half-life time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,14.86,44993,DB00759,Tetracycline
,26681141,mean residence time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,9.67,44994,DB00759,Tetracycline
,26681141,mean residence time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,11.45,44995,DB00759,Tetracycline
,26681141,mean residence time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,11.38,44996,DB00759,Tetracycline
,26681141,mean residence time,"The elimination half-life time was 27.41 ± 6.06 h, 10.23 ± 4.20 h, 7.83 ± 0.56 h, and 14.86 ± 9.23 h, and the mean residence time was 9.67 ± 1.7 h, 11.45 ± 1.76 h, 11.38 ± 0.59 h, and 10.37 ± 3.91 h after IV, IM, SC and PO administration, respectively.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),h,10.37,44997,DB00759,Tetracycline
,26681141,Bioavailability,"Bioavailability was 76.88 ± 12.90%, 92.20 ± 10.53% and 12.13 ± 4.56% after IM, SC and PO administration, respectively, which indicated that OTC is poorly absorbed from the gastrointestinal tract in broiler chickens.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),%,76.88,44998,DB00759,Tetracycline
,26681141,Bioavailability,"Bioavailability was 76.88 ± 12.90%, 92.20 ± 10.53% and 12.13 ± 4.56% after IM, SC and PO administration, respectively, which indicated that OTC is poorly absorbed from the gastrointestinal tract in broiler chickens.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),%,92.20,44999,DB00759,Tetracycline
,26681141,Bioavailability,"Bioavailability was 76.88 ± 12.90%, 92.20 ± 10.53% and 12.13 ± 4.56% after IM, SC and PO administration, respectively, which indicated that OTC is poorly absorbed from the gastrointestinal tract in broiler chickens.",Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681141/),%,12.13,45000,DB00759,Tetracycline
,12480318,minimum inhibitory concentration,The concentrations of OTC in plasma were maintained at or above 0.5 microg/ml (minimum inhibitory concentration) for approximately 6 days.,Controlled release of oxytetracycline in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12480318/),[μg] / [ml],0.5,46827,DB00759,Tetracycline
,24764254,C max,"After single high dose administration under fed condition, the C max of metronidazole, tetracycline and bismuth were 6.833 ± 0.742 μg/mL, 0.8513 ± 0.1253 μg/mL and 3.32 ± 1.89 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[μg] / [ml],6.833,47279,DB00759,Tetracycline
,24764254,C max,"After single high dose administration under fed condition, the C max of metronidazole, tetracycline and bismuth were 6.833 ± 0.742 μg/mL, 0.8513 ± 0.1253 μg/mL and 3.32 ± 1.89 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[μg] / [ml],0.8513,47280,DB00759,Tetracycline
,24764254,C max,"After single high dose administration under fed condition, the C max of metronidazole, tetracycline and bismuth were 6.833 ± 0.742 μg/mL, 0.8513 ± 0.1253 μg/mL and 3.32 ± 1.89 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[ng] / [ml],3.32,47281,DB00759,Tetracycline
,24764254,C av,"In the steady state, the C av of metronidazole, tetracycline and bismuth were 20.75 ± 3.52 μg/mL, 1.900 ± 0.243 μg/mL and 5.61 ± 1.34 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[μg] / [ml],20.75,47282,DB00759,Tetracycline
,24764254,C av,"In the steady state, the C av of metronidazole, tetracycline and bismuth were 20.75 ± 3.52 μg/mL, 1.900 ± 0.243 μg/mL and 5.61 ± 1.34 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[μg] / [ml],1.900,47283,DB00759,Tetracycline
,24764254,C av,"In the steady state, the C av of metronidazole, tetracycline and bismuth were 20.75 ± 3.52 μg/mL, 1.900 ± 0.243 μg/mL and 5.61 ± 1.34 ng/mL, respectively.","Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24764254/),[ng] / [ml],5.61,47284,DB00759,Tetracycline
,22380936,concentrations,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],208,47361,DB00759,Tetracycline
,22380936,concentrations,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],299,47362,DB00759,Tetracycline
,22380936,concentrations,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],60,47363,DB00759,Tetracycline
,22380936,residual,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],455,47364,DB00759,Tetracycline
,22380936,residual,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],332,47365,DB00759,Tetracycline
,22380936,residual,"For the 10% cross-contamination group, residual sulfadiazine concentrations of 208, 299 and 60 µg kg(-1) and residual doxycycline concentrations of 455, 332, 206 µg kg(-1) were detected in whole egg, egg white and egg yolk on day 13 of the treatment period, respectively.","Residues of sulfadiazine and doxycycline in egg matrices due to cross-contamination in the feed of laying hens and the possible correlation with physicochemical, pharmacokinetic and physiological parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22380936/),[μg] / [kg],206,47366,DB00759,Tetracycline
,1314064,IC50,"The IC50 of chemically modified tetracycline and tetracycline, as inhibitors of collagenase from rat polymorphonuclear leukocytes, was determined and found to be 4.1 x 10(-8) M (0.02 micrograms/ml) and 2.4 x 10(-4) M (120 micrograms/ml), respectively.",HPLC determination of a chemically modified nonantimicrobial tetracycline: biological implications. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1314064/),M,4.1 x 10(-8),47603,DB00759,Tetracycline
,1314064,IC50,"The IC50 of chemically modified tetracycline and tetracycline, as inhibitors of collagenase from rat polymorphonuclear leukocytes, was determined and found to be 4.1 x 10(-8) M (0.02 micrograms/ml) and 2.4 x 10(-4) M (120 micrograms/ml), respectively.",HPLC determination of a chemically modified nonantimicrobial tetracycline: biological implications. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1314064/),[μg] / [ml],0.02,47604,DB00759,Tetracycline
,1314064,IC50,"The IC50 of chemically modified tetracycline and tetracycline, as inhibitors of collagenase from rat polymorphonuclear leukocytes, was determined and found to be 4.1 x 10(-8) M (0.02 micrograms/ml) and 2.4 x 10(-4) M (120 micrograms/ml), respectively.",HPLC determination of a chemically modified nonantimicrobial tetracycline: biological implications. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1314064/),M,2.4 x 10(-4),47605,DB00759,Tetracycline
,1314064,IC50,"The IC50 of chemically modified tetracycline and tetracycline, as inhibitors of collagenase from rat polymorphonuclear leukocytes, was determined and found to be 4.1 x 10(-8) M (0.02 micrograms/ml) and 2.4 x 10(-4) M (120 micrograms/ml), respectively.",HPLC determination of a chemically modified nonantimicrobial tetracycline: biological implications. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1314064/),[μg] / [ml],120,47606,DB00759,Tetracycline
,14517195,terminal half-life,"COL-3 had a long terminal half-life (median = 59.8 h), large apparent volume of distribution (median = 50.2 L), and low apparent clearance (median = 9.93 mL/min).","Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517195/),h,59.8,47829,DB00759,Tetracycline
,14517195,apparent volume of distribution,"COL-3 had a long terminal half-life (median = 59.8 h), large apparent volume of distribution (median = 50.2 L), and low apparent clearance (median = 9.93 mL/min).","Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517195/),l,50.2,47830,DB00759,Tetracycline
,14517195,apparent clearance,"COL-3 had a long terminal half-life (median = 59.8 h), large apparent volume of distribution (median = 50.2 L), and low apparent clearance (median = 9.93 mL/min).","Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517195/),[ml] / [min],9.93,47831,DB00759,Tetracycline
,14517195,fu,"There was nonsaturable plasma protein binding of COL-3 (fu = 5.5%), with the majority of binding to albumin.","Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517195/),%,5.5,47832,DB00759,Tetracycline
≥,33283892,AUC0-12h × V/MIC ratio,Classification and regression tree analyses indicated that the combination of APACHEII score < 24 and AUC0-12h × V/MIC ratio ≥ 100 was associated with clinical success.,Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33283892/),,100,49287,DB00759,Tetracycline
,3798710,maximum plasma OTC concentrations,"The mean maximum plasma OTC concentrations varied between 4.5 and 6.8 micrograms/ml and were achieved between 5 and 10 h p.i., depending on the formulation involved.","Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798710/),[μg] / [ml],4.5 and 6.8,50524,DB00759,Tetracycline
,3798710,maximum milk concentrations,"The mean maximum milk concentrations, ranging from 1.12 to 1.92 micrograms/ml, were achieved 12 to 24 h p.i.","Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798710/),[μg] / [ml],1.12 to 1.92,50525,DB00759,Tetracycline
,3798710,withholding periods,Among the formulations the calculated withholding periods for milk were in the range of 3 to 4 days and for edible tissues of 9 to 14 days.,"Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798710/),,3 to 4,50526,DB00759,Tetracycline
,3798710,withholding periods,Among the formulations the calculated withholding periods for milk were in the range of 3 to 4 days and for edible tissues of 9 to 14 days.,"Comparative pharmacokinetics, bioavailability and renal clearance of five parenteral oxytetracycline-20% formulations in dairy cows. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798710/),,9 to 14,50527,DB00759,Tetracycline
,16958786,dispositional half-lives,The dispositional half-lives of all compartments was found to be 14-21 h.,The complete analysis of oxytetracycline pharmacokinetics in farmed Pacific white shrimp (Litopenaeus vannamei). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958786/),h,14-21,50599,DB00759,Tetracycline
,21950341,peak concentration,"At steady state, the mean ± s.d. peak concentration of minocycline in the plasma was 0.67 ± 0.26 µg/ml and the mean half-life was 11.48 ± 3.23 h.",Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.67,50696,DB00759,Tetracycline
,21950341,half-life,"At steady state, the mean ± s.d. peak concentration of minocycline in the plasma was 0.67 ± 0.26 µg/ml and the mean half-life was 11.48 ± 3.23 h.",Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),h,11.48,50697,DB00759,Tetracycline
,21950341,trough synovial fluid minocycline concentration,The highest trough synovial fluid minocycline concentration was 0.33 ± 0.12 µg/ml.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.33,50698,DB00759,Tetracycline
,21950341,AH concentration,The AH concentration of minocycline was 0.09 ± 0.03 µg/ml in normal eyes and 0.11 ± 0.04 µg/ml in blood aqueous barrier-disrupted eyes.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.09,50699,DB00759,Tetracycline
,21950341,AH concentration,The AH concentration of minocycline was 0.09 ± 0.03 µg/ml in normal eyes and 0.11 ± 0.04 µg/ml in blood aqueous barrier-disrupted eyes.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.11,50700,DB00759,Tetracycline
,21950341,CSF concentration,The mean CSF concentration of minocycline was 0.38 ± 0.09 µg/ml.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.38,50701,DB00759,Tetracycline
≤,21950341,MIC,This study supports the use of orally administered minocycline at a dose of 4 mg/kg bwt every 12 h for the treatment of nonocular infections caused by susceptible (MIC ≤ 0.25 µg/ml) organisms in horses.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.25,50702,DB00759,Tetracycline
,4095063,A,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),[μg] / [ml],2000,51196,DB00759,Tetracycline
,4095063,alpha,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],4.3,51197,DB00759,Tetracycline
,4095063,B,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),[μg] / [ml],82,51198,DB00759,Tetracycline
,4095063,beta,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],.252,51199,DB00759,Tetracycline
,4095063,K12,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],1.515,51200,DB00759,Tetracycline
,4095063,K21,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],.049,51201,DB00759,Tetracycline
,4095063,K10,"Pharmacokinetic parameters were found to be: A (microgram/ml) = 2000 +/- 450, alpha (hr-1) = 4.3 +/- .5, B (microgram/ml) = 82 +/- 6, beta (hr-1) = .252 +/- .009, K12 (hr-1) = 1.515, K21 (hr-1) = .049, and K10 (hr-1) = 2.652.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],2.652,51202,DB00759,Tetracycline
,4095063,biliary excretion rate,The maximum values for tetracycline biliary excretion rate (407 and 606 micrograms/hr) were reached at about 1 hr after iv administration of 10- and 15-mg/kg doses.,Pharmacokinetics of tetracycline in chickens after intravenous administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),[μg] / [h],407,51203,DB00759,Tetracycline
,4095063,biliary excretion rate,The maximum values for tetracycline biliary excretion rate (407 and 606 micrograms/hr) were reached at about 1 hr after iv administration of 10- and 15-mg/kg doses.,Pharmacokinetics of tetracycline in chickens after intravenous administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),[μg] / [h],606,51204,DB00759,Tetracycline
,4095063,Kbi,"First-order rate constants for the biliary excretion, Kbi (hr-1), were .834 and .665, respectively.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],.834,51205,DB00759,Tetracycline
,4095063,Kbi,"First-order rate constants for the biliary excretion, Kbi (hr-1), were .834 and .665, respectively.",Pharmacokinetics of tetracycline in chickens after intravenous administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4095063/),1/[h],.665,51206,DB00759,Tetracycline
,29036256,Cmax,"Following topical application of a 4-g maximal-use dose of minocycline foam 4% for 21 days, plasma minocycline concentration was very low, with geometric mean Cmax values ranging from 1.1 ng/mL to 1.5 ng/mL.",Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036256/),[ng] / [ml],1.1,51209,DB00759,Tetracycline
,29036256,Cmax,"Following topical application of a 4-g maximal-use dose of minocycline foam 4% for 21 days, plasma minocycline concentration was very low, with geometric mean Cmax values ranging from 1.1 ng/mL to 1.5 ng/mL.",Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036256/),[ng] / [ml],1.5,51210,DB00759,Tetracycline
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],136.9,52646,DB00759,Tetracycline
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],128.3,52647,DB00759,Tetracycline
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,12.9,52648,DB00759,Tetracycline
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,17.3,52649,DB00759,Tetracycline
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,54,52650,DB00759,Tetracycline
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,42,52651,DB00759,Tetracycline
,2704059,synovial fluid:serum area under curve (AUC) ratio,"Of the two penicillin G preparations, PPG gave a significantly higher synovial fluid:serum area under curve (AUC) ratio than did KPG; 0.76 +/- 0.10 and 0.54 +/- 0.12, respectively (P less than 0.05).","Concentrations of sulphadimidine, oxytetracycline and penicillin G in serum, synovial fluid and tissue cage fluid after parenteral administration to calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704059/),,0.76,52886,DB00759,Tetracycline
,2704059,synovial fluid:serum area under curve (AUC) ratio,"Of the two penicillin G preparations, PPG gave a significantly higher synovial fluid:serum area under curve (AUC) ratio than did KPG; 0.76 +/- 0.10 and 0.54 +/- 0.12, respectively (P less than 0.05).","Concentrations of sulphadimidine, oxytetracycline and penicillin G in serum, synovial fluid and tissue cage fluid after parenteral administration to calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704059/),,0.54,52887,DB00759,Tetracycline
,2704059,synovial fluid:serum AUC-ratio,"For OTC, the synovial fluid:serum AUC-ratio was 0.33 +/- 0.12 after i.m. and 0.34 +/- 0.08 after i.v. administration.","Concentrations of sulphadimidine, oxytetracycline and penicillin G in serum, synovial fluid and tissue cage fluid after parenteral administration to calves. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704059/),,0.33,52888,DB00759,Tetracycline
,2704059,synovial fluid:serum AUC-ratio,"For OTC, the synovial fluid:serum AUC-ratio was 0.33 +/- 0.12 after i.m. and 0.34 +/- 0.08 after i.v. administration.","Concentrations of sulphadimidine, oxytetracycline and penicillin G in serum, synovial fluid and tissue cage fluid after parenteral administration to calves. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704059/),,0.34,52889,DB00759,Tetracycline
,1763525,distribution half-lives,"2. The pharmacokinetics were best described by a two-compartment open model giving distribution half-lives of 0.31 h and 1.53 h, and elimination half-lives of 69.7 h and 60.3 h for oxolinic acid and oxytetracycline, respectively.",Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),h,0.31,53771,DB00759,Tetracycline
,1763525,distribution half-lives,"2. The pharmacokinetics were best described by a two-compartment open model giving distribution half-lives of 0.31 h and 1.53 h, and elimination half-lives of 69.7 h and 60.3 h for oxolinic acid and oxytetracycline, respectively.",Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),h,1.53,53772,DB00759,Tetracycline
,1763525,elimination half-lives,"2. The pharmacokinetics were best described by a two-compartment open model giving distribution half-lives of 0.31 h and 1.53 h, and elimination half-lives of 69.7 h and 60.3 h for oxolinic acid and oxytetracycline, respectively.",Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),h,69.7,53773,DB00759,Tetracycline
,1763525,elimination half-lives,"2. The pharmacokinetics were best described by a two-compartment open model giving distribution half-lives of 0.31 h and 1.53 h, and elimination half-lives of 69.7 h and 60.3 h for oxolinic acid and oxytetracycline, respectively.",Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),h,60.3,53774,DB00759,Tetracycline
,1763525,volumes of distribution (Vdarea),The respective volumes of distribution (Vdarea) were 1.94 l/kg and 1.34 l/kg.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),[l] / [kg],1.94,53775,DB00759,Tetracycline
,1763525,volumes of distribution (Vdarea),The respective volumes of distribution (Vdarea) were 1.94 l/kg and 1.34 l/kg.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),[l] / [kg],1.34,53776,DB00759,Tetracycline
,1763525,apparent oral bioavailability,3. The apparent oral bioavailability for oxolinic acid and oxytetracycline was 13.6% and 5.6%.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),%,13.6,53777,DB00759,Tetracycline
,1763525,apparent oral bioavailability,3. The apparent oral bioavailability for oxolinic acid and oxytetracycline was 13.6% and 5.6%.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),%,5.6,53778,DB00759,Tetracycline
,1763525,plasma protein binding,4. The plasma protein binding was 27% for oxolinic acid and 55% for oxytetracycline.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),%,27,53779,DB00759,Tetracycline
,1763525,plasma protein binding,4. The plasma protein binding was 27% for oxolinic acid and 55% for oxytetracycline.,Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),%,55,53780,DB00759,Tetracycline
exceeding,1763525,acute oral toxicities (LD50),"5. Both drugs were well tolerated, the acute oral toxicities (LD50) exceeding 4000 mg/kg.",Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763525/),[mg] / [kg],4000,53781,DB00759,Tetracycline
,2722658,peak plasma OTC concentration,The mean (+/- SD) peak plasma OTC concentration after OTC-LA administration was 6.0 +/- 2.2 micrograms/ml at 30 minutes; the mean peak plasma OTC concentration after OTC-100 administration was 6.7 +/- 3.4 micrograms/ml at 90 minutes.,Plasma concentrations of oxytetracycline in swine after administration of the drug intramuscularly and orally in feed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722658/),[μg] / [ml],6.0,55502,DB00759,Tetracycline
,2722658,peak plasma OTC concentration,The mean (+/- SD) peak plasma OTC concentration after OTC-LA administration was 6.0 +/- 2.2 micrograms/ml at 30 minutes; the mean peak plasma OTC concentration after OTC-100 administration was 6.7 +/- 3.4 micrograms/ml at 90 minutes.,Plasma concentrations of oxytetracycline in swine after administration of the drug intramuscularly and orally in feed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722658/),[μg] / [ml],6.7,55503,DB00759,Tetracycline
,19114676,half-life,"Tigecycline pharmacokinetics were best described by a two-compartment model, with a mean half-life of 9.9 h.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),h,9.9,55896,DB00759,Tetracycline
,19114676,MICs,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.25,55897,DB00759,Tetracycline
,19114676,MIC,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.5,55898,DB00759,Tetracycline
,19114676,MIC,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.125,55899,DB00759,Tetracycline
,19114676,effective exposure index,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],5.4,55900,DB00759,Tetracycline
,19114676,fAUC/MIC,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],5.4,55901,DB00759,Tetracycline
,19114676,fAUC/MIC,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],2.6,55902,DB00759,Tetracycline
,19114676,fAUC/MIC,Experiments with nonneutropenic mice infected with CA-MRSA 156 resulted in maximum kill at all fAUC/MIC exposures tested (1.8 to 8.8 microg/ml).,Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],1.8 to 8.8,55903,DB00759,Tetracycline
,12365509,maximum serum concentrations,"2. The maximum serum concentrations of doxy were reached 1.97 and 2.37 h after oral, and 1.57 and 2.92 h after i.m. dosage in healthy and aflatoxic birds, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),,2,55979,DB00759,Tetracycline
,12365509,maximum serum concentrations,"2. The maximum serum concentrations of doxy were reached 1.97 and 2.37 h after oral, and 1.57 and 2.92 h after i.m. dosage in healthy and aflatoxic birds, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),,1,55980,DB00759,Tetracycline
,12365509,maximum serum concentrations,"2. The maximum serum concentrations of doxy were reached 1.97 and 2.37 h after oral, and 1.57 and 2.92 h after i.m. dosage in healthy and aflatoxic birds, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),,2.92,55981,DB00759,Tetracycline
,12365509,volumes of distribution,3. The volumes of distribution and total body clearances were higher in aflatoxic birds (1.75 l/kg and 14.61 ml/kg/min) than in healthy chickens (0.93 l/kg and 4.6 ml/kg/min).,"Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),[l] / [kg],1.75,55982,DB00759,Tetracycline
,12365509,volumes of distribution,3. The volumes of distribution and total body clearances were higher in aflatoxic birds (1.75 l/kg and 14.61 ml/kg/min) than in healthy chickens (0.93 l/kg and 4.6 ml/kg/min).,"Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),[l] / [kg],0.93,55983,DB00759,Tetracycline
,12365509,total body clearances,3. The volumes of distribution and total body clearances were higher in aflatoxic birds (1.75 l/kg and 14.61 ml/kg/min) than in healthy chickens (0.93 l/kg and 4.6 ml/kg/min).,"Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),[ml] / [kg·min],14.61,55984,DB00759,Tetracycline
,12365509,total body clearances,3. The volumes of distribution and total body clearances were higher in aflatoxic birds (1.75 l/kg and 14.61 ml/kg/min) than in healthy chickens (0.93 l/kg and 4.6 ml/kg/min).,"Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),[ml] / [kg·min],4.6,55985,DB00759,Tetracycline
,12365509,systemic bioavailability,"4. Lower values of systemic bioavailability were observed in intoxicated birds (30.9 and 33.9%) than healthy ones (43.7 and 57.3%) after oral and i.m. administration, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),%,30.9,55986,DB00759,Tetracycline
,12365509,systemic bioavailability,"4. Lower values of systemic bioavailability were observed in intoxicated birds (30.9 and 33.9%) than healthy ones (43.7 and 57.3%) after oral and i.m. administration, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),%,33.9,55987,DB00759,Tetracycline
,12365509,systemic bioavailability,"4. Lower values of systemic bioavailability were observed in intoxicated birds (30.9 and 33.9%) than healthy ones (43.7 and 57.3%) after oral and i.m. administration, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),%,43.7,55988,DB00759,Tetracycline
,12365509,systemic bioavailability,"4. Lower values of systemic bioavailability were observed in intoxicated birds (30.9 and 33.9%) than healthy ones (43.7 and 57.3%) after oral and i.m. administration, respectively.","Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365509/),%,57.3,55989,DB00759,Tetracycline
,2322228,terminal half-life,"Following intramuscular and subcutaneous administration of 50 to 100 mg/kg body weight, plasma OTC concentrations of 7 to 15 micrograms/ml were obtained 3 hr following injection and declined with a terminal half-life between 8.9 to 14.7 hr.",Potential use of long-acting injectable oxytetracycline for treatment of chlamydiosis in Goffin's cockatoos. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322228/),h,8.9 to 14.7,56017,DB00759,Tetracycline
excess,2322228,Plasma concentrations,Plasma concentrations in excess of 1.0 microgram/ml were maintained for 48 to 68 hr.,Potential use of long-acting injectable oxytetracycline for treatment of chlamydiosis in Goffin's cockatoos. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322228/),[μg] / [ml],1.0,56018,DB00759,Tetracycline
,29696661,area under the concentration 0- to 24-hr curve (AUC0-24 ),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),[h·μg] / [ml],55.51,56633,DB00759,Tetracycline
,29696661,elimination half-life (T½ke ),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),[h·μg] / [ml],57.10,56634,DB00759,Tetracycline
,29696661,elimination half-life (T½ke ),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),h,8.28,56635,DB00759,Tetracycline
,29696661,elimination half-life (T½ke ),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),h,9.80,56636,DB00759,Tetracycline
,29696661,mean residence time (MRT),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),h,8.43,56637,DB00759,Tetracycline
,29696661,mean residence time (MRT),"The area under the concentration 0- to 24-hr curve (AUC0-24 ), elimination half-life (T½ke ), and mean residence time (MRT) of dox in healthy and H. parasuis-infected pigs were 55.51 ± 5.72 versus 57.10 ± 4.89 μg·hr/ml, 8.28 ± 0.91 versus 9.80 ± 2.38 hr, and 8.43 ± 0.27 versus 8.79 ± 0.18 hr, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),h,8.79,56638,DB00759,Tetracycline
,29696661,MIC50,"The minimal inhibitory concentration (MIC) of dox against 40 H. parasuis isolates was conducted through broth microdilution method, the corresponding MIC50 and MIC90 were 0.25 and 1 μg/ml, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),[μg] / [ml],0.25,56639,DB00759,Tetracycline
,29696661,MIC90,"The minimal inhibitory concentration (MIC) of dox against 40 H. parasuis isolates was conducted through broth microdilution method, the corresponding MIC50 and MIC90 were 0.25 and 1 μg/ml, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),[μg] / [ml],1,56640,DB00759,Tetracycline
,29696661,AUC,"Based on the observed AUC24 hr /MIC values by modeling PK-PD data in H. parasuis-infected pigs, the doses predicted to obtain bacteriostatic, bactericidal, and elimination effects for H. parasuis over 24 hr were 5.25, 8.55, and 10.37 mg/kg for the 50% target attainment rate (TAR), and 7.26, 13.82, and 18.17 mg/kg for 90% TAR, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),mg,5.25,56641,DB00759,Tetracycline
,29696661,AUC,"Based on the observed AUC24 hr /MIC values by modeling PK-PD data in H. parasuis-infected pigs, the doses predicted to obtain bacteriostatic, bactericidal, and elimination effects for H. parasuis over 24 hr were 5.25, 8.55, and 10.37 mg/kg for the 50% target attainment rate (TAR), and 7.26, 13.82, and 18.17 mg/kg for 90% TAR, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),mg,8.55,56642,DB00759,Tetracycline
,29696661,AUC,"Based on the observed AUC24 hr /MIC values by modeling PK-PD data in H. parasuis-infected pigs, the doses predicted to obtain bacteriostatic, bactericidal, and elimination effects for H. parasuis over 24 hr were 5.25, 8.55, and 10.37 mg/kg for the 50% target attainment rate (TAR), and 7.26, 13.82, and 18.17 mg/kg for 90% TAR, respectively.",Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29696661/),mg,10.37,56643,DB00759,Tetracycline
,32716292,Cmax,"In the non-CRRT group, Cmax, Cmin, and AUC0-24 were 1.00 ± 0.66 µg×mL-1, 0.20 ± 0.12 µg×mL-1, and 22.12 ± 14.46 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[μg] / [ml],1.00,59205,DB00759,Tetracycline
,32716292,Cmin,"In the non-CRRT group, Cmax, Cmin, and AUC0-24 were 1.00 ± 0.66 µg×mL-1, 0.20 ± 0.12 µg×mL-1, and 22.12 ± 14.46 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[μg] / [ml],0.20,59206,DB00759,Tetracycline
,32716292,AUC0-24,"In the non-CRRT group, Cmax, Cmin, and AUC0-24 were 1.00 ± 0.66 µg×mL-1, 0.20 ± 0.12 µg×mL-1, and 22.12 ± 14.46 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[h·μg] / [ml],22.12,59207,DB00759,Tetracycline
,32716292,Cmax,"In the CRRT group, Cmax, Cmin, and AUC0-24 were 0.96 ± 0.31 µg×mL-1, 0.22 ± 0.12 µg×mL-1, and 19.90 ± 8.14 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[μg] / [ml],0.96,59208,DB00759,Tetracycline
,32716292,Cmin,"In the CRRT group, Cmax, Cmin, and AUC0-24 were 0.96 ± 0.31 µg×mL-1, 0.22 ± 0.12 µg×mL-1, and 19.90 ± 8.14 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[μg] / [ml],0.22,59209,DB00759,Tetracycline
,32716292,AUC0-24,"In the CRRT group, Cmax, Cmin, and AUC0-24 were 0.96 ± 0.31 µg×mL-1, 0.22 ± 0.12 µg×mL-1, and 19.90 ± 8.14 µg×h×mL-1, respectively.",PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716292/),[h·μg] / [ml],19.90,59210,DB00759,Tetracycline
,2287034,elimination half-life,Doxycycline elimination half-life was 4.56 +/- 0.68 (SEM) h for cats and 6.99 +/- 1.09 h for dogs.,Comparative pharmacokinetics of doxycycline in cats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287034/),h,4.56,59636,DB00759,Tetracycline
,2287034,elimination half-life,Doxycycline elimination half-life was 4.56 +/- 0.68 (SEM) h for cats and 6.99 +/- 1.09 h for dogs.,Comparative pharmacokinetics of doxycycline in cats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287034/),h,6.99,59637,DB00759,Tetracycline
,17803738,AUC,"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[h·μg] / [ml],9524.60,60666,DB00759,Tetracycline
,17803738,MRT,"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),h,443.65,60667,DB00759,Tetracycline
,17803738,Clb,"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[ml] / [kg·min],0.044,60668,DB00759,Tetracycline
,17803738,Vd(ss),"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[l] / [kg],1.164,60669,DB00759,Tetracycline
,17803738,t(1/2),"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),h,128.3,60670,DB00759,Tetracycline
,17803738,Cmax,"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[μg] / [ml],55.90,60671,DB00759,Tetracycline
,17803738,C(ave),"The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[μg] / [ml],27.39,60672,DB00759,Tetracycline
,17803738,AUC,"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[h·μg] / [ml],5861.81,60673,DB00759,Tetracycline
,17803738,MRT,"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),h,395.89,60674,DB00759,Tetracycline
,17803738,Clb,"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[ml] / [kg·min],0.071,60675,DB00759,Tetracycline
,17803738,Vd(ss),"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[l] / [kg],1.688,60676,DB00759,Tetracycline
,17803738,t(1/2),"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),h,210.0,60677,DB00759,Tetracycline
,17803738,Cmax,"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[μg] / [ml],7.83,60678,DB00759,Tetracycline
,17803738,C(ave),"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),[μg] / [ml],2.89,60679,DB00759,Tetracycline
,17803738,F,"Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.","Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803738/),%,61.56,60680,DB00759,Tetracycline
,3083734,clearance,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),[ml] / [kg·min],5.94,61199,DB00759,Tetracycline
,3083734,steady-state volume of distribution,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),[l] / [kg],1.32,61200,DB00759,Tetracycline
,3083734,mean residence time,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,3.89,61201,DB00759,Tetracycline
,3083734,effective half-life,"The effective half-life, reported as the harmonic mean, increased from 2.57 hours in sheep before blood collection to 2.91 hours in sheep when they were hypoproteinemic.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,2.57,61202,DB00759,Tetracycline
,3083734,effective half-life,"The effective half-life, reported as the harmonic mean, increased from 2.57 hours in sheep before blood collection to 2.91 hours in sheep when they were hypoproteinemic.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,2.91,61203,DB00759,Tetracycline
,33802956,volume of distribution (tvV),"The estimated typical value of volume of distribution (tvV), total body clearance, and absorption rate constant were 4.429 L/kg, 1.473 L/kg/h, and 0.257 h-1, respectively.",Population Pharmacokinetic Modelling of Orally Administered Doxycycline to Rabbits at Different Ages. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33802956/),[l] / [kg],4.429,61877,DB00759,Tetracycline
,33802956,total body clearance,"The estimated typical value of volume of distribution (tvV), total body clearance, and absorption rate constant were 4.429 L/kg, 1.473 L/kg/h, and 0.257 h-1, respectively.",Population Pharmacokinetic Modelling of Orally Administered Doxycycline to Rabbits at Different Ages. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33802956/),[l] / [h·kg],1.473,61878,DB00759,Tetracycline
,33802956,absorption rate constant,"The estimated typical value of volume of distribution (tvV), total body clearance, and absorption rate constant were 4.429 L/kg, 1.473 L/kg/h, and 0.257 h-1, respectively.",Population Pharmacokinetic Modelling of Orally Administered Doxycycline to Rabbits at Different Ages. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33802956/),1/[h],0.257,61879,DB00759,Tetracycline
,33802956,MIC,An oral dose of 5 mg/kg could ensure percentage of the time from the dosing interval during which the concentration is above minimum inhibitory concentration (MIC) %fT > MIC of 35% if MIC of 0.18 μg·mL-1 and a dosing interval of 12 h is assumed which does not cover criteria for rational use of antibiotics.,Population Pharmacokinetic Modelling of Orally Administered Doxycycline to Rabbits at Different Ages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33802956/),[μg] / [ml],0.18,61880,DB00759,Tetracycline
> or =,19643776,MIC,"Nine E. coli isolates were studied, including three ESBL-producing isolates, three AmpC-producing isolates and three isolates demonstrating CRS (ertapenem MIC > or = 0.12 mg/L).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.12,64558,DB00759,Tetracycline
,19643776,fC(max),"The pharmacodynamic model was inoculated with organisms at 1 x 10(6) cfu/mL and tigecycline dosed once every 24 h to simulate the fC(max) (free peak serum concentration) and t(1/2) (serum half-life) obtained after standard dosing of 100 mg intravenously every 24 h (fC(max), 0.15 mg/L; t(1/2), 42 h).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.15,64559,DB00759,Tetracycline
,19643776,t(1/2),"The pharmacodynamic model was inoculated with organisms at 1 x 10(6) cfu/mL and tigecycline dosed once every 24 h to simulate the fC(max) (free peak serum concentration) and t(1/2) (serum half-life) obtained after standard dosing of 100 mg intravenously every 24 h (fC(max), 0.15 mg/L; t(1/2), 42 h).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),h,42,64560,DB00759,Tetracycline
,19643776,fAUC(24)/MIC,"For isolates with a tigecycline fAUC(24)/MIC of 2.0 (tigecycline MIC = 0.5 mg/L), tigecycline demonstrated bacteriostatic activity with < 1 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,2.0,64561,DB00759,Tetracycline
,19643776,MIC,"For isolates with a tigecycline fAUC(24)/MIC of 2.0 (tigecycline MIC = 0.5 mg/L), tigecycline demonstrated bacteriostatic activity with < 1 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.5,64562,DB00759,Tetracycline
,19643776,fAUC(24)/MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 4.0 (tigecycline MIC = 0.25 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 1.5 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,4.0,64563,DB00759,Tetracycline
,19643776,MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 4.0 (tigecycline MIC = 0.25 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 1.5 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.25,64564,DB00759,Tetracycline
,19643776,fAUC(24)/MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 8.0 (tigecycline MIC = 0.12 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 2.0 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,8.0,64565,DB00759,Tetracycline
,19643776,MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 8.0 (tigecycline MIC = 0.12 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 2.0 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.12,64566,DB00759,Tetracycline
,8910725,bioavailability,"It was concluded that the bioavailability of fluoride from sodium fluoride mixed with milk or water was similar following metabolism, despite 20-30 percent and 100 percent ionisation in milk and water respectively.",Fluoride uptake into the developing enamel and dentine of sheep incisors following daily ingestion of fluoridated milk or water. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910725/),%,20-30,65262,DB00759,Tetracycline
,8910725,bioavailability,"It was concluded that the bioavailability of fluoride from sodium fluoride mixed with milk or water was similar following metabolism, despite 20-30 percent and 100 percent ionisation in milk and water respectively.",Fluoride uptake into the developing enamel and dentine of sheep incisors following daily ingestion of fluoridated milk or water. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910725/),%,100,65263,DB00759,Tetracycline
,30844627,extraction recoveries,Mean extraction recoveries ranged between 64.3% and 84.6% for MC and 64.3% for the IS.,"Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30844627/),%,64.3,66637,DB00759,Tetracycline
,30844627,extraction recoveries,Mean extraction recoveries ranged between 64.3% and 84.6% for MC and 64.3% for the IS.,"Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30844627/),%,84.6,66638,DB00759,Tetracycline
,27682322,elimination half-life,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),h,8.5,67217,DB00759,Tetracycline
,27682322,systemic clearance,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),[ml] / [h·kg],113.3,67218,DB00759,Tetracycline
,27682322,apparent volume of distribution,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),[l] / [kg],1.24,67219,DB00759,Tetracycline
,27682322,Bioavailability,Bioavailability was significantly higher in foals (57.8 ± 19.3%) than in adult horses (32.0 ± 18.0%).,Comparative pharmacokinetics of minocycline in foals and adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),%,57.8,67220,DB00759,Tetracycline
,27682322,Bioavailability,Bioavailability was significantly higher in foals (57.8 ± 19.3%) than in adult horses (32.0 ± 18.0%).,Comparative pharmacokinetics of minocycline in foals and adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),%,32.0,67221,DB00759,Tetracycline
,24468780,total AUC0-12,The total AUC0-12 in plasma was 4.56±0.94 μg·h/ml with a mean fAUC0-12 of 0.77±0.14 μg·h/ml.,"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),[h·μg] / [ml],4.56,67937,DB00759,Tetracycline
,24468780,fAUC0-12,The total AUC0-12 in plasma was 4.56±0.94 μg·h/ml with a mean fAUC0-12 of 0.77±0.14 μg·h/ml.,"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),[h·μg] / [ml],0.77,67938,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,6.44,67939,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,8.25,67940,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,5.15,67941,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,1.77,67942,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,1,67943,DB00759,Tetracycline
,24468780,penetration ratio,"The eravacycline concentrations in ELF and AM at 2, 4, 6, and 12 h were means±the standard deviations (μg/ml) of 0.70±0.30, 0.57±0.20, 0.34±0.16, and 0.25±0.13 with a penetration ratio of 6.44 and 8.25±4.55, 5.15±1.25, 1.77±0.64, and 1.42±1.45 with a penetration ratio of 51.63, respectively.","Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468780/),,51.63,67944,DB00759,Tetracycline
,2319636,volume of distribution,The mean volume of distribution determined by area-under-the-curve calculations for the fasted pigs (0.967 +/- 0.210 l/kg) was significantly less (P less than 0.05) than the mean volume of distribution for the fed pigs (1.39 +/- 0.31 l/kg).,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),[l] / [kg],0.967,68616,DB00759,Tetracycline
,2319636,area-under-the-curve,The mean volume of distribution determined by area-under-the-curve calculations for the fasted pigs (0.967 +/- 0.210 l/kg) was significantly less (P less than 0.05) than the mean volume of distribution for the fed pigs (1.39 +/- 0.31 l/kg).,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),[l] / [kg],0.967,68617,DB00759,Tetracycline
,2319636,volume of distribution,The mean volume of distribution determined by area-under-the-curve calculations for the fasted pigs (0.967 +/- 0.210 l/kg) was significantly less (P less than 0.05) than the mean volume of distribution for the fed pigs (1.39 +/- 0.31 l/kg).,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),[l] / [kg],1.39,68618,DB00759,Tetracycline
,2319636,total body clearance,Mean total body clearance of the drug was also significantly less (P less than 0.05) in the fasted pigs (0.165 +/- 0.055 l/kg/h) as compared to the fed pigs (0.307 +/- 0.053 l/kg/h).,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),[l] / [h·kg],0.165,68619,DB00759,Tetracycline
,2319636,total body clearance,Mean total body clearance of the drug was also significantly less (P less than 0.05) in the fasted pigs (0.165 +/- 0.055 l/kg/h) as compared to the fed pigs (0.307 +/- 0.053 l/kg/h).,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),[l] / [h·kg],0.307,68620,DB00759,Tetracycline
,2319636,elimination constants (beta),The elimination constants (beta) were not found to be statistically different (P less than 0.05): 0.1811 +/- 0.0057 for the fasted pigs; 0.2260 +/- 0.0461 for the fed pigs.,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),,0.1811,68621,DB00759,Tetracycline
,2319636,elimination constants (beta),The elimination constants (beta) were not found to be statistically different (P less than 0.05): 0.1811 +/- 0.0057 for the fasted pigs; 0.2260 +/- 0.0461 for the fed pigs.,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),,0.2260,68622,DB00759,Tetracycline
,2319636,bioavailability,The bioavailability for both groups was similar; 19.12 +/- 8.3% for the fasted pigs and 17.88 +/- 5.3% for the fed pigs.,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),%,19.12,68623,DB00759,Tetracycline
,2319636,bioavailability,The bioavailability for both groups was similar; 19.12 +/- 8.3% for the fasted pigs and 17.88 +/- 5.3% for the fed pigs.,Chlortetracycline in swine--bioavailability and pharmacokinetics in fasted and fed pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319636/),%,17.88,68624,DB00759,Tetracycline
,8578898,elimination half-life (t1/2 beta),"The values of the elimination half-life (t1/2 beta) found in sheep, pigs, rabbits, chickens and pigeons were 1.51, 3.06, 2.18, 4.33 and 2.51 h respectively.",Species specific pharmacokinetics of rolitetracycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578898/),h,1.51,69873,DB00759,Tetracycline
,8578898,elimination half-life (t1/2 beta),"The values of the elimination half-life (t1/2 beta) found in sheep, pigs, rabbits, chickens and pigeons were 1.51, 3.06, 2.18, 4.33 and 2.51 h respectively.",Species specific pharmacokinetics of rolitetracycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578898/),h,3.06,69874,DB00759,Tetracycline
,8578898,elimination half-life (t1/2 beta),"The values of the elimination half-life (t1/2 beta) found in sheep, pigs, rabbits, chickens and pigeons were 1.51, 3.06, 2.18, 4.33 and 2.51 h respectively.",Species specific pharmacokinetics of rolitetracycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578898/),h,2.18,69875,DB00759,Tetracycline
,8578898,elimination half-life (t1/2 beta),"The values of the elimination half-life (t1/2 beta) found in sheep, pigs, rabbits, chickens and pigeons were 1.51, 3.06, 2.18, 4.33 and 2.51 h respectively.",Species specific pharmacokinetics of rolitetracycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578898/),h,4.33,69876,DB00759,Tetracycline
,8578898,elimination half-life (t1/2 beta),"The values of the elimination half-life (t1/2 beta) found in sheep, pigs, rabbits, chickens and pigeons were 1.51, 3.06, 2.18, 4.33 and 2.51 h respectively.",Species specific pharmacokinetics of rolitetracycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578898/),h,2.51,69877,DB00759,Tetracycline
,33913212,flow rate,The flow rate was 0.4 mL/min for 5.0 min.,Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913212/),[ml] / [min],0.4,70325,DB00759,Tetracycline
,33913212,intracellular peak concentration,"The uptake study showed that after incubation with tigecycline (1 mg/L) for 3 h at 37°C, the intracellular peak concentration of BEAS-2B cells was 14.44 ± 7.12 mg/L at 1 h, and 41.43 ± 25.66 mg/L in PMNs at 20 min.",Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913212/),[mg] / [l],14.44,70326,DB00759,Tetracycline
,33913212,intracellular peak concentration,"The uptake study showed that after incubation with tigecycline (1 mg/L) for 3 h at 37°C, the intracellular peak concentration of BEAS-2B cells was 14.44 ± 7.12 mg/L at 1 h, and 41.43 ± 25.66 mg/L in PMNs at 20 min.",Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913212/),[mg] / [l],41.43,70327,DB00759,Tetracycline
,33913212,intracellular concentrations,The mean intracellular concentrations fluctuated in the range of 0.8-14.44 mg/L in BEAS-2B cells and 10.14-41.43 mg/L in PMNs for 1 mg/L tigecycline exposure.,Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913212/),[mg] / [l],0.8-14.44,70328,DB00759,Tetracycline
,33913212,intracellular concentrations,The mean intracellular concentrations fluctuated in the range of 0.8-14.44 mg/L in BEAS-2B cells and 10.14-41.43 mg/L in PMNs for 1 mg/L tigecycline exposure.,Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography/tandem mass spectrometry and its application in a cellular pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913212/),[mg] / [l],10.14-41.43,70329,DB00759,Tetracycline
,6649399,Cmax,"The peak OTC concentrations (Cmax) were achieved with the s.c. and i.m. routes between 4 and 8 hours after injection, the highest being found after application in the shoulder (Cmax:6.9 +/- 0.82 microgram/ml plasma).",Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),[μg] / [ml·plasma],6.9,71489,DB00759,Tetracycline
,6649399,Cmax,"The Cmax for the s.c. and other i.m. routes in application was similar to each other, ranging from 5.0 to 5.5 micrograms/ml plasma.",Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),[μg] / [ml·plasma],5.0 to 5.5,71490,DB00759,Tetracycline
,6649399,maximal bioavailability,"At 52 h post injection (p.i.) maximal bioavailability was observed for the i.m. shoulder route, viz. 98.1 +/- 7.0 per cent of the administered dose, while at 76 h p.i. similar bioavailabilities were achieved for the i.m. neck and shoulder route, namely 93.3 +/- 8.9 and 99.4 +/- 4.2 per cent, respectively.",Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),%,98.1,71491,DB00759,Tetracycline
,6649399,bioavailabilities,"At 52 h post injection (p.i.) maximal bioavailability was observed for the i.m. shoulder route, viz. 98.1 +/- 7.0 per cent of the administered dose, while at 76 h p.i. similar bioavailabilities were achieved for the i.m. neck and shoulder route, namely 93.3 +/- 8.9 and 99.4 +/- 4.2 per cent, respectively.",Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),%,93.3,71492,DB00759,Tetracycline
,6649399,bioavailabilities,"At 52 h post injection (p.i.) maximal bioavailability was observed for the i.m. shoulder route, viz. 98.1 +/- 7.0 per cent of the administered dose, while at 76 h p.i. similar bioavailabilities were achieved for the i.m. neck and shoulder route, namely 93.3 +/- 8.9 and 99.4 +/- 4.2 per cent, respectively.",Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),%,99.4,71493,DB00759,Tetracycline
,6649399,bioavailability,The lowest bioavailability (83.1 +/- 13.4 per cent) was obtained following the i.m. buttock route at 76 p.i.,Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649399/),%,83.1,71494,DB00759,Tetracycline
,16343284,plasma concentration at steady-state,"The mean plasma concentration at steady-state was 1.37 +/- 1.21 microg/mL, which was reached at 68 +/- 27.2 h postadministration.",PK and PK/PD of doxycycline in drinking water after therapeutic use in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343284/),[μg] / [ml],1.37,71662,DB00759,Tetracycline
,16343284,Absorption,"Absorption and elimination half-life values were 7.20 +/- 2.42 and 7.01 +/- 2.10 h, respectively.",PK and PK/PD of doxycycline in drinking water after therapeutic use in pigs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343284/),h,7.20,71663,DB00759,Tetracycline
,16343284,elimination half-life,"Absorption and elimination half-life values were 7.20 +/- 2.42 and 7.01 +/- 2.10 h, respectively.",PK and PK/PD of doxycycline in drinking water after therapeutic use in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343284/),h,7.01,71664,DB00759,Tetracycline
,1506072,CPmax,"The CPmax and CPmin of OTC observed at 0.08 and 4 hr in normal goats were respectively 34.50 +/- 1.65 and 1.19 +/- 0.14 micrograms ml-1, while the CPmax and CPmin of OTC in presence of calcium at 0.08 and 8 hr were 20.81 +/- 2.18 and 1.04 +/- 0.05 micrograms ml-1 respectively.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[μg] / [ml],34.50,72610,DB00759,Tetracycline
,1506072,CPmin,"The CPmax and CPmin of OTC observed at 0.08 and 4 hr in normal goats were respectively 34.50 +/- 1.65 and 1.19 +/- 0.14 micrograms ml-1, while the CPmax and CPmin of OTC in presence of calcium at 0.08 and 8 hr were 20.81 +/- 2.18 and 1.04 +/- 0.05 micrograms ml-1 respectively.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[μg] / [ml],1.19,72611,DB00759,Tetracycline
,1506072,CPmax,"The CPmax and CPmin of OTC observed at 0.08 and 4 hr in normal goats were respectively 34.50 +/- 1.65 and 1.19 +/- 0.14 micrograms ml-1, while the CPmax and CPmin of OTC in presence of calcium at 0.08 and 8 hr were 20.81 +/- 2.18 and 1.04 +/- 0.05 micrograms ml-1 respectively.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[μg] / [ml],20.81,72612,DB00759,Tetracycline
,1506072,CPmin,"The CPmax and CPmin of OTC observed at 0.08 and 4 hr in normal goats were respectively 34.50 +/- 1.65 and 1.19 +/- 0.14 micrograms ml-1, while the CPmax and CPmin of OTC in presence of calcium at 0.08 and 8 hr were 20.81 +/- 2.18 and 1.04 +/- 0.05 micrograms ml-1 respectively.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[μg] / [ml],1.04,72613,DB00759,Tetracycline
,1506072,t1/2 (alpha),"Hypercalcemic state in goats increased t1/2 (alpha) (0.19 +/- 0.02 hr), t1/2 (beta) (2.77 +/- 0.03 hr), AUC (37.67 +/- 0.83 micrograms x hr x ml vd (area) (1.07 +/- 0.03 L kg-1) and vd (ss) (0.95 +/- 0.04 L kg-1) values of OTC compared to normal goats.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),h,0.19,72614,DB00759,Tetracycline
,1506072,t1/2 (beta),"Hypercalcemic state in goats increased t1/2 (alpha) (0.19 +/- 0.02 hr), t1/2 (beta) (2.77 +/- 0.03 hr), AUC (37.67 +/- 0.83 micrograms x hr x ml vd (area) (1.07 +/- 0.03 L kg-1) and vd (ss) (0.95 +/- 0.04 L kg-1) values of OTC compared to normal goats.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),h,2.77,72615,DB00759,Tetracycline
,1506072,AUC,"Hypercalcemic state in goats increased t1/2 (alpha) (0.19 +/- 0.02 hr), t1/2 (beta) (2.77 +/- 0.03 hr), AUC (37.67 +/- 0.83 micrograms x hr x ml vd (area) (1.07 +/- 0.03 L kg-1) and vd (ss) (0.95 +/- 0.04 L kg-1) values of OTC compared to normal goats.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),h·ml·μg,37.67,72616,DB00759,Tetracycline
,1506072,vd,"Hypercalcemic state in goats increased t1/2 (alpha) (0.19 +/- 0.02 hr), t1/2 (beta) (2.77 +/- 0.03 hr), AUC (37.67 +/- 0.83 micrograms x hr x ml vd (area) (1.07 +/- 0.03 L kg-1) and vd (ss) (0.95 +/- 0.04 L kg-1) values of OTC compared to normal goats.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[l] / [kg],1.07,72617,DB00759,Tetracycline
,1506072,vd (ss),"Hypercalcemic state in goats increased t1/2 (alpha) (0.19 +/- 0.02 hr), t1/2 (beta) (2.77 +/- 0.03 hr), AUC (37.67 +/- 0.83 micrograms x hr x ml vd (area) (1.07 +/- 0.03 L kg-1) and vd (ss) (0.95 +/- 0.04 L kg-1) values of OTC compared to normal goats.",Pharmacokinetics of oxytetracycline in presence of calcium gluconate in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506072/),[l] / [kg],0.95,72618,DB00759,Tetracycline
,3354235,plasma half-lives,"2. The pharmacokinetics of the intravascularly administered drug using a two-compartment open model revealed plasma half-lives of 1.3 and 16.5 h for the distribution and elimination phases, respectively.",Disposition and bioavailability of 3H-tetracycline in the channel catfish (Ictalurus punctatus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354235/),h,1.3,73378,DB00759,Tetracycline
,3354235,plasma half-lives,"2. The pharmacokinetics of the intravascularly administered drug using a two-compartment open model revealed plasma half-lives of 1.3 and 16.5 h for the distribution and elimination phases, respectively.",Disposition and bioavailability of 3H-tetracycline in the channel catfish (Ictalurus punctatus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354235/),h,16.5,73379,DB00759,Tetracycline
less,3354235,apparent bioavailability,4. The apparent bioavailability of the per os-administered drug was less than 5% and was influenced by the presence of feed material and the dosage.,Disposition and bioavailability of 3H-tetracycline in the channel catfish (Ictalurus punctatus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354235/),%,5,73380,DB00759,Tetracycline
,24611544,maximum plasma concentration (CMAX ),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],1.15,75760,DB00759,Tetracycline
,24611544,area under the curve (AUC),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],8.0,75761,DB00759,Tetracycline
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.33,75762,DB00759,Tetracycline
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],3.0,75763,DB00759,Tetracycline
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.97,75764,DB00759,Tetracycline
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],10.3,75765,DB00759,Tetracycline
,24611544,minimum inhibitory concentration (MIC),A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.25,75766,DB00759,Tetracycline
≥,24611544,AUC:MIC,A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),,33.9,75767,DB00759,Tetracycline
,15732588,maximum plasma concentration,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),[μg] / [ml],6.6,75813,DB00759,Tetracycline
,15732588,terminal phase half-life,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),h,66.1,75814,DB00759,Tetracycline
,15732588,terminal phase half-life,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),[ml] / [h·kg],290.7,75815,DB00759,Tetracycline
,15732588,systemic clearance,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),h,66.1,75816,DB00759,Tetracycline
,15732588,systemic clearance,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),[ml] / [h·kg],290.7,75817,DB00759,Tetracycline
,15732588,apparent volume of distribution at steady state,"For the i.v. route, means for maximum plasma concentration, terminal phase half-life, systemic clearance, and apparent volume of distribution at steady state were 6.6 microg/ml, 66.1 hr, 290.7 ml/hr/kg, and 18.4 L, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),l,18.4,75818,DB00759,Tetracycline
,15732588,systemic availability,"For the i.m. route, means for systemic availability, maximum plasma concentration, and elimination half-life were 91.8%, 1.6 microg/ml, and 61.9 hr, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),%,91.8,75819,DB00759,Tetracycline
,15732588,maximum plasma concentration,"For the i.m. route, means for systemic availability, maximum plasma concentration, and elimination half-life were 91.8%, 1.6 microg/ml, and 61.9 hr, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),[μg] / [ml],1.6,75820,DB00759,Tetracycline
,15732588,elimination half-life,"For the i.m. route, means for systemic availability, maximum plasma concentration, and elimination half-life were 91.8%, 1.6 microg/ml, and 61.9 hr, respectively.",Pharmacokinetics of oxytetracycline in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15732588/),h,61.9,75821,DB00759,Tetracycline
,12926599,protein binding,"Compared with meropenem, doxycycline had higher protein binding (11.87% [previously published value] vs 91.75 +/- 0.63%) and lipophilicity (partition coefficients, 0.02 +/- 0.01 vs 0.68 +/- 0.05).",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),%,11.87,76053,DB00759,Tetracycline
,12926599,protein binding,"Compared with meropenem, doxycycline had higher protein binding (11.87% [previously published value] vs 91.75 +/- 0.63%) and lipophilicity (partition coefficients, 0.02 +/- 0.01 vs 0.68 +/- 0.05).",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),%,91.75,76054,DB00759,Tetracycline
,12926599,partition coefficients,"Compared with meropenem, doxycycline had higher protein binding (11.87% [previously published value] vs 91.75 +/- 0.63%) and lipophilicity (partition coefficients, 0.02 +/- 0.01 vs 0.68 +/- 0.05).",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),,0.02,76055,DB00759,Tetracycline
,12926599,partition coefficients,"Compared with meropenem, doxycycline had higher protein binding (11.87% [previously published value] vs 91.75 +/- 0.63%) and lipophilicity (partition coefficients, 0.02 +/- 0.01 vs 0.68 +/- 0.05).",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),,0.68,76056,DB00759,Tetracycline
,12926599,Plasma half-life,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),h,4.56,76057,DB00759,Tetracycline
,12926599,volume of distribution,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),[l] / [kg],0.65,76058,DB00759,Tetracycline
,12926599,clearance,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),[ml] / [kg·min],1.66,76059,DB00759,Tetracycline
,12926599,clearance,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),h,0.73,76060,DB00759,Tetracycline
,12926599,clearance,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),[l] / [kg],0.34,76061,DB00759,Tetracycline
,12926599,clearance,"Plasma half-life, volume of distribution, and clearance were 4.56 +/- 0.57 hours, 0.65 +/- 0.82 L/kg, and 1.66 +/- 2.21 mL/min/kg, respectively, for doxycycline and 0.73 +/- 0.07 hours, 0.34 +/- 0.06 L/kg, and 5.65 +/- 2.76 mL/min/kg, respectively, for meropenem.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),[ml] / [kg·min],5.65,76062,DB00759,Tetracycline
,12926599,half-life,"The ISF half-life of doxycycline and meropenem was 4.94 +/- 0.67 and 2.31 +/- 0.36 hours, respectively.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),h,4.94,76063,DB00759,Tetracycline
,12926599,half-life,"The ISF half-life of doxycycline and meropenem was 4.94 +/- 0.67 and 2.31 +/- 0.36 hours, respectively.",Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926599/),h,2.31,76064,DB00759,Tetracycline
,29076375,bioavailability,"RESULTS Mean bioavailability of minocycline was 48% (range, 35% to 75%).",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),%,48,77056,DB00759,Tetracycline
,29076375,maximum concentration (Cmax),"At steady state, mean ± SD maximum concentration (Cmax) of minocycline in plasma was 2.3 ± 1.3 μg/mL, and terminal half-life was 11.8 ± 0.5 hours.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],2.3,77057,DB00759,Tetracycline
,29076375,terminal half-life,"At steady state, mean ± SD maximum concentration (Cmax) of minocycline in plasma was 2.3 ± 1.3 μg/mL, and terminal half-life was 11.8 ± 0.5 hours.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,11.8,77058,DB00759,Tetracycline
,29076375,time to Cmax (Tmax),"Median time to Cmax (Tmax) was 1.3 hours (interquartile range [IQR], 1.0 to 1.5 hours).",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,1.3,77059,DB00759,Tetracycline
,29076375,Cmax,"The Cmax and Tmax of minocycline in the PELF were 10.5 ± 12.8 μg/mL and 9.0 hours (IQR, 5.5 to 12.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],10.5,77060,DB00759,Tetracycline
,29076375,Tmax,"The Cmax and Tmax of minocycline in the PELF were 10.5 ± 12.8 μg/mL and 9.0 hours (IQR, 5.5 to 12.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,9.0,77061,DB00759,Tetracycline
,29076375,Cmax,"The Cmax and Tmax for BAL cells were 0.24 ± 0.1 μg/mL and 6.0 hours (IQR, 0 to 6.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],0.24,77062,DB00759,Tetracycline
,29076375,Tmax,"The Cmax and Tmax for BAL cells were 0.24 ± 0.1 μg/mL and 6.0 hours (IQR, 0 to 6.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,6.0,77063,DB00759,Tetracycline
,19139573,Drug,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77364,DB00759,Tetracycline
,19139573,recovery,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77365,DB00759,Tetracycline
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,9.9 to 16.1,77366,DB00759,Tetracycline
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,6.3 to 11.5,77367,DB00759,Tetracycline
,10718653,Recovery,Recovery from plasma or parotid saliva averaged 95%.,High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718653/),%,95,79302,DB00759,Tetracycline
,10718653,percent recovery,"Frozen at -30 degrees C, this drug was stable for at least 2 months, the percent recovery averaged 90%.",High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718653/),%,90,79303,DB00759,Tetracycline
,31185241,area under the curve (AUC),The results of pharmacokinetic studies demonstrated that DAC-OTC exhibited higher area under the curve (AUC) (482.8 μghmL-1) as compared to COTA (90.72 μghmL-1).,Potential of di-aldehyde cellulose for sustained release of oxytetracycline: A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31185241/),1/[μghml],482.8,79545,DB00759,Tetracycline
,31185241,area under the curve (AUC),The results of pharmacokinetic studies demonstrated that DAC-OTC exhibited higher area under the curve (AUC) (482.8 μghmL-1) as compared to COTA (90.72 μghmL-1).,Potential of di-aldehyde cellulose for sustained release of oxytetracycline: A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31185241/),1/[μghml],90.72,79546,DB00759,Tetracycline
,15145972,C(min),"After the last dose, mean (CV) C(min) for plasma bismuth was 2882 pg/mL (36%) and 1195 pg/mL (23%) (p< 0.001), with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],2882,80074,DB00759,Tetracycline
,15145972,C(min),"After the last dose, mean (CV) C(min) for plasma bismuth was 2882 pg/mL (36%) and 1195 pg/mL (23%) (p< 0.001), with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],1195,80075,DB00759,Tetracycline
,15145972,C(max),"Mean (CV) C(max) was 25493 pg/mL (69%) and 8061 pg/mL (28%) (p < 0.001) with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],25493,80076,DB00759,Tetracycline
,15145972,C(max),"Mean (CV) C(max) was 25493 pg/mL (69%) and 8061 pg/mL (28%) (p < 0.001) with and without OM, respectively.","Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145972/),[pg] / [ml],8061,80077,DB00759,Tetracycline
,30637925,limit of detection (LOD),A linear relationship between fluorescence intensity and TIGE concentration was observed over the concentration range 40-500 ng mL-1 with limit of quantification (LOQ) 21.09 ng mL-1 and limit of detection (LOD) 6.96 ng mL-1 .,"Utility of the fluorogenic characters of benzofurazan for analysis of tigecycline using spectrometric technique; application to pharmacokinetic study, urine and pharmaceutical formulations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30637925/),[ng] / [ml],6.96,80506,DB00759,Tetracycline
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],3.28,80932,DB00759,Tetracycline
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],8.49,80933,DB00759,Tetracycline
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],9.13,80934,DB00759,Tetracycline
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,345,80935,DB00759,Tetracycline
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,383,80936,DB00759,Tetracycline
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,428,80937,DB00759,Tetracycline
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,72.9,80938,DB00759,Tetracycline
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,31.3,80939,DB00759,Tetracycline
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,32.5,80940,DB00759,Tetracycline
,26918512,size,"The size, polydispersity index and zeta potential of microparticles were 1.46 ± 0.06 μm, 0.30 ± 0.02 and 1.53 ± 0.04 mV, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),μm,1.46,81000,DB00759,Tetracycline
,26918512,polydispersity index,"The size, polydispersity index and zeta potential of microparticles were 1.46 ± 0.06 μm, 0.30 ± 0.02 and 1.53 ± 0.04 mV, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),mv,0.30,81001,DB00759,Tetracycline
,26918512,zeta potential,"The size, polydispersity index and zeta potential of microparticles were 1.46 ± 0.06 μm, 0.30 ± 0.02 and 1.53 ± 0.04 mV, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),mv,1.53,81002,DB00759,Tetracycline
,26918512,encapsulation efficiency (EE),"The encapsulation efficiency (EE) of DoxHcl and FF was 45.28% ± 3.30% and 89.69% ± 2.71%, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),%,45.28,81003,DB00759,Tetracycline
,26918512,encapsulation efficiency (EE),"The encapsulation efficiency (EE) of DoxHcl and FF was 45.28% ± 3.30% and 89.69% ± 2.71%, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),%,89.69,81004,DB00759,Tetracycline
,26918512,re-dispersed time,The re-dispersed time and sedimentation rate of the suspension were 1 min and 1.,"Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),min,1,81005,DB00759,Tetracycline
,26918512,sedimentation rate,The re-dispersed time and sedimentation rate of the suspension were 1 min and 1.,"Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),,1,81006,DB00759,Tetracycline
,26918512,withdrawal volume,The suspension went through the 9-gage needle smoothly with withdrawal volume of 9.12 ± 0.87 mL/min.,"Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),[ml] / [min],9.12,81007,DB00759,Tetracycline
,26918512,elimination half-life (T½ke),"Compared to the control injection, the suspension increased the elimination half-life (T½ke) as well as mean residence time (MRT) of DoxHcl from 5.73 to 9.77 h and from 12.02 to 18.81 h, and those of FF from 12.02 to 26.19 h and from 12.02 to 28.16 h, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),h,5.73 to 9.77,81008,DB00759,Tetracycline
,26918512,elimination half-life (T½ke),"Compared to the control injection, the suspension increased the elimination half-life (T½ke) as well as mean residence time (MRT) of DoxHcl from 5.73 to 9.77 h and from 12.02 to 18.81 h, and those of FF from 12.02 to 26.19 h and from 12.02 to 28.16 h, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),h,12.02 to 26.19,81009,DB00759,Tetracycline
,26918512,mean residence time (MRT),"Compared to the control injection, the suspension increased the elimination half-life (T½ke) as well as mean residence time (MRT) of DoxHcl from 5.73 to 9.77 h and from 12.02 to 18.81 h, and those of FF from 12.02 to 26.19 h and from 12.02 to 28.16 h, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),h,12.02 to 18.81,81010,DB00759,Tetracycline
,26918512,mean residence time (MRT),"Compared to the control injection, the suspension increased the elimination half-life (T½ke) as well as mean residence time (MRT) of DoxHcl from 5.73 to 9.77 h and from 12.02 to 18.81 h, and those of FF from 12.02 to 26.19 h and from 12.02 to 28.16 h, respectively.","Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-β-cyclodextrin inclusion complexes suspension. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918512/),h,12.02 to 28.16,81011,DB00759,Tetracycline
,31970713,volume of distribution (Vd),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),l,190 to 204,81440,DB00759,Tetracycline
,31970713,terminal elimination half-life (t½),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),h,13.5-17.1,81441,DB00759,Tetracycline
,31970713,total clearance (CLT),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[l] / [h],8.8-10.6,81442,DB00759,Tetracycline
,31970713,protein binding,"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,21.3,81443,DB00759,Tetracycline
,31970713,Oral bioavailability,Oral bioavailability of omadacycline is estimated to be 34.5%.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,34.5,81444,DB00759,Tetracycline
,31970713,maximum plasma concentration (Cmax),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[mg] / [l],0.5-0.6,81445,DB00759,Tetracycline
,31970713,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[h·mg] / [l],9.6-11.9,81446,DB00759,Tetracycline
,2924580,peak concentrations,"Mean peak concentrations (micrograms/ml) of the drugs in control and inflamed joints were, respectively, 8.04 and 8.79 for OTC and 9.35 and 8.92 for PEN.",Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),[μg] / [ml],8.04,82112,DB00759,Tetracycline
,2924580,peak concentrations,"Mean peak concentrations (micrograms/ml) of the drugs in control and inflamed joints were, respectively, 8.04 and 8.79 for OTC and 9.35 and 8.92 for PEN.",Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),[μg] / [ml],8.79,82113,DB00759,Tetracycline
,2924580,peak concentrations,"Mean peak concentrations (micrograms/ml) of the drugs in control and inflamed joints were, respectively, 8.04 and 8.79 for OTC and 9.35 and 8.92 for PEN.",Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),[μg] / [ml],9.35,82114,DB00759,Tetracycline
,2924580,peak concentrations,"Mean peak concentrations (micrograms/ml) of the drugs in control and inflamed joints were, respectively, 8.04 and 8.79 for OTC and 9.35 and 8.92 for PEN.",Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),[μg] / [ml],8.92,82115,DB00759,Tetracycline
,2924580,t1/2 beta,Rates of elimination of OTC and PEN were similar in joint fluid and serum; t1/2 beta ranged from 11.83-19.81 h for OTC and 0.980-1.125 h for PEN.,Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),h,11.83-19.81,82116,DB00759,Tetracycline
,2924580,t1/2 beta,Rates of elimination of OTC and PEN were similar in joint fluid and serum; t1/2 beta ranged from 11.83-19.81 h for OTC and 0.980-1.125 h for PEN.,Effect of experimental synovitis on disposition of penicillin and oxytetracycline in neonatal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924580/),h,0.980-1.125,82117,DB00759,Tetracycline
,32284378,MIC,"These five isolates, for which MIC values were 1 or 2 mg/liter, were exposed to omadacycline total-drug epithelial lining fluid (ELF) concentration-time profiles based on those observed in healthy volunteers following intravenous omadacycline administration.",Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32284378/),[mg] / [l],1,83417,DB00759,Tetracycline
,32284378,MIC,"These five isolates, for which MIC values were 1 or 2 mg/liter, were exposed to omadacycline total-drug epithelial lining fluid (ELF) concentration-time profiles based on those observed in healthy volunteers following intravenous omadacycline administration.",Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32284378/),[mg] / [l],2,83418,DB00759,Tetracycline
,32284378,AUC/MIC ratios,"The median total-drug ELF AUC/MIC ratios associated with net bacterial stasis and 1- and 2-log10 CFU/ml reductions from baseline at 24 h were 6.91, 8.91, and 11.1, respectively.",Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32284378/),,6.91,83419,DB00759,Tetracycline
,32284378,AUC/MIC ratios,"The median total-drug ELF AUC/MIC ratios associated with net bacterial stasis and 1- and 2-log10 CFU/ml reductions from baseline at 24 h were 6.91, 8.91, and 11.1, respectively.",Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32284378/),,8.91,83420,DB00759,Tetracycline
,32284378,AUC/MIC ratios,"The median total-drug ELF AUC/MIC ratios associated with net bacterial stasis and 1- and 2-log10 CFU/ml reductions from baseline at 24 h were 6.91, 8.91, and 11.1, respectively.",Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32284378/),,11.1,83421,DB00759,Tetracycline
,837772,lung/serum ratio,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,2.2,83781,DB00759,Tetracycline
,837772,lung/serum ratio,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,0.5,83782,DB00759,Tetracycline
,837772,lung/serum ratio,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,1.1,83783,DB00759,Tetracycline
,837772,muscle/serum,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,2.3,83784,DB00759,Tetracycline
,837772,muscle/serum,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,0.2,83785,DB00759,Tetracycline
,837772,muscle/serum,"Compared to serum levels, lung, muscle, heart, testicle and spleen, levels are higher for doycycline, lower for ampicillin and variable for cephalothin: for example, lung/serum ratio at 1 h is 2.2, 0.5 and 1.1, respectively; muscle/serum is 2.3, 0.2 and 0.18.","Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837772/),,0.18,83786,DB00759,Tetracycline
≥,22143524,fAUC(0-24):MIC ratios,The odds of clinical success were 13.0 times higher for every 1-g/dl increase in albumin (P < 0.001) and 8.42 times higher for patients with fAUC(0-24):MIC ratios of ≥0.9 compared to patients with fAUC(0-24):MIC ratios of <0.9 (P = 0.008).,Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),,0.9,83894,DB00759,Tetracycline
<,22143524,fAUC(0-24):MIC ratios,The odds of clinical success were 13.0 times higher for every 1-g/dl increase in albumin (P < 0.001) and 8.42 times higher for patients with fAUC(0-24):MIC ratios of ≥0.9 compared to patients with fAUC(0-24):MIC ratios of <0.9 (P = 0.008).,Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),,0.9,83895,DB00759,Tetracycline
,22143524,MIC(50),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],0.5,83896,DB00759,Tetracycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],0.25,83897,DB00759,Tetracycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],16,83898,DB00759,Tetracycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],1,83899,DB00759,Tetracycline
≤,32975650,MIC,"Food and Drug Administration minimum inhibitory concentration (MIC) tigecycline breakpoints for susceptible (MIC ≤ 2 μg/mL), intermediate (MIC 4 μg/mL), and resistant (MIC ≥ 8 μg/mL) Enterobacteriaceae were used.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],2,85638,DB00759,Tetracycline
,32975650,MIC,"Food and Drug Administration minimum inhibitory concentration (MIC) tigecycline breakpoints for susceptible (MIC ≤ 2 μg/mL), intermediate (MIC 4 μg/mL), and resistant (MIC ≥ 8 μg/mL) Enterobacteriaceae were used.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],4,85639,DB00759,Tetracycline
≥,32975650,MIC,"Food and Drug Administration minimum inhibitory concentration (MIC) tigecycline breakpoints for susceptible (MIC ≤ 2 μg/mL), intermediate (MIC 4 μg/mL), and resistant (MIC ≥ 8 μg/mL) Enterobacteriaceae were used.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],8,85640,DB00759,Tetracycline
≥,32975650,MIC ratios,"MCS probability distributions for PK-PD target attainment of AUC for total tigecycline plasma concentration from 0 to 24 h following an intravenous dose (AUCtotal, 0-24h) to MIC ratios of ≥ 18, 7, and 4.5 were generated, with success defined as ≥ 80% probability of target attainment at a given MIC.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,18,85641,DB00759,Tetracycline
≥,32975650,MIC ratios,"MCS probability distributions for PK-PD target attainment of AUC for total tigecycline plasma concentration from 0 to 24 h following an intravenous dose (AUCtotal, 0-24h) to MIC ratios of ≥ 18, 7, and 4.5 were generated, with success defined as ≥ 80% probability of target attainment at a given MIC.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,7,85642,DB00759,Tetracycline
≥,32975650,MIC ratios,"MCS probability distributions for PK-PD target attainment of AUC for total tigecycline plasma concentration from 0 to 24 h following an intravenous dose (AUCtotal, 0-24h) to MIC ratios of ≥ 18, 7, and 4.5 were generated, with success defined as ≥ 80% probability of target attainment at a given MIC.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,4.5,85643,DB00759,Tetracycline
,32975650,MIC,"Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],0.48,85644,DB00759,Tetracycline
,32975650,MIC,"Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],1,85645,DB00759,Tetracycline
,32975650,MIC,"Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],2,85646,DB00759,Tetracycline
,32975650,"AUCtotal, 0-24h/MIC target attainment","Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,18,85647,DB00759,Tetracycline
,32975650,"AUCtotal, 0-24h/MIC target attainment","Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,7,85648,DB00759,Tetracycline
,32975650,"AUCtotal, 0-24h/MIC target attainment","Tigecycline 150 mg IV q12h for ward patients with resistant bacteria up to a MIC of 0.48, 1, and 2 μg/mL for an AUCtotal, 0-24h/MIC target attainment of 18, 7, and 4.5, respectively, may be appropriate.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),,4.5,85649,DB00759,Tetracycline
≥,32975650,MICs,"Bacterial infections with tigecycline MICs ≥ 0.48-2 μg/mL, depending on AUCtotal, 0-24h/MIC target, may require treatment with alternate antibiotics due to target attainment failure.",Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32975650/),[μg] / [ml],0.48-2,85650,DB00759,Tetracycline
,25851119,Oral bioavailability,Oral bioavailability was approximately 62%.,Pharmacokinetics of minocycline in domestic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,62,87182,DB00759,Tetracycline
,25851119,Plasma protein binding,Plasma protein binding was 60% at 5 µg/ml and 46% at 1 μg/ml.,Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,60,87183,DB00759,Tetracycline
,25851119,Plasma protein binding,Plasma protein binding was 60% at 5 µg/ml and 46% at 1 μg/ml.,Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,46,87184,DB00759,Tetracycline
,25851119,elimination half-life (t(½)),"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),h,6.7,87185,DB00759,Tetracycline
,25851119,apparent volume of distribution at steady-state,"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[l] / [kg],1.5,87186,DB00759,Tetracycline
,25851119,systemic clearance,"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[ml] / [kg·min],2.9,87187,DB00759,Tetracycline
,25851119,terminal t(½),"After oral administration the terminal t(½) and peak concentration (Cmax) were 6.3 h (CV 9%) and 4.77 µg/ml (CV 36%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),h,6.3,87188,DB00759,Tetracycline
,25851119,peak concentration (Cmax),"After oral administration the terminal t(½) and peak concentration (Cmax) were 6.3 h (CV 9%) and 4.77 µg/ml (CV 36%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[μg] / [ml],4.77,87189,DB00759,Tetracycline
,25851119,minimum inhibitory concentration,"Because most bacteria will have a minimum inhibitory concentration of ⩽0.5 μg/ml, an oral dose of 8.8 mg/kg q24h would be adequate to meet pharmacokinetic-pharmacodynamic targets after adjusting for protein binding.",Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[μg] / [ml],⩽0.5,87190,DB00759,Tetracycline
,17720208,bioavailability,DOX-h-LA showed the greatest values for bioavailability (602%); maximum serum concentration (C(max)) value was 1.99microg/mL with a time to reach C(max) (T(max)) of 25h and an elimination half-life of 40.81h.,Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17720208/),%,602,90340,DB00759,Tetracycline
,17720208,maximum serum concentration (C(max)),DOX-h-LA showed the greatest values for bioavailability (602%); maximum serum concentration (C(max)) value was 1.99microg/mL with a time to reach C(max) (T(max)) of 25h and an elimination half-life of 40.81h.,Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17720208/),[μg] / [ml],1.99,90341,DB00759,Tetracycline
,17720208,time to reach C(max) (T(max)),DOX-h-LA showed the greatest values for bioavailability (602%); maximum serum concentration (C(max)) value was 1.99microg/mL with a time to reach C(max) (T(max)) of 25h and an elimination half-life of 40.81h.,Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17720208/),h,25,90342,DB00759,Tetracycline
,17720208,elimination half-life,DOX-h-LA showed the greatest values for bioavailability (602%); maximum serum concentration (C(max)) value was 1.99microg/mL with a time to reach C(max) (T(max)) of 25h and an elimination half-life of 40.81h.,Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17720208/),h,40.81,90343,DB00759,Tetracycline
,17720208,minimum effective serum concentration,"Considering minimum effective serum concentration of 0.5microg/mL a dose-interval of 80h can be achieved for DOX-h-LA, and only 9.7h and 17h after the i.v. or i.m. administration of DOX-h, respectively.",Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17720208/),[μg] / [ml],0.5,90344,DB00759,Tetracycline
,25131164,observed maximum CTC concentrations (Cmax ),Mean observed maximum CTC concentrations (Cmax ) were 20.0 ng/mL (80 mg dose) and 101 ng/mL (500 mg dose).,Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131164/),[ng] / [ml],20.0,90567,DB00759,Tetracycline
,25131164,observed maximum CTC concentrations (Cmax ),Mean observed maximum CTC concentrations (Cmax ) were 20.0 ng/mL (80 mg dose) and 101 ng/mL (500 mg dose).,Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131164/),[ng] / [ml],101,90568,DB00759,Tetracycline
,25131164,apparent elimination half-life,Mean apparent elimination half-life was 18 h (80 mg dose) and 20 h (500 mg dose).,Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131164/),h,18,90569,DB00759,Tetracycline
,25131164,apparent elimination half-life,Mean apparent elimination half-life was 18 h (80 mg dose) and 20 h (500 mg dose).,Pharmacokinetics of oral chlortetracycline in nonpregnant adult ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25131164/),h,20,90570,DB00759,Tetracycline
,7199309,absorption,The absorption of doxycycline administered p.o. was about 92% and seemed not to be influenced by food in the stomach.,Comparison of distribution of doxycycline in mice after oral and intravenous application measured by a high-performance liquid chromatographic method. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199309/),%,92,91542,DB00759,Tetracycline
,7199309,elimination half-life,The elimination half-life in mice was 170 min independent of the route of administration.,Comparison of distribution of doxycycline in mice after oral and intravenous application measured by a high-performance liquid chromatographic method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199309/),min,170,91543,DB00759,Tetracycline
,22595330,elimination half-lives,Mean elimination half-lives in plasma were 7.96 and 13.15 h after IV and multiple oral administration.,"Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595330/),h,7.96,91855,DB00759,Tetracycline
,22595330,elimination half-lives,Mean elimination half-lives in plasma were 7.96 and 13.15 h after IV and multiple oral administration.,"Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595330/),h,13.15,91856,DB00759,Tetracycline
,22595330,Maximum plasma concentration,Maximum plasma concentration was 4.33 μg/ml and the interval from oral administration until maximal concentration was 1.79 h.,"Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595330/),[μg] / [ml],4.33,91857,DB00759,Tetracycline
,22595330,Oral bioavailability,Oral bioavailability was 17.76%.,"Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595330/),%,17.76,91858,DB00759,Tetracycline
,23415880,Cmax/MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),,5.13,93873,DB00759,Tetracycline
,23415880,T>MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,49.3,93874,DB00759,Tetracycline
,23415880,AUC(96h)/MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,126.6,93875,DB00759,Tetracycline
,23415880,Cmax/MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),,0.277,93876,DB00759,Tetracycline
,23415880,T>MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,0,93877,DB00759,Tetracycline
,23415880,AUC(96h)/MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,6.84,93878,DB00759,Tetracycline
,22249106,C(max),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[ng] / [ml],1899,94328,DB00759,Tetracycline
,22249106,T(max),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),h,0.56,94329,DB00759,Tetracycline
,22249106,AUC,"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[h·ng] / [ml],2833,94330,DB00759,Tetracycline
,22249106,weight-normalized clearance,"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[l] / [h·kg],0.503,94331,DB00759,Tetracycline
,22249106,Vd(ss),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[l] / [kg],4.88,94332,DB00759,Tetracycline
,22249106,Overall clinical cure rates,"Overall clinical cure rates at test-of-cure were 94% (16/17), 76% (16/21), and 75% (15/20) in the 0.75-, 1-, and 1.25-mg/kg cohorts, respectively.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),%,94,94333,DB00759,Tetracycline
,22249106,Overall clinical cure rates,"Overall clinical cure rates at test-of-cure were 94% (16/17), 76% (16/21), and 75% (15/20) in the 0.75-, 1-, and 1.25-mg/kg cohorts, respectively.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),%,76,94334,DB00759,Tetracycline
,15885987,C(max),"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.72,94708,DB00759,Tetracycline
,15885987,C(max),"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.37,94709,DB00759,Tetracycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],1.73,94710,DB00759,Tetracycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.37,94711,DB00759,Tetracycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],2.28,94712,DB00759,Tetracycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],15.2,94713,DB00759,Tetracycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,15.0,94714,DB00759,Tetracycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,39.1,94715,DB00759,Tetracycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],15.2,94716,DB00759,Tetracycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],134,94717,DB00759,Tetracycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,23.7,94718,DB00759,Tetracycline
,15885987,C(max)/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,30.4,94719,DB00759,Tetracycline
,15885987,C(max)/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,507,94720,DB00759,Tetracycline
,15885987,AUC/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,268,94721,DB00759,Tetracycline
,15885987,AUC/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,4467,94722,DB00759,Tetracycline
<,11393692,run time,The method is fast (single liquid extraction and run time of <3 min) and sensitive (5 ng/ml) and it was employed in a bioequivalence study of two 100 mg tablet formulations in 24 healthy volunteers.,Determination of minocycline in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393692/),min,3,95184,DB00759,Tetracycline
,9266665,maximum serum concentrations (Cmax),"The maximum serum concentrations (Cmax) of doxycycline were lower in pneumonic goats than in healthy goats (3.87 +/- 0.52 and 5.56 +/- 0.213 micrograms/ml, respectively), suggesting an increased distribution volume in the peripheral compartment.",Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),[μg] / [ml],3.87,97920,DB00759,Tetracycline
,9266665,maximum serum concentrations (Cmax),"The maximum serum concentrations (Cmax) of doxycycline were lower in pneumonic goats than in healthy goats (3.87 +/- 0.52 and 5.56 +/- 0.213 micrograms/ml, respectively), suggesting an increased distribution volume in the peripheral compartment.",Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),[μg] / [ml],5.56,97921,DB00759,Tetracycline
,9266665,absorption rate (ka),"The mean +/- SEM absorption rate (ka) before infection (1.13 +/- 0.02 h-1) was smaller than the after infection (8.23 +/- 3.81 h-1), but the difference was not significant.",Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),1/[h],1.13,97922,DB00759,Tetracycline
,9266665,absorption rate (ka),"The mean +/- SEM absorption rate (ka) before infection (1.13 +/- 0.02 h-1) was smaller than the after infection (8.23 +/- 3.81 h-1), but the difference was not significant.",Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),1/[h],8.23,97923,DB00759,Tetracycline
,9266665,apparent elimination half-life (t 1/2 beta),"The apparent elimination half-life (t 1/2 beta) (24.51 +/- 0.02 h) after infection was significantly increased (p < 0.05), while the corresponding rate constant (beta) was decreased (p < 0.01).",Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),h,24.51,97924,DB00759,Tetracycline
,9266665,absorption half-life (t 1/2(alpha)),The absorption half-life (t 1/2(alpha)) (0.137 +/- 0.03 h) was significantly decreased (p < 0.01) after infection.,Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266665/),h,0.137,97925,DB00759,Tetracycline
,3349401,0 intercept beta curve B,"Mean serum pharmacokinetic parameters following intravenous administration were; 0 intercept beta curve B (microgram/mL) = 7.5, rate of elimination from body -b (min-1) = 0.0058, half life elimination from body -t 1/2 b (min) = 120.0, wt(kg) = 3.2 determined using combined male and female data.",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),[μg] / [ml],7.5,98355,DB00759,Tetracycline
,3349401,rate of elimination from body -b,"Mean serum pharmacokinetic parameters following intravenous administration were; 0 intercept beta curve B (microgram/mL) = 7.5, rate of elimination from body -b (min-1) = 0.0058, half life elimination from body -t 1/2 b (min) = 120.0, wt(kg) = 3.2 determined using combined male and female data.",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),1/[min],0.005,98356,DB00759,Tetracycline
,3349401,half life elimination from body -t 1/2 b,"Mean serum pharmacokinetic parameters following intravenous administration were; 0 intercept beta curve B (microgram/mL) = 7.5, rate of elimination from body -b (min-1) = 0.0058, half life elimination from body -t 1/2 b (min) = 120.0, wt(kg) = 3.2 determined using combined male and female data.",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),min,120.0,98357,DB00759,Tetracycline
,3349401,w,"Mean serum pharmacokinetic parameters following intravenous administration were; 0 intercept beta curve B (microgram/mL) = 7.5, rate of elimination from body -b (min-1) = 0.0058, half life elimination from body -t 1/2 b (min) = 120.0, wt(kg) = 3.2 determined using combined male and female data.",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),,3.2,98358,DB00759,Tetracycline
,3349401,-B,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),[μg] / [ml],1.54,98359,DB00759,Tetracycline
,3349401,-B,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),[μg] / [ml],2.71,98360,DB00759,Tetracycline
,3349401,b(,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),,0.0037,98361,DB00759,Tetracycline
,3349401,b(,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),,0.0035,98362,DB00759,Tetracycline
,3349401,t 1/2 b,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),min,190.3,98363,DB00759,Tetracycline
,3349401,t 1/2 b,"Mean serum pharmacokinetic parameters after oral administration (single bolus) were -B (microgram/mL) = 1.54 (full stomach) and 2.71 (empty stomach), b(min-1) = 0.0037 (full stomach) and 0.0035 (empty stomach), t 1/2 b (min) = 190.3 (full stomach) and 216.2 (empty stomach).",Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349401/),min,216.2,98364,DB00759,Tetracycline
,19648505,concentrations at steady state,"Plasma tetracycline concentrations at steady state were 0, 0.33, 0.47, and 0.77 microg/mL for 0-, 125-, 250-, and 500-mg/L exposures, respectively.",Pharmacology of tetracycline water medication in swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648505/),[μg] / [ml],0,98409,DB00759,Tetracycline
,19648505,concentrations at steady state,"Plasma tetracycline concentrations at steady state were 0, 0.33, 0.47, and 0.77 microg/mL for 0-, 125-, 250-, and 500-mg/L exposures, respectively.",Pharmacology of tetracycline water medication in swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648505/),[μg] / [ml],0.33,98410,DB00759,Tetracycline
,19648505,concentrations at steady state,"Plasma tetracycline concentrations at steady state were 0, 0.33, 0.47, and 0.77 microg/mL for 0-, 125-, 250-, and 500-mg/L exposures, respectively.",Pharmacology of tetracycline water medication in swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648505/),[μg] / [ml],0.47,98411,DB00759,Tetracycline
,19648505,concentrations at steady state,"Plasma tetracycline concentrations at steady state were 0, 0.33, 0.47, and 0.77 microg/mL for 0-, 125-, 250-, and 500-mg/L exposures, respectively.",Pharmacology of tetracycline water medication in swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648505/),[μg] / [ml],0.77,98412,DB00759,Tetracycline
,24243316,maximum concentration,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[ng] / [ml],"1,118",98451,DB00759,Tetracycline
,24243316,area under the concentration-time curve 0-12 hours,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[h·ng] / [ml],"3,261",98452,DB00759,Tetracycline
,24243316,clearance,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[l] / [h·kg],0.25,98453,DB00759,Tetracycline
,24243316,half-life,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),h,60.7,98454,DB00759,Tetracycline
,24243316,volume of distribution,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[l] / [kg],11.9,98455,DB00759,Tetracycline
,1771646,volume of distribution,"In the absence of doxycycline, the volume of distribution of quinine (mean +/- SD) was estimated to be 1.32 +/- 0.32 L/kg, and its clearance was 0.125 +/- 0.47 L/h/kg, which was only in partial agreement with previously published data.",Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771646/),[l] / [kg],1.32,98561,DB00759,Tetracycline
,1771646,clearance,"In the absence of doxycycline, the volume of distribution of quinine (mean +/- SD) was estimated to be 1.32 +/- 0.32 L/kg, and its clearance was 0.125 +/- 0.47 L/h/kg, which was only in partial agreement with previously published data.",Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771646/),[l] / [h·kg],0.125,98562,DB00759,Tetracycline
,31548185,clearance,We developed a 1 compartment PK model and found doxycycline clearance to be 3.32 L/h/70 kg and volume to be 96.8 L/70kg for all patients; comparable to values reported in adults.,Population Pharmacokinetics of Doxycycline in Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31548185/),[l] / [70·h·kg],3.32,99955,DB00759,Tetracycline
,31548185,volume,We developed a 1 compartment PK model and found doxycycline clearance to be 3.32 L/h/70 kg and volume to be 96.8 L/70kg for all patients; comparable to values reported in adults.,Population Pharmacokinetics of Doxycycline in Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31548185/),[l] / [70kg],96.8,99956,DB00759,Tetracycline
,31548185,bioavailability,"We estimated a bioavailability of 89.6%, also consistent with adult data.",Population Pharmacokinetics of Doxycycline in Children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31548185/),%,89.6,99957,DB00759,Tetracycline
,23403419,maximum concentration of drug in serum (C(max)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[ng] / [ml],432,101692,DB00759,Tetracycline
,23403419,area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[h·ng] / [ml],"2,366",101693,DB00759,Tetracycline
,23403419,clearance (CL),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[l] / [h],21.1,101694,DB00759,Tetracycline
,23403419,volume of distribution at steady state (V(ss)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),l,610,101695,DB00759,Tetracycline
,23403419,terminal half-life (t(1/2)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),h,22.1,101696,DB00759,Tetracycline
,33294925,fAUC/MIC ratios,Exposure experiments with fAUC/MIC ratios ranging from 0 to 1200 were performed using five strains of E. coli and five strains of A. baumannii.,In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,0 to 1200,102093,DB00759,Tetracycline
,33294925,fAUC/MIC,"The fAUC/MIC targets against E. coli for 24 h static and -1 log reduction in load were 25.3 ± 17.2 and 42.7 ± 32.5, respectively.",In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,25.3,102094,DB00759,Tetracycline
,33294925,fAUC/MIC,"The fAUC/MIC targets against E. coli for 24 h static and -1 log reduction in load were 25.3 ± 17.2 and 42.7 ± 32.5, respectively.",In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,42.7,102095,DB00759,Tetracycline
,33294925,fAUC/MIC,For A. baumannii the fAUC/MIC for 24 h static effect was 108.1 ± 38.6.,In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,108.1,102096,DB00759,Tetracycline
≤,33294925,fAUC/MIC ratios,Changes in population profiles were observed for E. coli at fAUC/MIC ratios of ≤200 and for A. baumannii up to 1200.,In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,200,102097,DB00759,Tetracycline
up to,33294925,fAUC/MIC ratios,Changes in population profiles were observed for E. coli at fAUC/MIC ratios of ≤200 and for A. baumannii up to 1200.,In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33294925/),,1200,102098,DB00759,Tetracycline
,3184852,half-life of the distribution phase,"The half-life of the distribution phase was 0.097 hours, the rapid elimination half-life was 3.74 hours and the slow elimination half-life was 27.26 hours.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,0.097,103647,DB00759,Tetracycline
,3184852,rapid elimination half-life,"The half-life of the distribution phase was 0.097 hours, the rapid elimination half-life was 3.74 hours and the slow elimination half-life was 27.26 hours.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,3.74,103648,DB00759,Tetracycline
,3184852,slow elimination half-life,"The half-life of the distribution phase was 0.097 hours, the rapid elimination half-life was 3.74 hours and the slow elimination half-life was 27.26 hours.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,27.26,103649,DB00759,Tetracycline
,3184852,elimination half-life,"Subcutaneous and intramuscular injection resulted in a rapid elimination half-life of 6.09 and 6.02 hours, respectively.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,6.09,103650,DB00759,Tetracycline
,3184852,elimination half-life,"Subcutaneous and intramuscular injection resulted in a rapid elimination half-life of 6.09 and 6.02 hours, respectively.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,6.02,103651,DB00759,Tetracycline
,3184852,elimination half-life,"In comparison, a standard form of oxytetracycline given subcutaneously had a rapid elimination half-life of 4.22 hours.",Pharmacokinetics of long acting oxytetracycline in the laboratory rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184852/),h,4.22,103652,DB00759,Tetracycline
,32858577,Cmin,The Cmin of tigecycline was 417.1 ± 263.8 ng/mL (mean ± SD).,Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858577/),[ng] / [ml],417.1,104600,DB00759,Tetracycline
,32858577,Cmin,Cmin can be a useful predictor of hepatotoxicity with a cut-off of 474.8 ng/mL.,Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858577/),ng,474.8,104601,DB00759,Tetracycline
,11549049,Vss,Estimates of kinetic variables following IV administration were: Vss= 400.0+/-120.0 mL/kg and CL= 110.0+/-14.0 (mL/h)/kg.,Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),[ml] / [kg],400.0,105089,DB00759,Tetracycline
,11549049,CL,Estimates of kinetic variables following IV administration were: Vss= 400.0+/-120.0 mL/kg and CL= 110.0+/-14.0 (mL/h)/kg.,Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),[ml] / [h)·kg],110.0,105090,DB00759,Tetracycline
,11549049,t(fi),"The t(fi) for IV= 3.0+/-0.3 h; IM, CF = 10.5+/-2.1 h and IM, LA = 15.1+/-3.1 h.",Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),h,3.0,105091,DB00759,Tetracycline
,11549049,t(fi),"The t(fi) for IV= 3.0+/-0.3 h; IM, CF = 10.5+/-2.1 h and IM, LA = 15.1+/-3.1 h.",Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),h,10.5,105092,DB00759,Tetracycline
,11549049,t(fi),"The t(fi) for IV= 3.0+/-0.3 h; IM, CF = 10.5+/-2.1 h and IM, LA = 15.1+/-3.1 h.",Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),h,15.1,105093,DB00759,Tetracycline
,11549049,penetration,The concentration of OTC in milk at 48 h was: IV= 0.6+/-0.4; IM CF= 1.1+/-0.2 and at 72 h (IM LA)= 0.6+/-0.1 microg/mL and the penetration in milk of OTC was: IV= 70.0+/-18.0; IM CF= 79.0+/-14.0 and IM LA= 66.0+/-6.0%.,Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),%,70.0,105094,DB00759,Tetracycline
,11549049,penetration,The concentration of OTC in milk at 48 h was: IV= 0.6+/-0.4; IM CF= 1.1+/-0.2 and at 72 h (IM LA)= 0.6+/-0.1 microg/mL and the penetration in milk of OTC was: IV= 70.0+/-18.0; IM CF= 79.0+/-14.0 and IM LA= 66.0+/-6.0%.,Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),%,79.0,105095,DB00759,Tetracycline
,11549049,penetration,The concentration of OTC in milk at 48 h was: IV= 0.6+/-0.4; IM CF= 1.1+/-0.2 and at 72 h (IM LA)= 0.6+/-0.1 microg/mL and the penetration in milk of OTC was: IV= 70.0+/-18.0; IM CF= 79.0+/-14.0 and IM LA= 66.0+/-6.0%.,Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),%,66.0,105096,DB00759,Tetracycline
,11549049,bioavailability,"Finally, the bioavailability of OTC CF = 92.0+/-22.0 and LA= 78.0+/-23.0% was suitable for its usage by the IM route in lactating goats.",Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),%,92.0,105097,DB00759,Tetracycline
,11549049,bioavailability,"Finally, the bioavailability of OTC CF = 92.0+/-22.0 and LA= 78.0+/-23.0% was suitable for its usage by the IM route in lactating goats.",Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549049/),%,78.0,105098,DB00759,Tetracycline
,28696233,area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24),"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],17.23,106328,DB00759,Tetracycline
,28696233,area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24),"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),,1,106329,DB00759,Tetracycline
,28696233,ratio,"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],17.23,106330,DB00759,Tetracycline
,28696233,ratio,"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),,1,106331,DB00759,Tetracycline
,28696233,AUC0-24,"The AUC0-24 value in AC was 302.46 mg · h/liter, and the ratio of the AC to total plasma omadacycline concentration was 25.8.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],302.46,106332,DB00759,Tetracycline
,28696233,AUC from time zero to 12 h postdosing (AUC0-12),"In comparison, the values of the AUC from time zero to 12 h postdosing (AUC0-12) based on the mean concentrations of tigecycline in ELF and AC were 3.16 and 38.50 mg · h/liter, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],3.16,106333,DB00759,Tetracycline
,28696233,AUC from time zero to 12 h postdosing (AUC0-12),"In comparison, the values of the AUC from time zero to 12 h postdosing (AUC0-12) based on the mean concentrations of tigecycline in ELF and AC were 3.16 and 38.50 mg · h/liter, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],38.50,106334,DB00759,Tetracycline
,33066989,Cmax,The Cmax of MINO with 1.79 and 2.63 μg mL-1 was obtained at 2.96 and 1.41 h in TCF (tissue cage fluid) and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],1.79,107585,DB00759,Tetracycline
,33066989,Cmax,The Cmax of MINO with 1.79 and 2.63 μg mL-1 was obtained at 2.96 and 1.41 h in TCF (tissue cage fluid) and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],2.63,107586,DB00759,Tetracycline
,33066989,absorption half-lives (t1/2ka),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,0.71,107587,DB00759,Tetracycline
,33066989,absorption half-lives (t1/2ka),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,0.32,107588,DB00759,Tetracycline
,33066989,elimination half-lives (t1/2ke),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,10.46,107589,DB00759,Tetracycline
,33066989,elimination half-lives (t1/2ke),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,5.95,107590,DB00759,Tetracycline
,33066989,distribution volume (Vd/F),The distribution volume (Vd/F) of MINO was estimated to be 1.84 L kg-1 in TCF and 1.28 L kg-1 in plasma.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [kg],1.84,107591,DB00759,Tetracycline
,33066989,distribution volume (Vd/F),The distribution volume (Vd/F) of MINO was estimated to be 1.84 L kg-1 in TCF and 1.28 L kg-1 in plasma.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [kg],1.28,107592,DB00759,Tetracycline
,33066989,total clearance (CLb/F),The total clearance (CLb/F) of MINO was computed as 0.12 and 0.15 L/ (h·kg) in TCF and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [h·kg],0.12,107593,DB00759,Tetracycline
,33066989,total clearance (CLb/F),The total clearance (CLb/F) of MINO was computed as 0.12 and 0.15 L/ (h·kg) in TCF and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [h·kg],0.15,107594,DB00759,Tetracycline
,33066989,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of MINO was 32.77 μg mL-1h in TCF and 25.27 μg mL-1h in plasma, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],32.77,107595,DB00759,Tetracycline
,33066989,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of MINO was 32.77 μg mL-1h in TCF and 25.27 μg mL-1h in plasma, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],25.27,107596,DB00759,Tetracycline
,33066989,MIC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.08,107597,DB00759,Tetracycline
,33066989,MIC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.04,107598,DB00759,Tetracycline
,33066989,MBC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.16,107599,DB00759,Tetracycline
,33066989,MBC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.08,107600,DB00759,Tetracycline
,33066989,plasma,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,32.88,107601,DB00759,Tetracycline
,33066989,Cmax/MIC,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,32.88,107602,DB00759,Tetracycline
,33066989,AUC/MIC,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,315.88,107603,DB00759,Tetracycline
,33066989,Cmax/MIC,"The TCF Cmax/MIC and AUC/MIC values after IM administration were 44.75 ± 9.32 and 819.25 ± 65.23 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,44.75,107604,DB00759,Tetracycline
,33066989,AUC/MIC,"The TCF Cmax/MIC and AUC/MIC values after IM administration were 44.75 ± 9.32 and 819.25 ± 65.23 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,819.25,107605,DB00759,Tetracycline
>,33066989,T > MIC,The values of T > MIC were approximately >36 h in plasma and > 65 h in TCF.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,36,107606,DB00759,Tetracycline
>,33066989,T > MIC,The values of T > MIC were approximately >36 h in plasma and > 65 h in TCF.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,65,107607,DB00759,Tetracycline
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,156,109115,DB00759,Tetracycline
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,227,109116,DB00759,Tetracycline
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,13,109117,DB00759,Tetracycline
,28339766,Bioavailability,"Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and 13% and 23% for doxy-ref, on the same days.",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),%,23,109118,DB00759,Tetracycline
,28339766,MRT,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,26,109119,DB00759,Tetracycline
,28339766,MRT,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,5.2,109120,DB00759,Tetracycline
,28339766,T½β,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,18,109121,DB00759,Tetracycline
,28339766,T½β,"Mean residence time (MRT) and elimination half-life (T½β) were statistically different (P < 0.05) in doxy-FOLA group as compared to doxy-ref group (MRT: 26 h and 5.2 h; and T½β: 18 h vs 3 h, on the first day for doxy-FOLA and doxy-ref, respectively).",Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28339766/),h,3,109122,DB00759,Tetracycline
,6838280,t 1/2 alpha,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,0.12,109451,DB00759,Tetracycline
,6838280,t 1/2 alpha,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,0.28,109452,DB00759,Tetracycline
,6838280,t 1/2 alpha,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,1.48,109453,DB00759,Tetracycline
,6838280,t 1/2 alpha,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,0.17,109454,DB00759,Tetracycline
,6838280,t 1/2 beta,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,1.09,109455,DB00759,Tetracycline
,6838280,t 1/2 beta,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,8.28,109456,DB00759,Tetracycline
,6838280,t 1/2 beta,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,6.20,109457,DB00759,Tetracycline
,6838280,t 1/2 beta,"The highest serum concentrations were reached after 0.42, 1.44, 4.02 and 0.94 hr for P, S, C, and O respectively with corresponding t 1/2 alpha values of 0.12, 0.28, 1.48 and 0.17 hr and t 1/2 beta values of 1.09, 8.28, 6.20 and 7.00 hr.",Pharmacokinetic interpretation of some antibiotics in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838280/),h,7.00,109458,DB00759,Tetracycline
,3586124,half-life of elimination t1/2 (beta),"This was exemplified by a decrease in the half-life of elimination t1/2 (beta) from 672.5 +/- 99.4 in the newborn to 385.6 +/- 76.8 at 6 weeks of age, and 377.3 +/- 40.8 min in the 250-day-old calf.","Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586124/),min,672.5,109599,DB00759,Tetracycline
,3586124,half-life of elimination t1/2 (beta),"This was exemplified by a decrease in the half-life of elimination t1/2 (beta) from 672.5 +/- 99.4 in the newborn to 385.6 +/- 76.8 at 6 weeks of age, and 377.3 +/- 40.8 min in the 250-day-old calf.","Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586124/),min,385.6,109600,DB00759,Tetracycline
,3586124,half-life of elimination t1/2 (beta),"This was exemplified by a decrease in the half-life of elimination t1/2 (beta) from 672.5 +/- 99.4 in the newborn to 385.6 +/- 76.8 at 6 weeks of age, and 377.3 +/- 40.8 min in the 250-day-old calf.","Comparative pharmacokinetics of gentamicin, neomycin and oxytetracycline in newborn calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586124/),min,377.3,109601,DB00759,Tetracycline
,21219344,elimination half-life of the terminal part of the elimination phase (t(1/2β) ),The elimination half-life of the terminal part of the elimination phase (t(1/2β) ) ranged from 87.9 to 114.3 h.,"Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),h,87.9 to 114.3,110379,DB00759,Tetracycline
,21219344,total body clearance (CL(b) ),"The total body clearance (CL(b) ) was 0.0430 L/kg/h at the lower dose, 0.0123 L/kg/h at the medium dose and 0.0013 L/kg/h at the higher dose.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [h·kg],0.0430,110380,DB00759,Tetracycline
,21219344,total body clearance (CL(b) ),"The total body clearance (CL(b) ) was 0.0430 L/kg/h at the lower dose, 0.0123 L/kg/h at the medium dose and 0.0013 L/kg/h at the higher dose.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [h·kg],0.0123,110381,DB00759,Tetracycline
,21219344,total body clearance (CL(b) ),"The total body clearance (CL(b) ) was 0.0430 L/kg/h at the lower dose, 0.0123 L/kg/h at the medium dose and 0.0013 L/kg/h at the higher dose.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [h·kg],0.0013,110382,DB00759,Tetracycline
,21219344,apparent volume of the central compartment (V(c) ),"The apparent volume of the central compartment (V(c) ) was found to be 1.383, 0.699 and 0.143 L/kg respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [kg],1.383,110383,DB00759,Tetracycline
,21219344,apparent volume of the central compartment (V(c) ),"The apparent volume of the central compartment (V(c) ) was found to be 1.383, 0.699 and 0.143 L/kg respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [kg],0.699,110384,DB00759,Tetracycline
,21219344,apparent volume of the central compartment (V(c) ),"The apparent volume of the central compartment (V(c) ) was found to be 1.383, 0.699 and 0.143 L/kg respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),[l] / [kg],0.143,110385,DB00759,Tetracycline
,21219344,depuration time,"The depuration time for each dose was 13.6, 29.6 and 57.6 days, respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),d,13.6,110386,DB00759,Tetracycline
,21219344,depuration time,"The depuration time for each dose was 13.6, 29.6 and 57.6 days, respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),d,29.6,110387,DB00759,Tetracycline
,21219344,depuration time,"The depuration time for each dose was 13.6, 29.6 and 57.6 days, respectively.","Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219344/),d,57.6,110388,DB00759,Tetracycline
,9618735,parasite,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,36.0,110901,DB00759,Tetracycline
,9618735,fever clearance times,"An oral dose of 10 mg/kg quinine dihydrochloride administered 8-hourly for 7 days gave parasite and fever clearance times of 36.0 +/- 16.6 h and 18.0 +/- 6.4 h, respectively.",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),h,18.0,110902,DB00759,Tetracycline
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],37.9,110903,DB00759,Tetracycline
,9618735,AUC(0-12),In acute malaria plasma quinine levels were more than two-fold higher than in convalescence; the mean AUC(0-12) in malaria was 37.9 +/- 14.7 micrograms.h/ml compared to 17.9 +/- 8.5 micrograms.h/ml in convalescence.,Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[h·μg] / [ml],17.9,110904,DB00759,Tetracycline
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],1.9,110905,DB00759,Tetracycline
,9618735,apparent oral clearance (CL/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[ml] / [kg·min],4.5,110906,DB00759,Tetracycline
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],1.8,110907,DB00759,Tetracycline
,9618735,volume of distribution (Vd/F),"The apparent oral clearance (CL/F) and volume of distribution (Vd/F) during the acute phase of the malaria (1.9 +/- 0.7 ml/min/kg and 1.8 +/- 0.9 l/kg, respectively) were significantly lower than in convalescence (4.5 +/- 2.1 ml/min/kg and 4.2 +/- 3.2 l/kg).",Pharmacokinetics of quinine in African patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9618735/),[l] / [kg],4.2,110908,DB00759,Tetracycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,89.7,114575,DB00759,Tetracycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,86.3,114576,DB00759,Tetracycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,81.0,114577,DB00759,Tetracycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,79.7,114578,DB00759,Tetracycline
,24840325,elimination half-lives,"A large volume of distribution after oral administration, with plasma and ISF elimination half-lives of 4.1 and 7.4 h, respectively, demonstrated that the ISF serves as a drug reservoir for sustained tissue concentrations.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),h,4.1,114993,DB00759,Tetracycline
,24840325,elimination half-lives,"A large volume of distribution after oral administration, with plasma and ISF elimination half-lives of 4.1 and 7.4 h, respectively, demonstrated that the ISF serves as a drug reservoir for sustained tissue concentrations.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),h,7.4,114994,DB00759,Tetracycline
≤,24840325,minimal inhibitory concentrations,"Monte Carlo simulation, used to assess target attainment at different drug dosages, indicated that p.o. administration of 5 mg/kg twice daily is sufficient to inhibit S. pseudintermedius strains with minimal inhibitory concentrations ≤0.25 μg/mL.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),[μg] / [ml],0.25,114995,DB00759,Tetracycline
,6647022,availability,The availability of OTC was found to be 5% and of CTC 37% after oral administration of 10 mg/kg.,The availability of tetracyclines in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6647022/),%,5,116163,DB00759,Tetracycline
,6647022,availability,The availability of OTC was found to be 5% and of CTC 37% after oral administration of 10 mg/kg.,The availability of tetracyclines in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6647022/),%,37,116164,DB00759,Tetracycline
,26378888,extraction recovery,The mean extraction recovery in rat brain was 83.6%.,Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26378888/),%,83.6,117423,DB00759,Tetracycline
> or =,20038623,ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio),"A final multivariable logistic regression model demonstrated six factors based on 123 patients to be predictive of clinical success: a weight of <94 kg (P = 0.026), the absence of Pseudomonas aeruginosa in baseline cultures (P = 0.021), an APACHE II score of <13 (P = 0.029), non-Hispanic race (P = 0.005), complicated appendicitis or cholecystitis (P = 0.004), and a ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio) of > or =3.1 (P = 0.003).",Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038623/),,3.1,118165,DB00759,Tetracycline
<,20038623,AUC/MIC ratio,This probability was lower (0.855) when the AUC/MIC ratio was < 3.1 and the remaining five factors were set to the favorable condition.,Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038623/),,3.1,118166,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],5.5,119198,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],0.7,119199,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],4.6,119200,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],6.2,119201,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],0.8,119202,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],9.0,119203,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],15.0,119204,DB00759,Tetracycline
,11172678,peak concentrations (C(max)),"The results showed that the peak concentrations (C(max)) in rat sera 1-12 hours after oral administration of CMTs -1, -2,-3, -4,-5,-6,-7,-8 and doxycycline were 5.5, 0.7, 4.6, 6.2, 0.8, 0.7, 9.0 (note: the 3 peaks detected for CMT-7 were combined), 15.0 and 0.9 microg/ml, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),[μg] / [ml],0.9,119205,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,11,119206,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,5,119207,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,22,119208,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,32,119209,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,15,119210,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,37,119211,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,38,119212,DB00759,Tetracycline
,11172678,half-lives (t(1/2)),"Their in vivo half-lives (t(1/2)) were 11, 5, 22, 11, 32, 15, 37, 38, and 17 hours, respectively.","The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11172678/),h,17,119213,DB00759,Tetracycline
,11107001,area under the concentration time curve,The mean values obtained indicated a relatively low area under the concentration time curve (25.19+/-12.61 microg/mg per h) and maximum plasma concentration (Cmax) (0.549+/-0.278 microg/mL) with delayed time to Cmax (11.71+/-4.15 h) and elimination half-life (21.96+/-4.42 h).,Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107001/),[μg] / [h·mg],25.19,119438,DB00759,Tetracycline
,11107001,maximum plasma concentration (Cmax),The mean values obtained indicated a relatively low area under the concentration time curve (25.19+/-12.61 microg/mg per h) and maximum plasma concentration (Cmax) (0.549+/-0.278 microg/mL) with delayed time to Cmax (11.71+/-4.15 h) and elimination half-life (21.96+/-4.42 h).,Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107001/),[μg] / [ml],0.549,119439,DB00759,Tetracycline
,11107001,time to Cmax,The mean values obtained indicated a relatively low area under the concentration time curve (25.19+/-12.61 microg/mg per h) and maximum plasma concentration (Cmax) (0.549+/-0.278 microg/mL) with delayed time to Cmax (11.71+/-4.15 h) and elimination half-life (21.96+/-4.42 h).,Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107001/),h,11.71,119440,DB00759,Tetracycline
,11107001,elimination half-life,The mean values obtained indicated a relatively low area under the concentration time curve (25.19+/-12.61 microg/mg per h) and maximum plasma concentration (Cmax) (0.549+/-0.278 microg/mL) with delayed time to Cmax (11.71+/-4.15 h) and elimination half-life (21.96+/-4.42 h).,Pharmacokinetics and residual behaviour in milk of oxytetracycline in cows following administration of uterine pessaries. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107001/),h,21.96,119441,DB00759,Tetracycline
,27821446,plasma protein binding levels,The plasma protein binding levels were 26% in the rat and 15% to 21% in other species.,"Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),%,26,120831,DB00759,Tetracycline
,27821446,plasma protein binding levels,The plasma protein binding levels were 26% in the rat and 15% to 21% in other species.,"Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),%,15,120832,DB00759,Tetracycline
,27821446,plasma protein binding levels,The plasma protein binding levels were 26% in the rat and 15% to 21% in other species.,"Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),%,21,120833,DB00759,Tetracycline
,27821446,plasma clearance,"Omadacycline plasma clearance was 1.2 liters/h/kg, and its half-life was 4.6 h; the steady-state volume of distribution (Vss) was 6.89 liters/kg.","Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),[l] / [h·kg],1.2,120834,DB00759,Tetracycline
,27821446,half-life,"Omadacycline plasma clearance was 1.2 liters/h/kg, and its half-life was 4.6 h; the steady-state volume of distribution (Vss) was 6.89 liters/kg.","Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),h,4.6,120835,DB00759,Tetracycline
,27821446,steady-state volume of distribution (Vss),"Omadacycline plasma clearance was 1.2 liters/h/kg, and its half-life was 4.6 h; the steady-state volume of distribution (Vss) was 6.89 liters/kg.","Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),[l] / [kg],6.89,120836,DB00759,Tetracycline
,27821446,urinary excretion,"However, urinary excretion (∼30%) was equally prominent after i.v. dosing.","Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27821446/),%,∼30,120837,DB00759,Tetracycline
,19279050,half-life,Tigecycline displayed linear pharmacokinetics with a mean half-life of 11.3 +/- 1.4 h.,Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),h,11.3,121025,DB00759,Tetracycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,17,121026,DB00759,Tetracycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,8,121027,DB00759,Tetracycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,6,121028,DB00759,Tetracycline
,15616299,Systemic clearance,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [h·kg],0.2 to 0.3,121812,DB00759,Tetracycline
,15616299,half-life,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),h,37 to 67,121813,DB00759,Tetracycline
,15616299,volume of distribution,"Tigecycline had a large volume of distribution (7 to 10 liters/kg), indicating extensive distribution into the tissues.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [kg],7 to 10,121814,DB00759,Tetracycline
,9316108,Maximal plasma concentration (Cmax),"Maximal plasma concentration (Cmax) values of 5.7 (+/-1.0) microgram/mL and 4.9 (+/-1.4) micrograms/mL obtained after DoxHCl administration during 2 and 7 d, respectively, were not significantly different.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],5.7,122378,DB00759,Tetracycline
,9316108,Maximal plasma concentration (Cmax),"Maximal plasma concentration (Cmax) values of 5.7 (+/-1.0) microgram/mL and 4.9 (+/-1.4) micrograms/mL obtained after DoxHCl administration during 2 and 7 d, respectively, were not significantly different.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],4.9,122379,DB00759,Tetracycline
,9316108,"area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168))","A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[h·μg] / [m],431.9,122380,DB00759,Tetracycline
,9316108,"area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168))","A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],4.9,122381,DB00759,Tetracycline
,9316108,"area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168))","A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[h·μg] / [ml],"1,176.5",122382,DB00759,Tetracycline
,9316108,Cmax,"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],4.9,122383,DB00759,Tetracycline
,9316108,Cmax,"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[h·μg] / [ml],"1,176.5",122384,DB00759,Tetracycline
,9316108,minimal plasma concentration (Cmin),"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],0.7,122385,DB00759,Tetracycline
,9316108,minimal plasma concentration (Cmin),"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[h·μg] / [ml],"1,176.5",122386,DB00759,Tetracycline
,9316108,minimal plasma concentration (Cmin),"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],12.5,122387,DB00759,Tetracycline
,9316108,minimal plasma concentration (Cmin),"A significant difference was found between the area under the plasma concentration-time profile, calculated between 0 and 168 h (AUC(0-168)), Cmax, and the minimal plasma concentration (Cmin) values obtained after medication with a DoxHCl solution at a concentration of 250 mg/L (431.9 +/- 96.6 micrograms.h/mL, 4.9 +/- 1.4 micrograms/mL and 0.7 +/- 0.3 microgram/mL) and after medication with a DoxHCl solution at a concentration of 750 mg/L (1,176.5 +/- 201.8 micrograms.h/mL, 12.5 +/- 2.7 micrograms/mL and 2.9 +/- 0.4 micrograms/mL), respectively.",Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],2.9,122388,DB00759,Tetracycline
,9316108,Cmax,A Cmax value of 1.7 +/- 0.6 micrograms/mL and a Cmin value of 0.5 +/- 0.1 microgram/mL were observed during the field experiment.,Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],1.7,122389,DB00759,Tetracycline
,9316108,Cmin,A Cmax value of 1.7 +/- 0.6 micrograms/mL and a Cmin value of 0.5 +/- 0.1 microgram/mL were observed during the field experiment.,Administration of doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316108/),[μg] / [ml],0.5,122390,DB00759,Tetracycline
,9915145,apparent volume of distribution,Mean apparent volume of distribution was 0.77+/-0.02 litre kg(-1) and the harmonic mean half-life was three hours.,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),[l] / [kg],0.77,122574,DB00759,Tetracycline
,9915145,half-life,Mean apparent volume of distribution was 0.77+/-0.02 litre kg(-1) and the harmonic mean half-life was three hours.,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,three,122575,DB00759,Tetracycline
,9915145,half-lives,"After intramuscular administrations of both formulations, half-lives were longer than after intravenous administration (mean values of 14.1 and 58.2 hours for T-100 and OTC-L respectively).","Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,14.1,122576,DB00759,Tetracycline
,9915145,half-lives,"After intramuscular administrations of both formulations, half-lives were longer than after intravenous administration (mean values of 14.1 and 58.2 hours for T-100 and OTC-L respectively).","Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,58.2,122577,DB00759,Tetracycline
,9915145,minimum inhibitory concentration,OTC-L provided therapeutic plasma concentrations over 0.5 microg ml(-1) (the minimum inhibitory concentration for most susceptible pathogens) for a longer period of time than T-100 (72 hours compared with 36 or 48 hours).,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),[μg] / [ml],0.5,122578,DB00759,Tetracycline
,18727530,flow rate,"The mobile phase consisted of acetonitrile-formic acid 0.1% (48 + 52, v/v), run at a flow rate of 1 ml/min (split 1:5).",Development and validation of a liquid chromatographic/tandem mass spectrometric method for determination of tetracycline in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18727530/),[ml] / [min],1,123439,DB00759,Tetracycline
,18727530,extraction recoveries,"The mean extraction recoveries for tetracycline and IS from plasma were 92.14 and 94.04%, respectively.",Development and validation of a liquid chromatographic/tandem mass spectrometric method for determination of tetracycline in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18727530/),%,92.14,123440,DB00759,Tetracycline
,18727530,extraction recoveries,"The mean extraction recoveries for tetracycline and IS from plasma were 92.14 and 94.04%, respectively.",Development and validation of a liquid chromatographic/tandem mass spectrometric method for determination of tetracycline in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18727530/),%,94.04,123441,DB00759,Tetracycline
,9704514,t1/2 beta,"The values of t1/2 beta and Vd(area) were 3.22 +/- 0.20 h and 0.49 +/- 0.02 L. kg-1 in healthy calves and 4.06 +/- 0.32 h and 0.70 +/- 0.09 L kg-1, respectively, in febrile calves.",Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704514/),h,3.22,124380,DB00759,Tetracycline
,9704514,t1/2 beta,"The values of t1/2 beta and Vd(area) were 3.22 +/- 0.20 h and 0.49 +/- 0.02 L. kg-1 in healthy calves and 4.06 +/- 0.32 h and 0.70 +/- 0.09 L kg-1, respectively, in febrile calves.",Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704514/),h,4.06,124381,DB00759,Tetracycline
,9704514,Vd(area),"The values of t1/2 beta and Vd(area) were 3.22 +/- 0.20 h and 0.49 +/- 0.02 L. kg-1 in healthy calves and 4.06 +/- 0.32 h and 0.70 +/- 0.09 L kg-1, respectively, in febrile calves.",Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704514/),[l] / [kg],0.49,124382,DB00759,Tetracycline
,9704514,Vd(area),"The values of t1/2 beta and Vd(area) were 3.22 +/- 0.20 h and 0.49 +/- 0.02 L. kg-1 in healthy calves and 4.06 +/- 0.32 h and 0.70 +/- 0.09 L kg-1, respectively, in febrile calves.",Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704514/),[l] / [kg],0.70,124383,DB00759,Tetracycline
> or =,9704514,minimum therapeutic plasma concentration,An intravenous dosage regimen suitable for maintaining the minimum therapeutic plasma concentration of > or = 2 micrograms/ml in febrile animals would be 10 mg kg-1 repeated at 12-h intervals.,Influence of Escherichia coli endotoxin induced fever on the pharmacokinetics and dosage regimen of oxytetracycline in cross-bred calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704514/),[μg] / [ml],2,124384,DB00759,Tetracycline
,10066127,half-lives,"The half-lives of oxytetracycline after intravenous and intramuscular administration were 7.8 h and 24 h, respectively.",Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),h,7.8,124647,DB00759,Tetracycline
,10066127,half-lives,"The half-lives of oxytetracycline after intravenous and intramuscular administration were 7.8 h and 24 h, respectively.",Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),h,24,124648,DB00759,Tetracycline
,10066127,volume of distribution,"The volume of distribution and total body clearance values of the drug were 0.86+/-0.07 L and 76.1+/-3.3 (ml/h)/kg, respectively.",Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),l,0.86,124649,DB00759,Tetracycline
,10066127,total body clearance,"The volume of distribution and total body clearance values of the drug were 0.86+/-0.07 L and 76.1+/-3.3 (ml/h)/kg, respectively.",Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),[ml] / [h)·kg],76.1,124650,DB00759,Tetracycline
,10066127,maximum concentration,The maximum concentration of the drug in the serum (4.7-7.4 microg/ml) was achieved 8-10 h after intramuscular administration.,Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),[μg] / [ml],4.7-7.4,124651,DB00759,Tetracycline
> or =,10066127,minimum therapeutic serum concentration of drug,The minimum therapeutic serum concentration of drug of > or = 0.5 microg/ml was maintained between 15 min and 84 h after intramuscular administration.,Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),[μg] / [ml],0.5,124652,DB00759,Tetracycline
,10066127,intramuscular bioavailability,The intramuscular bioavailability of the drug was 89.1+/-4.2%.,Some pharmacokinetic parameters and dosage regimens for a long-acting formulation of oxytetracycline in 6- to 8-month-old male calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10066127/),%,89.1,124653,DB00759,Tetracycline
,22024822,maximum concentration of drug in serum (C(max)),"The maximum concentration of drug in serum (C(max)) and area under the concentration-time curve from 0 h to infinity (AUC(0-∞)) values ranged from 1.0 to 3.16 mg/liter and 15.2 to 47.8 mg/liter × h, respectively, following single intravenous doses of 40 to 200 mg.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),[mg] / [l],1.0 to 3.16,126417,DB00759,Tetracycline
,22024822,area under the concentration-time curve from 0 h to infinity (AUC(0-∞)),"The maximum concentration of drug in serum (C(max)) and area under the concentration-time curve from 0 h to infinity (AUC(0-∞)) values ranged from 1.0 to 3.16 mg/liter and 15.2 to 47.8 mg/liter × h, respectively, following single intravenous doses of 40 to 200 mg.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),[mg] / [h·l],15.2 to 47.8,126418,DB00759,Tetracycline
,22024822,C(max),"C(max) and time to maximum concentration of drug in serum (T(max)) values following multiple-dose oral administration ranged from 1.15 to 3.04 mg/liter and 1.50 to 2.33 h, respectively, on day 14 and 1.48 to 3.57 mg/liter and 1.00 to 2.17 on day 28.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),[mg] / [l],1.15 to 3.04,126419,DB00759,Tetracycline
,22024822,C(max),"C(max) and time to maximum concentration of drug in serum (T(max)) values following multiple-dose oral administration ranged from 1.15 to 3.04 mg/liter and 1.50 to 2.33 h, respectively, on day 14 and 1.48 to 3.57 mg/liter and 1.00 to 2.17 on day 28.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),[mg] / [l],1.48 to 3.57,126420,DB00759,Tetracycline
,22024822,time to maximum concentration of drug in serum (T(max)),"C(max) and time to maximum concentration of drug in serum (T(max)) values following multiple-dose oral administration ranged from 1.15 to 3.04 mg/liter and 1.50 to 2.33 h, respectively, on day 14 and 1.48 to 3.57 mg/liter and 1.00 to 2.17 on day 28.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),h,1.50 to 2.33,126421,DB00759,Tetracycline
,22024822,Pre,"Predose sputum/plasma concentration ratios on days 14 and 28 ranged from 0.33 to 1.1 (mean, 0.71 ± 0.33), indicating moderate pulmonary penetration.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),,0.71,126422,DB00759,Tetracycline
,22024822,sputum/plasma concentration ratios,"Predose sputum/plasma concentration ratios on days 14 and 28 ranged from 0.33 to 1.1 (mean, 0.71 ± 0.33), indicating moderate pulmonary penetration.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),,0.71,126423,DB00759,Tetracycline
,22024822,absorption rate constant [K(a)],"Absorption was slow and delayed (absorption rate constant [K(a)], 0.414 h(-1); lag time, 0.484 h) but complete (bioavailability [F], 1.16).",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),1/[h],0.414,126424,DB00759,Tetracycline
,22024822,lag time,"Absorption was slow and delayed (absorption rate constant [K(a)], 0.414 h(-1); lag time, 0.484 h) but complete (bioavailability [F], 1.16).",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),h,0.484,126425,DB00759,Tetracycline
,22024822,bioavailability [F],"Absorption was slow and delayed (absorption rate constant [K(a)], 0.414 h(-1); lag time, 0.484 h) but complete (bioavailability [F], 1.16).",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),,1.16,126426,DB00759,Tetracycline
,22024822,distribution,"The distribution and elimination half-lives were 0.557 and 18.1 h, respectively.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),h,0.557,126427,DB00759,Tetracycline
,22024822,elimination half-lives,"The distribution and elimination half-lives were 0.557 and 18.1 h, respectively.",Pharmacokinetics of doxycycline in adults with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024822/),h,18.1,126428,DB00759,Tetracycline
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB00759,Tetracycline
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB00759,Tetracycline
,8560757,serum concentration (Cmax),"The mean serum concentration (Cmax) and the time of maximum concentration (Tmax) were 1.87 micrograms/ml and 0.85 h, respectively.",Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),[μg] / [ml],1.87,127294,DB00759,Tetracycline
,8560757,time of maximum concentration (Tmax),"The mean serum concentration (Cmax) and the time of maximum concentration (Tmax) were 1.87 micrograms/ml and 0.85 h, respectively.",Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),h,0.85,127295,DB00759,Tetracycline
,8560757,terminal elimination half-life,"A three-phase disposition of doxycycline was found, the terminal elimination half-life being approximately 40 h.",Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),h,40,127296,DB00759,Tetracycline
,8560757,mean residence time (MRT),The value obtained for the mean residence time (MRT) was 16.4 h.,Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),h,16.4,127297,DB00759,Tetracycline
,8560757,volume of distribution at steady state (Vdss),"The mean values for the volume of distribution at steady state (Vdss), determined by compartmental and non-compartmental analyses, were 8.73 and 13.19 L/kg, respectively.",Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),[l] / [kg],8.73,127298,DB00759,Tetracycline
,8560757,volume of distribution at steady state (Vdss),"The mean values for the volume of distribution at steady state (Vdss), determined by compartmental and non-compartmental analyses, were 8.73 and 13.19 L/kg, respectively.",Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560757/),[l] / [kg],13.19,127299,DB00759,Tetracycline
,20950348,oral bioavailability,The oral bioavailability of doxycycline was calculated to 17% after intragastric administration and 6% after topdressing administration in nonfasted horses.,"Antimicrobial disposition in pulmonary epithelial lining fluid of horses, part II. Doxycycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950348/),%,17,130159,DB00759,Tetracycline
,20950348,oral bioavailability,The oral bioavailability of doxycycline was calculated to 17% after intragastric administration and 6% after topdressing administration in nonfasted horses.,"Antimicrobial disposition in pulmonary epithelial lining fluid of horses, part II. Doxycycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950348/),%,6,130160,DB00759,Tetracycline
,20950348,AUC,"The degree of penetration of doxycycline into PELF, as described by AUC(PELF) /AUC(plasma) ratios, was 0.87 after intragastric administration.","Antimicrobial disposition in pulmonary epithelial lining fluid of horses, part II. Doxycycline. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950348/),,0.87,130161,DB00759,Tetracycline
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,80,131317,DB00759,Tetracycline
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,90,131318,DB00759,Tetracycline
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,100,131319,DB00759,Tetracycline
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,70,131320,DB00759,Tetracycline
,25411077,distribution volume (Vz),"3. After IV administration, doxycycline had a mean (±SD) distribution volume (Vz) of 1761.9 ± 328.5 ml/kg and was slowly eliminated with a terminal half-life (t₁/₂λz) of 21.21±1.47 h and a total body clearance (Cl) of 57.51 ± 9.50 ml/h/kg.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),[ml] / [kg],1761.9,132672,DB00759,Tetracycline
,25411077,terminal half-life (t₁/₂λz),"3. After IV administration, doxycycline had a mean (±SD) distribution volume (Vz) of 1761.9 ± 328.5 ml/kg and was slowly eliminated with a terminal half-life (t₁/₂λz) of 21.21±1.47 h and a total body clearance (Cl) of 57.51 ± 9.50 ml/h/kg.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),h,21.21,132673,DB00759,Tetracycline
,25411077,total body clearance (Cl),"3. After IV administration, doxycycline had a mean (±SD) distribution volume (Vz) of 1761.9 ± 328.5 ml/kg and was slowly eliminated with a terminal half-life (t₁/₂λz) of 21.21±1.47 h and a total body clearance (Cl) of 57.51 ± 9.50 ml/h/kg.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),[ml] / [h·kg],57.51,132674,DB00759,Tetracycline
,25411077,peak concentrations (Cmax),"Following PO and IM administration, doxycycline was relatively slowly absorbed - the peak concentrations (Cmax) were 17.57 ± 4.66 μg/ml at 2 h and 25.01 ± 4.18 μg/ml at 1.5 h, respectively.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),[μg] / [ml],17.57,132675,DB00759,Tetracycline
,25411077,peak concentrations (Cmax),"Following PO and IM administration, doxycycline was relatively slowly absorbed - the peak concentrations (Cmax) were 17.57 ± 4.66 μg/ml at 2 h and 25.01 ± 4.18 μg/ml at 1.5 h, respectively.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),[μg] / [ml],25.01,132676,DB00759,Tetracycline
,25411077,absolute bioavailabilities (F),"The absolute bioavailabilities (F) of doxycycline after PO and IM administration were 39.13% and 70.71%, respectively.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),%,39.13,132677,DB00759,Tetracycline
,25411077,absolute bioavailabilities (F),"The absolute bioavailabilities (F) of doxycycline after PO and IM administration were 39.13% and 70.71%, respectively.","Pharmacokinetics of doxycycline after a single intravenous, oral or intramuscular dose in Muscovy ducks (Cairina moschata). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25411077/),%,70.71,132678,DB00759,Tetracycline
,18307499,maximum serum concentration (C(max)),Pradofloxacin reached a mean maximum serum concentration (C(max)) of 1.1 +/- 0.5 microg/mL after 1.8 +/- 1.3 h (t(max)).,"Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),[μg] / [ml],1.1,133126,DB00759,Tetracycline
,18307499,t(max),Pradofloxacin reached a mean maximum serum concentration (C(max)) of 1.1 +/- 0.5 microg/mL after 1.8 +/- 1.3 h (t(max)).,"Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),h,1.8,133127,DB00759,Tetracycline
,18307499,C(max),"In saliva and tear fluid, mean C(max) was 6.3 +/- 7.0 and 13.4 +/- 20.9 microg/mL, respectively, and mean t(max) was 0.5 +/- 0 and 0.8 +/- 0.3 h, respectively.","Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),[μg] / [ml],6.3,133128,DB00759,Tetracycline
,18307499,C(max),"In saliva and tear fluid, mean C(max) was 6.3 +/- 7.0 and 13.4 +/- 20.9 microg/mL, respectively, and mean t(max) was 0.5 +/- 0 and 0.8 +/- 0.3 h, respectively.","Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),[μg] / [ml],13.4,133129,DB00759,Tetracycline
,18307499,t(max),"In saliva and tear fluid, mean C(max) was 6.3 +/- 7.0 and 13.4 +/- 20.9 microg/mL, respectively, and mean t(max) was 0.5 +/- 0 and 0.8 +/- 0.3 h, respectively.","Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),h,0.5,133130,DB00759,Tetracycline
,18307499,t(max),"In saliva and tear fluid, mean C(max) was 6.3 +/- 7.0 and 13.4 +/- 20.9 microg/mL, respectively, and mean t(max) was 0.5 +/- 0 and 0.8 +/- 0.3 h, respectively.","Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),h,0.8,133131,DB00759,Tetracycline
,18307499,C(max),Doxycycline reached a mean C(max) in serum of 4.0 +/- 0.8 microg/mL after 4.3 +/- 3.2 h.,"Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307499/),[μg] / [ml],4.0,133132,DB00759,Tetracycline
,4071951,maximum plasma OTC concentrations,"The mean maximum plasma OTC concentrations, ranging from 2.0 to 4.1 micrograms/ml, were achieved between 4 and 12 hours post injection, depending on the formulation involved.",Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071951/),[μg] / [ml],2.0 to 4.1,133524,DB00759,Tetracycline
,4071951,maximum milk OTC concentrations,"The mean maximum milk OTC concentrations, in the range between 0.92 and 1.43 micrograms/ml, were achieved 12 to 24 h p.i.",Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071951/),[μg] / [ml],0.92 and 1.43,133525,DB00759,Tetracycline
,4071951,peak milk OTC concentration,"After intravenous administration the time for the appearance of OTC in milk was shorter (1-2 hours p.i.), the peak milk OTC concentration was higher (1.7-1.9 micrograms/ml) and achieved earlier (6-8 h p.i.), and the OTC persistence in milk shorter than after i.m. administration.",Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071951/),[μg] / [ml],1.7-1.9,133526,DB00759,Tetracycline
,4071951,plasma,The plasma and milk protein binding for OTC was respectively 71.7 +/- 7.4% and 84.8 +/- 5.45%.,Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071951/),%,71.7,133527,DB00759,Tetracycline
,4071951,milk protein binding,The plasma and milk protein binding for OTC was respectively 71.7 +/- 7.4% and 84.8 +/- 5.45%.,Comparative pharmacokinetics and bioavailability of eight parenteral oxytetracycline-10% formulations in dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071951/),%,84.8,133528,DB00759,Tetracycline
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,82,134636,DB00759,Tetracycline
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,81,134637,DB00759,Tetracycline
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,93,134638,DB00759,Tetracycline
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,99,134639,DB00759,Tetracycline
,8116811,side effects,"The side effects score was lower (2 versus 11; P < 0.001), there were less days on which side effects occurred (2.0 days versus 5.5 days; P < 0.001), and fewer patients had adverse effects on every treatment day (4% versus 42%; P < 0.01).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),,2,134640,DB00759,Tetracycline
,6870294,half life of slow space,"The mean half life of slow space was 33.3 hr, which suggested delayed excretion of this drug from pleural space.",[Pharmacokinetics and pleural reaction of doxycycline after intrapleural administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6870294/),h,33.3,135266,DB00759,Tetracycline
,14614269,area under the curve (AUC0- infinity ),"The mean area under the curve (AUC0- infinity ) and peak plasma concentration (C(max)) values for test and reference OTCs were 7.22 +/- 3.90 and 11.04 +/- 7.37 microg h/ml, 1.11 +/- 0.65 and 1.85 +/- 1.15 microg/ml, respectively.",Lack of bioequivalence of two oxytetracycline formulations in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614269/),[h·μg] / [ml],7.22,135539,DB00759,Tetracycline
,14614269,peak plasma concentration (C(max)),"The mean area under the curve (AUC0- infinity ) and peak plasma concentration (C(max)) values for test and reference OTCs were 7.22 +/- 3.90 and 11.04 +/- 7.37 microg h/ml, 1.11 +/- 0.65 and 1.85 +/- 1.15 microg/ml, respectively.",Lack of bioequivalence of two oxytetracycline formulations in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614269/),[h·μg] / [ml],11.04,135540,DB00759,Tetracycline
,14614269,peak plasma concentration (C(max)),"The mean area under the curve (AUC0- infinity ) and peak plasma concentration (C(max)) values for test and reference OTCs were 7.22 +/- 3.90 and 11.04 +/- 7.37 microg h/ml, 1.11 +/- 0.65 and 1.85 +/- 1.15 microg/ml, respectively.",Lack of bioequivalence of two oxytetracycline formulations in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614269/),[μg] / [ml],1.85,135541,DB00759,Tetracycline
,14614269,relative bioavailability,"The relative bioavailability and C(max) of test product to those of reference product was 65.4% and 60.0%, respectively.",Lack of bioequivalence of two oxytetracycline formulations in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614269/),%,65.4,135542,DB00759,Tetracycline
,14614269,C(max),"The relative bioavailability and C(max) of test product to those of reference product was 65.4% and 60.0%, respectively.",Lack of bioequivalence of two oxytetracycline formulations in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614269/),%,60.0,135543,DB00759,Tetracycline
,3653454,detection threshold,The detection threshold was 0.07 micrograms/g for albumen and 0.2 micrograms/g for yolk.,Excretion of oxytetracycline in eggs after medication of laying hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653454/),[μg] / [g],0.07,136740,DB00759,Tetracycline
,3653454,detection threshold,The detection threshold was 0.07 micrograms/g for albumen and 0.2 micrograms/g for yolk.,Excretion of oxytetracycline in eggs after medication of laying hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653454/),[μg] / [g],0.2,136741,DB00759,Tetracycline
,16080071,steady-state maximum concentration,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),[μg] / [ml],0.6,137110,DB00759,Tetracycline
,16080071,steady-state area under the concentration-time curve,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),[h·μg] / [ml],5-6,137111,DB00759,Tetracycline
,16080071,terminal elimination half-life,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),h,40,137112,DB00759,Tetracycline
,2712419,peak bile-to-plasma OTC concentration ratio,"At 2 hours after administration, the peak bile-to-plasma OTC concentration ratio was 60:1.",Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary and urinary excretion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712419/),,60:1,138216,DB00759,Tetracycline
,2712419,Bioavailability,Bioavailability of OTC was 47.6% when it was administered orally to fasted turkeys and was 9.4% when administered to fed turkeys.,Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary and urinary excretion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712419/),%,47.6,138217,DB00759,Tetracycline
,2712419,Bioavailability,Bioavailability of OTC was 47.6% when it was administered orally to fasted turkeys and was 9.4% when administered to fed turkeys.,Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary and urinary excretion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712419/),%,9.4,138218,DB00759,Tetracycline
,20807146,elimination half-life,The mean+/-SD elimination half-life was 7.70+/-1.91 hours.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),h,7.70,138917,DB00759,Tetracycline
,20807146,total body clearance,"The total body clearance was 0.16+/-0.04 L/h/kg, and the volume of distribution at steady state was 1.53+/-0.09 L/kg.",Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[l] / [h·kg],0.16,138918,DB00759,Tetracycline
,20807146,volume of distribution at steady state,"The total body clearance was 0.16+/-0.04 L/h/kg, and the volume of distribution at steady state was 1.53+/-0.09 L/kg.",Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[l] / [kg],1.53,138919,DB00759,Tetracycline
,20807146,percentage of plasma protein binding,The percentage of plasma protein binding was 68.1+/-2.6%.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),%,68.1,138920,DB00759,Tetracycline
,20807146,Plasma concentration,Plasma concentration of free minocycline was 0.12 microg/mL at 12 hours.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[μg] / [ml],0.12,138921,DB00759,Tetracycline
,9280365,elimination half life (t[1/2beta]),"Ampicillin elimination half life (t[1/2beta]) in goats (1.20 h) was shorter than that in sheep (2.48 h), and its clearance (Cl) significantly higher in goats (2921 mL/h x kg) compared to sheep (262 mL/h x kg) (P < 0.01).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),h,1.20,139152,DB00759,Tetracycline
,9280365,elimination half life (t[1/2beta]),"Ampicillin elimination half life (t[1/2beta]) in goats (1.20 h) was shorter than that in sheep (2.48 h), and its clearance (Cl) significantly higher in goats (2921 mL/h x kg) compared to sheep (262 mL/h x kg) (P < 0.01).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),h,2.48,139153,DB00759,Tetracycline
,9280365,clearance (Cl),"Ampicillin elimination half life (t[1/2beta]) in goats (1.20 h) was shorter than that in sheep (2.48 h), and its clearance (Cl) significantly higher in goats (2921 mL/h x kg) compared to sheep (262 mL/h x kg) (P < 0.01).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [h·kg],2921,139154,DB00759,Tetracycline
,9280365,clearance (Cl),"Ampicillin elimination half life (t[1/2beta]) in goats (1.20 h) was shorter than that in sheep (2.48 h), and its clearance (Cl) significantly higher in goats (2921 mL/h x kg) compared to sheep (262 mL/h x kg) (P < 0.01).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [h·kg],262,139155,DB00759,Tetracycline
,9280365,volume of distribution (Vd[area]),Ampicillin volume of distribution (Vd[area]) was found to be significantly larger in goats (5673 mL/kg) than in sheep (992 mL/kg) (P < 0.01).,"Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [kg],5673,139156,DB00759,Tetracycline
,9280365,volume of distribution (Vd[area]),Ampicillin volume of distribution (Vd[area]) was found to be significantly larger in goats (5673 mL/kg) than in sheep (992 mL/kg) (P < 0.01).,"Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [kg],992,139157,DB00759,Tetracycline
,9280365,t(1/2beta),"For oxytetracycline, the t(1/2beta) in goats (3.89 h) was significantly shorter than that in sheep (6.30 h) and the Cl value in goats (437 mL/h x kg) was significantly higher than in sheep (281 mL/h x kg).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),h,3.89,139158,DB00759,Tetracycline
,9280365,t(1/2beta),"For oxytetracycline, the t(1/2beta) in goats (3.89 h) was significantly shorter than that in sheep (6.30 h) and the Cl value in goats (437 mL/h x kg) was significantly higher than in sheep (281 mL/h x kg).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),h,6.30,139159,DB00759,Tetracycline
,9280365,Cl,"For oxytetracycline, the t(1/2beta) in goats (3.89 h) was significantly shorter than that in sheep (6.30 h) and the Cl value in goats (437 mL/h x kg) was significantly higher than in sheep (281 mL/h x kg).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [h·kg],437,139160,DB00759,Tetracycline
,9280365,Cl,"For oxytetracycline, the t(1/2beta) in goats (3.89 h) was significantly shorter than that in sheep (6.30 h) and the Cl value in goats (437 mL/h x kg) was significantly higher than in sheep (281 mL/h x kg).","Comparative pharmacokinetics of ampicillin trihydrate, gentamicin sulphate and oxytetracycline hydrochloride in Nubian goats and desert sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280365/),[ml] / [h·kg],281,139161,DB00759,Tetracycline
,16178844,T(max),Doxycycline was rapidly absorbed after the first dose (T(max) value of 1.42 +/- 1.28 h); and elimination of doxycycline occurred slowly (median t(1/2) = 10.88 h).,Ocular penetration of oral doxycycline in the horse. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16178844/),h,1.42,139494,DB00759,Tetracycline
,16178844,t(1/2),Doxycycline was rapidly absorbed after the first dose (T(max) value of 1.42 +/- 1.28 h); and elimination of doxycycline occurred slowly (median t(1/2) = 10.88 h).,Ocular penetration of oral doxycycline in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16178844/),h,10.88,139495,DB00759,Tetracycline
<,16178844,steady state serum concentrations,"Repeated oral administration of doxycycline in the horse resulted in steady state serum concentrations of < 1 microg/mL; however, it did not result in appreciable concentrations of drug in the aqueous and vitreous in normal eyes.",Ocular penetration of oral doxycycline in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16178844/),[μg] / [ml],1,139496,DB00759,Tetracycline
,28193651,Penetration,Penetration into ELF ranged from 72 to 102%.,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),%,72 to 102,140416,DB00759,Tetracycline
,28193651,AUC/MIC,The plasma 24-h static dose AUC/MIC values were 16 to 20 (24-h ELF AUC/MIC of 14 to 18).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,16 to 20,140417,DB00759,Tetracycline
,28193651,AUC/MIC,The plasma 24-h static dose AUC/MIC values were 16 to 20 (24-h ELF AUC/MIC of 14 to 18).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,14 to 18,140418,DB00759,Tetracycline
,28193651,plasma AUC/MIC,A 1-log10 kill was achieved at 24-h plasma AUC/MIC values of 6.1 to 180 (24-h ELF AUC/MIC values 6.0 to 200).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,6.1 to 180,140419,DB00759,Tetracycline
,28193651,AUC/MIC,A 1-log10 kill was achieved at 24-h plasma AUC/MIC values of 6.1 to 180 (24-h ELF AUC/MIC values 6.0 to 200).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,6.0 to 200,140420,DB00759,Tetracycline
,28193651,plasma AUC/MIC,A 2-log10 kill was achieved at 24-h plasma AUC/MIC values of 19 to 56 (24-h ELF AUC/MIC of 17 to 47).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,19 to 56,140421,DB00759,Tetracycline
,28193651,AUC/MIC,A 2-log10 kill was achieved at 24-h plasma AUC/MIC values of 19 to 56 (24-h ELF AUC/MIC of 17 to 47).,In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193651/),,17 to 47,140422,DB00759,Tetracycline
,17106222,elimination half-life (t(1/2beta)),"After IV administration, the elimination half-life (t(1/2beta)), mean residence time (MRT), volume of distribution at the steady-state (V(ss)), volume of distribution (Vd(area)) and total body clearance (Cl(B)) were 7.67+/-0.62 h, 6.68+/-0.86 h, 0.86+/-0.16 l/kg, 1.67+/-0.52 l/kg and 2.51+/-0.63 ml/min/kg, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),h,7.67,140439,DB00759,Tetracycline
,17106222,total body clearance (Cl(B)),"After IV administration, the elimination half-life (t(1/2beta)), mean residence time (MRT), volume of distribution at the steady-state (V(ss)), volume of distribution (Vd(area)) and total body clearance (Cl(B)) were 7.67+/-0.62 h, 6.68+/-0.86 h, 0.86+/-0.16 l/kg, 1.67+/-0.52 l/kg and 2.51+/-0.63 ml/min/kg, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[ml] / [kg·min],2.51,140440,DB00759,Tetracycline
,17106222,peak plasma concentrations (Cmax),"After IM and oral dosing, the mean peak plasma concentrations (Cmax) were 1.34+/-0.33 and 0.30+/-0.04 microgram/ml, respectively, which were achieved at a postadministration time (tmax) of 0.75+/-0.18, 3.03+/-0.48 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[μg] / [ml],1.34,140441,DB00759,Tetracycline
,17106222,peak plasma concentrations (Cmax),"After IM and oral dosing, the mean peak plasma concentrations (Cmax) were 1.34+/-0.33 and 0.30+/-0.04 microgram/ml, respectively, which were achieved at a postadministration time (tmax) of 0.75+/-0.18, 3.03+/-0.48 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[μg] / [ml],0.30,140442,DB00759,Tetracycline
,17106222,time (tmax),"After IM and oral dosing, the mean peak plasma concentrations (Cmax) were 1.34+/-0.33 and 0.30+/-0.04 microgram/ml, respectively, which were achieved at a postadministration time (tmax) of 0.75+/-0.18, 3.03+/-0.48 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),h,0.75,140443,DB00759,Tetracycline
,17106222,time (tmax),"After IM and oral dosing, the mean peak plasma concentrations (Cmax) were 1.34+/-0.33 and 0.30+/-0.04 microgram/ml, respectively, which were achieved at a postadministration time (tmax) of 0.75+/-0.18, 3.03+/-0.48 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),h,3.03,140444,DB00759,Tetracycline
,17106222,t(1/2beta),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),h,25.02,140445,DB00759,Tetracycline
,17106222,Vd(area),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[l] / [kg],23.99,140446,DB00759,Tetracycline
,17106222,Vd(area),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),h,19.25,140447,DB00759,Tetracycline
,17106222,Vd(area),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[l] / [kg],61.49,140448,DB00759,Tetracycline
,17106222,Cl(B),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[ml] / [kg·min],12.14,140449,DB00759,Tetracycline
,17106222,Cl(B),"The t(1/2beta), Vd(area) and Cl(B) after IM administration were 25.02+/-3.98 h, 23.99+/-3.4 l/kg and 12.14+/-1.71 ml/min/kg, respectively and 19.25+/-2.53 h, 61.49+/-7 l/kg and 40.19+/-3.79 ml/min/kg after oral administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),[ml] / [kg·min],40.19,140450,DB00759,Tetracycline
,17106222,absolute bioavailability (F),"The absolute bioavailability (F) of doxycycline was 5.03 and 17.52% after oral and IM administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),%,5.03,140451,DB00759,Tetracycline
,17106222,absolute bioavailability (F),"The absolute bioavailability (F) of doxycycline was 5.03 and 17.52% after oral and IM administration, respectively.",Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106222/),%,17.52,140452,DB00759,Tetracycline
,10933520,flow rate,"The isocratic elution is performed with methanol-0.01 M oxalic acid, pH 3.0 (30:70, v/v) at a flow rate of 0.95 ml min, using a Silasorb C8 analytical column, 250 x 4 mm, 10 microm.",A rapid high performance liquid chromatographic (HPLC) assay for the determination of oxytetracycline in commercial pharmaceuticals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933520/),min·ml,0.95,141074,DB00759,Tetracycline
,10933520,Total analysis time,Total analysis time was approximately 7 min.,A rapid high performance liquid chromatographic (HPLC) assay for the determination of oxytetracycline in commercial pharmaceuticals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933520/),min,7,141075,DB00759,Tetracycline
,28223382,MIC90,Omadacycline was active in vitro against Y. pestis (MIC90 of 1 μg/ml) and B. anthracis (MIC90 of 0.06 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],1,141668,DB00759,Tetracycline
,28223382,MIC90,Omadacycline was active in vitro against Y. pestis (MIC90 of 1 μg/ml) and B. anthracis (MIC90 of 0.06 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.06,141669,DB00759,Tetracycline
,28223382,MIC90,Omadacycline was less active in vitro than ciprofloxacin (CIP) against Y. pestis (CIP MIC90 of 0.03 μg/ml) but was more potent in vitro against B. anthracis (CIP MIC90 of 0.12 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.03,141670,DB00759,Tetracycline
,28223382,MIC90,Omadacycline was less active in vitro than ciprofloxacin (CIP) against Y. pestis (CIP MIC90 of 0.03 μg/ml) but was more potent in vitro against B. anthracis (CIP MIC90 of 0.12 μg/ml).,"In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223382/),[μg] / [ml],0.12,141671,DB00759,Tetracycline
,18672975,bioavailability,"The long-acting parenteral formulation of doxycycline hyclate had the greatest bioavailability (545%); mean +/- SD maximum serum concentration was 2.4 +/- 0.95 microg/mL, peak time to maximum concentration was 19.23 +/- 2.03 hours, and elimination half-life was 40.92 +/- 4.25 hours.",Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672975/),%,545,141690,DB00759,Tetracycline
,18672975,maximum serum concentration,"The long-acting parenteral formulation of doxycycline hyclate had the greatest bioavailability (545%); mean +/- SD maximum serum concentration was 2.4 +/- 0.95 microg/mL, peak time to maximum concentration was 19.23 +/- 2.03 hours, and elimination half-life was 40.92 +/- 4.25 hours.",Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672975/),[μg] / [ml],2.4,141691,DB00759,Tetracycline
,18672975,peak time to maximum concentration,"The long-acting parenteral formulation of doxycycline hyclate had the greatest bioavailability (545%); mean +/- SD maximum serum concentration was 2.4 +/- 0.95 microg/mL, peak time to maximum concentration was 19.23 +/- 2.03 hours, and elimination half-life was 40.92 +/- 4.25 hours.",Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672975/),h,19.23,141692,DB00759,Tetracycline
,18672975,elimination half-life,"The long-acting parenteral formulation of doxycycline hyclate had the greatest bioavailability (545%); mean +/- SD maximum serum concentration was 2.4 +/- 0.95 microg/mL, peak time to maximum concentration was 19.23 +/- 2.03 hours, and elimination half-life was 40.92 +/- 4.25 hours.",Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672975/),h,40.92,141693,DB00759,Tetracycline
,27144397,zeta potential,"DPNPs were constructed using a novel solvent diffusion method aided by probe sonication, which resulted in an average size 95.43 ± 0.8 nm as per DLS, PDI 0.168 ± 0.03, zeta potential -7.38 ± 0.32, entrapment efficiency 75.58 ± 1.94%, and refrigerator stability of 7 days with respect to size in the optimized batch.",Subcutaneously Administered Ultrafine PLGA Nanoparticles Containing Doxycycline Hydrochloride Target Lymphatic Filarial Parasites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27144397/),,7.38,141934,DB00759,Tetracycline
,27144397,entrapment efficiency,"DPNPs were constructed using a novel solvent diffusion method aided by probe sonication, which resulted in an average size 95.43 ± 0.8 nm as per DLS, PDI 0.168 ± 0.03, zeta potential -7.38 ± 0.32, entrapment efficiency 75.58 ± 1.94%, and refrigerator stability of 7 days with respect to size in the optimized batch.",Subcutaneously Administered Ultrafine PLGA Nanoparticles Containing Doxycycline Hydrochloride Target Lymphatic Filarial Parasites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27144397/),%,75.58,141935,DB00759,Tetracycline
,27144397,elimination half-life,Pharmacokinetic studies in Wistar rats further revealed that DPNPs caused a 16-fold prolongation in attainment of plasma Tmax and a 2-fold extension of elimination half-life (28.569 ± 1.27 h) at a dose of 5 mg/kg when compared to native drug (DOX solution) of the same strength.,Subcutaneously Administered Ultrafine PLGA Nanoparticles Containing Doxycycline Hydrochloride Target Lymphatic Filarial Parasites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27144397/),h,28.569,141936,DB00759,Tetracycline
,27144397,Cmax,"Contrastingly the trend was reversed in regional lymph nodes where Cmax for DPNPs (820 ± 84 ng/mg) was 4-fold greater, and lymphatic Tmax was attained in one-fourth of what was required for DOX solution.",Subcutaneously Administered Ultrafine PLGA Nanoparticles Containing Doxycycline Hydrochloride Target Lymphatic Filarial Parasites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27144397/),[ng] / [mg],820,141937,DB00759,Tetracycline
,30558639,saturation coefficients,"Tigecycline dialysability was high, as indicated by the high mean saturation coefficients of 0.79 and 0.90 for CVVHD and CVVHDF, respectively, and in range of the concentration-dependent unbound fraction of tigecycline (45-94%).",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),,0.79,142260,DB00759,Tetracycline
,30558639,saturation coefficients,"Tigecycline dialysability was high, as indicated by the high mean saturation coefficients of 0.79 and 0.90 for CVVHD and CVVHDF, respectively, and in range of the concentration-dependent unbound fraction of tigecycline (45-94%).",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),,0.90,142261,DB00759,Tetracycline
,30558639,unbound fraction,"Tigecycline dialysability was high, as indicated by the high mean saturation coefficients of 0.79 and 0.90 for CVVHD and CVVHDF, respectively, and in range of the concentration-dependent unbound fraction of tigecycline (45-94%).",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),%,45-94,142262,DB00759,Tetracycline
,30558639,clearance (CL),"However, the contribution of CRRT to tigecycline clearance (CL) was only moderate (CLCVVHD: 1.69 L/h, CLCVVHDF: 2.71 L/h) in comparison with CLbody (physiological part of the total clearance) of 18.3 L/h.",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),[l] / [h],1.69,142263,DB00759,Tetracycline
,30558639,clearance (CL),"However, the contribution of CRRT to tigecycline clearance (CL) was only moderate (CLCVVHD: 1.69 L/h, CLCVVHDF: 2.71 L/h) in comparison with CLbody (physiological part of the total clearance) of 18.3 L/h.",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),[l] / [h],2.,142264,DB00759,Tetracycline
,30558639,CLbody,"However, the contribution of CRRT to tigecycline clearance (CL) was only moderate (CLCVVHD: 1.69 L/h, CLCVVHDF: 2.71 L/h) in comparison with CLbody (physiological part of the total clearance) of 18.3 L/h.",Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),[l] / [h],18.3,142265,DB00759,Tetracycline
≤,30558639,minimal inhibitory concentration (MIC),The probability of target attainment under CRRT for abdominal infections was ≥ 0.88 for minimal inhibitory concentration (MIC) values ≤ 0.5 mg/L and similar to patients without AKI.,Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30558639/),[mg] / [l],0.5,142266,DB00759,Tetracycline
,11168911,AUC,The AUC for the calves was 168+/-14.6 (microg ? h/mL) and was significantly less than the AUC for sheep (209+/-43 microg ? h/mL).,Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),,168,142747,DB00759,Tetracycline
,11168911,AUC,The AUC for the calves was 168+/-14.6 (microg ? h/mL) and was significantly less than the AUC for sheep (209+/-43 microg ? h/mL).,Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),[?·h·μg] / [ml],209,142748,DB00759,Tetracycline
,11168911,Cmax,"Using the standard two-stage approach and a one-compartment model, the mean Cmax for the calves was 5.2+/-0.8 microg /mL, and for the sheep was 6.1+/-1.3 microg /mL.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),[μg] / [ml],5.2,142749,DB00759,Tetracycline
,11168911,Cmax,"Using the standard two-stage approach and a one-compartment model, the mean Cmax for the calves was 5.2+/-0.8 microg /mL, and for the sheep was 6.1+/-1.3 microg /mL.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),[μg] / [ml],6.1,142750,DB00759,Tetracycline
,11168911,terminal phase rate constants,"The mean terminal phase rate constants were 0.031 and 0.033 h, and the Vdss were 3.3 and 3.08 L/kg for the calves and sheep respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,0.031,142751,DB00759,Tetracycline
,11168911,terminal phase rate constants,"The mean terminal phase rate constants were 0.031 and 0.033 h, and the Vdss were 3.3 and 3.08 L/kg for the calves and sheep respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,0.033,142752,DB00759,Tetracycline
,11168911,Vdss,"The mean terminal phase rate constants were 0.031 and 0.033 h, and the Vdss were 3.3 and 3.08 L/kg for the calves and sheep respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),[l] / [kg],3.3,142753,DB00759,Tetracycline
,11168911,Vdss,"The mean terminal phase rate constants were 0.031 and 0.033 h, and the Vdss were 3.3 and 3.08 L/kg for the calves and sheep respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),[l] / [kg],3.08,142754,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,38.6,142755,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,33.4,142756,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,28.6,142757,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,25.4,142758,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,21.3,142759,DB00759,Tetracycline
,11168911,Half-lives,"Half-lives of OTC residues in the tissues were 38.6, 33.4, 28.6, 25.4, 21.3, and 19.9 h for injection site, kidney, muscle, liver, mesenteric fat and renal fat, respectively.",Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168911/),h,19.9,142760,DB00759,Tetracycline
,1491343,detection limit,"Linearity was observed over the 0-8.5-micrograms/mL range, and the detection limit approximated 5 ng/mL.",Liquid chromatographic determination of oxytetracycline in bovine plasma by double-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491343/),[ng] / [ml],5,143964,DB00759,Tetracycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,158.5,144160,DB00759,Tetracycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,18.5,144161,DB00759,Tetracycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,37,144162,DB00759,Tetracycline
,2600787,elimination constants,"The elimination constants of the isotope per day in plasma were -0.148 in weaning rats (4-7 weeks), -0.071 in adolescent rats (10-14 weeks), and -0.025 in mature rats (15-23 weeks).",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),,-,144256,DB00759,Tetracycline
,2600787,elimination constants,"The elimination constants of the isotope per day in plasma were -0.148 in weaning rats (4-7 weeks), -0.071 in adolescent rats (10-14 weeks), and -0.025 in mature rats (15-23 weeks).",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),,0.148,144257,DB00759,Tetracycline
,2600787,elimination constants,"The elimination constants of the isotope per day in plasma were -0.148 in weaning rats (4-7 weeks), -0.071 in adolescent rats (10-14 weeks), and -0.025 in mature rats (15-23 weeks).",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),,0.071,144258,DB00759,Tetracycline
,2600787,elimination constants,"The elimination constants of the isotope per day in plasma were -0.148 in weaning rats (4-7 weeks), -0.071 in adolescent rats (10-14 weeks), and -0.025 in mature rats (15-23 weeks).",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),,0.025,144259,DB00759,Tetracycline
,2600787,half-lives,"The half-lives of the isotope in the femur were 10 d in neonatal rats (0-2 weeks), 32 d in weaning rats, 63 d in adolescent rats, and 198 d in mature rats.",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),d,10,144260,DB00759,Tetracycline
,2600787,half-lives,"The half-lives of the isotope in the femur were 10 d in neonatal rats (0-2 weeks), 32 d in weaning rats, 63 d in adolescent rats, and 198 d in mature rats.",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),d,32,144261,DB00759,Tetracycline
,2600787,half-lives,"The half-lives of the isotope in the femur were 10 d in neonatal rats (0-2 weeks), 32 d in weaning rats, 63 d in adolescent rats, and 198 d in mature rats.",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),d,63,144262,DB00759,Tetracycline
,2600787,half-lives,"The half-lives of the isotope in the femur were 10 d in neonatal rats (0-2 weeks), 32 d in weaning rats, 63 d in adolescent rats, and 198 d in mature rats.",A pharmacokinetic model in the rat and rabbit of the direct measurement of mature bone resorption in vivo with [3H]tetracycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600787/),d,198,144263,DB00759,Tetracycline
,997179,half-life,"In the case of Berenil, administered in the form of the combination drug, the second slow elimination phase with a 63 hour half-life, as found after the administration of Berenil only, could not be observed.",Pharmacokinetic investigations on diminazene and rolitetracycline in comparison to a combination of both. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/997179/),h,63,144337,DB00759,Tetracycline
,3354964,peak bile/plasma concentration ratio,The peak bile/plasma concentration ratio for CTC was 254 at 2 hours.,Pharmacokinetics of chlortetracycline in the turkey: evaluation of biliary secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354964/),,254,144611,DB00759,Tetracycline
greater,3354964,bile/plasma concentration ratio,The bile/plasma concentration ratio was greater than 1 from 10 to 240 minutes after CTC administration.,Pharmacokinetics of chlortetracycline in the turkey: evaluation of biliary secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354964/),,1,144612,DB00759,Tetracycline
,17436824,time of maximum concentration (tmax,"An extended-release (ER) minocycline hydrochloride tablet formulation was developed that demonstrated delayed time of maximum concentration (tmax, 3 1/2 - 4 hours) compared with a nonmodified-release minocycline (tmax, 2 1/4 - 3 hours), and a lower maximum concentration of drug (cmax) in the blood (90%) compared with nonmodified-release formulations.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),1,3,145082,DB00759,Tetracycline
,17436824,tmax,"An extended-release (ER) minocycline hydrochloride tablet formulation was developed that demonstrated delayed time of maximum concentration (tmax, 3 1/2 - 4 hours) compared with a nonmodified-release minocycline (tmax, 2 1/4 - 3 hours), and a lower maximum concentration of drug (cmax) in the blood (90%) compared with nonmodified-release formulations.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),1,2,145083,DB00759,Tetracycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[h·μg] / [ml],33.32,145084,DB00759,Tetracycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.63,145085,DB00759,Tetracycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μh] / [ml],46.35,145086,DB00759,Tetracycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.92,145087,DB00759,Tetracycline
,17436824,area under the curve (AUC(0-24)),"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[h·μg] / [ml],33.32,145088,DB00759,Tetracycline
,17436824,area under the curve (AUC(0-24)),"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μh] / [ml],46.35,145089,DB00759,Tetracycline
,17436824,cmax,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.63,145090,DB00759,Tetracycline
,17436824,cmax,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.92,145091,DB00759,Tetracycline
,30878630,MIC,"Moreover, the sensitivity was ascertained to be 63% and the specificity was 80% when the MIC cut-off value was considered to be 1.75 mg/L.",Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30878630/),[mg] / [l],1.75,145125,DB00759,Tetracycline
≥,30878630,AUIC,"The AUIC and MIC are associated with tigecycline treatment outcomes in pneumonia due to MDR bacteria, and aiming to achieve an individualized AUIC ≥ 10.12 when MIC < 1.75 mg/L could improve outcomes.",Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30878630/),,10.12,145126,DB00759,Tetracycline
<,30878630,MIC,"The AUIC and MIC are associated with tigecycline treatment outcomes in pneumonia due to MDR bacteria, and aiming to achieve an individualized AUIC ≥ 10.12 when MIC < 1.75 mg/L could improve outcomes.",Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30878630/),[mg] / [l],1.75,145127,DB00759,Tetracycline
,29941646,areas under the concentration-time curves (AUCs),Mean areas under the concentration-time curves (AUCs) following a single eravacycline dose ranged from 5.39 μg · h/ml to 183.53 μg · h/ml.,Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941646/),[h·μg] / [ml],5.39,145338,DB00759,Tetracycline
,29941646,areas under the concentration-time curves (AUCs),Mean areas under the concentration-time curves (AUCs) following a single eravacycline dose ranged from 5.39 μg · h/ml to 183.53 μg · h/ml.,Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941646/),[h·μg] / [ml],183.53,145339,DB00759,Tetracycline
,29941646,AUCs,"Within the multidose study, mean AUCs ranged from 2.53 μg · h/ml to 29.89 μg · h/ml.",Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941646/),[h·μg] / [ml],2.53,145340,DB00759,Tetracycline
,29941646,AUCs,"Within the multidose study, mean AUCs ranged from 2.53 μg · h/ml to 29.89 μg · h/ml.",Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941646/),[h·μg] / [ml],29.89,145341,DB00759,Tetracycline
,15793165,volumes of distribution at steady state,"Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters.",Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793165/),l,350,145949,DB00759,Tetracycline
,15793165,volumes of distribution at steady state,"Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters.",Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793165/),l,500,145950,DB00759,Tetracycline
,18440843,volume of distribution at steady-state (V(ss)),"Mean pharmacokinetic parameters obtained using a 2-compartmental model included a volume of distribution at steady-state (V(ss)) of 1.759+/-0.3149L/kg, a total clearance (Cl) of 3.045+/-0.5264mL/kg/min and an elimination half-life (t(1/2beta)) of 7.027+/-1.128h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[l] / [kg],1.759,146962,DB00759,Tetracycline
,18440843,total clearance (Cl),"Mean pharmacokinetic parameters obtained using a 2-compartmental model included a volume of distribution at steady-state (V(ss)) of 1.759+/-0.3149L/kg, a total clearance (Cl) of 3.045+/-0.5264mL/kg/min and an elimination half-life (t(1/2beta)) of 7.027+/-1.128h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[ml] / [kg·min],3.045,146963,DB00759,Tetracycline
,18440843,elimination half-life (t(1/2beta)),"Mean pharmacokinetic parameters obtained using a 2-compartmental model included a volume of distribution at steady-state (V(ss)) of 1.759+/-0.3149L/kg, a total clearance (Cl) of 3.045+/-0.5264mL/kg/min and an elimination half-life (t(1/2beta)) of 7.027+/-1.128h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,7.027,146964,DB00759,Tetracycline
,18440843,V(ss),"Comparative values obtained from the 3-compartmental mean values were: V(ss) of 1.801+/-0.3429L/kg, a Cl of 2.634+/-0.6376mL/kg/min and a t(1/2beta) of 12.11+/-2.060h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[l] / [kg],1.801,146965,DB00759,Tetracycline
,18440843,Cl,"Comparative values obtained from the 3-compartmental mean values were: V(ss) of 1.801+/-0.3429L/kg, a Cl of 2.634+/-0.6376mL/kg/min and a t(1/2beta) of 12.11+/-2.060h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[ml] / [kg·min],2.634,146966,DB00759,Tetracycline
,18440843,t(1/2beta),"Comparative values obtained from the 3-compartmental mean values were: V(ss) of 1.801+/-0.3429L/kg, a Cl of 2.634+/-0.6376mL/kg/min and a t(1/2beta) of 12.11+/-2.060h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,12.11,146967,DB00759,Tetracycline
,18440843,Mean residence time (MRT(0-infinity)),Mean residence time (MRT(0-infinity)) was 11.18+/-3.152h.,Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,11.18,146968,DB00759,Tetracycline
,18440843,maximum plasma concentration (C(max)),"The pharmacokinetic parameter mean values were: maximum plasma concentration (C(max)), 2.130+/-0.950microg/mL; time to reach C(max) (t(max)), 3.595+/-3.348h, and absorption half-life (t(1)/(2k)(01)), 36.28+/-14.57h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[μg] / [ml],2.130,146969,DB00759,Tetracycline
,18440843,time to reach C(max) (t(max)),"The pharmacokinetic parameter mean values were: maximum plasma concentration (C(max)), 2.130+/-0.950microg/mL; time to reach C(max) (t(max)), 3.595+/-3.348h, and absorption half-life (t(1)/(2k)(01)), 36.28+/-14.57h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,3.595,146970,DB00759,Tetracycline
,18440843,absorption half-life (t(1)/(2k),"The pharmacokinetic parameter mean values were: maximum plasma concentration (C(max)), 2.130+/-0.950microg/mL; time to reach C(max) (t(max)), 3.595+/-3.348h, and absorption half-life (t(1)/(2k)(01)), 36.28+/-14.57h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,36.28,146971,DB00759,Tetracycline
,18440843,C(max),"Non-compartmental parameter values were: C(max), 2.182+/-0.9117microg/mL; t(max), 3.432+/-3.307h; F, 35.77+/-10.20%, and mean absorption time (MAT(0-infinity)), 25.55+/-15.27h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),[μg] / [ml],2.182,146972,DB00759,Tetracycline
,18440843,t(max),"Non-compartmental parameter values were: C(max), 2.182+/-0.9117microg/mL; t(max), 3.432+/-3.307h; F, 35.77+/-10.20%, and mean absorption time (MAT(0-infinity)), 25.55+/-15.27h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,3.432,146973,DB00759,Tetracycline
,18440843,F,"Non-compartmental parameter values were: C(max), 2.182+/-0.9117microg/mL; t(max), 3.432+/-3.307h; F, 35.77+/-10.20%, and mean absorption time (MAT(0-infinity)), 25.55+/-15.27h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),%,35.77,146974,DB00759,Tetracycline
,18440843,mean absorption time (MAT(0-infinity)),"Non-compartmental parameter values were: C(max), 2.182+/-0.9117microg/mL; t(max), 3.432+/-3.307h; F, 35.77+/-10.20%, and mean absorption time (MAT(0-infinity)), 25.55+/-15.27h.",Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440843/),h,25.55,146975,DB00759,Tetracycline
,9174875,total u,The other collection periods and the total urinary excretion of tetracycline (24 h) did not differ from the control session.,Renal excretion of tetracycline is transiently decreased during short-term heat exposure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174875/),h,24,147386,DB00759,Tetracycline
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,15,147756,DB00759,Tetracycline
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,30,147757,DB00759,Tetracycline
,27650184,MICs,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.125-1,148291,DB00759,Tetracycline
,27650184,MICs,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],2,148292,DB00759,Tetracycline
,27650184,fCmax concentrations,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.15,148293,DB00759,Tetracycline
,27650184,fCmax concentrations,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],1.5,148294,DB00759,Tetracycline
,27650184,MICs,"At lung concentrations and low inocula, a bacteriostatic and killing effect was found for isolates with MICs of 0.25 and 0.125 mg/L, respectively.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.25,148295,DB00759,Tetracycline
,27650184,MICs,"At lung concentrations and low inocula, a bacteriostatic and killing effect was found for isolates with MICs of 0.25 and 0.125 mg/L, respectively.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.125,148296,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],16,148297,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],103,148298,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],28,148299,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],105,148300,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],79,148301,DB00759,Tetracycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],107,148302,DB00759,Tetracycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],16,148303,DB00759,Tetracycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],28,148304,DB00759,Tetracycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],79,148305,DB00759,Tetracycline
,3349389,half-life,"Compartmental pharmacokinetic evaluation of the serum concentration time data indicated that doxycycline has a half-life of 10.36 h, a body clearance of 1.68 +/- 0.44 mL/min/kg, and a volume of distribution at steady state of 1.468 +/- 0.237 L/kg.",Pharmacokinetics of doxycycline in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349389/),h,10.36,148461,DB00759,Tetracycline
,3349389,body clearance,"Compartmental pharmacokinetic evaluation of the serum concentration time data indicated that doxycycline has a half-life of 10.36 h, a body clearance of 1.68 +/- 0.44 mL/min/kg, and a volume of distribution at steady state of 1.468 +/- 0.237 L/kg.",Pharmacokinetics of doxycycline in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349389/),[ml] / [kg·min],1.68,148462,DB00759,Tetracycline
,3349389,volume of distribution at steady state,"Compartmental pharmacokinetic evaluation of the serum concentration time data indicated that doxycycline has a half-life of 10.36 h, a body clearance of 1.68 +/- 0.44 mL/min/kg, and a volume of distribution at steady state of 1.468 +/- 0.237 L/kg.",Pharmacokinetics of doxycycline in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349389/),[l] / [kg],1.468,148463,DB00759,Tetracycline
,24155157,serum,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [ml],"2,402",148723,DB00759,Tetracycline
,24155157,area under the curve,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [ml],"2,402",148724,DB00759,Tetracycline
,24155157,area under the curve,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [g],"11,465",148725,DB00759,Tetracycline
,24155157,maximum concentration (Cmax ),"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[ng] / [ml],974,148726,DB00759,Tetracycline
,24155157,maximum concentration (Cmax ),"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[ng] / [g],"2,262",148727,DB00759,Tetracycline
,24155157,bone to serum ratio,"The bone to serum ratio calculated using the AUCτ values was 4.77, confirming tigecycline penetration into bone.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),,4.77,148728,DB00759,Tetracycline
,15220014,minimum concentration,Values for the minimum concentration of tigecycline that is inhibitory for 90% of all isolates ranged from 0.06 to 0.50 microg/mL for the selected pathogens.,"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),[μg] / [ml],0.06 to 0.50,151189,DB00759,Tetracycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,74,151190,DB00759,Tetracycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,70,151191,DB00759,Tetracycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,67,151192,DB00759,Tetracycline
,15793157,penetration rate,"Tigecycline penetrates into blister fluid well, with a mean penetration rate of 74%.",Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793157/),%,74,151281,DB00759,Tetracycline
,8039533,bioavailability,"The two formulations were bioequivalent (rate and extent) during fasting without omeprazole pre-treatment, whereas after omeprazole, the monohydrate showed a highly significant decrease in bioavailability (38% for AUC and 45% for Cmax) compared to the carrageenate formulation, which was not affected by prior administration of omeprazole.",Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039533/),%,38,151661,DB00759,Tetracycline
,8039533,bioavailability,"The two formulations were bioequivalent (rate and extent) during fasting without omeprazole pre-treatment, whereas after omeprazole, the monohydrate showed a highly significant decrease in bioavailability (38% for AUC and 45% for Cmax) compared to the carrageenate formulation, which was not affected by prior administration of omeprazole.",Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039533/),%,45,151662,DB00759,Tetracycline
,27993102,steady-state DC concentration,The steady-state DC concentration (8.3 ± 0.9 μg/mL) was reached on the third day of medication.,Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),[μg] / [ml],8.3,152124,DB00759,Tetracycline
,27993102,elimination constant,"The elimination constant (0.05 ± 0.01 1/h), half-life (14.9 ± 1.4 h), area under concentration versus time curve (81.0 ± 9.9 h·μg/mL) and mean residence time (22.7 ± 2.5 h) were obtained using a non-compartmental pharmacokinetic model.",Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),[1] / [h],0.05,152125,DB00759,Tetracycline
,27993102,half-life,"The elimination constant (0.05 ± 0.01 1/h), half-life (14.9 ± 1.4 h), area under concentration versus time curve (81.0 ± 9.9 h·μg/mL) and mean residence time (22.7 ± 2.5 h) were obtained using a non-compartmental pharmacokinetic model.",Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),h,14.9,152126,DB00759,Tetracycline
,27993102,area under concentration versus time curve,"The elimination constant (0.05 ± 0.01 1/h), half-life (14.9 ± 1.4 h), area under concentration versus time curve (81.0 ± 9.9 h·μg/mL) and mean residence time (22.7 ± 2.5 h) were obtained using a non-compartmental pharmacokinetic model.",Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),[h·μg] / [ml],81.0,152127,DB00759,Tetracycline
,27993102,mean residence time,"The elimination constant (0.05 ± 0.01 1/h), half-life (14.9 ± 1.4 h), area under concentration versus time curve (81.0 ± 9.9 h·μg/mL) and mean residence time (22.7 ± 2.5 h) were obtained using a non-compartmental pharmacokinetic model.",Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),h,22.7,152128,DB00759,Tetracycline
,27993102,MRL,The unregulated heart and gizzard were considered safe even when the lowest MRL of muscle (100 ng/g) was applied.,Pharmacokinetics and tissue depletion of doxycycline administered at high dosage to broiler chickens via the drinking water. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993102/),[ng] / [g],100,152129,DB00759,Tetracycline
,28797073,elimination half-lives,"Both antibiotics showed evident, albeit slow elimination phase with elimination half-lives ranging from 22 to 88 hours.","Assessment of veterinary drugs in plants using pharmacokinetic approaches: The absorption, distribution and elimination of tetracycline and sulfamethoxazole in ephemeral vegetables. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28797073/),h,22 to 88,152259,DB00759,Tetracycline
,2272707,tmax,The results of this study show that DC is absorbed rapidly (tmax 3.3-3.8 h) and with equal bioavailability (AUC values 52.9-58.5 mg/l x h) from both hydrochloride and monohydrate tablets.,Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets--comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272707/),h,3.3-3.8,152442,DB00759,Tetracycline
,2272707,AUC,The results of this study show that DC is absorbed rapidly (tmax 3.3-3.8 h) and with equal bioavailability (AUC values 52.9-58.5 mg/l x h) from both hydrochloride and monohydrate tablets.,Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets--comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272707/),[mg] / [h·l],52.9-58.5,152443,DB00759,Tetracycline
,26033620,mean residence time,"The mean residence time for DPPC was the highest (111.78 hours), followed by sphing (56.00 hours) and STD (6.86 hours).",A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26033620/),h,111.78,154594,DB00759,Tetracycline
,26033620,mean residence time,"The mean residence time for DPPC was the highest (111.78 hours), followed by sphing (56.00 hours) and STD (6.86 hours).",A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26033620/),h,56.00,154595,DB00759,Tetracycline
,26033620,mean residence time,"The mean residence time for DPPC was the highest (111.78 hours), followed by sphing (56.00 hours) and STD (6.86 hours).",A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26033620/),h,6.86,154596,DB00759,Tetracycline
,28090673,ratios of average concentration over 48 h (Cav0-48 h )/MIC,"PK/PD integration established ratios of average concentration over 48 h (Cav0-48 h )/MIC of 5.87 and 0.27 μg/mL (P. multocida) and 0.70 and 0.85 μg/mL (A. pleuropneumoniae) for broth and serum MICs, respectively.",Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28090673/),[μg] / [ml],5.87,154641,DB00759,Tetracycline
,28090673,ratios of average concentration over 48 h (Cav0-48 h )/MIC,"PK/PD integration established ratios of average concentration over 48 h (Cav0-48 h )/MIC of 5.87 and 0.27 μg/mL (P. multocida) and 0.70 and 0.85 μg/mL (A. pleuropneumoniae) for broth and serum MICs, respectively.",Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28090673/),[μg] / [ml],0.27,154642,DB00759,Tetracycline
,28090673,ratios of average concentration over 48 h (Cav0-48 h )/MIC,"PK/PD integration established ratios of average concentration over 48 h (Cav0-48 h )/MIC of 5.87 and 0.27 μg/mL (P. multocida) and 0.70 and 0.85 μg/mL (A. pleuropneumoniae) for broth and serum MICs, respectively.",Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28090673/),[μg] / [ml],0.70,154643,DB00759,Tetracycline
,28090673,ratios of average concentration over 48 h (Cav0-48 h )/MIC,"PK/PD integration established ratios of average concentration over 48 h (Cav0-48 h )/MIC of 5.87 and 0.27 μg/mL (P. multocida) and 0.70 and 0.85 μg/mL (A. pleuropneumoniae) for broth and serum MICs, respectively.",Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28090673/),[μg] / [ml],0.85,154644,DB00759,Tetracycline
,27353264,"area under the concentration-time curve for the free, unbound fraction of the drug","The 2.5-mg/kg i.v. q12h dose in mice resulted in an area under the concentration-time curve for the free, unbound fraction of the drug of 1.64 mg · h/liter, which closely resembles the human exposure level.",Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353264/),[h·mg] / [l],1.64,154700,DB00759,Tetracycline
,34057219,minimum inhibitory concentration (MIC),"Tissue chambers (TC) were implanted subcutaneously in the cervical region of 7 horses and inoculated with a single S. zooepidemicus isolate with a minimum inhibitory concentration (MIC) of 0.25 µg/ml, determined by agar dilution.",Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34057219/),[μg] / [ml],0.25,155151,DB00759,Tetracycline
,34057219,plasma peak concentration (Cmax ),"The mean plasma peak concentration (Cmax ) of DXC was 0.32 µg/ml, and concentrations above the MIC were only reached in 3 TC samples.",Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34057219/),[μg] / [ml],0.32,155152,DB00759,Tetracycline
,34057219,T > MIC,"In plasma, mean T > MIC was 2.4 h, mean Cmax /MIC was 1.30, and mean AUClast /MIC was 11.63 h.",Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34057219/),h,2.4,155153,DB00759,Tetracycline
,34057219,Cmax /MIC,"In plasma, mean T > MIC was 2.4 h, mean Cmax /MIC was 1.30, and mean AUClast /MIC was 11.63 h.",Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34057219/),,1.30,155154,DB00759,Tetracycline
,34057219,AUClast /MIC,"In plasma, mean T > MIC was 2.4 h, mean Cmax /MIC was 1.30, and mean AUClast /MIC was 11.63 h.",Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34057219/),h,11.63,155155,DB00759,Tetracycline
,28160001,F,"No effects were observed of any of the mycotoxin binders on the relative oral bioavailability of the coccidiostats (i.e., F between 82 and 101% and 79 and 93% for diclazuril and salinomycin, respectively).","Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160001/),%,82 and 101,157349,DB00759,Tetracycline
,28160001,F,"No effects were observed of any of the mycotoxin binders on the relative oral bioavailability of the coccidiostats (i.e., F between 82 and 101% and 79 and 93% for diclazuril and salinomycin, respectively).","Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160001/),%,79,157350,DB00759,Tetracycline
,28160001,F,"Also, no significant effects could be noticed of any of the mycotoxin binders on the relative oral bioavailability of the antimicrobials doxycycline and tylosin (i.e., F between 67 and 83% and between 43 and 104%, respectively).","Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160001/),%,67 and 83,157351,DB00759,Tetracycline
,28160001,F,"Also, no significant effects could be noticed of any of the mycotoxin binders on the relative oral bioavailability of the antimicrobials doxycycline and tylosin (i.e., F between 67 and 83% and between 43 and 104%, respectively).","Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28160001/),%,43 and 104,157352,DB00759,Tetracycline
,22838083,AUC(ss),The average OTC AUC(ss) was 29.2 microg x h/mL and was estimated using nonlinear mixed-effects modeling and bootstrap resampling techniques.,Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22838083/),[h·μg] / [ml],29.2,158112,DB00759,Tetracycline
,22838083,elimination half-life,"The elimination half-life was estimated as 85.0 h, and the fraction of steady state achieved was estimated as 0.85.",Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22838083/),h,85.0,158113,DB00759,Tetracycline
,22838083,fraction of steady state achieved,"The elimination half-life was estimated as 85.0 h, and the fraction of steady state achieved was estimated as 0.85.",Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22838083/),,0.85,158114,DB00759,Tetracycline
,22838083,AUC(ss),The calculated AUC(ss) (24.8 microg x h/mL) following 10 d of oral dosing with 75 mg OTC/kg BW was less than the estimated AUC(ss).,Oxytetracycline pharmacokinetics in rainbow trout during and after an orally administered medicated feed regimen. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22838083/),[h·μg] / [ml],24.8,158115,DB00759,Tetracycline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.44,158191,DB00759,Tetracycline
,7184676,apparent volume of distribution,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[l] / [kg],0.42,158192,DB00759,Tetracycline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.82,158193,DB00759,Tetracycline
,7184676,clearance,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),[min·ml] / [kg],0.73,158194,DB00759,Tetracycline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.27,158195,DB00759,Tetracycline
,7184676,elimination half-life,"At each phase of study the mean +/- S.D. pharmacokinetic values were as follows: apparent volume of distribution (liter/kg), 0.44 +/- 0.05 (control) and 0.42 +/- 0.04 (experimental); clearance (ml . min/kg) 0.82 +/- 0.15 (control) and 0.73 +/- 0.07, (experimental); and elimination half-life (hours), 6.27 +/- 1.08 (control) and 6.72 +/- 0.78 (experimental).",Effect of tetracycline hydrochloride on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184676/),h,6.72,158196,DB00759,Tetracycline
,7250150,elimination constants,The three preparations gave the elimination constants of the same order of magnitude (0.045 h-1 to 0.051 h-1).,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),1/[h],0.045,158823,DB00759,Tetracycline
,7250150,elimination constants,The three preparations gave the elimination constants of the same order of magnitude (0.045 h-1 to 0.051 h-1).,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),1/[h],0.051,158824,DB00759,Tetracycline
,7250150,plasma half-life t 1/2 beta,"The plasma half-life t 1/2 beta was 14.143 h for DP, 15.400 h for DHC and 13.588 h for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),h,14.143,158825,DB00759,Tetracycline
,7250150,plasma half-life t 1/2 beta,"The plasma half-life t 1/2 beta was 14.143 h for DP, 15.400 h for DHC and 13.588 h for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),h,15.400,158826,DB00759,Tetracycline
,7250150,plasma half-life t 1/2 beta,"The plasma half-life t 1/2 beta was 14.143 h for DP, 15.400 h for DHC and 13.588 h for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),h,13.588,158827,DB00759,Tetracycline
,7250150,Vd,Vd is higher for DB (91.955 L) than for DPP (73.401 L) and DHC (64.827 L).,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),l,91.955,158828,DB00759,Tetracycline
,7250150,Vd,Vd is higher for DB (91.955 L) than for DPP (73.401 L) and DHC (64.827 L).,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),l,73.401,158829,DB00759,Tetracycline
,7250150,Vd,Vd is higher for DB (91.955 L) than for DPP (73.401 L) and DHC (64.827 L).,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),l,64.827,158830,DB00759,Tetracycline
,7250150,Total plasma clearance,"Total plasma clearance is 52.767 ml/min for DPP, 48.728 ml/min for DHC and 60.174 ml/min for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),[ml] / [min],52.767,158831,DB00759,Tetracycline
,7250150,Total plasma clearance,"Total plasma clearance is 52.767 ml/min for DPP, 48.728 ml/min for DHC and 60.174 ml/min for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),[ml] / [min],48.728,158832,DB00759,Tetracycline
,7250150,Total plasma clearance,"Total plasma clearance is 52.767 ml/min for DPP, 48.728 ml/min for DHC and 60.174 ml/min for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),[ml] / [min],60.174,158833,DB00759,Tetracycline
,7250150,Urinary elimination,"Urinary elimination 72 hours after administration is 29.24% for DPP, 35.60% and 28.15% for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),%,29.24,158834,DB00759,Tetracycline
,7250150,Urinary elimination,"Urinary elimination 72 hours after administration is 29.24% for DPP, 35.60% and 28.15% for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),%,35.60,158835,DB00759,Tetracycline
,7250150,Urinary elimination,"Urinary elimination 72 hours after administration is 29.24% for DPP, 35.60% and 28.15% for DB.","Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),%,28.15,158836,DB00759,Tetracycline
,7250150,Relative bioavailability,Relative bioavailability of the capsule form of DPP is 111.15% of that of DHC.,"Pharmacokinetic study of doxycycline polyphosphate (PPD), hydrochloride (CHD) and base (DB). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250150/),%,111.15,158837,DB00759,Tetracycline
,33168615,free,"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,12,158904,DB00759,Tetracycline
,33168615,area under the curve above the MIC [fAUC:MIC],"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,12,158905,DB00759,Tetracycline
,33168615,area under the curve above the MIC [fAUC:MIC],"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,18,158906,DB00759,Tetracycline
>,33168615,MIC,"In the PK-PD probability of target attainment analyses, minocycline 200 mg i.v. every 12 h (Q12H) was predicted to result in a suboptimal PK-PD profile for patients with A. baumannii infections with MIC values of >1 mg/liter.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),[mg] / [l],1,158907,DB00759,Tetracycline
,16454638,time to maximum concentration,"After multiple doses, mean +/- SD time to maximum concentration was 1.63 +/- 1.36 hours, maximum concentration was 1.74 +/- 0.3 microg/mL, and elimination half-life was 12.07 +/- 3.17 hours.",Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),h,1.63,159109,DB00759,Tetracycline
,16454638,maximum concentration,"After multiple doses, mean +/- SD time to maximum concentration was 1.63 +/- 1.36 hours, maximum concentration was 1.74 +/- 0.3 microg/mL, and elimination half-life was 12.07 +/- 3.17 hours.",Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),[μg] / [ml],1.74,159110,DB00759,Tetracycline
,16454638,elimination half-life,"After multiple doses, mean +/- SD time to maximum concentration was 1.63 +/- 1.36 hours, maximum concentration was 1.74 +/- 0.3 microg/mL, and elimination half-life was 12.07 +/- 3.17 hours.",Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),h,12.07,159111,DB00759,Tetracycline
,16454638,Plasma protein binding,Plasma protein binding was 81.76 +/- 2.43%.,Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),%,81.76,159112,DB00759,Tetracycline
<,16454638,minimum inhibitory concentration,"Results suggest that doxycycline administered at a dosage of 20 mg/kg, PO, every 24 hours will result in drug concentrations adequate for killing intracellular bacteria and bacteria with minimum inhibitory concentration < or = 0.25 microg/mL.",Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),[μg] / [ml],0.25,159113,DB00759,Tetracycline
,16454638,minimum inhibitory concentration,"For bacteria with minimum inhibitory concentration of 0.5 to 1.0 microg/mL, a dosage of 20 mg/kg, PO, every 12 hours may be required; extreme caution should be exercised with the higher dosage until more safety data are available.",Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454638/),[μg] / [ml],0.5 to 1.0,159114,DB00759,Tetracycline
< or =,15360093,MIC,"Of these agents, only amoxicillin-clavulanate potassium powder for oral suspension and amoxicillin-clavulanate potassium extended-release tablets were designed to treat infections caused by penicillin-resistant pneumococci (penicillin MIC < or =2 microg/mL).",Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15360093/),[μg] / [ml],2,159240,DB00759,Tetracycline
,21395609,maximum concentration of drug (C(max) ),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),[μg] / [ml],19.4,159967,DB00759,Tetracycline
,21395609,time at which this maximum concentration of drug (T(max) ),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,4.0,159968,DB00759,Tetracycline
,21395609,time at which this maximum concentration of drug (T(max) ),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,5.1,159969,DB00759,Tetracycline
,21395609,elimination half-life (t½),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,4.0,159970,DB00759,Tetracycline
,21395609,elimination half-life (t½),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,5.1,159971,DB00759,Tetracycline
,21395609,area under the concentration vs. time curve (AUC),"In plasma, the maximum concentration of drug (C(max) ), the time at which this maximum concentration of drug (T(max) ) was reached, the elimination half-life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),[h·μg] / [ml],150,159972,DB00759,Tetracycline
,21395609,C(max),"In nasal secretions, C(max) , T(max) , t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),[μg] / [ml],6.29,159973,DB00759,Tetracycline
,21395609,T(max),"In nasal secretions, C(max) , T(max) , t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,4.0,159974,DB00759,Tetracycline
,21395609,t½,"In nasal secretions, C(max) , T(max) , t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,4.0,159975,DB00759,Tetracycline
,21395609,AUC,"In nasal secretions, C(max) , T(max) , t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),h,6.6,159976,DB00759,Tetracycline
,21395609,AUC,"In nasal secretions, C(max) , T(max) , t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.",Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395609/),[h·μg] / [ml],51.1,159977,DB00759,Tetracycline
,9653956,detection limits,"The detection limits of the method were estimated at 1.2 ng/g and 1.0 ng/g of doxycycline in liver and muscle tissue, respectively, using a signal-to-noise ratio of 3:1.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),[ng] / [g],1.2,160754,DB00759,Tetracycline
,9653956,detection limits,"The detection limits of the method were estimated at 1.2 ng/g and 1.0 ng/g of doxycycline in liver and muscle tissue, respectively, using a signal-to-noise ratio of 3:1.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),[ng] / [g],1.0,160755,DB00759,Tetracycline
,9653956,signal-to-noise ratio,"The detection limits of the method were estimated at 1.2 ng/g and 1.0 ng/g of doxycycline in liver and muscle tissue, respectively, using a signal-to-noise ratio of 3:1.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),,3:1,160756,DB00759,Tetracycline
,9653956,recovery,"The recovery of doxycycline was determined from spiked tissues and was 63+/-3.8% and 66+/-3.1% for liver and muscle, respectively (n = 6).",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),%,63,160757,DB00759,Tetracycline
,9653956,recovery,"The recovery of doxycycline was determined from spiked tissues and was 63+/-3.8% and 66+/-3.1% for liver and muscle, respectively (n = 6).",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),%,66,160758,DB00759,Tetracycline
,9653956,elimination half-life (T1/2),"The elimination half-life (T1/2) of doxycycline was 77.7 h and 78.0 h in muscle and liver, respectively.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),h,77.7,160759,DB00759,Tetracycline
,9653956,elimination half-life (T1/2),"The elimination half-life (T1/2) of doxycycline was 77.7 h and 78.0 h in muscle and liver, respectively.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),h,78.0,160760,DB00759,Tetracycline
,9653956,withdrawal times,"The withdrawal times necessary to reach concentrations below maximum residue limits (MRLs), as imposed by the EU, were 12 days and 17 days for liver and muscle tissue, respectively.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),d,12,160761,DB00759,Tetracycline
,9653956,withdrawal times,"The withdrawal times necessary to reach concentrations below maximum residue limits (MRLs), as imposed by the EU, were 12 days and 17 days for liver and muscle tissue, respectively.",Liquid chromatographic separation of doxycycline and 4-epidoxycycline in a tissue depletion study of doxycycline in turkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653956/),d,17,160762,DB00759,Tetracycline
,27137900,volume of distribution (Vd),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[ml] / [kg],865.15,161551,DB00759,Tetracycline
,27137900,distribution rate constant (α),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[1] / [h],2.28,161552,DB00759,Tetracycline
,27137900,elimination rate constant (β),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[1] / [h],0.08,161553,DB00759,Tetracycline
,27137900,total body clearance (Cl),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[ml] / [h·kg],104.11,161554,DB00759,Tetracycline
,27137900,absorption rate constant (Ka),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[1] / [h],2.55,161555,DB00759,Tetracycline
,27137900,peak concentration (Cmax),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[μg] / [ml],5.88,161556,DB00759,Tetracycline
,27137900,peak concentration (Cmax),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),h,1.73,161557,DB00759,Tetracycline
,27137900,time to reach Cmax (tmax),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),[μg] / [ml],5.88,161558,DB00759,Tetracycline
,27137900,time to reach Cmax (tmax),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),h,1.73,161559,DB00759,Tetracycline
,27137900,absolute bioavailability (F),"The disposition of doxycycline after one single IV injection was best described by a two-compartment open model and the main pharmacokinetic parameters were as follows: volume of distribution (Vd) was 865.15 ± 127.64 ml/kg, distribution rate constant (α) was (2.28 ± 0.38) 1/h, elimination rate constant (β) was 0.08 ± 0.02 1/h and total body clearance (Cl) was104.11 ± 18.32 ml/h/kg, while after PO administration, the concentration versus time curve was best described by a one-compartment open model and absorption rate constant (Ka), peak concentration (Cmax), time to reach Cmax (tmax) and absolute bioavailability (F) were 2.55 ± 1.40 1/h, 5.88 ± 0.70 μg/ml, 1.73 ± 0.75 h and 52.33%, respectively.",Pharmacokinetics of doxycycline in laying hens after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137900/),%,52.33,161560,DB00759,Tetracycline
,6887337,elimination half-life,"After intravenous administration of OTC-C the elimination half-life for OTC was 3.75 h, with approximately 75% of the dose being excreted in the urine in 1 week.",Comparison of pharmacokinetic parameters for two oxytetracycline preparations in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887337/),h,3.75,162386,DB00759,Tetracycline
,6887337,bioavailability,For both preparations the bioavailability after i.m. administration was 95-100% and about 70% of the dose was excreted in the urine during the first week.,Comparison of pharmacokinetic parameters for two oxytetracycline preparations in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887337/),%,95-100,162387,DB00759,Tetracycline
,6887337,bioavailability,For both preparations the bioavailability after i.m. administration was 95-100% and about 70% of the dose was excreted in the urine during the first week.,Comparison of pharmacokinetic parameters for two oxytetracycline preparations in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887337/),%,70,162388,DB00759,Tetracycline
<,11020264,MIC90,The MIC90 of glycylcycline (< or =0.06 mg/L) against 55 strains of Streptococcus pneumoniae was 100-fold lower than that of minocycline or tetracycline.,"Efficacy of a novel tetracycline derivative, glycylcycline, against penicillin-resistant Streptococcus pneumoniae in a mouse model of pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020264/),[mg] / [l],0.06,162410,DB00759,Tetracycline
,3798709,Vf,"Analysis of the intravenous data according to the three compartment pharmacokinetic model revealed that OTC was well distributed in the body (Vf: 1.62 l/kg), had an overall body clearance of 0.25 litre/kg/h, and the elimination half-lives were in the range between 11.6 and 17.2 hrs.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[l] / [kg],1.62,162508,DB00759,Tetracycline
,3798709,overall body clearance,"Analysis of the intravenous data according to the three compartment pharmacokinetic model revealed that OTC was well distributed in the body (Vf: 1.62 l/kg), had an overall body clearance of 0.25 litre/kg/h, and the elimination half-lives were in the range between 11.6 and 17.2 hrs.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[l] / [h·kg],0.25,162509,DB00759,Tetracycline
,3798709,elimination half-lives,"Analysis of the intravenous data according to the three compartment pharmacokinetic model revealed that OTC was well distributed in the body (Vf: 1.62 l/kg), had an overall body clearance of 0.25 litre/kg/h, and the elimination half-lives were in the range between 11.6 and 17.2 hrs.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),h,11.6 and 17.2,162510,DB00759,Tetracycline
,3798709,binding to,The mean OTC binding to plasma proteins was 75.5 +/- 4%.,Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),%,75.5,162511,DB00759,Tetracycline
,3798709,maximum plasma OTC concentration,Following the drench route of administration the maximum plasma OTC concentration was achieved between 1 and 5 h post application and ranged between 1.18 and 1.41 micrograms/ml.,Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[μg] / [ml],1.18 and 1.41,162512,DB00759,Tetracycline
,3798709,maximum plasma OTC concentration,"The mean maximum plasma OTC concentration during medicated feed administration was 0.20 +/- 0.06 microgram/ml, which was achieved approximately 30 hours after the onset of the administration.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[μg] / [ml],0.20,162513,DB00759,Tetracycline
,3798709,steady state OTC plasma level,A steady state OTC plasma level (approximately 0.2 microgram/ml) was maintained till the end of the trial.,Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[μg] / [ml],0.2,162514,DB00759,Tetracycline
,3798709,bioavailabilities,"The mean OTC bioavailabilities of the oral routes were low: after the drench route of administration 9.0 +/- 0.67%, and after medicated pelleted feed administration 3.69 +/- 0.8%.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),%,9.0,162515,DB00759,Tetracycline
,3798709,bioavailabilities,"The mean OTC bioavailabilities of the oral routes were low: after the drench route of administration 9.0 +/- 0.67%, and after medicated pelleted feed administration 3.69 +/- 0.8%.",Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),%,3.69,162516,DB00759,Tetracycline
,3798709,renal clearances,The mean OTC renal clearances of each piglet ranged between 10.1 and 13.9 ml/min/kg (based on free OTC plasma fractions).,Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3798709/),[ml] / [kg·min],10.1 and 13.9,162517,DB00759,Tetracycline
,19861604,C(max),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[ng] / [ml],212,164255,DB00759,Tetracycline
,19861604,C(max),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[ng] / [ml],122,164256,DB00759,Tetracycline
,19861604,AUC(0-24),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[h·ng] / [ml],"1,909",164257,DB00759,Tetracycline
,19861604,AUC(0-24),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[h·ng] / [ml],917,164258,DB00759,Tetracycline
,31039251,MIC,"The MIC for 50% and 90% of cumulative clinical isolates was 8 and 64 mg/L, respectively.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],8,165582,DB00759,Tetracycline
,31039251,MIC,"The MIC for 50% and 90% of cumulative clinical isolates was 8 and 64 mg/L, respectively.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],64,165583,DB00759,Tetracycline
,31039251,microbial kill,"In the HFS-MAC model, minocycline achieved a microbial kill of 3.6 log10 cfu/mL below stasis.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[cfu] / [ml],3.6,165584,DB00759,Tetracycline
,31039251,AUC0-24/MIC,The AUC0-24/MIC exposure associated with a bactericidal effect was 59.,Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),,59,165585,DB00759,Tetracycline
,31039251,MIC,Monte Carlo experiments identified a minocycline susceptibility MIC breakpoint of 16 mg/L.,Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],16,165586,DB00759,Tetracycline
,11555179,maximum concentration (C(max)),"After 2 h the mean maximum concentration (C(max)) reached values of 8.1 +/- 2.2 and 15.4 +/- 11.1 microg/mL, respectively.",Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555179/),[μg] / [ml],8.1,165701,DB00759,Tetracycline
,11555179,maximum concentration (C(max)),"After 2 h the mean maximum concentration (C(max)) reached values of 8.1 +/- 2.2 and 15.4 +/- 11.1 microg/mL, respectively.",Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555179/),[μg] / [ml],15.4,165702,DB00759,Tetracycline
,11555179,area under the concentration time curve (AUC09 days),The area under the concentration time curve (AUC09 days) of each formulation was 255 +/- 76.5 and 399.2 +/- 123 microg.,Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555179/),μg,255,165703,DB00759,Tetracycline
,11555179,area under the concentration time curve (AUC09 days),The area under the concentration time curve (AUC09 days) of each formulation was 255 +/- 76.5 and 399.2 +/- 123 microg.,Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555179/),μg,399.2,165704,DB00759,Tetracycline
,11555179,mean residence time (MRT),"h/mL, respectively, and the mean residence time (MRT) was around 3 days for both formulations.",Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555179/),d,3,165705,DB00759,Tetracycline
,4026008,half-life,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),h,6.48 and 7.24,165831,DB00759,Tetracycline
,4026008,volume of distribution at steady state,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[l] / [kg],1.859,165832,DB00759,Tetracycline
,4026008,volume of distribution at steady state,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[l] / [kg],2.001,165833,DB00759,Tetracycline
,4026008,clearance,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[ml] / [kg·min],3.195,165834,DB00759,Tetracycline
,4026008,clearance,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[ml] / [kg·min],3.424,165835,DB00759,Tetracycline
,3038010,MIC,"The MIC of CP-62,993 was 0.26 to 1.02 micrograms/ml for 100% inclusion inhibition and 0.031 to 0.063 microgram/ml for 50% inclusion inhibition.","In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3038010/),[μg] / [ml],0.26 to 1.02,167935,DB00759,Tetracycline
,3038010,MIC,"The MIC of CP-62,993 was 0.26 to 1.02 micrograms/ml for 100% inclusion inhibition and 0.031 to 0.063 microgram/ml for 50% inclusion inhibition.","In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3038010/),[μg] / [ml],0.031 to 0.063,167936,DB00759,Tetracycline
,8866455,elimination half-life,"The mean (+/-SD) elimination half-life was 10.6 +/- 0.7, 10.8 +/- 1.5, 7.9 +/- 1.4 and 10.0 +/- 0.9 h in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,10.6,170341,DB00759,Tetracycline
,8866455,elimination half-life,"The mean (+/-SD) elimination half-life was 10.6 +/- 0.7, 10.8 +/- 1.5, 7.9 +/- 1.4 and 10.0 +/- 0.9 h in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,10.8,170342,DB00759,Tetracycline
,8866455,elimination half-life,"The mean (+/-SD) elimination half-life was 10.6 +/- 0.7, 10.8 +/- 1.5, 7.9 +/- 1.4 and 10.0 +/- 0.9 h in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,7.9,170343,DB00759,Tetracycline
,8866455,elimination half-life,"The mean (+/-SD) elimination half-life was 10.6 +/- 0.7, 10.8 +/- 1.5, 7.9 +/- 1.4 and 10.0 +/- 0.9 h in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,10.0,170344,DB00759,Tetracycline
,8866455,total body clearance,"Mean (+/- SD) total body clearance was 0.19 (+/-0.01), 0.27 (+/-0.03), 0.11 (+/-0.03) and 0.06 (+/-0.01) L/h.kg in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [h·kg],0.19,170345,DB00759,Tetracycline
,8866455,total body clearance,"Mean (+/- SD) total body clearance was 0.19 (+/-0.01), 0.27 (+/-0.03), 0.11 (+/-0.03) and 0.06 (+/-0.01) L/h.kg in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [h·kg],0.27,170346,DB00759,Tetracycline
,8866455,total body clearance,"Mean (+/- SD) total body clearance was 0.19 (+/-0.01), 0.27 (+/-0.03), 0.11 (+/-0.03) and 0.06 (+/-0.01) L/h.kg in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [h·kg],0.11,170347,DB00759,Tetracycline
,8866455,total body clearance,"Mean (+/- SD) total body clearance was 0.19 (+/-0.01), 0.27 (+/-0.03), 0.11 (+/-0.03) and 0.06 (+/-0.01) L/h.kg in 3 day, 3-, 6- and 12-week-old turkeys, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [h·kg],0.06,170348,DB00759,Tetracycline
,8866455,steady-state volume of distribution,"The steady-state volume of distribution was 1.77 (+/-0.2), 2.1 (+/-0.2), 0.7 (+/-0.4) and 0.5 (+/-0.2) L/kg in turkeys of the above mentioned ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [kg],1.77,170349,DB00759,Tetracycline
,8866455,steady-state volume of distribution,"The steady-state volume of distribution was 1.77 (+/-0.2), 2.1 (+/-0.2), 0.7 (+/-0.4) and 0.5 (+/-0.2) L/kg in turkeys of the above mentioned ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [kg],2.1,170350,DB00759,Tetracycline
,8866455,steady-state volume of distribution,"The steady-state volume of distribution was 1.77 (+/-0.2), 2.1 (+/-0.2), 0.7 (+/-0.4) and 0.5 (+/-0.2) L/kg in turkeys of the above mentioned ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [kg],0.7,170351,DB00759,Tetracycline
,8866455,steady-state volume of distribution,"The steady-state volume of distribution was 1.77 (+/-0.2), 2.1 (+/-0.2), 0.7 (+/-0.4) and 0.5 (+/-0.2) L/kg in turkeys of the above mentioned ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[l] / [kg],0.5,170352,DB00759,Tetracycline
,8866455,maximal plasma concentrations,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],3.8,170353,DB00759,Tetracycline
,8866455,maximal plasma concentrations,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],5.6,170354,DB00759,Tetracycline
,8866455,maximal plasma concentrations,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],7.4,170355,DB00759,Tetracycline
,8866455,maximal plasma concentrations,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],5.7,170356,DB00759,Tetracycline
,8866455,tmax,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,4.7,170357,DB00759,Tetracycline
,8866455,tmax,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,1.5,170358,DB00759,Tetracycline
,8866455,tmax,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,2.8,170359,DB00759,Tetracycline
,8866455,tmax,"The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,5.4,170360,DB00759,Tetracycline
,8866455,Cmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],2.5,170361,DB00759,Tetracycline
,8866455,Cmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],6.1,170362,DB00759,Tetracycline
,8866455,Cmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],4.8,170363,DB00759,Tetracycline
,8866455,Cmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),[μg] / [ml],3.0,170364,DB00759,Tetracycline
,8866455,tmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,4.2,170365,DB00759,Tetracycline
,8866455,tmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,5.3,170366,DB00759,Tetracycline
,8866455,tmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,4.5,170367,DB00759,Tetracycline
,8866455,tmax,"In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively.",Pharmacokinetics and bioavailability of doxycycline in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),h,7.5,170368,DB00759,Tetracycline
,8866455,absolute bioavailability,The absolute bioavailability in fasted turkeys varied between 25.0 +/- 9.0% (for 12-week-old birds) and 63.5 +/- 7.1% (for 3-week-old birds).,Pharmacokinetics and bioavailability of doxycycline in turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),%,25.0,170369,DB00759,Tetracycline
,8866455,absolute bioavailability,The absolute bioavailability in fasted turkeys varied between 25.0 +/- 9.0% (for 12-week-old birds) and 63.5 +/- 7.1% (for 3-week-old birds).,Pharmacokinetics and bioavailability of doxycycline in turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),%,63.5,170370,DB00759,Tetracycline
,8866455,relative bioavailability,The relative bioavailability varied between 40.0 +/- 13.0% (for 12-week-old birds) and 83.7 +/- 14.3% (for 3-week-old birds).,Pharmacokinetics and bioavailability of doxycycline in turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),%,40.0,170371,DB00759,Tetracycline
,8866455,relative bioavailability,The relative bioavailability varied between 40.0 +/- 13.0% (for 12-week-old birds) and 83.7 +/- 14.3% (for 3-week-old birds).,Pharmacokinetics and bioavailability of doxycycline in turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866455/),%,83.7,170372,DB00759,Tetracycline
,1905732,run times,The chromatographic procedures allow run times ranging from 2.1-7.3 min using different reversed-phase materials as supports and eluents based on acetonitrile or isopropanol-diethanolamine-EDTA.,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),min,2.1-7.3,170772,DB00759,Tetracycline
,1905732,Detection limits,Detection limits are estimated at 10-500 ng/mL according to the derivative analyzed.,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),[ng] / [ml],10-500,170773,DB00759,Tetracycline
,1905732,recovery,The recovery of 13 derivatives from spiked plasma samples (100 micrograms/mL) reached 85-94% (n = 5).,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),%,85-94,170774,DB00759,Tetracycline
,18293616,maximum (Cmax),Plasma oxytetracycline concentration showed a maximum (Cmax) of 3.89 +/- 1.48 microg/ml and a prolonged elimination half-life (T1/2beta: 47.73 +/- 18.33 h).,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),[μg] / [ml],3.89,170809,DB00759,Tetracycline
,18293616,elimination half-life (T1/2beta,Plasma oxytetracycline concentration showed a maximum (Cmax) of 3.89 +/- 1.48 microg/ml and a prolonged elimination half-life (T1/2beta: 47.73 +/- 18.33 h).,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,47.73,170810,DB00759,Tetracycline
,18293616,Cmax,"The diclofenac plasma profile showed high Cmax (577.62 +/- 238.40 ng/ml), and its T1/2beta was also prolonged (30.48 +/- 9.42 h).",Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),[ng] / [ml],577.62,170811,DB00759,Tetracycline
,18293616,T1/2beta,"The diclofenac plasma profile showed high Cmax (577.62 +/- 238.40 ng/ml), and its T1/2beta was also prolonged (30.48 +/- 9.42 h).",Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,30.48,170812,DB00759,Tetracycline
,18293616,T1/2beta,The long elimination half-life of diclofenac was an unexpected finding; its T1/2beta in humans is 1.1 h.,Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18293616/),h,1.1,170813,DB00759,Tetracycline
,20444029,volume of distribution (V/F,"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),[l] / [kg],40.9,171335,DB00759,Tetracycline
,20444029,rate constant (k,"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),1/[h],0.0478,171336,DB00759,Tetracycline
,20444029,dose-normalized area under the curve (AUC/D,"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),[h·μg] / [l],0.29,171337,DB00759,Tetracycline
,20444029,clearance (Cl/F,"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),[l] / [h·kg],1.8,171338,DB00759,Tetracycline
,20444029,elimination half-life (t(1/2),"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),h,16.2,171339,DB00759,Tetracycline
,20444029,C(max/Dose),"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),[ng] / [ml],4.5,171340,DB00759,Tetracycline
,20444029,time of C(max) (T(max),"NLMEM determined the primary pharmacokinetic parameters: volume of distribution (V/F, 40.9 L/kg) and rate constant (k, 0.0478 h(-1)), and the secondary parameters: dose-normalized area under the curve (AUC/D, 0.29 h x microg/L), clearance (Cl/F, 1.8 L/kg/h), elimination half-life (t(1/2), 16.2 h), C(max/Dose) (4.5 ng/mL), and time of C(max) (T(max), 23.3 h) with improved CV estimates over NCA.","Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444029/),h,23.3,171341,DB00759,Tetracycline
,28456999,maximum concentrations (Cmax ),The maximum concentrations (Cmax ) of drug with values of 4021 ± 836 ng/ml in oral fluid and 4447 ± 735 ng/ml in plasma were reached (Tmax ) at 2 and 1 hr after drug administration respectively.,Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),[ng] / [ml],4021,171542,DB00759,Tetracycline
,28456999,maximum concentrations (Cmax ),The maximum concentrations (Cmax ) of drug with values of 4021 ± 836 ng/ml in oral fluid and 4447 ± 735 ng/ml in plasma were reached (Tmax ) at 2 and 1 hr after drug administration respectively.,Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),[ng] / [ml],4447,171543,DB00759,Tetracycline
,28456999,Tmax,The maximum concentrations (Cmax ) of drug with values of 4021 ± 836 ng/ml in oral fluid and 4447 ± 735 ng/ml in plasma were reached (Tmax ) at 2 and 1 hr after drug administration respectively.,Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,2,171544,DB00759,Tetracycline
,28456999,Tmax,The maximum concentrations (Cmax ) of drug with values of 4021 ± 836 ng/ml in oral fluid and 4447 ± 735 ng/ml in plasma were reached (Tmax ) at 2 and 1 hr after drug administration respectively.,Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,1,171545,DB00759,Tetracycline
,28456999,area under concentration-time curve (AUC),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),[h·ng] / [ml],75613,171546,DB00759,Tetracycline
,28456999,mean residence time (MRT),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,62.8,171547,DB00759,Tetracycline
,28456999,mean residence time (MRT),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),[h·ng] / [ml],115314,171548,DB00759,Tetracycline
,28456999,mean residence time (MRT),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,31.4,171549,DB00759,Tetracycline
,28456999,elimination half-life (t1/2β ),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,117,171550,DB00759,Tetracycline
,28456999,elimination half-life (t1/2β ),"The area under concentration-time curve (AUC), mean residence time (MRT) and the elimination half-life (t1/2β ) were, respectively, 75613 ng × hr/ml, 62.8 hr and 117 hr in oral fluid and 115314 ng × hr/ml, 31.4 hr and 59.2 hr in plasma.",Correlation between oral fluid and plasma oxytetracycline concentrations after intramuscular administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28456999/),h,59.2,171551,DB00759,Tetracycline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.57,172222,DB00759,Tetracycline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.61,172223,DB00759,Tetracycline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.63,172224,DB00759,Tetracycline
,445960,volume of distribution,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[l] / [kg],0.62,172225,DB00759,Tetracycline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,7.9,172226,DB00759,Tetracycline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,9.2,172227,DB00759,Tetracycline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,10.3,172228,DB00759,Tetracycline
,445960,elimination half-life (t1/2),"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),h,8.6,172229,DB00759,Tetracycline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.90,172230,DB00759,Tetracycline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.84,172231,DB00759,Tetracycline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.78,172232,DB00759,Tetracycline
,445960,total clearance,"Mean kinetic variables for theophylline during control, tetracycline, erythromycin, and cephalexin trials, respectively, were: volume of distribution, 0.57, 0.61, 0.63, and 0.62 l/kg; elimination half-life (t1/2), 7.9, 9.2, 10.3, and 8.6 hr; total clearance, 0.90, 0.84, 0.78, and 0.89 ml/min/kg.",Effects of three antibiotics on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445960/),[ml] / [kg·min],0.89,172233,DB00759,Tetracycline
,8291822,elimination half-life (T1/2),"No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates.",Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291822/),h,20.8,174032,DB00759,Tetracycline
,8291822,elimination half-life (T1/2),"No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates.",Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291822/),h,21.9,174033,DB00759,Tetracycline
,8291822,steady-state average plasma concentration,"No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates.",Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291822/),[ng] / [ml],1626,174034,DB00759,Tetracycline
,8291822,steady-state average plasma concentration,"No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates.",Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291822/),[ng] / [ml],1698,174035,DB00759,Tetracycline
,31251331,flow rate,The flow rate was 1 mL/min and maximum absorption was measured using Diode Array (DAD) detector at 285 nm.,"Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[ml] / [min],1,174358,DB00759,Tetracycline
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,2.68,174359,DB00759,Tetracycline
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,3.52,174360,DB00759,Tetracycline
,31251331,retention times,"The retention times of OXY, TIN and ESM were recorded to be 2.68, 3.52 and 5.17 minutes, respectively, indicating a shorter analysis time.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),min,5.17,174361,DB00759,Tetracycline
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.10,174362,DB00759,Tetracycline
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.07,174363,DB00759,Tetracycline
,31251331,Limits of detection,"Limits of detection were also reported to be 0.10, 0.07 and 0.04 μg/mL for OXY, TIN and ESM, respectively, showing a high degree of the method sensitivity.","Developing a High-Performance Liquid Chromatography (HPLC) Method for Simultaneous Determination of Oxytetracycline, Tinidazole and Esomeprazole in Human Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251331/),[μg] / [ml],0.04,174364,DB00759,Tetracycline
,12641404,fever subsidence times,The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31.5 +/- 10.1 hours) and (31.4 +/- 11.1 hours).,Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12641404/),h,31.4,175608,DB00759,Tetracycline
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB00759,Tetracycline
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB00759,Tetracycline
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB00759,Tetracycline
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB00759,Tetracycline
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB00759,Tetracycline
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB00759,Tetracycline
,6838044,half-life (t1/2),"The half-life (t1/2) after IV administration varied between 169.02 and 216.56 minutes and that after IM administration, between 630 and 990 minutes.",Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838044/),min,169.02 and 216.56,177981,DB00759,Tetracycline
,6838044,half-life (t1/2),"The half-life (t1/2) after IV administration varied between 169.02 and 216.56 minutes and that after IM administration, between 630 and 990 minutes.",Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838044/),min,630 and 990,177982,DB00759,Tetracycline
,6838044,Vdarea,The drug was distributed well in the body after IM administration (Vdarea 1.18 to 2.15 L/kg).,Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838044/),[l] / [kg],1.18 to 2.15,177983,DB00759,Tetracycline
,6838044,total body clearances,"The total body clearances varied between 1.02 and 1.45 and between 1.17 and 1.49 ml/kg/min after the IV and the Im dosings, respectively.",Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838044/),[ml] / [kg·min],1.02 and 1.45,177984,DB00759,Tetracycline
,6838044,total body clearances,"The total body clearances varied between 1.02 and 1.45 and between 1.17 and 1.49 ml/kg/min after the IV and the Im dosings, respectively.",Pharmacokinetics and plasma protein binding (in vitro) of oxytetracycline in buffalo (Bubalus bubalis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6838044/),[ml] / [kg·min],1.17 and 1.49,177985,DB00759,Tetracycline
,1796678,bioavailability,"Chlortetracycline bioavailability was 12.6% at 0.7% dietary calcium, and 9.5% at 1.4% dietary calcium.",Influence of dietary citric acid and calcium on the bioavailability of orally administered chlortetracycline in piglets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796678/),%,12.6,179175,DB00759,Tetracycline
,1796678,bioavailability,"Chlortetracycline bioavailability was 12.6% at 0.7% dietary calcium, and 9.5% at 1.4% dietary calcium.",Influence of dietary citric acid and calcium on the bioavailability of orally administered chlortetracycline in piglets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796678/),%,9.5,179176,DB00759,Tetracycline
,8888537,concentrations (Cmax),"Peaks of OTC concentrations (Cmax) occurred at 4 h for blood and kidney and 72 h for liver and were 134.1 micrograms/mL, 129.8 micrograms/g and 333.4 micrograms/g, respectively.","Concentration-time profiles of oxytetracycline in blood, kidney and liver of tench (Tinca tinca L) after intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888537/),[μg] / [ml],134.1,179198,DB00759,Tetracycline
,8888537,concentrations (Cmax),"Peaks of OTC concentrations (Cmax) occurred at 4 h for blood and kidney and 72 h for liver and were 134.1 micrograms/mL, 129.8 micrograms/g and 333.4 micrograms/g, respectively.","Concentration-time profiles of oxytetracycline in blood, kidney and liver of tench (Tinca tinca L) after intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888537/),[μg] / [g],129.8,179199,DB00759,Tetracycline
,8888537,concentrations (Cmax),"Peaks of OTC concentrations (Cmax) occurred at 4 h for blood and kidney and 72 h for liver and were 134.1 micrograms/mL, 129.8 micrograms/g and 333.4 micrograms/g, respectively.","Concentration-time profiles of oxytetracycline in blood, kidney and liver of tench (Tinca tinca L) after intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888537/),[μg] / [g],333.4,179200,DB00759,Tetracycline
,8888537,half-life,The plasma OTC half-life (21.2 h) was longer than in homeothermic species.,"Concentration-time profiles of oxytetracycline in blood, kidney and liver of tench (Tinca tinca L) after intramuscular administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888537/),h,21.2,179201,DB00759,Tetracycline
,22682068,bioavailability,DOX-h-LA showed the greatest values for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax (Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h.,Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22682068/),%,199.48,179202,DB00759,Tetracycline
,22682068,maximum serum concentration (Cmax),DOX-h-LA showed the greatest values for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax (Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h.,Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22682068/),,2.8,179203,DB00759,Tetracycline
,22682068,time to reach Cmax (Tmax),DOX-h-LA showed the greatest values for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax (Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h.,Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22682068/),h,2.11,179204,DB00759,Tetracycline
,22682068,elimination half-life,DOX-h-LA showed the greatest values for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax (Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h.,Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22682068/),h,133.61,179205,DB00759,Tetracycline
,22682068,minimum effective serum concentration,"Considering minimum effective serum concentration of 0.5 μg/mL, a dose-interval of at least 1 week h can be achieved for DOX-h-LA, and only 48 h and 24 h after the IV or PO administration of DOX-h as a solution or as tablets, respectively.",Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22682068/),[μg] / [ml],0.5,179206,DB00759,Tetracycline
,17537869,half-life,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),h,55.8,180052,DB00759,Tetracycline
,17537869,volume of distribution,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),[l] / [kg],21.0,180053,DB00759,Tetracycline
,17537869,half-life,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),h,6.9,180054,DB00759,Tetracycline
,17537869,volume of distribution,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),[l] / [kg],3.3,180055,DB00759,Tetracycline
,15206992,C(max),"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[μg] / [ml],0.43,180436,DB00759,Tetracycline
,15206992,C(max),"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[μg] / [ml],1.06,180437,DB00759,Tetracycline
,15206992,AUC,"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[h·μg] / [ml],32.0,180438,DB00759,Tetracycline
,15206992,AUC,"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[h·μg] / [ml],63.7,180439,DB00759,Tetracycline
,15206992,"t(1/2,z","(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),h,90.8,180440,DB00759,Tetracycline
,15206992,"t(1/2,z","(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),h,157.4,180441,DB00759,Tetracycline
,7406475,lymph level,"Lymph sorption lowered the antibiotic lymph level to 30 per cent, which indicated the necessity of an adequate increase in the drug dose.","[Tetraolean pharmacokinetics in the lymph and blood in complicated, acute inflammatory diseases of the abdominal cavity organs]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406475/),%,30,181676,DB00759,Tetracycline
,9802705,release,"The release of doxycycline in the GCF peaked at 2 hours (1473 microg/ml in the NE group, and 1986 microg/ml in the 2-octyl group).","The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],1473,181918,DB00759,Tetracycline
,9802705,release,"The release of doxycycline in the GCF peaked at 2 hours (1473 microg/ml in the NE group, and 1986 microg/ml in the 2-octyl group).","The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],1986,181919,DB00759,Tetracycline
,9802705,concentration,The mean concentration at day 7 was 309 microg/ml for the NE group and 148 microg/ml for the 2-octyl group.,"The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],309,181920,DB00759,Tetracycline
,9802705,concentration,The mean concentration at day 7 was 309 microg/ml for the NE group and 148 microg/ml for the 2-octyl group.,"The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],148,181921,DB00759,Tetracycline
,9802705,peak concentration,Minimal levels of drug were detected in the GCF of the oral doxycycline group with a peak concentration of 2.53 microg/ml at 12 hours.,"The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],2.53,181922,DB00759,Tetracycline
,9802705,Salivary concentrations,Salivary concentrations for both local delivery groups peaked at hour 2 (4.05 microg/ml for the NE group and 8.78 microg/ml for the 2-octyl group); by the end of day 1 levels were < or = 2 microg/ml.,"The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],4.05,181923,DB00759,Tetracycline
,9802705,Salivary concentrations,Salivary concentrations for both local delivery groups peaked at hour 2 (4.05 microg/ml for the NE group and 8.78 microg/ml for the 2-octyl group); by the end of day 1 levels were < or = 2 microg/ml.,"The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802705/),[μg] / [ml],8.78,181924,DB00759,Tetracycline
,17258829,Limit of quantification (L.O.Q.),Limit of quantification (L.O.Q.) was accepted as 1 ng using 40-microl plasma or 7.5-microl urine sample.,Bioassay for determination of fosmidomycin in plasma and urine: application for pharmacokinetic dose optimisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258829/),ng,1,183265,DB00759,Tetracycline
greater,17258829,recovery,The mean recovery for fosmidomycin was greater than 99%.,Bioassay for determination of fosmidomycin in plasma and urine: application for pharmacokinetic dose optimisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258829/),%,99,183266,DB00759,Tetracycline
,1483498,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[ng] / [ml],1600,183339,DB00759,Tetracycline
,1483498,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[ng] / [ml],1160,183340,DB00759,Tetracycline
,1483498,terminal half-life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,14.4,183341,DB00759,Tetracycline
,1483498,terminal half-life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,19.3,183342,DB00759,Tetracycline
,1483498,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,11.9,183343,DB00759,Tetracycline
,1483498,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,16.0,183344,DB00759,Tetracycline
,1483498,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[1] / [kg],13.3,183345,DB00759,Tetracycline
,1483498,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[1] / [kg],19.9,183346,DB00759,Tetracycline
,1483498,AUC from zero time to infinity,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],6.18,183347,DB00759,Tetracycline
,1483498,AUC from zero time to 7 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],6.18,183348,DB00759,Tetracycline
,1483498,AUC from zero time to 7 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],4.76,183349,DB00759,Tetracycline
,3723664,rate constant beta,The hybrid rate constant beta for oxytetracycline was increased in calves with pneumonia from 0.0034 +/- 0.0003/min to 0.0048 +/- 0.0007/min between 2 h and 8 h.,"Chloramphenicol, lincomycin and oxytetracycline disposition in calves with experimental pneumonic pasteurellosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723664/),1/[min],0.0034,183736,DB00759,Tetracycline
,3723664,rate constant beta,The hybrid rate constant beta for oxytetracycline was increased in calves with pneumonia from 0.0034 +/- 0.0003/min to 0.0048 +/- 0.0007/min between 2 h and 8 h.,"Chloramphenicol, lincomycin and oxytetracycline disposition in calves with experimental pneumonic pasteurellosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723664/),1/[min],0.0048,183737,DB00759,Tetracycline
,3723664,elimination half-life,Thus the elimination half-life in serum was shortened from 212.4 +/- 20.3 min to 149.3 +/- 19.5 min.,"Chloramphenicol, lincomycin and oxytetracycline disposition in calves with experimental pneumonic pasteurellosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723664/),min,212.4,183738,DB00759,Tetracycline
,3723664,elimination half-life,Thus the elimination half-life in serum was shortened from 212.4 +/- 20.3 min to 149.3 +/- 19.5 min.,"Chloramphenicol, lincomycin and oxytetracycline disposition in calves with experimental pneumonic pasteurellosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723664/),min,149.3,183739,DB00759,Tetracycline
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],1.0,184129,DB00759,Tetracycline
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184130,DB00759,Tetracycline
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],10.1,184131,DB00759,Tetracycline
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184132,DB00759,Tetracycline
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],17.3,184133,DB00759,Tetracycline
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184134,DB00759,Tetracycline
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.2,184135,DB00759,Tetracycline
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184136,DB00759,Tetracycline
,14998560,half-lives of distribution (t1/2 alpha),"The drug was rapidly distributed and slowly eliminated with half-lives of distribution (t1/2 alpha) and elimination (t1/2 beta) of 0.52 and 4.62 h, respectively.",Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),h,0.52,185232,DB00759,Tetracycline
,14998560,elimination (t1/2 beta),"The drug was rapidly distributed and slowly eliminated with half-lives of distribution (t1/2 alpha) and elimination (t1/2 beta) of 0.52 and 4.62 h, respectively.",Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),h,4.62,185233,DB00759,Tetracycline
,14998560,peak serum concentration C(max),"After i.m. injection of the same dose, the peak serum concentration C(max) was 1.60 microg ml-1 attained at 0.86 h (Tmax).",Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),[μg] / [ml],1.60,185234,DB00759,Tetracycline
,14998560,Tmax,"After i.m. injection of the same dose, the peak serum concentration C(max) was 1.60 microg ml-1 attained at 0.86 h (Tmax).",Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),h,0.86,185235,DB00759,Tetracycline
,14998560,serum protein binding percent,The extent of serum protein binding percent was 32.8% and the systemic bioavailability was 99.40% after i.m. injection of 5 mg kg-1 BW,Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),%,32.8,185236,DB00759,Tetracycline
,14998560,systemic bioavailability,The extent of serum protein binding percent was 32.8% and the systemic bioavailability was 99.40% after i.m. injection of 5 mg kg-1 BW,Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998560/),%,99.40,185237,DB00759,Tetracycline
,1818082,signal-to-noise ratio,"Using a signal-to-noise ratio of 5:1, the OTC detection limit was 0.5 ppm in salmon muscle tissue.",High-performance liquid chromatographic analysis of oxytetracycline in chinook salmon following administration of medicated feed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818082/),,5:1,186370,DB00759,Tetracycline
,1818082,detection limit,"Using a signal-to-noise ratio of 5:1, the OTC detection limit was 0.5 ppm in salmon muscle tissue.",High-performance liquid chromatographic analysis of oxytetracycline in chinook salmon following administration of medicated feed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818082/),ppm,0.5,186371,DB00759,Tetracycline
,1818082,recovery,OTC recovery (74.4%) and intra-assay variability (2.3%) were optimized for salmon muscle tissue.,High-performance liquid chromatographic analysis of oxytetracycline in chinook salmon following administration of medicated feed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818082/),%,74.4,186372,DB00759,Tetracycline
,1818082,half-life,The half-life for the elimination of OTC in chinook salmon muscle tissue was found to be 5.4 days.,High-performance liquid chromatographic analysis of oxytetracycline in chinook salmon following administration of medicated feed. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818082/),d,5.4,186373,DB00759,Tetracycline
,9779560,Steady-state plasma concentrations,Steady-state plasma concentrations ranged between 0.7 and 1 microgram/mL.,Pharmacokinetics of doxycycline in pigs following oral administration in feed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779560/),[μg] / [ml],0.7 and 1,187533,DB00759,Tetracycline
,9779560,accumulation factor,"The mean accumulation factor and elimination half-life were, respectively, 1.8 +/- 0.4 and 5.9 +/- 1.0 h.",Pharmacokinetics of doxycycline in pigs following oral administration in feed. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779560/),h,1.8,187534,DB00759,Tetracycline
,9779560,elimination half-life,"The mean accumulation factor and elimination half-life were, respectively, 1.8 +/- 0.4 and 5.9 +/- 1.0 h.",Pharmacokinetics of doxycycline in pigs following oral administration in feed. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779560/),h,5.9,187535,DB00759,Tetracycline
,9779560,steady-state plasma concentrations,"Following ad libitum administration of medicated feed, steady-state plasma concentrations ranged between 0.9 and 1.5 micrograms/mL.",Pharmacokinetics of doxycycline in pigs following oral administration in feed. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779560/),[μg] / [ml],0.9 and 1.5,187536,DB00759,Tetracycline
,17472649,time to peak serum doxycycline activity (tmax),"Following administration at 10 mg/kg, mean+/-SD time to peak serum doxycycline activity (tmax) was 3.0+/-1.2 h, maximum serum activity (Cmax) was 2.54+/-0.27 microg/mL, and terminal half-life (t1/2) was 8.5+/-2.8 h.",Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),h,3.0,188809,DB00759,Tetracycline
,17472649,maximum serum activity (Cmax),"Following administration at 10 mg/kg, mean+/-SD time to peak serum doxycycline activity (tmax) was 3.0+/-1.2 h, maximum serum activity (Cmax) was 2.54+/-0.27 microg/mL, and terminal half-life (t1/2) was 8.5+/-2.8 h.",Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),[μg] / [ml],2.54,188810,DB00759,Tetracycline
,17472649,terminal half-life (t1/2),"Following administration at 10 mg/kg, mean+/-SD time to peak serum doxycycline activity (tmax) was 3.0+/-1.2 h, maximum serum activity (Cmax) was 2.54+/-0.27 microg/mL, and terminal half-life (t1/2) was 8.5+/-2.8 h.",Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),h,8.5,188811,DB00759,Tetracycline
,17472649,tmax,Administration at a dose of 20 mg/kg resulted in a significantly longer tmax (5.5+/-1.8 h) as well as a tendency toward higher Cmax (2.89+/-0.33 microg/mL) and longer t1/2 (11.9+/-2.6 h).,Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),h,5.5,188812,DB00759,Tetracycline
,17472649,Cmax,Administration at a dose of 20 mg/kg resulted in a significantly longer tmax (5.5+/-1.8 h) as well as a tendency toward higher Cmax (2.89+/-0.33 microg/mL) and longer t1/2 (11.9+/-2.6 h).,Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),[μg] / [ml],2.89,188813,DB00759,Tetracycline
,17472649,t1/2,Administration at a dose of 20 mg/kg resulted in a significantly longer tmax (5.5+/-1.8 h) as well as a tendency toward higher Cmax (2.89+/-0.33 microg/mL) and longer t1/2 (11.9+/-2.6 h).,Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472649/),h,11.9,188814,DB00759,Tetracycline
,21470247,elimination half-life,"The elimination half-life for OTC in tilapia fillet and the withdrawal period were 1.65 and 6 days, respectively, considering a percentile of 99% with 95% of confidence and a maximum residue limit of 100 ng/g.",Depletion study and estimation of the withdrawal period for oxytetracycline in tilapia cultured in Brazil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21470247/),d,1.65,189354,DB00759,Tetracycline
,21470247,elimination half-life,"The elimination half-life for OTC in tilapia fillet and the withdrawal period were 1.65 and 6 days, respectively, considering a percentile of 99% with 95% of confidence and a maximum residue limit of 100 ng/g.",Depletion study and estimation of the withdrawal period for oxytetracycline in tilapia cultured in Brazil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21470247/),d,6,189355,DB00759,Tetracycline
,21470247,maximum residue limit,"The elimination half-life for OTC in tilapia fillet and the withdrawal period were 1.65 and 6 days, respectively, considering a percentile of 99% with 95% of confidence and a maximum residue limit of 100 ng/g.",Depletion study and estimation of the withdrawal period for oxytetracycline in tilapia cultured in Brazil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21470247/),[ng] / [g],100,189356,DB00759,Tetracycline
,2773301,t1/2 alpha,The low t1/2 alpha of 0.73 +/- 0.11 h and high t1/2 beta of 16.63 +/- 1.58 h show that the drug is rapidly distributed but slowly eliminated from the body.,Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773301/),h,0.73,189651,DB00759,Tetracycline
,2773301,t1/2 beta,The low t1/2 alpha of 0.73 +/- 0.11 h and high t1/2 beta of 16.63 +/- 1.58 h show that the drug is rapidly distributed but slowly eliminated from the body.,Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773301/),h,16.63,189652,DB00759,Tetracycline
,2773301,tissue:plasma concentration,"The tissue:plasma concentration of 4.86 +/- 1.06 during the elimination phase [K12/(K21-beta)] indicates a high expected tissue concentration, which is supported by similarly increased drug concentration in interstitial fluid and milk.",Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773301/),,4.86,189653,DB00759,Tetracycline
,2773301,Vdarea,"The high Vdarea of 9.78 +/- 0.86 L/kg observed denotes that, apart from its wide distribution, the drug may be stored in fat depots as it is known to be highly lipophilic.",Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773301/),[l] / [kg],9.78,189654,DB00759,Tetracycline
,2773301,minimal plasma concentration,"As the drug maintained a therapeutic concentration for a shorter time in plasma, and the calculated dose rate for maintaining a minimal plasma concentration of 0.5-1.5 micrograms/ml is relatively high, it may not be of much use in treating septicaemia in this species.",Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773301/),[μg] / [ml],0.5-1.5,189655,DB00759,Tetracycline
,8556227,Cmax,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [ml],9.317,191953,DB00759,Tetracycline
,8556227,Cmax,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [ml],12.362,191954,DB00759,Tetracycline
,8556227,AUC,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [h·ml],62.65,191955,DB00759,Tetracycline
,8556227,AUC,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [h·ml],94.28,191956,DB00759,Tetracycline
,24094266,maximum plasma doxycycline concentration,"Following administration of doxycycline (10 mg/kg/d, PO), maximum plasma doxycycline concentration was 2.2 μg/mL at 6.1 hours on day 1 and was 1.5 μg/mL at 4.0 hours on day 4.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),[μg] / [ml],2.2,192990,DB00759,Tetracycline
,24094266,maximum plasma doxycycline concentration,"Following administration of doxycycline (10 mg/kg/d, PO), maximum plasma doxycycline concentration was 2.2 μg/mL at 6.1 hours on day 1 and was 1.5 μg/mL at 4.0 hours on day 4.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),[μg] / [ml],1.5,192991,DB00759,Tetracycline
,24094266,maximum plasma doxycycline concentration,"Administration of doxycycline (20 mg/kg/d, PO) produced a maximum plasma doxycycline concentration of 2.4 μg/mL at 2.3 hours on day 1 and 1.9 μg/mL at 5.8 hours on day 4.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),[μg] / [ml],2.4,192992,DB00759,Tetracycline
,24094266,maximum plasma doxycycline concentration,"Administration of doxycycline (20 mg/kg/d, PO) produced a maximum plasma doxycycline concentration of 2.4 μg/mL at 2.3 hours on day 1 and 1.9 μg/mL at 5.8 hours on day 4.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),[μg] / [ml],1.9,192993,DB00759,Tetracycline
,24094266,elimination half-life,"Doxycycline elimination half-life on day 4 in animals receiving doxycycline at a dosage of 10 or 20 mg/kg/d was 6.7 or 5.6 hours, respectively.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),h,6.7,192994,DB00759,Tetracycline
,24094266,elimination half-life,"Doxycycline elimination half-life on day 4 in animals receiving doxycycline at a dosage of 10 or 20 mg/kg/d was 6.7 or 5.6 hours, respectively.",Population pharmacokinetics of doxycycline in the tears and plasma of northern elephant seals (Mirounga angustirostris) following oral drug administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24094266/),h,5.6,192995,DB00759,Tetracycline
,19998582,AUC(t),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],18038.55,193242,DB00759,Tetracycline
,19998582,AUC(inf),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],19648.21,193243,DB00759,Tetracycline
,19998582,AUC(inf),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[ng] / [ml],1076.01,193244,DB00759,Tetracycline
,19998582,C(max),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],19648.21,193245,DB00759,Tetracycline
,19998582,C(max),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[ng] / [ml],1076.01,193246,DB00759,Tetracycline
,19998582,t,"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,17.33,193247,DB00759,Tetracycline
,19998582,t,"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,16.44,193248,DB00759,Tetracycline
,19998582,t(max),"The median (range) of t(max) of the test drug and reference drug were 2.0 (1.0-4.0) h and 2.0 (0.67-4.0) h, respectively.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,2.0,193249,DB00759,Tetracycline
,19998582,t(max),"The median (range) of t(max) of the test drug and reference drug were 2.0 (1.0-4.0) h and 2.0 (0.67-4.0) h, respectively.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,2.0,193250,DB00759,Tetracycline
,11874523,AUC,"The serum pharmacokinetic parameters of OTC in goats were determined, with a mean AUC=67.4 microg h/mL, mean terminal half-life=14.4 h, and apparent clearance=0.33 L/kg h.",Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874523/),[h·μg] / [ml],67.4,193254,DB00759,Tetracycline
,11874523,terminal half-life,"The serum pharmacokinetic parameters of OTC in goats were determined, with a mean AUC=67.4 microg h/mL, mean terminal half-life=14.4 h, and apparent clearance=0.33 L/kg h.",Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874523/),h,14.4,193255,DB00759,Tetracycline
,11874523,apparent clearance,"The serum pharmacokinetic parameters of OTC in goats were determined, with a mean AUC=67.4 microg h/mL, mean terminal half-life=14.4 h, and apparent clearance=0.33 L/kg h.",Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874523/),[l] / [h·kg],0.33,193256,DB00759,Tetracycline
,11874523,terminal slope half-lives,"One-compartment model describing milk depletion data for i.m. and s.c. dosing had terminal slope half-lives of 20.1 and 36.1 h, respectively.",Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874523/),h,20.1,193257,DB00759,Tetracycline
,11874523,terminal slope half-lives,"One-compartment model describing milk depletion data for i.m. and s.c. dosing had terminal slope half-lives of 20.1 and 36.1 h, respectively.",Serum pharmacokinetics and tissue and milk residues of oxytetracycline in goats following a single intramuscular injection of a long-acting preparation and milk residues following a single subcutaneous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874523/),h,36.1,193258,DB00759,Tetracycline
,8087147,CMAX,The comparison of the CMAX did not reveal any significant differences (4.45 +/- 1.30 and 4.40 +/- 0.9 micrograms/ml).,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[μg] / [ml],4.45,194473,DB00759,Tetracycline
,8087147,CMAX,The comparison of the CMAX did not reveal any significant differences (4.45 +/- 1.30 and 4.40 +/- 0.9 micrograms/ml).,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[μg] / [ml],4.40,194474,DB00759,Tetracycline
,8087147,AUC0-84 h,The AUC0-84 h results were respectively 92.8 +/- 14.1 and 96.3 +/- 11.3 mg.h/l and the AUC0-infinity results were 99.5 +/- 14.7 and 106.7 +/- 15.4 mg.h/l.,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[h·mg] / [l],92.8,194475,DB00759,Tetracycline
,8087147,AUC0-84 h,The AUC0-84 h results were respectively 92.8 +/- 14.1 and 96.3 +/- 11.3 mg.h/l and the AUC0-infinity results were 99.5 +/- 14.7 and 106.7 +/- 15.4 mg.h/l.,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[h·mg] / [l],96.3,194476,DB00759,Tetracycline
,8087147,AUC0-infinity,The AUC0-84 h results were respectively 92.8 +/- 14.1 and 96.3 +/- 11.3 mg.h/l and the AUC0-infinity results were 99.5 +/- 14.7 and 106.7 +/- 15.4 mg.h/l.,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[h·mg] / [l],99.5,194477,DB00759,Tetracycline
,8087147,AUC0-infinity,The AUC0-84 h results were respectively 92.8 +/- 14.1 and 96.3 +/- 11.3 mg.h/l and the AUC0-infinity results were 99.5 +/- 14.7 and 106.7 +/- 15.4 mg.h/l.,Plasma bioavailability of 2 long-acting oxytetracycline formulations in the pig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8087147/),[h·mg] / [l],106.7,194478,DB00759,Tetracycline
,23497696,relative bioavailability,"Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),%,548,194868,DB00759,Tetracycline
,23497696,maximum serum concentration (Cmax),"Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),[μg] / [ml],1.3,194869,DB00759,Tetracycline
,23497696,time to reach the Cmax (Tmax),"Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),h,5.9,194870,DB00759,Tetracycline
,23497696,area under the curve (AUC),"Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),[h·μg] / [ml],17.0,194871,DB00759,Tetracycline
,23497696,elimination half-life (T½ β),"Dox-pol showed the greatest values for relative bioavailability (548%); maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h, area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),h,4.9,194872,DB00759,Tetracycline
,23497696,minimal inhibitory concentration MIC,"Considering a minimal inhibitory concentration MIC of 0.25 μg/mL, clinically effective plasma concentrations might be obtained for up to 24 h administering Dox-pol.",Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497696/),[μg] / [ml],0.25,194873,DB00759,Tetracycline
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,15,195393,DB00759,Tetracycline
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,63,195394,DB00759,Tetracycline
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,67,195395,DB00759,Tetracycline
,19857105,peak concentrations,"Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mug/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),[μg] / [g],180,195396,DB00759,Tetracycline
,19857105,half-life,"Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mug/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,125,195397,DB00759,Tetracycline
,12887604,area under the curve (AUC),"The plasma concentration-time profile of OTC after a single i.v. injection at 20 mg/kg was best fit to an open two-compartmental model, with the following pharmacokinetic parameters: area under the curve (AUC) = 36.72 mg.",In vivo release of oxytetracycline from a biodegradable controlled-release gel injected subcutaneously in Japanese quail (Coturnix coturnix japonica). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887604/),mg,36.72,195890,DB00759,Tetracycline
,12887604,terminal elimination half-life,"h/L, terminal elimination half-life = 2.34 h, clearance (Cl) = 0.545 L/kg/h.",In vivo release of oxytetracycline from a biodegradable controlled-release gel injected subcutaneously in Japanese quail (Coturnix coturnix japonica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887604/),h,2.34,195891,DB00759,Tetracycline
,12887604,clearance (Cl),"h/L, terminal elimination half-life = 2.34 h, clearance (Cl) = 0.545 L/kg/h.",In vivo release of oxytetracycline from a biodegradable controlled-release gel injected subcutaneously in Japanese quail (Coturnix coturnix japonica). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887604/),[l] / [h·kg],0.545,195892,DB00759,Tetracycline
>,12887604,Plasma [OTC],Plasma [OTC] was >1.0 micro g/mL for at least 4 h following i.v. injection.,In vivo release of oxytetracycline from a biodegradable controlled-release gel injected subcutaneously in Japanese quail (Coturnix coturnix japonica). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887604/),[μg] / [ml],1.0,195893,DB00759,Tetracycline
,12888200,retention times,The retention times were approximately 1.7 min for COL-3 and 1.8 min for the I.S.,Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888200/),min,1.7,196017,DB00759,Tetracycline
,12888200,retention times,The retention times were approximately 1.7 min for COL-3 and 1.8 min for the I.S.,Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888200/),min,1.8,196018,DB00759,Tetracycline
,12888200,extraction recoveries,The extraction recoveries were 99% for COL-3 and 93% for I.S.,Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888200/),%,99,196019,DB00759,Tetracycline
,12888200,extraction recoveries,The extraction recoveries were 99% for COL-3 and 93% for I.S.,Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888200/),%,93,196020,DB00759,Tetracycline
,2231874,elimination half-lives (t1/2 beta),The elimination half-lives (t1/2 beta) were approximately 6 h in the healthy pigs and 5 h in the diseased animals.,The pharmacokinetics of oxytetracycline following intravenous administration in healthy and diseased pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231874/),h,6,196533,DB00759,Tetracycline
,2231874,elimination half-lives (t1/2 beta),The elimination half-lives (t1/2 beta) were approximately 6 h in the healthy pigs and 5 h in the diseased animals.,The pharmacokinetics of oxytetracycline following intravenous administration in healthy and diseased pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231874/),h,5,196534,DB00759,Tetracycline
,2912795,elimination period,"The drug was excreted preferentially into the yolk (about 75% of the total amount) and the elimination period lasted between 6 and 11 days for TC and 9 days for CTC, after treatment.",Excretion of tetracycline and chlortetracycline in eggs after oral medication of laying hens. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912795/),d,6 and 11,196656,DB00759,Tetracycline
,2912795,elimination period,"The drug was excreted preferentially into the yolk (about 75% of the total amount) and the elimination period lasted between 6 and 11 days for TC and 9 days for CTC, after treatment.",Excretion of tetracycline and chlortetracycline in eggs after oral medication of laying hens. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912795/),,9,196657,DB00759,Tetracycline
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],38.6,198791,DB00759,Tetracycline
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],6.0,198792,DB00759,Tetracycline
,3631718,distribution half-life,"After 10 mg of OTC/kg of body weight was administered IV, the distribution half-life was 0.06 hour, terminal half-life was 1.32 hours, volume of distribution area was 0.861 L/kg, and total body clearance was 0.434 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),h,0.06,199167,DB00759,Tetracycline
,3631718,terminal half-life,"After 10 mg of OTC/kg of body weight was administered IV, the distribution half-life was 0.06 hour, terminal half-life was 1.32 hours, volume of distribution area was 0.861 L/kg, and total body clearance was 0.434 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),h,1.32,199168,DB00759,Tetracycline
,3631718,volume of distribution area,"After 10 mg of OTC/kg of body weight was administered IV, the distribution half-life was 0.06 hour, terminal half-life was 1.32 hours, volume of distribution area was 0.861 L/kg, and total body clearance was 0.434 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[l] / [kg],0.861,199169,DB00759,Tetracycline
,3631718,total body clearance,"After 10 mg of OTC/kg of body weight was administered IV, the distribution half-life was 0.06 hour, terminal half-life was 1.32 hours, volume of distribution area was 0.861 L/kg, and total body clearance was 0.434 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[l] / [h·kg],0.434,199170,DB00759,Tetracycline
,3631718,absorption half-life,"After 10 mg of OTC/kg was given IM, the absorption half-life was 2.09 hours, extent of absorption was 71.4%, and total body clearance of the absorbed fraction was 0.576 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),h,2.09,199171,DB00759,Tetracycline
,3631718,total body clearance of the absorbed fraction,"After 10 mg of OTC/kg was given IM, the absorption half-life was 2.09 hours, extent of absorption was 71.4%, and total body clearance of the absorbed fraction was 0.576 L/kg/h.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[l] / [h·kg],0.576,199172,DB00759,Tetracycline
,3631718,observed,"This dose given IM for 7 consecutive days resulted in observed steady-state maximum and minimum concentrations (mean +/- SD) of 4.7 +/- 0.3 micrograms/ml and 3.2 +/- 0.6 micrograms/ml, respectively.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[μg] / [ml],4.7,199173,DB00759,Tetracycline
,3631718,steady-state maximum,"This dose given IM for 7 consecutive days resulted in observed steady-state maximum and minimum concentrations (mean +/- SD) of 4.7 +/- 0.3 micrograms/ml and 3.2 +/- 0.6 micrograms/ml, respectively.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[μg] / [ml],4.7,199174,DB00759,Tetracycline
,3631718,minimum concentrations,"This dose given IM for 7 consecutive days resulted in observed steady-state maximum and minimum concentrations (mean +/- SD) of 4.7 +/- 0.3 micrograms/ml and 3.2 +/- 0.6 micrograms/ml, respectively.",Pharmacokinetics of oxytetracycline hydrochloride in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631718/),[μg] / [ml],3.2,199175,DB00759,Tetracycline
,30150464,Accumulation,Accumulation ranged from approximately 7% to 38% with the q24h dosing regimens and was 45% with 1 mg/kg q12h.,"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30150464/),%,7,199311,DB00759,Tetracycline
,30150464,Accumulation,Accumulation ranged from approximately 7% to 38% with the q24h dosing regimens and was 45% with 1 mg/kg q12h.,"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30150464/),%,38,199312,DB00759,Tetracycline
,30150464,Accumulation,Accumulation ranged from approximately 7% to 38% with the q24h dosing regimens and was 45% with 1 mg/kg q12h.,"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30150464/),%,45,199313,DB00759,Tetracycline
,10836479,peak serum concentration,Mean peak serum concentration was 0.22 microg/ml 1 h postadministration.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.22,199348,DB00759,Tetracycline
,10836479,peak serum doxycycline concentration,The mean +/- s.e. peak serum doxycycline concentration was 0.32+/-0.16 microg/ml 1 h after the first dose and 0.42+/-0.05 microg/ml 2 h after the fifth dose.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.32,199349,DB00759,Tetracycline
,10836479,peak serum doxycycline concentration,The mean +/- s.e. peak serum doxycycline concentration was 0.32+/-0.16 microg/ml 1 h after the first dose and 0.42+/-0.05 microg/ml 2 h after the fifth dose.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.42,199350,DB00759,Tetracycline
>,10836479,trough serum concentrations,The mean trough serum concentrations were > 0.16 microg/ml.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.16,199351,DB00759,Tetracycline
,10836479,synovial concentration,"Highest mean synovial concentration was 0.46+/-0.13 microg/ml and highest mean peritoneal concentration was 0.43+/-0.07 microg/ml, both 2 h after the fifth dose.","Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.46,199352,DB00759,Tetracycline
,10836479,peritoneal concentration,"Highest mean synovial concentration was 0.46+/-0.13 microg/ml and highest mean peritoneal concentration was 0.43+/-0.07 microg/ml, both 2 h after the fifth dose.","Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.43,199353,DB00759,Tetracycline
,10836479,Highest urine concentration,Highest urine concentration was mean +/- s.e. 145+/-25.4 microg/ml 2 h after the last dose.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],145,199354,DB00759,Tetracycline
,10836479,Highest endometrial concentration,Highest endometrial concentration was mean +/- s.e. 1.30+/-0.36 microg/ml 3 h after the fifth dose.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],1.30,199355,DB00759,Tetracycline
,10836479,Vd(area),Mean +/- s.e. Vd(area) was 25.3+/-5.0 l/kg and mean t1/2 was 8.7+/-1.6 h.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[l] / [kg],25.3,199356,DB00759,Tetracycline
,10836479,t1/2,Mean +/- s.e. Vd(area) was 25.3+/-5.0 l/kg and mean t1/2 was 8.7+/-1.6 h.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),h,8.7,199357,DB00759,Tetracycline
<,10836479,MIC90,The MIC90 was < or = 1.0 microg/ml for Streptococcus zooepidemicus and 0.25 microg/ml for Staphylococcus aureus.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],1.0,199358,DB00759,Tetracycline
,10836479,MIC90,The MIC90 was < or = 1.0 microg/ml for Streptococcus zooepidemicus and 0.25 microg/ml for Staphylococcus aureus.,"Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.25,199359,DB00759,Tetracycline
<,10836479,MIC,"Based on drug concentrations achieved in the serum, synovial and peritoneal fluids and endometrial tissues and MIC values determined in the present study, doxycycline at a dose of 10 mg/kg bwt per os every 12 h may be appropriate for the treatment of infections caused by susceptible (MIC < 0.25 microg/ml) gram-positive organisms in horses.","Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836479/),[μg] / [ml],0.25,199360,DB00759,Tetracycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,32.59,199436,DB00759,Tetracycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,34.91,199437,DB00759,Tetracycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,0.97,199438,DB00759,Tetracycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,23.49,199439,DB00759,Tetracycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,25.42,199440,DB00759,Tetracycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,26.62,199441,DB00759,Tetracycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,7.92,199442,DB00759,Tetracycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,19.62,199443,DB00759,Tetracycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,17.55,199444,DB00759,Tetracycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],14.85,199445,DB00759,Tetracycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],14.68,199446,DB00759,Tetracycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],15.37,199447,DB00759,Tetracycline
,21163728,volume of distribution,Daptomycin has a very small volume of distribution of 7L indicating very little tissue distribution whereas tigecycline has a very large volume of distribution of 350-500 L.,"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,7,200704,DB00759,Tetracycline
,21163728,volume of distribution,Daptomycin has a very small volume of distribution of 7L indicating very little tissue distribution whereas tigecycline has a very large volume of distribution of 350-500 L.,"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,350-500,200705,DB00759,Tetracycline
,21163728,volumes of distribution,"Vancomycin and linezolid are in-between with volumes of distribution of approximately 30 and 50 L, close to total body water.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,30,200706,DB00759,Tetracycline
,21163728,volumes of distribution,"Vancomycin and linezolid are in-between with volumes of distribution of approximately 30 and 50 L, close to total body water.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,50,200707,DB00759,Tetracycline
,21163728,half-lives,"Although the elimination pathways are very different, the resulting half-lives of linezolid, vancomycin, and daptomycin are not greatly different and vary from 4-8 h.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),h,4-8,200708,DB00759,Tetracycline
up to,21163728,half-life,"Tigecycline, however, has a much longer half-life of up to 1-2 days due to the slow redistribution from tissue binding sites.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),d,1-2,200709,DB00759,Tetracycline
,10372599,biliary excretion rate,The maximum value for OTC biliary excretion rate (3.69+/-0.6 microg/min/kg) was reached at approximately 17.5 min (time to maximum concentration (tmax)).,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),[μg] / [kg·min],3.69,201553,DB00759,Tetracycline
,10372599,time to maximum concentration (tmax),The maximum value for OTC biliary excretion rate (3.69+/-0.6 microg/min/kg) was reached at approximately 17.5 min (time to maximum concentration (tmax)).,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),min,17.5,201554,DB00759,Tetracycline
,10372599,biliary excretion (k),"The first-order rate constant for the biliary excretion (k) and the half-life (t1/2) were 6.7x10(-3) min(-1) and 110.55 min, respectively.",Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),1/[min],6.7x10(-3),201555,DB00759,Tetracycline
,10372599,half-life (t1/2),"The first-order rate constant for the biliary excretion (k) and the half-life (t1/2) were 6.7x10(-3) min(-1) and 110.55 min, respectively.",Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),min,110.55,201556,DB00759,Tetracycline
,10372599,area under the biliary excretion rate time curve (AUC),The mean value of area under the biliary excretion rate time curve (AUC) indicated that 839.77 microg/kg body weight (b.w.) were eliminated by the biliary route.,Biliary elimination kinetics and tissue concentrations of oxytetracycline after intravenous administration in hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372599/),[μg] / [kg],839.77,201557,DB00759,Tetracycline
,20179255,penetration ratio,"The calculated tigecycline penetration ratio in this patient ranged from 0% to 52%, depending on the calculation methodology utilized.",Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20179255/),%,0,204537,DB00759,Tetracycline
,20179255,penetration ratio,"The calculated tigecycline penetration ratio in this patient ranged from 0% to 52%, depending on the calculation methodology utilized.",Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20179255/),%,52,204538,DB00759,Tetracycline
,7197954,t0.5 beta,"The mean kel at this time decreased, while t0.5 beta was prolonged from 1.0 h to 3.0 h.",Effect of unilateral nephrectomy on the pharmacokinetics of rolitetracycline in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197954/),h,1.0,206560,DB00759,Tetracycline
,7197954,t0.5 beta,"The mean kel at this time decreased, while t0.5 beta was prolonged from 1.0 h to 3.0 h.",Effect of unilateral nephrectomy on the pharmacokinetics of rolitetracycline in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197954/),h,3.0,206561,DB00759,Tetracycline
,29158281,area under the concentration-time curve from time zero,"The mean area under the concentration-time curve from time zero extrapolated to infinity in plasma was 10.30 μg · h/ml when omadacycline was administered to ESRD subjects after dialysis, 10.20 μg · h/ml when omadacycline was administered to ESRD subjects before dialysis, and 9.76 μg · h/ml when omadacycline was administered to healthy subjects.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[h·μg] / [ml],10.30,206644,DB00759,Tetracycline
,29158281,area under the concentration-time curve from time zero,"The mean area under the concentration-time curve from time zero extrapolated to infinity in plasma was 10.30 μg · h/ml when omadacycline was administered to ESRD subjects after dialysis, 10.20 μg · h/ml when omadacycline was administered to ESRD subjects before dialysis, and 9.76 μg · h/ml when omadacycline was administered to healthy subjects.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[h·μg] / [ml],10.20,206645,DB00759,Tetracycline
,29158281,area under the concentration-time curve from time zero,"The mean area under the concentration-time curve from time zero extrapolated to infinity in plasma was 10.30 μg · h/ml when omadacycline was administered to ESRD subjects after dialysis, 10.20 μg · h/ml when omadacycline was administered to ESRD subjects before dialysis, and 9.76 μg · h/ml when omadacycline was administered to healthy subjects.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[h·μg] / [ml],9.76,206646,DB00759,Tetracycline
,29158281,maximum observed concentration,"The mean maximum observed concentration of omadacycline in plasma in ESRD subjects was 1.88 μg/ml when it was administered after dialysis and 2.33 μg/ml when it was administered before dialysis, and in healthy subjects it was 1.92 μg/ml.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[μg] / [ml],1.88,206647,DB00759,Tetracycline
,29158281,maximum observed concentration,"The mean maximum observed concentration of omadacycline in plasma in ESRD subjects was 1.88 μg/ml when it was administered after dialysis and 2.33 μg/ml when it was administered before dialysis, and in healthy subjects it was 1.92 μg/ml.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[μg] / [ml],2.33,206648,DB00759,Tetracycline
,29158281,maximum observed concentration,"The mean maximum observed concentration of omadacycline in plasma in ESRD subjects was 1.88 μg/ml when it was administered after dialysis and 2.33 μg/ml when it was administered before dialysis, and in healthy subjects it was 1.92 μg/ml.",Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29158281/),[μg] / [ml],1.92,206649,DB00759,Tetracycline
,3406529,half-life of the elimination phase,The half-life of the elimination phase was calculated to be 11.4 hours and the apparent volume of distribution was found to be 2.041 litres kg-1.,Pharmacokinetics of oxytetracycline in clinical cases in the red-necked wallaby (Macropus rufogriseus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3406529/),h,11.4,207835,DB00759,Tetracycline
,3406529,apparent volume of distribution,The half-life of the elimination phase was calculated to be 11.4 hours and the apparent volume of distribution was found to be 2.041 litres kg-1.,Pharmacokinetics of oxytetracycline in clinical cases in the red-necked wallaby (Macropus rufogriseus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3406529/),[l] / [kg],2.041,207836,DB00759,Tetracycline
,22978593,relative bioavailability,3. Dox-LA had a high relative bioavailability (1200%).,Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),%,1200,208414,DB00759,Tetracycline
,22978593,Maximum serum concentrations,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],5·1,208415,DB00759,Tetracycline
,22978593,Maximum serum concentrations,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],6·1,208416,DB00759,Tetracycline
,22978593,half-life,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),h,73·0,208417,DB00759,Tetracycline
,22978593,half-life,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),h,2·0,208418,DB00759,Tetracycline
,22978593,minimum effective serum concentration,"4. In conclusion, considering the minimum effective serum concentration against Mycoplasma spp is 0·5 µg/ml, a dose-interval of 180 h can be achieved with Dox-LA, but only for 24 h after Dox-PO.",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],0·5,208419,DB00759,Tetracycline
,7886888,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) and the central compartment volume (Vc) were 1.443 litres/kg and 0.453 litre/kg, respectively, and the total body clearance was 0.156 litre/kg/hour.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),[l] / [kg],1.443,209914,DB00759,Tetracycline
,7886888,central compartment volume (Vc),"The apparent volume of distribution (Vz) and the central compartment volume (Vc) were 1.443 litres/kg and 0.453 litre/kg, respectively, and the total body clearance was 0.156 litre/kg/hour.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),[l] / [kg],0.453,209915,DB00759,Tetracycline
,7886888,total body clearance,"The apparent volume of distribution (Vz) and the central compartment volume (Vc) were 1.443 litres/kg and 0.453 litre/kg, respectively, and the total body clearance was 0.156 litre/kg/hour.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),[l] / [h·kg],0.156,209916,DB00759,Tetracycline
,7886888,half-lives (T1/2 lambda z),"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),h,six,209917,DB00759,Tetracycline
,7886888,half-lives (T1/2 lambda z),"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),min,28,209918,DB00759,Tetracycline
,7886888,half-lives (T1/2 lambda z),"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),h,10,209919,DB00759,Tetracycline
,7886888,half-lives (T1/2 lambda z),"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),min,38,209920,DB00759,Tetracycline
,7886888,half-lives,"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),seconds,six,209921,DB00759,Tetracycline
,7886888,half-lives,"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),seconds,36,209922,DB00759,Tetracycline
,7886888,half-lives,"The mean half-lives (T1/2 lambda z) of the conventional formulation after intravenous and intramuscular administration were six hours 28 minutes and 10 hours 38 minutes, respectively, whereas the long-acting formulation had half-lives of six hours 36 seconds and 29 hours, respectively, after intravenous and intramuscular injection.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),h,29,209923,DB00759,Tetracycline
over,7886888,minimum concentrations,"From the results of these single administrations two intramuscular dosage regimens can be proposed that achieve minimum concentrations of over 0.5 mg/litre (the minimum inhibitory concentration for most susceptible pathogens): with the conventional formulation by administering an initial dose of 10 mg/kg and a maintenance dose of 8.5 mg/kg every 24 hours, and with the long-acting formulation by administering an initial dose of 20 mg/kg and a maintenance dose of 14 mg/kg every 48 hours.",Pharmacokinetics of oxytetracycline in goats: modifications induced by a long-acting formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886888/),[mg] / [l],0.5,209924,DB00759,Tetracycline
,24406009,maximum residue levels,"The maximum residue levels of tetracycline in pork stomach tissue in Russia, Europe, and the United States are 10, 200, and 2,000 ppb, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,10,212901,DB00759,Tetracycline
,24406009,maximum residue levels,"The maximum residue levels of tetracycline in pork stomach tissue in Russia, Europe, and the United States are 10, 200, and 2,000 ppb, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,200,212902,DB00759,Tetracycline
,24406009,maximum residue levels,"The maximum residue levels of tetracycline in pork stomach tissue in Russia, Europe, and the United States are 10, 200, and 2,000 ppb, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,"2,000",212903,DB00759,Tetracycline
,24406009,residues,"The stomach tissue residues averaged 671.72, 330.31, 297.77, 136.36, and 268.08 ppb on withdrawal days 0, 1, 2, 4, and 8, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,671.72,212904,DB00759,Tetracycline
,24406009,residues,"The stomach tissue residues averaged 671.72, 330.31, 297.77, 136.36, and 268.08 ppb on withdrawal days 0, 1, 2, 4, and 8, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,330.31,212905,DB00759,Tetracycline
,24406009,residues,"The stomach tissue residues averaged 671.72, 330.31, 297.77, 136.36, and 268.08 ppb on withdrawal days 0, 1, 2, 4, and 8, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,297.77,212906,DB00759,Tetracycline
,24406009,residues,"The stomach tissue residues averaged 671.72, 330.31, 297.77, 136.36, and 268.08 ppb on withdrawal days 0, 1, 2, 4, and 8, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,136.36,212907,DB00759,Tetracycline
,24406009,residues,"The stomach tissue residues averaged 671.72, 330.31, 297.77, 136.36, and 268.08 ppb on withdrawal days 0, 1, 2, 4, and 8, respectively.",Tetracycline residues in porcine stomach after administration via drinking water on a swine farm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24406009/),ppb,268.08,212908,DB00759,Tetracycline
,31706017,bioavailability,PEG suppository showed 49.13% bioavailability and CBT 51.43% with Cmax equal to 2.06 ± 2.96 µg.,Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31706017/),%,49.13,214139,DB00759,Tetracycline
,31706017,CBT,PEG suppository showed 49.13% bioavailability and CBT 51.43% with Cmax equal to 2.06 ± 2.96 µg.,Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31706017/),%,51.43,214140,DB00759,Tetracycline
,31706017,Cmax,PEG suppository showed 49.13% bioavailability and CBT 51.43% with Cmax equal to 2.06 ± 2.96 µg.,Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31706017/),μg,2.06,214141,DB00759,Tetracycline
,23442695,detection limit,The detection limit of TC (S/N=3) was 1.8 ng mL(-1).,Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),[ng] / [ml],3,214559,DB00759,Tetracycline
,23442695,detection limit,The detection limit of TC (S/N=3) was 1.8 ng mL(-1).,Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),[ng] / [ml],1.8,214560,DB00759,Tetracycline
,23442695,S/N,The detection limit of TC (S/N=3) was 1.8 ng mL(-1).,Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),[ng] / [ml],3,214561,DB00759,Tetracycline
,23442695,S/N,The detection limit of TC (S/N=3) was 1.8 ng mL(-1).,Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),[ng] / [ml],1.8,214562,DB00759,Tetracycline
,23442695,recovery,The recovery of TC was 97.8% (n=5).,Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),%,97.8,214563,DB00759,Tetracycline
,23442695,maximum concentration,"After administration of 75 mg kg(-1) TC, the maximum concentration and peak time of TC in crucian carp muscle were 7.33 mg kg(-1) and 8h, respectively.",Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),[mg] / [kg],7.33,214564,DB00759,Tetracycline
,23442695,peak time,"After administration of 75 mg kg(-1) TC, the maximum concentration and peak time of TC in crucian carp muscle were 7.33 mg kg(-1) and 8h, respectively.",Pharmacokinetics and residues of tetracycline in crucian carp muscle using capillary electrophoresis on-line coupled with electrochemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23442695/),h,8,214565,DB00759,Tetracycline
,2703423,Peak plasma OTC concentration,"Plasma OTC concentration increased rapidly after drug administration, and by 2 hours, mean (+/- SD) values were 7.4 +/- 2.6 micrograms/ml, Peak plasma OTC concentration was 9.6 +/- 2.6 micrograms/ml, and the time to peak plasma concentration was 7.6 +/- 4.0 hours.","Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703423/),[μg] / [ml],9.6,215241,DB00759,Tetracycline
,2703423,time to peak plasma concentration,"Plasma OTC concentration increased rapidly after drug administration, and by 2 hours, mean (+/- SD) values were 7.4 +/- 2.6 micrograms/ml, Peak plasma OTC concentration was 9.6 +/- 2.6 micrograms/ml, and the time to peak plasma concentration was 7.6 +/- 4.0 hours.","Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703423/),h,7.6,215242,DB00759,Tetracycline
,2703423,elimination half-life,"Plasma OTC concentration decreased slowly for 168 hours (elimination phase) after drug administration, and the elimination half-life was 23.9 hours.","Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703423/),h,23.9,215243,DB00759,Tetracycline
,2703423,depletion half-life,"This slower phase was termed the depletion phase, and the depletion half-life was 280.7 hours.","Oxytetracycline pharmacokinetics, tissue depletion, and toxicity after administration of a long-acting preparation at double the label dosage. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703423/),h,280.7,215244,DB00759,Tetracycline
,3309808,T1/2,"Moreover, as regard doxycycline half-life, a difference was observed between these two groups before rifampicin treatment: in one case T1/2 was of 17.9 + 6.6 hours, while in the other it was of 9.2 + 2.3 hours.",[Effects of rifampicin on the pharmacokinetics of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3309808/),h,17.9,215856,DB00759,Tetracycline
,3309808,T1/2,"Moreover, as regard doxycycline half-life, a difference was observed between these two groups before rifampicin treatment: in one case T1/2 was of 17.9 + 6.6 hours, while in the other it was of 9.2 + 2.3 hours.",[Effects of rifampicin on the pharmacokinetics of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3309808/),h,9.2,215857,DB00759,Tetracycline
,16105560,terminal elimination half-life,"Pharmacokinetic analysis of data from phase 1 trials of healthy subjects indicate that tigecycline has a large volume of distribution, signifying extensive tissue penetration, and a long terminal elimination half-life (approximately 40 h), easily allowing for twice-daily dose administration.",Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16105560/),h,40,216167,DB00759,Tetracycline
,15526889,plasma concentration at time zero,"Intravenous administration of oxytetracycline resulted in an extrapolated mean plasma concentration at time zero of 60.63 +/- 28.26 microg/ml, with average plasma drug levels of 2.82 +/- 0.71 microg/ml at the end of the 192-hr sampling period.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),[μg] / [ml],60.63,216522,DB00759,Tetracycline
,15526889,Plasma volume of distribution,"Plasma volume of distribution for i.v. oxytetracycline was 0.20 +/- 0.09 L/kg, with a harmonic mean elimination half-life of 15.15 hr and mean total body clearance rate of 0.007 +/- 0.002 L/hr/kg.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),[l] / [kg],0.20,216523,DB00759,Tetracycline
,15526889,elimination half-life,"Plasma volume of distribution for i.v. oxytetracycline was 0.20 +/- 0.09 L/kg, with a harmonic mean elimination half-life of 15.15 hr and mean total body clearance rate of 0.007 +/- 0.002 L/hr/kg.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),h,15.15,216524,DB00759,Tetracycline
,15526889,total body clearance rate,"Plasma volume of distribution for i.v. oxytetracycline was 0.20 +/- 0.09 L/kg, with a harmonic mean elimination half-life of 15.15 hr and mean total body clearance rate of 0.007 +/- 0.002 L/hr/kg.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),[l] / [h·kg],0.007,216525,DB00759,Tetracycline
,15526889,peak plasma concentration,"Intramuscular administration of oxytetracycline achieved a mean peak plasma concentration of 6.85 +/- 1.96 microg/ml at 1 hr after administration, with average plasma drug levels of 4.96 +/- 1.97 microg/ml at the end of the 192-hr sampling period.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),[μg] / [ml],6.85,216526,DB00759,Tetracycline
,15526889,terminal elimination half-life,The harmonic mean terminal elimination half-life for i.m. oxytetracycline was 131.23 hr.,Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),h,131.23,216527,DB00759,Tetracycline
,15526889,minimum inhibitory concentration,"Based on the results of this study, long-acting preparations of oxytetracycline administered parenterally to American alligators at 10 mg/kg q 5 days is expected to maintain plasma concentrations above the minimum inhibitory concentration of 4.0 microg/ml for susceptible organisms.",Pharmacokinetic disposition of a long-acting oxytetracycline formulation after single-dose intravenous and intramuscular administrations in the American alligator (Alligator mississippiensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15526889/),[μg] / [ml],4.0,216528,DB00759,Tetracycline
,27499331,AUClast,The AUClast of plasma radioactivity (only quantifiable to 8 h due to low radioactivity) was 3096 ngEq h/mL and apparent terminal half-life was 11.1 h.,"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),[h·ngeq] / [ml],3096,218169,DB00759,Tetracycline
,27499331,apparent terminal half-life,The AUClast of plasma radioactivity (only quantifiable to 8 h due to low radioactivity) was 3096 ngEq h/mL and apparent terminal half-life was 11.1 h.,"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),h,11.1,218170,DB00759,Tetracycline
,27499331,Apparent plasma half-life,Apparent plasma half-life was 17.6 h with biphasic elimination.,"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),h,17.6,218171,DB00759,Tetracycline
,27499331,Plasma exposure (AUCinf),"Plasma exposure (AUCinf) averaged 9418 ng h/mL, with high clearance (CL/F, 32.8 L/h) and volume of distribution (Vz/F 828 L).","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),[h·ng] / [ml],9418,218172,DB00759,Tetracycline
,27499331,clearance (CL/F,"Plasma exposure (AUCinf) averaged 9418 ng h/mL, with high clearance (CL/F, 32.8 L/h) and volume of distribution (Vz/F 828 L).","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),[l] / [h],32.8,218173,DB00759,Tetracycline
,27499331,volume of distribution (Vz/F,"Plasma exposure (AUCinf) averaged 9418 ng h/mL, with high clearance (CL/F, 32.8 L/h) and volume of distribution (Vz/F 828 L).","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),l,828,218174,DB00759,Tetracycline
>,27499331,Radioactivity recovery,"4. Radioactivity recovery of the administered dose in excreta was complete (>95%); renal and fecal elimination were 14.4% and 81.1%, respectively.","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),%,95,218175,DB00759,Tetracycline
,27499331,renal,"4. Radioactivity recovery of the administered dose in excreta was complete (>95%); renal and fecal elimination were 14.4% and 81.1%, respectively.","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),%,14.4,218176,DB00759,Tetracycline
,27499331,renal,"4. Radioactivity recovery of the administered dose in excreta was complete (>95%); renal and fecal elimination were 14.4% and 81.1%, respectively.","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),%,81.1,218177,DB00759,Tetracycline
,27499331,fecal elimination,"4. Radioactivity recovery of the administered dose in excreta was complete (>95%); renal and fecal elimination were 14.4% and 81.1%, respectively.","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),%,14.4,218178,DB00759,Tetracycline
,27499331,fecal elimination,"4. Radioactivity recovery of the administered dose in excreta was complete (>95%); renal and fecal elimination were 14.4% and 81.1%, respectively.","Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27499331/),%,81.1,218179,DB00759,Tetracycline
,6688049,terminal half-life,"Elimination parameters of doxycycline were impaired by milk; a decrease of the terminal half-life from 28 h to 15 h, and apparent decrease of the enterohepatic circulation and an increase in total body clearance from 40 to 62 ml/min.",Pharmacokinetic study of doxycycline polyphosphate+ after simultaneous ingestion of milk. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688049/),h,28,219422,DB00759,Tetracycline
,6688049,terminal half-life,"Elimination parameters of doxycycline were impaired by milk; a decrease of the terminal half-life from 28 h to 15 h, and apparent decrease of the enterohepatic circulation and an increase in total body clearance from 40 to 62 ml/min.",Pharmacokinetic study of doxycycline polyphosphate+ after simultaneous ingestion of milk. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688049/),h,15,219423,DB00759,Tetracycline
,6688049,total body clearance,"Elimination parameters of doxycycline were impaired by milk; a decrease of the terminal half-life from 28 h to 15 h, and apparent decrease of the enterohepatic circulation and an increase in total body clearance from 40 to 62 ml/min.",Pharmacokinetic study of doxycycline polyphosphate+ after simultaneous ingestion of milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688049/),[ml] / [min],40,219424,DB00759,Tetracycline
,6688049,total body clearance,"Elimination parameters of doxycycline were impaired by milk; a decrease of the terminal half-life from 28 h to 15 h, and apparent decrease of the enterohepatic circulation and an increase in total body clearance from 40 to 62 ml/min.",Pharmacokinetic study of doxycycline polyphosphate+ after simultaneous ingestion of milk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688049/),[ml] / [min],62,219425,DB00759,Tetracycline
,27190106,absolute bioavailability,The absolute bioavailability of OTC in the group of birds exposed to higher ions concentration was reduced (8.68% ± 2.56) as compared to the control (13.71% ± 2.60).,Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),%,8.68,219910,DB00759,Tetracycline
,27190106,absolute bioavailability,The absolute bioavailability of OTC in the group of birds exposed to higher ions concentration was reduced (8.68% ± 2.56) as compared to the control (13.71% ± 2.60).,Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),%,13.71,219911,DB00759,Tetracycline
,27190106,area under the concentration-time curve from 0 to infinity,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],15.36,219912,DB00759,Tetracycline
,27190106,from,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],14.78,219913,DB00759,Tetracycline
,27190106,0 to t,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],14.78,219914,DB00759,Tetracycline
,27190106,area under the first moment of curve from 0 to t,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],107.54,219915,DB00759,Tetracycline
,27190106,maximum plasma concentration,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[μg] / [ml],2.13,219916,DB00759,Tetracycline
,21797013,flow rate,"A Hypersil BDS RP-C18 column (250 x 4.6 mm, 5 microm particle size) was used with the mobile phase phosphate buffer (pH 7.10, 0.070 M)-acetonitrile (76 + 24, v/v) at a flow rate of 1.0 mL/min.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ml] / [min],1.0,219954,DB00759,Tetracycline
,21797013,elution time,"The elution time of tigecycline and minocycline was approximately 8.1 and 9.9 min, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),min,8.1,219955,DB00759,Tetracycline
,21797013,elution time,"The elution time of tigecycline and minocycline was approximately 8.1 and 9.9 min, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),min,9.9,219956,DB00759,Tetracycline
,21797013,LOD,"The LOD and LOQ in plasma were estimated as 7 and 21 ng/mL, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ng] / [ml],7,219957,DB00759,Tetracycline
,21797013,LOQ,"The LOD and LOQ in plasma were estimated as 7 and 21 ng/mL, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ng] / [ml],21,219958,DB00759,Tetracycline
,19696049,penetration ratio,"The group without pulmonary infection displayed an ELF penetration ratio of 8.1 and 6.2 for the 50 and 25 mg/kg doses, respectively.",Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,8.1,220067,DB00759,Tetracycline
,19696049,penetration ratio,"The group without pulmonary infection displayed an ELF penetration ratio of 8.1 and 6.2 for the 50 and 25 mg/kg doses, respectively.",Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,6.2,220068,DB00759,Tetracycline
,19696049,penetration ratios,The respective penetration ratios in the infected lungs were 23.3 and 12.9.,Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,23.3,220069,DB00759,Tetracycline
,19696049,penetration ratios,The respective penetration ratios in the infected lungs were 23.3 and 12.9.,Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,12.9,220070,DB00759,Tetracycline
,8498009,bioavailability,The bioavailability of doxycycline after oral administration in a milk replacer was approximately 70%.,Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498009/),%,70,220384,DB00759,Tetracycline
,8498009,elimination half-life,The elimination half-life of doxycycline was found to be 9.5 +/- 3.0 h.,Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498009/),h,9.5,220385,DB00759,Tetracycline
,8498009,Cmin,"During the period of administration, the plasma concentrations varied between Cmin of 1.0 +/- 0.19 mg/L and Cmax of 2.3 +/- 0.19 mg/L.",Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498009/),[mg] / [l],1.0,220386,DB00759,Tetracycline
,8498009,Cmax,"During the period of administration, the plasma concentrations varied between Cmin of 1.0 +/- 0.19 mg/L and Cmax of 2.3 +/- 0.19 mg/L.",Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498009/),[mg] / [l],2.3,220387,DB00759,Tetracycline
,11402688,distribution half-life,Following i.v. administration the drug was rapidly distributed in the body with a distribution half-life of 0.21 +/- 0.01 h.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,0.21,220766,DB00759,Tetracycline
,11402688,elimination half-life,The elimination half-life of 6.78 +/- 0.06 h was relatively long and resulted from both a low total body clearance of 0.139 +/- 0.007 L/h.kg and a large volume of distribution of 1.36 +/- 0.06 L/kg.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,6.78,220767,DB00759,Tetracycline
,11402688,total body clearance,The elimination half-life of 6.78 +/- 0.06 h was relatively long and resulted from both a low total body clearance of 0.139 +/- 0.007 L/h.kg and a large volume of distribution of 1.36 +/- 0.06 L/kg.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),[l] / [h·kg],0.139,220768,DB00759,Tetracycline
,11402688,volume of distribution,The elimination half-life of 6.78 +/- 0.06 h was relatively long and resulted from both a low total body clearance of 0.139 +/- 0.007 L/h.kg and a large volume of distribution of 1.36 +/- 0.06 L/kg.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),[l] / [kg],1.36,220769,DB00759,Tetracycline
,11402688,absorption half-life,"After oral administration to fasted chickens, the absorption of doxycycline was quite fast and substantial as shown by the absorption half-life of 0.39 +/- 0.03 h, the maximal plasma concentration of 4.47 +/- 0.16 micrograms/mL and the time to reach the Cmax of 1.73 +/- 0.06 h.",Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,0.39,220770,DB00759,Tetracycline
,11402688,maximal plasma concentration,"After oral administration to fasted chickens, the absorption of doxycycline was quite fast and substantial as shown by the absorption half-life of 0.39 +/- 0.03 h, the maximal plasma concentration of 4.47 +/- 0.16 micrograms/mL and the time to reach the Cmax of 1.73 +/- 0.06 h.",Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),[μg] / [ml],4.47,220771,DB00759,Tetracycline
,11402688,time to reach the Cmax,"After oral administration to fasted chickens, the absorption of doxycycline was quite fast and substantial as shown by the absorption half-life of 0.39 +/- 0.03 h, the maximal plasma concentration of 4.47 +/- 0.16 micrograms/mL and the time to reach the Cmax of 1.73 +/- 0.06 h.",Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,1.73,220772,DB00759,Tetracycline
,11402688,absolute bioavailability,The absolute bioavailability was 73.4 +/- 2.5%.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),%,73.4,220773,DB00759,Tetracycline
,11402688,t1/2a,The presence of food in the intestinal tract reduced and extended the absorption (t1/2a = 1.23 +/- 0.21 h; Cmax = 3.07 +/- 0.23 micrograms/mL; tmax = 3.34 +/- 0.21 h).,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,1.23,220774,DB00759,Tetracycline
,11402688,Cmax,The presence of food in the intestinal tract reduced and extended the absorption (t1/2a = 1.23 +/- 0.21 h; Cmax = 3.07 +/- 0.23 micrograms/mL; tmax = 3.34 +/- 0.21 h).,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),[μg] / [ml],3.07,220775,DB00759,Tetracycline
,11402688,tmax,The presence of food in the intestinal tract reduced and extended the absorption (t1/2a = 1.23 +/- 0.21 h; Cmax = 3.07 +/- 0.23 micrograms/mL; tmax = 3.34 +/- 0.21 h).,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),h,3.34,220776,DB00759,Tetracycline
,11402688,absolute bioavailability,The absolute bioavailability was reduced to 61.1% +/- 4.4%.,Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402688/),%,61.1,220777,DB00759,Tetracycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),[muw] / [ml],2.0,221556,DB00759,Tetracycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,7.3,221557,DB00759,Tetracycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,6.6,221558,DB00759,Tetracycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,4.5,221559,DB00759,Tetracycline
,791106,MIC,"The MIC for all the tetracyclines tested, determined by the broth dilution technique, was 0.8 mug/ml.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),[μg] / [ml],0.8,221560,DB00759,Tetracycline
,28677837,flow rate,"The analyte and IS were separated on a reversed-phase Waters Acquity UPLC® BEH-C18 column (2.1 × 50 mm i.d., 1.7 μm) with a flow rate of 0.25 mL/min.",Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28677837/),[ml] / [min],0.25,223128,DB00759,Tetracycline
above,20486976,Plasma concentrations,Plasma concentrations of doxycycline were above 0.21 microg/ml at t=0.5 h.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),[μg] / [ml],0.21,223714,DB00759,Tetracycline
,20486976,peak concentration (Cmax),The mean+/-s.d. peak concentration (Cmax) of doxycycline in plasma was 0.37+/-0.22 microg/ml and time to peak concentration was 0.54+/-0.19 h.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),[μg] / [ml],0.37,223715,DB00759,Tetracycline
,20486976,time to peak concentration,The mean+/-s.d. peak concentration (Cmax) of doxycycline in plasma was 0.37+/-0.22 microg/ml and time to peak concentration was 0.54+/-0.19 h.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),h,0.54,223716,DB00759,Tetracycline
above,20486976,Synovial fluid concentrations,Synovial fluid concentrations of doxycycline were above 0.12 microg/ml 1 h after drug administration.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),[μg] / [ml],0.12,223717,DB00759,Tetracycline
,20486976,Cmax,The mean Cmax of doxycycline in the synovial fluid was 0.27+/-0.10 microg/ml.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),[μg] / [ml],0.27,223718,DB00759,Tetracycline
,20486976,penetration factor,"The penetration factor of doxycycline from plasma into synovial fluid, as determined by a ratio of the area-under-the-curve for synovial fluid:plasma during the sampling period, was 4.6.",Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),,4.6,223719,DB00759,Tetracycline
,20486976,penetration factor,Orally administered doxycycline distributes easily into synovial fluid with a penetration factor of 4.6.,Orally administered doxycycline accumulates in synovial fluid compared to plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20486976/),,4.6,223720,DB00759,Tetracycline
,28891075,bioavailability,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),%,38.6,225487,DB00759,Tetracycline
,28891075,bioavailability,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),%,15.7,225488,DB00759,Tetracycline
,28891075,Cmax,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),[μg] / [ml],1.343,225489,DB00759,Tetracycline
,28891075,Cmax,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),[μg] / [ml],0.281,225490,DB00759,Tetracycline
,28891075,Tmax,Median (range) Tmax (hr) in fasted horses was 2.0 (1.5-3.5) and in fed horses was 5.0 (1.0-8.0) and was not significantly different between groups.,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),h,2.0,225491,DB00759,Tetracycline
,28891075,Tmax,Median (range) Tmax (hr) in fasted horses was 2.0 (1.5-3.5) and in fed horses was 5.0 (1.0-8.0) and was not significantly different between groups.,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),h,5.0,225492,DB00759,Tetracycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],4,226343,DB00759,Tetracycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],0.125,226344,DB00759,Tetracycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],0.25,226345,DB00759,Tetracycline
,12543655,peak serum,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],2.3,226346,DB00759,Tetracycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],1.8,226347,DB00759,Tetracycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [g],1.2,226348,DB00759,Tetracycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [g],1.5,226349,DB00759,Tetracycline
,12543655,areas under the concentration time curve from 0 to 24 h,"The serum and lung areas under the concentration time curve from 0 to 24 h were 13.7 and 15.8 micro g. h/ml, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[h·μg] / [ml],15.8,226350,DB00759,Tetracycline
,12543655,lung,"Tigecycline-treated guinea pigs had average end of therapy lung counts of 1 x 10(6) CFU/g (range, 2.5 x 10(4) to 3.2 x 10(6) CFU/g) versus <1 x 10(2) CFU/g for azithromycin (range, undetectable to 100 CFU/g).",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[cfu] / [g],1 x 10,226351,DB00759,Tetracycline
,30559132,volume of distribution,"The volume of distribution (217 liters) was greater than that of extracellular fluid, which suggests distribution beyond the central compartment.",Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559132/),l,217,226567,DB00759,Tetracycline
,7086670,elimination half-life,Kinetic analysis revealed a significant prolongation in the elimination half-life (38.2 +/- 4.2 hr) of the shunted dogs as compared with controls (14.5 +/- 1.5 hr) after the i.v. administration of tetracycline.,Hepatorenal failure induced by tetracycline in dogs with portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086670/),h,38.2,226921,DB00759,Tetracycline
,7086670,elimination half-life,Kinetic analysis revealed a significant prolongation in the elimination half-life (38.2 +/- 4.2 hr) of the shunted dogs as compared with controls (14.5 +/- 1.5 hr) after the i.v. administration of tetracycline.,Hepatorenal failure induced by tetracycline in dogs with portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086670/),h,14.5,226922,DB00759,Tetracycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],29.8,227549,DB00759,Tetracycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],31.2,227550,DB00759,Tetracycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],22.1,227551,DB00759,Tetracycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],13.5,227552,DB00759,Tetracycline
,19399726,absorption,"Moreover, their absorption is highly variable and incomplete, ranging usually from 25 % to 60 % (absorption of tetracycline ranges from 77 % to 88 %).",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,77,228006,DB00759,Tetracycline
,19399726,absorption,"Moreover, their absorption is highly variable and incomplete, ranging usually from 25 % to 60 % (absorption of tetracycline ranges from 77 % to 88 %).",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,88,228007,DB00759,Tetracycline
more,19399726,bioavailability,"Doxycycline, the most common member of this group, features more than 80 % bioavailability.",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,80,228008,DB00759,Tetracycline
,33066710,terminal elimination half-life,"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),h,10.98,228327,DB00759,Tetracycline
,33066710,area under the concentration-time curve from 0 to infinitive time,"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),[h·µg] / [ml],215.84,228328,DB00759,Tetracycline
,33066710,area under the concentration-time curve from 0 to infinitive time,"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),[μg] / [ml],15.33,228329,DB00759,Tetracycline
,33066710,peak plasma concentration (Cmax),"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),[h·µg] / [ml],215.84,228330,DB00759,Tetracycline
,33066710,peak plasma concentration (Cmax),"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),[μg] / [ml],15.33,228331,DB00759,Tetracycline
,33066710,time to reach Cmax,"Following single oral administration, terminal elimination half-life, area under the concentration-time curve from 0 to infinitive time, peak plasma concentration (Cmax) and time to reach Cmax were 10.98 h, 215.84 (h*µg)/mL, 15.33 μg/mL, and 2 h, respectively.","Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),h,2,228332,DB00759,Tetracycline
,33066710,oral bioavailability,The oral bioavailability was 25.84% in quails.,"Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),%,25.84,228333,DB00759,Tetracycline
,33066710,withdrawal times,These results indicate that the withdrawal times required for doxycycline to reach concentrations <MRLs after 5-day oral administration at 20 mg/kg dose in Japanese quail are 6 days in Europe and China and 9 days in Japan.,"Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),d,6,228334,DB00759,Tetracycline
,33066710,withdrawal times,These results indicate that the withdrawal times required for doxycycline to reach concentrations <MRLs after 5-day oral administration at 20 mg/kg dose in Japanese quail are 6 days in Europe and China and 9 days in Japan.,"Pharmacokinetics, bioavailability and tissue residues of doxycycline in Japanese quails (Coturnix coturnix japonica) after oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066710/),,9,228335,DB00759,Tetracycline
,17688080,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 1,715.1 ng/ml (test) and 1,613.3 ng/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),[ng] / [ml],"1,715.1",231860,DB00759,Tetracycline
,17688080,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 1,715.1 ng/ml (test) and 1,613.3 ng/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),[ng] / [ml],"1,613.3",231861,DB00759,Tetracycline
,17688080,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 28,586.5 ng x h/ml (test) and 29,047.5 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),[h·ng] / [ml],"28,586.5",231862,DB00759,Tetracycline
,17688080,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 28,586.5 ng x h/ml (test) and 29,047.5 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),[h·ng] / [ml],"29,047.5",231863,DB00759,Tetracycline
,17688080,tmax,The median tmax was 1.88 h (test) and 2.00 h (reference).,Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),h,1.88,231864,DB00759,Tetracycline
,17688080,tmax,The median tmax was 1.88 h (test) and 2.00 h (reference).,Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),h,2.00,231865,DB00759,Tetracycline
,17688080,Plasma elimination half-lives (t1/2),Plasma elimination half-lives (t1/2) of 16.49 h (test) and 16.75 h (reference) were determined.,Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),h,16.49,231866,DB00759,Tetracycline
,17688080,Plasma elimination half-lives (t1/2),Plasma elimination half-lives (t1/2) of 16.49 h (test) and 16.75 h (reference) were determined.,Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688080/),h,16.75,231867,DB00759,Tetracycline
,25822587,absorption half-life,"For the single dose, the absorption half-life was 5.79, 9.40, 6.96, and 8.06 h in the plasma, liver, kidney, and muscle, respectively.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,5.79,235258,DB00759,Tetracycline
,25822587,absorption half-life,"For the single dose, the absorption half-life was 5.79, 9.40, 6.96, and 8.06 h in the plasma, liver, kidney, and muscle, respectively.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,9.40,235259,DB00759,Tetracycline
,25822587,absorption half-life,"For the single dose, the absorption half-life was 5.79, 9.40, 6.96, and 8.06 h in the plasma, liver, kidney, and muscle, respectively.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,6.96,235260,DB00759,Tetracycline
,25822587,absorption half-life,"For the single dose, the absorption half-life was 5.79, 9.40, 6.96, and 8.06 h in the plasma, liver, kidney, and muscle, respectively.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,8.06,235261,DB00759,Tetracycline
,25822587,absorption half-life,"However, the absorption half-life was 3.62, 7.33, 4.59, and 6.02 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,3.62,235262,DB00759,Tetracycline
,25822587,absorption half-life,"However, the absorption half-life was 3.62, 7.33, 4.59, and 6.02 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,7.33,235263,DB00759,Tetracycline
,25822587,absorption half-life,"However, the absorption half-life was 3.62, 7.33, 4.59, and 6.02 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,4.59,235264,DB00759,Tetracycline
,25822587,absorption half-life,"However, the absorption half-life was 3.62, 7.33, 4.59, and 6.02 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,6.02,235265,DB00759,Tetracycline
,25822587,elimination half-time,"The elimination half-time in the plasma, liver, kidney, and muscle was 58.63, 126.43, 65.1, and 58.85 h when M. amblycephala was treated with a single dose.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,58.63,235266,DB00759,Tetracycline
,25822587,elimination half-time,"The elimination half-time in the plasma, liver, kidney, and muscle was 58.63, 126.43, 65.1, and 58.85 h when M. amblycephala was treated with a single dose.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,126.43,235267,DB00759,Tetracycline
,25822587,elimination half-time,"The elimination half-time in the plasma, liver, kidney, and muscle was 58.63, 126.43, 65.1, and 58.85 h when M. amblycephala was treated with a single dose.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,65.1,235268,DB00759,Tetracycline
,25822587,elimination half-time,"The elimination half-time in the plasma, liver, kidney, and muscle was 58.63, 126.43, 65.1, and 58.85 h when M. amblycephala was treated with a single dose.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,58.85,235269,DB00759,Tetracycline
,25822587,elimination half-time,"However, the elimination half-time changed to 91.75, 214.87, 126.22, and 135.84 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,91.75,235270,DB00759,Tetracycline
,25822587,elimination half-time,"However, the elimination half-time changed to 91.75, 214.87, 126.22, and 135.84 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,214.87,235271,DB00759,Tetracycline
,25822587,elimination half-time,"However, the elimination half-time changed to 91.75, 214.87, 126.22, and 135.84 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,126.22,235272,DB00759,Tetracycline
,25822587,elimination half-time,"However, the elimination half-time changed to 91.75, 214.87, 126.22, and 135.84 h with multiple-dose oral administration.",Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25822587/),h,135.84,235273,DB00759,Tetracycline
,625605,Body clearance,Body clearance was 4.23+/-1.29 ml/kg/min.,Pharmacokinetics and dosage of oxytetracycline in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/625605/),[ml] / [kg·min],4.23,235309,DB00759,Tetracycline
,625605,overall,"A dosage regimen (intravenous route of drug administration), based on overall elimincation rate constant (0.1155 h-1) and apparent specific volume of distribution (2 litre/kg), and consisting of a priming dose (10 mg/kg) followed by maintenance doses (7.5 mg/kg) at 12 h intervals was proposed.",Pharmacokinetics and dosage of oxytetracycline in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/625605/),1/[h],0.1155,235310,DB00759,Tetracycline
,625605,apparent specific volume of distribution,"A dosage regimen (intravenous route of drug administration), based on overall elimincation rate constant (0.1155 h-1) and apparent specific volume of distribution (2 litre/kg), and consisting of a priming dose (10 mg/kg) followed by maintenance doses (7.5 mg/kg) at 12 h intervals was proposed.",Pharmacokinetics and dosage of oxytetracycline in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/625605/),[l] / [kg],2,235311,DB00759,Tetracycline
,625605,steady state serum concentrations,"This dosage regimen was predicted to rapidly achieve and maintain steady state serum concentrations within the range 1.25 to 5.0 microgram/ml, which is therapeutic level for the majority of susceptible microorganisms.",Pharmacokinetics and dosage of oxytetracycline in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/625605/),[μg] / [ml],1.25 to 5.0,235312,DB00759,Tetracycline
,3802746,percent penetration,Tetracycline penetrated into the lymph better than minocycline (percent penetration 67.3% of cf. 38.2%).,Ovine pulmonary transit of tetracycline and minocycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802746/),%,67.3,235845,DB00759,Tetracycline
,3802746,percent penetration,Tetracycline penetrated into the lymph better than minocycline (percent penetration 67.3% of cf. 38.2%).,Ovine pulmonary transit of tetracycline and minocycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802746/),%,38.2,235846,DB00759,Tetracycline
,24811802,MIC,97% isolates displayed susceptibility and 3% were tigecycline-intermediate strains and the values of MIC ranged from 0.125 to 4 μ g/ml.,A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24811802/),[g·μ] / [ml],0.125 to 4,237128,DB00759,Tetracycline
,10674962,TC,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],1.02,237666,DB00759,Tetracycline
,10674962,MN,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],2.18,237667,DB00759,Tetracycline
,10674962,MN,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],2.35,237668,DB00759,Tetracycline
,10674962,TC,"Saliva concentrations (TC=0.09 MN=0.31, DX=0.47 microg/ml) were the lowest of the 3 fluids monitored.","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),,0.09,237669,DB00759,Tetracycline
,10674962,DX,"Saliva concentrations (TC=0.09 MN=0.31, DX=0.47 microg/ml) were the lowest of the 3 fluids monitored.","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],0.47,237670,DB00759,Tetracycline
,28736817,mean residence time,"After intramuscular administration, the PK was characterized by a long mean residence time of 28.3 hr.",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,28.3,237876,DB00759,Tetracycline
,28736817,area under serum concentration-time curve (AUC0-∞ )/MIC ratios,"Based on minimum inhibitory concentrations (MICs) for six isolates each of Mannheimia haemolytica and Pasteurella multocida, measured in serum, integration of in vivo PK and in vitro PD data established area under serum concentration-time curve (AUC0-∞ )/MIC ratios of 30.0 and 24.3 hr for M. haemolytica and P. multocida, respectively.",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,30.0,237877,DB00759,Tetracycline
,28736817,area under serum concentration-time curve (AUC0-∞ )/MIC ratios,"Based on minimum inhibitory concentrations (MICs) for six isolates each of Mannheimia haemolytica and Pasteurella multocida, measured in serum, integration of in vivo PK and in vitro PD data established area under serum concentration-time curve (AUC0-∞ )/MIC ratios of 30.0 and 24.3 hr for M. haemolytica and P. multocida, respectively.",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,24.3,237878,DB00759,Tetracycline
,28736817,AUC0-∞ /MIC ratios,"Corresponding AUC0-∞ /MIC ratios based on MICs in broth were 656 and 745 hr, respectively.",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,656,237879,DB00759,Tetracycline
,28736817,AUC0-∞ /MIC ratios,"Corresponding AUC0-∞ /MIC ratios based on MICs in broth were 656 and 745 hr, respectively.",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,745,237880,DB00759,Tetracycline
,28736817,AUC0-24 hr /MIC ratios,PK-PD modelling of in vitro bacterial time-kill curves for oxytetracycline in serum established mean AUC0-24 hr /MIC ratios for 3log10 decrease in bacterial count of 27.5 hr (M. haemolytica) and 60.9 hr (P. multocida).,Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,27.5,237881,DB00759,Tetracycline
,28736817,AUC0-24 hr /MIC ratios,PK-PD modelling of in vitro bacterial time-kill curves for oxytetracycline in serum established mean AUC0-24 hr /MIC ratios for 3log10 decrease in bacterial count of 27.5 hr (M. haemolytica) and 60.9 hr (P. multocida).,Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736817/),h,60.9,237882,DB00759,Tetracycline
,26327274,peak (Cmax),"DOX brain concentration gradually increased and reached a peak (Cmax) of 1034.9 ng/mL at 240 min postdose, resulting in a brain plasma ratio of 31%.",Rapid and widespread distribution of doxycycline in rat brain: a mass spectrometric imaging study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26327274/),[ng] / [ml],1034.9,238497,DB00759,Tetracycline
,26327274,brain plasma ratio,"DOX brain concentration gradually increased and reached a peak (Cmax) of 1034.9 ng/mL at 240 min postdose, resulting in a brain plasma ratio of 31%.",Rapid and widespread distribution of doxycycline in rat brain: a mass spectrometric imaging study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26327274/),%,31,238498,DB00759,Tetracycline
,16343282,lambda(z),"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),h,3.14,238756,DB00759,Tetracycline
,16343282,lambda(z),"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),h,4.57,238757,DB00759,Tetracycline
,16343282,lambda(z),"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),h,3.71,238758,DB00759,Tetracycline
,16343282,AUC,"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),[h·μg] / [ml],38.9,238759,DB00759,Tetracycline
,16343282,AUC,"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),[h·μg] / [ml],42.7,238760,DB00759,Tetracycline
,16343282,AUC,"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),[h·μg] / [ml],49.6,238761,DB00759,Tetracycline
,16343282,Cl,"Noncompartmental analysis of the mean data yielded the following parameters for quail, cockatiels and Poicephalus parrots respectively: lambda(z) = 3.14, 4.57, 3.71 h; AUC = 38.9, 42.7, 49.6 microg x h/mL; and Cl = 514, 468, 403 mL/h/kg.",Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343282/),[ml] / [h·kg],"514, 468, 403",238762,DB00759,Tetracycline
,11773164,overall response rate,"There was one complete response and seven partial responses, for an overall response rate of 44%, with a median response duration of 25+ weeks.",Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11773164/),%,44,238763,DB00759,Tetracycline
,11773164,half-life,"The median COL-3 half-life was 39.3 hours (range, 4.1 to 251.1 hours).",Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11773164/),h,39.3,238764,DB00759,Tetracycline
,27736760,absolute bioavailability,The absolute bioavailability of the tablets was approximately 34.5%.,"Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27736760/),%,34.5,239357,DB00759,Tetracycline
,21547395,MTD,The MTD was 75 mg/m(2)/day in the -EIAD patients while one was not determined in +EIAD patients.,Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21547395/),[mg] / [d·m(2)],75,241031,DB00759,Tetracycline
,28416552,MICs,MICs were determined using CLSI methods and ranged from 0.125 to 0.25 mg/liter.,In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),[mg] / [l],0.125 to 0.25,241948,DB00759,Tetracycline
,28416552,maximum plasma concentration (Cmax),"Pharmacokinetic studies exhibited maximum plasma concentration (Cmax) values of 0.34 to 2.58 mg/liter, area under the concentration-time curve (AUC) from time zero to infinity (AUC0-∞) values of 2.44 to 57.6 mg · h/liter, and elimination half-lives of 3.9 to 17.6 h.",In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),[mg] / [l],0.34 to 2.58,241949,DB00759,Tetracycline
,28416552,area under the concentration-time curve (AUC) from time zero to infinity (AUC0-∞),"Pharmacokinetic studies exhibited maximum plasma concentration (Cmax) values of 0.34 to 2.58 mg/liter, area under the concentration-time curve (AUC) from time zero to infinity (AUC0-∞) values of 2.44 to 57.6 mg · h/liter, and elimination half-lives of 3.9 to 17.6 h.",In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),[h·mg] / [l],2.44 to 57.6,241950,DB00759,Tetracycline
,28416552,elimination half-lives,"Pharmacokinetic studies exhibited maximum plasma concentration (Cmax) values of 0.34 to 2.58 mg/liter, area under the concentration-time curve (AUC) from time zero to infinity (AUC0-∞) values of 2.44 to 57.6 mg · h/liter, and elimination half-lives of 3.9 to 17.6 h.",In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),h,3.9 to 17.6,241951,DB00759,Tetracycline
,28416552,fAUC/MIC,"The mean fAUC/MIC magnitudes associated with the net stasis and the 1-log-kill endpoints were 27.97 ± 8.29 and 32.60 ± 10.85, respectively.",In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),,27.97,241952,DB00759,Tetracycline
,28416552,fAUC/MIC,"The mean fAUC/MIC magnitudes associated with the net stasis and the 1-log-kill endpoints were 27.97 ± 8.29 and 32.60 ± 10.85, respectively.",In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416552/),,32.60,241953,DB00759,Tetracycline
,2782715,elimination half-life,Median elimination half-life was 14.17 hours (Angus) and 9.84 hours (Holstein).,Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),h,14.17,242106,DB00759,Tetracycline
,2782715,elimination half-life,Median elimination half-life was 14.17 hours (Angus) and 9.84 hours (Holstein).,Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),h,9.84,242107,DB00759,Tetracycline
,2782715,total body clearance,"Mean (+/- SEM) total body clearance was 1.07 (+/- 0.06) and 2.20 (+/- 0.21) ml/min/kg in Angus and Holstein calves, respectively.",Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),[ml] / [kg·min],1.07,242108,DB00759,Tetracycline
,2782715,total body clearance,"Mean (+/- SEM) total body clearance was 1.07 (+/- 0.06) and 2.20 (+/- 0.21) ml/min/kg in Angus and Holstein calves, respectively.",Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),[ml] / [kg·min],2.20,242109,DB00759,Tetracycline
,2782715,binding,Mean extent of doxycycline binding to serum proteins was 92.3% (+/- 0.8%).,Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),%,92.3,242110,DB00759,Tetracycline
,2782715,steady-state volume of distribution,"The large steady-state volume of distribution (1.31 +/- 0.11 L/kg in Angus and 1.81 +/- 0.24 L/kg in Holstein calves), despite the small free fraction in serum, suggested a relatively unrestricted access of drug into the intracellular compartment and/or appreciable tissue binding.",Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),[l] / [kg],1.31,242111,DB00759,Tetracycline
,2782715,steady-state volume of distribution,"The large steady-state volume of distribution (1.31 +/- 0.11 L/kg in Angus and 1.81 +/- 0.24 L/kg in Holstein calves), despite the small free fraction in serum, suggested a relatively unrestricted access of drug into the intracellular compartment and/or appreciable tissue binding.",Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782715/),[l] / [kg],1.81,242112,DB00759,Tetracycline
,3757782,Css,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[μg] / [ml],9.3,243391,DB00759,Tetracycline
,3757782,Css,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[μg] / [ml],10.6,243392,DB00759,Tetracycline
,3757782,Cl,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[ml] / [h]·kg],49.0,243393,DB00759,Tetracycline
,3757782,Cl,"However, when the five nonsmokers were evaluated separately, differences were observed for Css (micrograms/ml; mean +/- SD) 9.3 +/- 3.0, control, and 10.6 +/- 3.8, treatment (p = 0.041); and for Cl [( ml/h]/kg; mean +/- SD) 49.0 +/- 11.1, control, and 43.6 +/- 10.2, treatment (p = 0.019).",Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757782/),[ml] / [h]·kg],43.6,243394,DB00759,Tetracycline
,2746722,zero time concentration,Compared to catfish (COP = 86 +/- 10 micrograms/ml) an eightfold higher extrapolated zero time concentration was obtained in trout (COP = 753 +/- 290 micrograms/ml).,Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),[μg] / [ml],753,244312,DB00759,Tetracycline
,2746722,apparent distribution volumes (Vd(area],"A significant difference was observed with respect to the relatively large apparent distribution volumes (Vd(area] after i.v. OTC administration (trout, mean value: 2.1 l/kg; catfish, mean value: 1.3 l/kg).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),[l] / [kg],2.1,244313,DB00759,Tetracycline
,2746722,apparent distribution volumes (Vd(area],"A significant difference was observed with respect to the relatively large apparent distribution volumes (Vd(area] after i.v. OTC administration (trout, mean value: 2.1 l/kg; catfish, mean value: 1.3 l/kg).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),[l] / [kg],1.3,244314,DB00759,Tetracycline
,2746722,final elimination half-lives,"The mean final elimination half-lives of both fish species were greater than previously reported in mammals (trout, 89.5 h; catfish, 80.3 h).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),h,89.5,244315,DB00759,Tetracycline
,2746722,final elimination half-lives,"The mean final elimination half-lives of both fish species were greater than previously reported in mammals (trout, 89.5 h; catfish, 80.3 h).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),h,80.3,244316,DB00759,Tetracycline
,2746722,maximum plasma concentration (Cmax,A mean maximum plasma concentration (Cmax = 56.9 micrograms/ml) was obtained in trout at 4 h after i.m. administration of OTC.,Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),[μg] / [ml],56.9,244317,DB00759,Tetracycline
,2746722,Cmax,In catfish a lower Cmax of 43.4 micrograms/ml was determined at about 7 h.,Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),[μg] / [ml],43.4,244318,DB00759,Tetracycline
,2746722,bioavailability,"No significant difference was observed with respect to bioavailability following i.m. administration of OTC (trout, 85%; catfish, 86%).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),%,85,244319,DB00759,Tetracycline
,2746722,bioavailability,"No significant difference was observed with respect to bioavailability following i.m. administration of OTC (trout, 85%; catfish, 86%).",Comparative pharmacokinetics of oxytetracycline in rainbow trout (Salmo gairdneri) and African catfish (Clarias gariepinus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746722/),%,86,244320,DB00759,Tetracycline
,9185262,cure rate,The cure rate of artemether-azithromycin regimen was significantly lower than that of artemether-doxycycline regimen (14.8 vs 53.3%).,Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9185262/),%,14.8,244895,DB00759,Tetracycline
,9185262,cure rate,The cure rate of artemether-azithromycin regimen was significantly lower than that of artemether-doxycycline regimen (14.8 vs 53.3%).,Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9185262/),%,53.3,244896,DB00759,Tetracycline
,4087164,fraction of dose absorbed,"When minerals (0.3 g/L Ca2+, 0.1 g/L Mg2+) were dissolved in the bird's drinking water, the model indicated that the addition of citric acid (mass ratio of 10 citrate: 1 CTC) increased the fraction of dose absorbed from 0.06 to 0.16; once absorbed, the fractions of drug eliminated by renal excretion, biliary secretion, and chemical decomposition were 50, 46, and 4%, respectively.",The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087164/),,0,245041,DB00759,Tetracycline
<,31927013,relative bioavailability,"The relative bioavailability of OA in all three i.g. administration groups (40, 120, and 360 mg/kg) were <2%.","Pharmacokinetics, tissue distribution and excretion study of Oroxylin A, Oroxylin A 7-O-glucuronide and Oroxylin A sodium sulfonate in rats after administration of Oroxylin A. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31927013/),%,2,247687,DB00759,Tetracycline
,2080848,Bioavailabilities,Bioavailabilities for both im et sc routes were close to 85%.,[The bioequivalence of intramuscular and subcutaneous administration of a formulation of oxytetracycline in the young bull]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080848/),%,85,248776,DB00759,Tetracycline
,26863149,Oral bioavailability,"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),%,28,250081,DB00759,Tetracycline
,26863149,maximum plasma concentration (C max),"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[mg] / [l],0.23,250082,DB00759,Tetracycline
,26863149,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[h·mg] / [l],3.34,250083,DB00759,Tetracycline
,26863149,steady-state volume of distribution (V ss),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),l,320,250084,DB00759,Tetracycline
,26863149,steady-state volume of distribution (V ss),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[l] / [kg],4.2,250085,DB00759,Tetracycline
,26863149,terminal elimination half-life (t ½),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),h,48,250086,DB00759,Tetracycline
,26863149,total clearance (CL),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[l] / [h],13.5,250087,DB00759,Tetracycline
,12499194,MICs,MICs of GAR-936 were 0.06 micro g/ml for the three strains.,Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499194/),[μg] / [ml],0.06,250833,DB00759,Tetracycline
,12499194,serum elimination half-life,Mean serum elimination half-life ranged from 3.3 to 3.6 h.,Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499194/),h,3.3 to 3.6,250834,DB00759,Tetracycline
,8866460,volume of distribution,"The volume of distribution was 1.4, 1.2 and 0.7 L/kg body weight for OTC, TC and CTC respectively.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),[l] / [body·kg·weight],1.4,251697,DB00759,Tetracycline
,8866460,volume of distribution,"The volume of distribution was 1.4, 1.2 and 0.7 L/kg body weight for OTC, TC and CTC respectively.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),[l] / [body·kg·weight],1.2,251698,DB00759,Tetracycline
,8866460,volume of distribution,"The volume of distribution was 1.4, 1.2 and 0.7 L/kg body weight for OTC, TC and CTC respectively.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),[l] / [body·kg·weight],0.7,251699,DB00759,Tetracycline
,8866460,bioavailability,"The presence of food did not affect the bioavailability of OTC, which was only 3% in both fasted and fed pigs.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),%,3,251700,DB00759,Tetracycline
,8866460,bioavailability,"For TC there was a significantly higher bioavailability in fasted (18%) than in fed (5%) pigs, whereas for CTC the difference was not significant, being 11% in fasted vs. 6% in fed pigs.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),%,18,251701,DB00759,Tetracycline
,8866460,bioavailability,"For TC there was a significantly higher bioavailability in fasted (18%) than in fed (5%) pigs, whereas for CTC the difference was not significant, being 11% in fasted vs. 6% in fed pigs.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),%,5,251702,DB00759,Tetracycline
,8866460,bioavailability,"For TC there was a significantly higher bioavailability in fasted (18%) than in fed (5%) pigs, whereas for CTC the difference was not significant, being 11% in fasted vs. 6% in fed pigs.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),%,11,251703,DB00759,Tetracycline
,8866460,bioavailability,"For TC there was a significantly higher bioavailability in fasted (18%) than in fed (5%) pigs, whereas for CTC the difference was not significant, being 11% in fasted vs. 6% in fed pigs.","Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866460/),%,6,251704,DB00759,Tetracycline
,30043978,elimination half-life,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),h,7.78,251898,DB00759,Tetracycline
,30043978,area under the concentration-time curve from 0 hr to ∞,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[h·μg] / [ml],94.19,251899,DB00759,Tetracycline
,30043978,area under the concentration-time curve from 0 hr to ∞,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),h,3.50,251900,DB00759,Tetracycline
,30043978,peak concentration,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[h·μg] / [ml],94.19,251901,DB00759,Tetracycline
,30043978,time to reach peak concentration,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[h·μg] / [ml],94.19,251902,DB00759,Tetracycline
,30043978,time to reach peak concentration,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),h,3.50,251903,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[ml] / [kg],"2,502.65",251904,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),h,19.90,251905,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[h·μg] / [ml],121.08,251906,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[μg] / [ml],5.71,251907,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),h,7.25,251908,DB00759,Tetracycline
,30043978,volume of distribution per fraction absorbed,"After the first dosing, the elimination half-life, area under the concentration-time curve from 0 hr to ∞, peak concentration, time to reach peak concentration, and volume of distribution per fraction absorbed were determined as 7.78 hr, 94.19 μg·hr/ml, 5.65 μg/ml, 3.50 hr, and 2,502.65 ml/kg, respectively, while the corresponding values of these parameters after the last dose were 19.90 hr, 121.08 μg·hr/ml, 5.71 μg/ml, 7.25 hr, and 5,285.28 ml/kg, respectively.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),[ml] / [kg],"5,285.28",251909,DB00759,Tetracycline
,30043978,accumulation factor,"However, after multiple oral doses, accumulation of doxycycline in plasma was not observed with an average accumulation factor of 1.11.",Pharmacokinetics of doxycycline after oral administration of single and multiple dose in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043978/),,1.11,251910,DB00759,Tetracycline
,15977966,apparent volume of distribution,Administration of a 100mg loading dose of tigecycline followed by twice-daily doses of 50mg yielded an apparent volume of distribution of 7-10 L/kg.,Tigecycline: a novel glycylcycline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),[l] / [kg],7-10,254329,DB00759,Tetracycline
,15977966,Systemic clearance,Systemic clearance ranged from 0.2 to 0.3 L/h/kg and its half-life varied from 37 to 67 hours.,Tigecycline: a novel glycylcycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),[l] / [h·kg],0.2 to 0.3,254330,DB00759,Tetracycline
,15977966,half-life,Systemic clearance ranged from 0.2 to 0.3 L/h/kg and its half-life varied from 37 to 67 hours.,Tigecycline: a novel glycylcycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),h,37 to 67,254331,DB00759,Tetracycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.04,254724,DB00759,Tetracycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.19,254725,DB00759,Tetracycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.06,254726,DB00759,Tetracycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.75,254727,DB00759,Tetracycline
<,18519719,MICs,"Minocycline alone produced a 1.5- to 2.0-log(10)-unit reduction in viable count for the strains with MICs of <0.2 mg/liter, while the addition of rifampin increased the ABE for these strains (P < 0.05).",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.2,254728,DB00759,Tetracycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,33.9,254729,DB00759,Tetracycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,75.9,254730,DB00759,Tetracycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"1,350",254731,DB00759,Tetracycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"2,000",254732,DB00759,Tetracycline
,22136488,serum peak,"The mean serum peak and trough concentrations of tigecycline were 0.56±0.25 mg/L and 0.26±0.12 mg/L, respectively.",Tigecycline penetration into skin and soft tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),[mg] / [l],0.56,255079,DB00759,Tetracycline
,22136488,trough concentrations,"The mean serum peak and trough concentrations of tigecycline were 0.56±0.25 mg/L and 0.26±0.12 mg/L, respectively.",Tigecycline penetration into skin and soft tissue. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),[mg] / [l],0.26,255080,DB00759,Tetracycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,3.8,255081,DB00759,Tetracycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,5.2,255082,DB00759,Tetracycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,2.8,255083,DB00759,Tetracycline
,28887388,time to peak concentration (Tmax),"Although the literature supports a time to peak concentration (Tmax) of 1 hour for oral minocycline, the Tmax was estimated to be at least 6 hours in this cohort.",Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,1,255848,DB00759,Tetracycline
,28887388,Tmax,"Although the literature supports a time to peak concentration (Tmax) of 1 hour for oral minocycline, the Tmax was estimated to be at least 6 hours in this cohort.",Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,6,255849,DB00759,Tetracycline
,28887388,elimination half-life,The elimination half-life (available on 7 patients) was 17.5 hours (SD±3.5).,Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,17.5,255850,DB00759,Tetracycline
,18677974,bioavailability,"Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively).",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),%,951,257196,DB00759,Tetracycline
,18677974,bioavailability,"Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively).",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),%,477,257197,DB00759,Tetracycline
,18677974,bioavailability,"Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively).",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),%,106,257198,DB00759,Tetracycline
,18677974,bioavailability,"Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively).",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),%,82,257199,DB00759,Tetracycline
,18677974,maximum serum concentration,"Corresponding values for maximum serum concentration were 3.19 microg/ml and 3.00 microg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),[μg] / [ml],3.19,257200,DB00759,Tetracycline
,18677974,maximum serum concentration,"Corresponding values for maximum serum concentration were 3.19 microg/ml and 3.00 microg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),[μg] / [ml],3.00,257201,DB00759,Tetracycline
,18677974,elimination half-lives,"Corresponding values for maximum serum concentration were 3.19 microg/ml and 3.00 microg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),h,42.49,257202,DB00759,Tetracycline
,18677974,elimination half-lives,"Corresponding values for maximum serum concentration were 3.19 microg/ml and 3.00 microg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),h,2.77,257203,DB00759,Tetracycline
<,18677974,minimal inhibitory concentrations,"Considering minimal inhibitory concentrations of doxycycline for sensitive and resistant bacteria (from < or = 0.5 to > or =1.5 microg/ml), doxycycline-h-LA could be injected every 2 or 3 days, while aqueous doxycycline-h would require a dosing interval from 7.5 to 11 h.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),[μg] / [ml],0.5,257204,DB00759,Tetracycline
>,18677974,minimal inhibitory concentrations,"Considering minimal inhibitory concentrations of doxycycline for sensitive and resistant bacteria (from < or = 0.5 to > or =1.5 microg/ml), doxycycline-h-LA could be injected every 2 or 3 days, while aqueous doxycycline-h would require a dosing interval from 7.5 to 11 h.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),[μg] / [ml],1.5,257205,DB00759,Tetracycline
,18677974,tissue:serum ratios,"For doxycycline-h-LA, mean tissue:serum ratios were 2:1 for lungs, 9.8:1 for kidneys and 2.2:1 for intestine homogenates.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),,2:,257206,DB00759,Tetracycline
,18677974,tissue:serum ratios,"For doxycycline-h-LA, mean tissue:serum ratios were 2:1 for lungs, 9.8:1 for kidneys and 2.2:1 for intestine homogenates.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),,9.8,257207,DB00759,Tetracycline
,18677974,tissue:serum ratios,"For doxycycline-h-LA, mean tissue:serum ratios were 2:1 for lungs, 9.8:1 for kidneys and 2.2:1 for intestine homogenates.",Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677974/),,2.2,257208,DB00759,Tetracycline
,1940278,bioavailability,Ofloxacin has favorable pharmacokinetics with almost 100% bioavailability; peak serum concentrations obtained one to two hours following oral dosing are higher than those achieved with ciprofloxacin.,Ofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940278/),,100,258002,DB00759,Tetracycline
,31367744,bioavailability,Oral omadacycline bioavailability is 34.5%; similar exposures are obtained following 300 mg oral and 100 mg IV doses.,Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31367744/),%,34.5,258647,DB00759,Tetracycline
,31367744,protein binding,"Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing.",Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31367744/),%,21,258648,DB00759,Tetracycline
,31367744,volume of distribution,"Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing.",Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31367744/),l,190,258649,DB00759,Tetracycline
,31367744,systemic clearance,"Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing.",Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31367744/),[l] / [h],10,258650,DB00759,Tetracycline
,31367744,elimination half-life,"Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing.",Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31367744/),h,16-17,258651,DB00759,Tetracycline
,4083606,minimum OTC concentration,"Dosage regimens to maintain minimum OTC concentration of 5 micrograms/ml of serum were calculated from the t 1/2 and Vd values obtained, using steady-state pharmacokinetics.","Pharmacokinetics of a long-acting oxytetracycline preparation in ring-necked pheasants, great horned owls, and Amazon parrots. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4083606/),[μg] / [ml],5,258669,DB00759,Tetracycline
,6854733,total body clearance (ClB),"In the 3-week-old calves, the total body clearance (ClB) was 0.0022 ml/min/kg, the total distribution volume (Vd area) was 2.48 l/kg, and the distribution volume of the central compartment (V1) was 0.56 l/kg.",Age-dependent pharmacokinetics of oxytetracycline in ruminants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854733/),[ml] / [kg·min],0.0022,258813,DB00759,Tetracycline
,6854733,total distribution volume (Vd area),"In the 3-week-old calves, the total body clearance (ClB) was 0.0022 ml/min/kg, the total distribution volume (Vd area) was 2.48 l/kg, and the distribution volume of the central compartment (V1) was 0.56 l/kg.",Age-dependent pharmacokinetics of oxytetracycline in ruminants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854733/),[l] / [kg],2.48,258814,DB00759,Tetracycline
,6854733,distribution volume of the central compartment (V1),"In the 3-week-old calves, the total body clearance (ClB) was 0.0022 ml/min/kg, the total distribution volume (Vd area) was 2.48 l/kg, and the distribution volume of the central compartment (V1) was 0.56 l/kg.",Age-dependent pharmacokinetics of oxytetracycline in ruminants. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854733/),[l] / [kg],0.56,258815,DB00759,Tetracycline
,1215947,Biological half-life,"Biological half-life was 11.9 h, final distribution volume 50.0 litres and urine recovery 70%.",[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),h,11.9,258909,DB00759,Tetracycline
,1215947,final distribution volume,"Biological half-life was 11.9 h, final distribution volume 50.0 litres and urine recovery 70%.",[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),l,50.0,258910,DB00759,Tetracycline
,1215947,urine recovery,"Biological half-life was 11.9 h, final distribution volume 50.0 litres and urine recovery 70%.",[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),%,70,258911,DB00759,Tetracycline
,1215947,serum peaks,After oral administration of 200 mg doxycycline the serum peaks measured were 3.4 mug/ml (2 1/2 h later).,[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),[μg] / [ml],3.4,258912,DB00759,Tetracycline
,1215947,serum peaks,With repeated doses of 100 mg every 24 h serum peaks were 2.8 mug/ml and serum concentrations after 24 h 0.8-0.9 mug/ml (urine recovery 43%).,[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),[μg] / [ml],2.8,258913,DB00759,Tetracycline
,1215947,serum concentrations after 24 h,With repeated doses of 100 mg every 24 h serum peaks were 2.8 mug/ml and serum concentrations after 24 h 0.8-0.9 mug/ml (urine recovery 43%).,[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),[μg] / [ml],0.8-0.9,258914,DB00759,Tetracycline
,1215947,urine recovery,With repeated doses of 100 mg every 24 h serum peaks were 2.8 mug/ml and serum concentrations after 24 h 0.8-0.9 mug/ml (urine recovery 43%).,[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),%,43,258915,DB00759,Tetracycline
,1215947,half-life,In 7 adults with chronic renal failure the half-life of doxycycline varied between 10 and 24 h.,[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),h,10 and 24,258916,DB00759,Tetracycline
,1215947,distribution volume,"In 12 geriatric patients without renal disease, serum levels of doxycycline after i.v. injection of 200 mg were not significantly different from those of young adults (distribution volume 46.2 +/- 16.2 litres).",[The pharmacokinetics of doxycycline in kidney insufficiency in geriatric patients compared to younger adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1215947/),l,46.2,258917,DB00759,Tetracycline
,29325762,MICs,Eravacycline MICs ranged from 0.125-0.5 µg/mL.,Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325762/),[μg] / [ml],0.125-0.5,260541,DB00759,Tetracycline
,29325762,fAUC/MIC,"The mean fAUC/MIC magnitudes required for stasis and 1-log reduction for the eight isolates were 2.9 ± 3.1 and 5.6 ± 5.0, respectively.",Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325762/),,2.9,260542,DB00759,Tetracycline
,29325762,fAUC/MIC,"The mean fAUC/MIC magnitudes required for stasis and 1-log reduction for the eight isolates were 2.9 ± 3.1 and 5.6 ± 5.0, respectively.",Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325762/),,5.6,260543,DB00759,Tetracycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,537,260634,DB00759,Tetracycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,23,260635,DB00759,Tetracycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,2.6,260636,DB00759,Tetracycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,2.0,260637,DB00759,Tetracycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,0,260638,DB00759,Tetracycline
,7721226,apparent volume of distribution,Mefloquine has a large apparent volume of distribution of 200 L and is highly bound (98%) to plasma proteins.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),l,200,260923,DB00759,Tetracycline
,7721226,terminal half-life,The elimination is slow; the terminal half-life is 13 10 to 14 days in Thai patients with falciparum malaria.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),d,13 10 to 14,260924,DB00759,Tetracycline
,7091807,biological half-life,The biological half-life of OTC was 6.5 hours.,Distribution of oxytetracycline in the genital tract of cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7091807/),h,6.5,261347,DB00759,Tetracycline
,9811436,elimination half-life (t1/2),"Following i.m. administration, the elimination half-life (t1/2) was 62.65 +/- 1.25 h and the bioavailability was 49.80 +/- 0.01%.",Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),h,62.65,262407,DB00759,Tetracycline
,9811436,bioavailability,"Following i.m. administration, the elimination half-life (t1/2) was 62.65 +/- 1.25 h and the bioavailability was 49.80 +/- 0.01%.",Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),%,49.80,262408,DB00759,Tetracycline
,9811436,t1/2,"After i.v. administration the t1/2 was 50.97 +/- 2.99 h, the Vd was 534.11 +/- 38.58 mL/kg, and CI(b) was 0.121 +/- 0.003 mL/min x kg.",Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),h,50.97,262409,DB00759,Tetracycline
,9811436,Vd,"After i.v. administration the t1/2 was 50.97 +/- 2.99 h, the Vd was 534.11 +/- 38.58 mL/kg, and CI(b) was 0.121 +/- 0.003 mL/min x kg.",Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),[ml] / [kg],534.11,262410,DB00759,Tetracycline
,9811436,CI(b),"After i.v. administration the t1/2 was 50.97 +/- 2.99 h, the Vd was 534.11 +/- 38.58 mL/kg, and CI(b) was 0.121 +/- 0.003 mL/min x kg.",Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),[ml] / [kg·min],0.121,262411,DB00759,Tetracycline
below,9811436,MIC,These MIC values are below the susceptible range (4 microg/mL) listed by the National Committee for Clinical Laboratory Standards (NCCLS) as determined by the NCCLS susceptibility interpretive criteria.,Pharmacokinetics of oxytetracycline in the red pacu (Colossoma brachypomum) following different routes of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811436/),[μg] / [ml],4,262412,DB00759,Tetracycline
,702271,apparent lag time,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),min,23.6,262878,DB00759,Tetracycline
,702271,apparent lag time,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),min,22.8,262879,DB00759,Tetracycline
,702271,peak serum tetracycline concentration,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),[μg] / [ml],1.72,262880,DB00759,Tetracycline
,702271,peak serum tetracycline concentration,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),[μg] / [ml],1.75,262881,DB00759,Tetracycline
,702271,time of attainment of peak concentrations,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,3.35,262882,DB00759,Tetracycline
,702271,time of attainment of peak concentrations,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,3.42,262883,DB00759,Tetracycline
,702271,apparent first-order absorption half-life,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,1.8,262884,DB00759,Tetracycline
,702271,apparent first-order absorption half-life,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,1.4,262885,DB00759,Tetracycline
,702271,apparent first-order elimination half-life,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,8.0,262886,DB00759,Tetracycline
,702271,apparent first-order elimination half-life,"There were no significance differences between control subjects and gastrectomized patients in the apparent lag time prior to the start of absorption (23.6 vs. 22.8 min), peak serum tetracycline concentration (1.72 vs. 1.75 microgram/ml), the time of attainment of peak concentrations (3.35 vs. 3.42 hr), the apparent first-order absorption half-life (1.8 vs. 1.4 hr), or the apparent first-order elimination half-life (8.0 vs. 8.7 hr).",Absorption of oral tetracycline in patients with Billroth-II gastrectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/702271/),h,8.7,262887,DB00759,Tetracycline
,1416372,mean residence time,"After IV administration (5 mg/kg of body weight), mean residence time was 7.7 +/- 2.8 hours, steady-state volume distribution was 706.1 +/- 168.6 ml.kg-1 and serum clearance was 75.3 +/- 23.2 ml.kg-1.h-1.",Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416372/),h,7.7,263490,DB00759,Tetracycline
,1416372,steady-state volume distribution,"After IV administration (5 mg/kg of body weight), mean residence time was 7.7 +/- 2.8 hours, steady-state volume distribution was 706.1 +/- 168.6 ml.kg-1 and serum clearance was 75.3 +/- 23.2 ml.kg-1.h-1.",Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416372/),[ml] / [kg],706.1,263491,DB00759,Tetracycline
,1416372,serum clearance,"After IV administration (5 mg/kg of body weight), mean residence time was 7.7 +/- 2.8 hours, steady-state volume distribution was 706.1 +/- 168.6 ml.kg-1 and serum clearance was 75.3 +/- 23.2 ml.kg-1.h-1.",Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416372/),[ml] / [h·kg],75.3,263492,DB00759,Tetracycline
,1416372,maximal OTC concentration,"After IM administration of the long-acting OTC formulation (10 mg/kg), maximal OTC concentration (3.49 +/- 0.44 micrograms.ml-1) was observed after 7.3 +/- 3.5 hours; the mean systemic availability was near 100%, and serum concentration greater than 0.5 micrograms.",Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416372/),[μg] / [ml],3.49,263493,DB00759,Tetracycline
,1416372,systemic availability,"After IM administration of the long-acting OTC formulation (10 mg/kg), maximal OTC concentration (3.49 +/- 0.44 micrograms.ml-1) was observed after 7.3 +/- 3.5 hours; the mean systemic availability was near 100%, and serum concentration greater than 0.5 micrograms.",Pharmacokinetics and local tolerance of a long-acting oxytetracycline formulation in camels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416372/),%,100,263494,DB00759,Tetracycline
,2386327,elimination half-life,"Median elimination half-life, estimated in 4 pigs, was 3.92 hours.",Pharmacokinetics and metabolic inertness of doxycycline in young pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386327/),h,3.92,263922,DB00759,Tetracycline
,2386327,total body clearance,"Mean (+/- SEM) total body clearance was 1.67 +/- 0.18 ml/min/kg, and mean apparent volume of distribution at steady state was 0.53 +/- 0.04 L/kg.",Pharmacokinetics and metabolic inertness of doxycycline in young pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386327/),[ml] / [kg·min],1.67,263923,DB00759,Tetracycline
,2386327,apparent volume of distribution at steady state,"Mean (+/- SEM) total body clearance was 1.67 +/- 0.18 ml/min/kg, and mean apparent volume of distribution at steady state was 0.53 +/- 0.04 L/kg.",Pharmacokinetics and metabolic inertness of doxycycline in young pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386327/),[l] / [kg],0.53,263924,DB00759,Tetracycline
,2386327,binding,The extent of doxycycline binding to serum protein was 93.1 +/- 0.2%.,Pharmacokinetics and metabolic inertness of doxycycline in young pigs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386327/),%,93.1,263925,DB00759,Tetracycline
,32408259,brain,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),[ng] / [g],"420, 315",265912,DB00759,Tetracycline
,32408259,peak concentration,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),[ng] / [g],"420, 315",265913,DB00759,Tetracycline
,32408259,AUC 0-360 min,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),ng,57130,265914,DB00759,Tetracycline
,32408259,AUC 0-360 min,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),ng,48693.13,265915,DB00759,Tetracycline
,32408259,drug-targeting efficiency (DTE %),"The optimized LD-SLN-HPMC gel gave a drug-targeting efficiency (DTE %) of 149.815 and 161.969 for LEVO and DOX, respectively, in comparison to the intravenous route.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,149.815,265916,DB00759,Tetracycline
,32408259,drug-targeting efficiency (DTE %),"The optimized LD-SLN-HPMC gel gave a drug-targeting efficiency (DTE %) of 149.815 and 161.969 for LEVO and DOX, respectively, in comparison to the intravenous route.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,161.969,265917,DB00759,Tetracycline
,32408259,direct transport percentage (DTP %),"Moreover, the optimized formulation had a direct transport percentage (DTP %) of 33.285 and 40.236 for LEVO and DOX, respectively, which indicates a significant contribution of direct nose-to-brain pathway in brain drug delivery.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,33.285,265918,DB00759,Tetracycline
,32408259,direct transport percentage (DTP %),"Moreover, the optimized formulation had a direct transport percentage (DTP %) of 33.285 and 40.236 for LEVO and DOX, respectively, which indicates a significant contribution of direct nose-to-brain pathway in brain drug delivery.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,40.236,265919,DB00759,Tetracycline
,2506691,Peak concentrations,"Peak concentrations of 21.70 +/- 4.06, 2.67 +/- 0.23, 5.65 +/- 0.45 and 82.23 +/- 10.06 micrograms/ml were attained at 5 min and at 6, 8 and 8 h in plasma, isf, milk and urine respectively.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],21.70,266673,DB00759,Tetracycline
,2506691,Peak concentrations,"Peak concentrations of 21.70 +/- 4.06, 2.67 +/- 0.23, 5.65 +/- 0.45 and 82.23 +/- 10.06 micrograms/ml were attained at 5 min and at 6, 8 and 8 h in plasma, isf, milk and urine respectively.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],2.67,266674,DB00759,Tetracycline
,2506691,Peak concentrations,"Peak concentrations of 21.70 +/- 4.06, 2.67 +/- 0.23, 5.65 +/- 0.45 and 82.23 +/- 10.06 micrograms/ml were attained at 5 min and at 6, 8 and 8 h in plasma, isf, milk and urine respectively.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],5.65,266675,DB00759,Tetracycline
,2506691,Peak concentrations,"Peak concentrations of 21.70 +/- 4.06, 2.67 +/- 0.23, 5.65 +/- 0.45 and 82.23 +/- 10.06 micrograms/ml were attained at 5 min and at 6, 8 and 8 h in plasma, isf, milk and urine respectively.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],82.23,266676,DB00759,Tetracycline
,2506691,distribution half life (t1/2 alpha),A low distribution half life (t1/2 alpha) of 0.44 +/- 0.04 h and a high elimination half life (t1/2 beta) of 19.24 +/- 1.22 h denote rapid distribution but very slow elimination of the drug in goats.,Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),h,0.44,266677,DB00759,Tetracycline
,2506691,elimination half life (t1/2 beta),A low distribution half life (t1/2 alpha) of 0.44 +/- 0.04 h and a high elimination half life (t1/2 beta) of 19.24 +/- 1.22 h denote rapid distribution but very slow elimination of the drug in goats.,Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),h,19.24,266678,DB00759,Tetracycline
,2506691,tissue plasma concentration ratio [K12:(K21-beta)],A high tissue plasma concentration ratio [K12:(K21-beta)] of 5.12 +/- 0.97 during the elimination phase and a Vdarea of 1.59 +/- 0.18 L/kg indicate uniform distribution of demeclocycline in the tissues and body fluids of goats.,Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),,5.12,266679,DB00759,Tetracycline
,2506691,Vdarea,A high tissue plasma concentration ratio [K12:(K21-beta)] of 5.12 +/- 0.97 during the elimination phase and a Vdarea of 1.59 +/- 0.18 L/kg indicate uniform distribution of demeclocycline in the tissues and body fluids of goats.,Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[l] / [kg],1.59,266680,DB00759,Tetracycline
,2506691,minimum plasma concentration (Cp infinity min = MIC),"The dosage regimen for maintaining minimum plasma concentration (Cp infinity min = MIC) of 0.5, 1.0 and 1.5 micrograms/ml at selected dosage intervals of 12 and 24 h was also calculated.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],0.5,266681,DB00759,Tetracycline
,2506691,minimum plasma concentration (Cp infinity min = MIC),"The dosage regimen for maintaining minimum plasma concentration (Cp infinity min = MIC) of 0.5, 1.0 and 1.5 micrograms/ml at selected dosage intervals of 12 and 24 h was also calculated.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],1.0,266682,DB00759,Tetracycline
,2506691,minimum plasma concentration (Cp infinity min = MIC),"The dosage regimen for maintaining minimum plasma concentration (Cp infinity min = MIC) of 0.5, 1.0 and 1.5 micrograms/ml at selected dosage intervals of 12 and 24 h was also calculated.",Disposition kinetics and distribution of demeclocycline in various biological fluids in female goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506691/),[μg] / [ml],1.5,266683,DB00759,Tetracycline
,31220539,withdrawal time,The results suggest a withdrawal time of 41 days for Europe and China and 50 days for Japan is needed for DC in grass carp after 3 daily oral administrations at 20 mg/kg.,"Tissue residue depletion kinetics and withdrawal time estimation of doxycycline in grass carp, Ctenopharyngodon idella, following multiple oral administrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31220539/),d,41,266984,DB00759,Tetracycline
,31220539,withdrawal time,The results suggest a withdrawal time of 41 days for Europe and China and 50 days for Japan is needed for DC in grass carp after 3 daily oral administrations at 20 mg/kg.,"Tissue residue depletion kinetics and withdrawal time estimation of doxycycline in grass carp, Ctenopharyngodon idella, following multiple oral administrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31220539/),d,50,266985,DB00759,Tetracycline
,20736042,distribution half-life (t(½α)),"Diclazuril and halofuginone resulted in a significant short distribution half-life (t(½α)) (7.17±0.39 and 11.88±1.05 min, respectively) and increased total body clearance (Cl(tot)) 0.37±0.024 and 0.295±0.034 L/kg/h, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,7.17,267941,DB00759,Tetracycline
,20736042,distribution half-life (t(½α)),"Diclazuril and halofuginone resulted in a significant short distribution half-life (t(½α)) (7.17±0.39 and 11.88±1.05 min, respectively) and increased total body clearance (Cl(tot)) 0.37±0.024 and 0.295±0.034 L/kg/h, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,11.88,267942,DB00759,Tetracycline
,20736042,total body clearance (Cl(tot)),"Diclazuril and halofuginone resulted in a significant short distribution half-life (t(½α)) (7.17±0.39 and 11.88±1.05 min, respectively) and increased total body clearance (Cl(tot)) 0.37±0.024 and 0.295±0.034 L/kg/h, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[l] / [h·kg],0.37,267943,DB00759,Tetracycline
,20736042,total body clearance (Cl(tot)),"Diclazuril and halofuginone resulted in a significant short distribution half-life (t(½α)) (7.17±0.39 and 11.88±1.05 min, respectively) and increased total body clearance (Cl(tot)) 0.37±0.024 and 0.295±0.034 L/kg/h, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[l] / [h·kg],0.295,267944,DB00759,Tetracycline
,20736042,t(½ab),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,41.38,267945,DB00759,Tetracycline
,20736042,t(½ab),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,17.48,267946,DB00759,Tetracycline
,20736042,t(½ab),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,41.83,267947,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],3.18,267948,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],5.425,267949,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],0.986,267950,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),h,2.07,267951,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),h,1.403,267952,DB00759,Tetracycline
,20736042,C(max),"Following oral dosing the tested drug absorbed with t(½ab) of 41.38±1.6, 17.48±0.86 and 41.83±1.8 min, respectively and their C(max) values (3.18±0.18, 5.425±0.48 and 0.986±0.037 μg/ml) were attained at 2.07±0.097, 1.403±0.074 and 2.55±0.106 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),h,2.55,267953,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.64±3.46, 86.74±9.23 and 22.38±3.09%, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,22.64,267954,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.64±3.46, 86.74±9.23 and 22.38±3.09%, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,86.74,267955,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.64±3.46, 86.74±9.23 and 22.38±3.09%, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,22.38,267956,DB00759,Tetracycline
,20736042,t(½ab),"Following IM injection t(½ab) were 9.096±1.34 for doxycycline alone, 16.24±2.21 and 15.6±1.7 min in the presence of diclazuril and halofuginone, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,9.096,267957,DB00759,Tetracycline
,20736042,t(½ab),"Following IM injection t(½ab) were 9.096±1.34 for doxycycline alone, 16.24±2.21 and 15.6±1.7 min in the presence of diclazuril and halofuginone, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,16.24,267958,DB00759,Tetracycline
,20736042,t(½ab),"Following IM injection t(½ab) were 9.096±1.34 for doxycycline alone, 16.24±2.21 and 15.6±1.7 min in the presence of diclazuril and halofuginone, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),min,15.6,267959,DB00759,Tetracycline
,20736042,C(max),"C(max) was 3.10±0.28, 4.63±0.57 and 0.55±0.07 μg/ml reached at 0.8±0.083, 1.13±0.126 and 1.21±0.105 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],3.10,267960,DB00759,Tetracycline
,20736042,C(max),"C(max) was 3.10±0.28, 4.63±0.57 and 0.55±0.07 μg/ml reached at 0.8±0.083, 1.13±0.126 and 1.21±0.105 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],4.63,267961,DB00759,Tetracycline
,20736042,C(max),"C(max) was 3.10±0.28, 4.63±0.57 and 0.55±0.07 μg/ml reached at 0.8±0.083, 1.13±0.126 and 1.21±0.105 h.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),[μg] / [ml],0.55,267962,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.41±3.86, 88.97±12.9 and 12.31±0.99% in chickens fed on anticoccidial-free, diclazuril- and halofuginone-containing rations, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,22.41,267963,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.41±3.86, 88.97±12.9 and 12.31±0.99% in chickens fed on anticoccidial-free, diclazuril- and halofuginone-containing rations, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,88.97,267964,DB00759,Tetracycline
,20736042,Systemic bioavailability,"Systemic bioavailability was 22.41±3.86, 88.97±12.9 and 12.31±0.99% in chickens fed on anticoccidial-free, diclazuril- and halofuginone-containing rations, respectively.",Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736042/),%,12.31,267965,DB00759,Tetracycline
,28705678,area under the unbound drug concentration-time curve to minimum inhibitory concentration ratio (fAUC/MIC),The mean ± standard deviation area under the unbound drug concentration-time curve to minimum inhibitory concentration ratio (fAUC/MIC) associated with a 24-h bacteriostatic effect was 16.4 ± 2.6 and with a -1 log reduction in bacterial load at 24 h was 23.3 ± 3.7.,Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,16.4,269002,DB00759,Tetracycline
>,28705678,fAUC/MIC ratios,"Changes in population profiles were noted for two of the three strains studied, especially at fAUC/MIC ratios of >5-15.",Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,5-15,269003,DB00759,Tetracycline
,28705678,fAUC/MIC,A reasonable translational pharmacodynamic target for MNO against A. baumannii could be an fAUC/MIC of 20-25.,Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,20-25,269004,DB00759,Tetracycline
,111939,elimination half-life,"DPP is rapidly absorbed, the peak serum level is reached three hours after absorption and slowly eliminated (elimination half-life = 12 hours).",Serum kinetics of doxycycline polyphosphate in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/111939/),h,12,269719,DB00759,Tetracycline
,28607024,clearance (CL),"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),[l] / [h],7.50,270031,DB00759,Tetracycline
,28607024,volume in the central compartment,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),l,72.50,270032,DB00759,Tetracycline
,28607024,rate constant,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),1/[h],0.31,270033,DB00759,Tetracycline
,28607024,rate constant,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),1/[h],0.29,270034,DB00759,Tetracycline
,28607024,AUC0-24/MIC target,"Licensed doses were found to be sufficient for Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus for an AUC0-24/MIC target of 4.5 or 6.96.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),,4.5,270035,DB00759,Tetracycline
,28607024,AUC0-24/MIC target,"Licensed doses were found to be sufficient for Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus for an AUC0-24/MIC target of 4.5 or 6.96.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),,6.96,270036,DB00759,Tetracycline
,11736877,first-order absorption rate constant (Ka),"The population estimates of the first-order absorption rate constant (Ka), CL/F and V/F were 0.694 h(-1), 3.20 l h(-1) and 1820 l, respectively.",Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736877/),1/[h],0.694,270576,DB00759,Tetracycline
,11736877,CL/F,"The population estimates of the first-order absorption rate constant (Ka), CL/F and V/F were 0.694 h(-1), 3.20 l h(-1) and 1820 l, respectively.",Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736877/),[l] / [h],3.20,270577,DB00759,Tetracycline
,11736877,V/F,"The population estimates of the first-order absorption rate constant (Ka), CL/F and V/F were 0.694 h(-1), 3.20 l h(-1) and 1820 l, respectively.",Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736877/),l,1820,270578,DB00759,Tetracycline
,11736877,absorption,"The absorption and elimination half-lives were 1.0 h and 16.4 days, respectively.",Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736877/),h,1.0,270579,DB00759,Tetracycline
,11736877,elimination half-lives,"The absorption and elimination half-lives were 1.0 h and 16.4 days, respectively.",Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736877/),d,16.4,270580,DB00759,Tetracycline
,27539539,AUC0-∞,"Fasted AUC0-∞ , AUC0-t , and AUC0-24 were 10.2, 7.2, and 7.2 μg·h/mL, respectively, and Cmax was 0.6 μg/mL.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),[h·μg] / [ml],10.2,271156,DB00759,Tetracycline
,27539539,AUC0-t,"Fasted AUC0-∞ , AUC0-t , and AUC0-24 were 10.2, 7.2, and 7.2 μg·h/mL, respectively, and Cmax was 0.6 μg/mL.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),[h·μg] / [ml],7.2,271157,DB00759,Tetracycline
,27539539,AUC0-24,"Fasted AUC0-∞ , AUC0-t , and AUC0-24 were 10.2, 7.2, and 7.2 μg·h/mL, respectively, and Cmax was 0.6 μg/mL.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),[h·μg] / [ml],7.2,271158,DB00759,Tetracycline
,27539539,Cmax,"Fasted AUC0-∞ , AUC0-t , and AUC0-24 were 10.2, 7.2, and 7.2 μg·h/mL, respectively, and Cmax was 0.6 μg/mL.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),[μg] / [ml],0.6,271159,DB00759,Tetracycline
,27539539,bioavailability,"Compared with a fasted dose, bioavailability was reduced by 15% to 17% by a nondairy meal 4 hours before dosing, 40% to 42% by a nondairy meal 2 hours before dosing, and 59% to 63% for a dairy meal 2 hours before dosing.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),,40,271160,DB00759,Tetracycline
,27539539,bioavailability,"Compared with a fasted dose, bioavailability was reduced by 15% to 17% by a nondairy meal 4 hours before dosing, 40% to 42% by a nondairy meal 2 hours before dosing, and 59% to 63% for a dairy meal 2 hours before dosing.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),,59,271161,DB00759,Tetracycline
,27539539,bioavailability,"Compared with a fasted dose, bioavailability was reduced by 15% to 17% by a nondairy meal 4 hours before dosing, 40% to 42% by a nondairy meal 2 hours before dosing, and 59% to 63% for a dairy meal 2 hours before dosing.",Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27539539/),,63,271162,DB00759,Tetracycline
,23866042,bioavailability,DOX-h-LA showed the greatest values for bioavailability (115.38%); maximum serum concentration (Cmax) value was 1.5 ± 0.2 with a time to reach Cmax of 3.41 ± 0.04 h and an elimination rate constant of 70.93 ± 0.87( ) h.,Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23866042/),%,115.38,271283,DB00759,Tetracycline
,23866042,maximum serum concentration (Cmax),DOX-h-LA showed the greatest values for bioavailability (115.38%); maximum serum concentration (Cmax) value was 1.5 ± 0.2 with a time to reach Cmax of 3.41 ± 0.04 h and an elimination rate constant of 70.93 ± 0.87( ) h.,Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23866042/),,1.5,271284,DB00759,Tetracycline
,23866042,time to reach Cmax,DOX-h-LA showed the greatest values for bioavailability (115.38%); maximum serum concentration (Cmax) value was 1.5 ± 0.2 with a time to reach Cmax of 3.41 ± 0.04 h and an elimination rate constant of 70.93 ± 0.87( ) h.,Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23866042/),h,3.41,271285,DB00759,Tetracycline
,23866042,elimination rate constant,DOX-h-LA showed the greatest values for bioavailability (115.38%); maximum serum concentration (Cmax) value was 1.5 ± 0.2 with a time to reach Cmax of 3.41 ± 0.04 h and an elimination rate constant of 70.93 ± 0.87( ) h.,Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23866042/),h,70.93,271286,DB00759,Tetracycline
,23866042,minimum effective serum concentration,"Considering minimum effective serum concentration of 0.5 μg/mL, a dose interval of at least 5 days can be achieved for DOX-h-LA, whereas p.o. and i.v. dosing of DOX-h may only last 11 and 15 h, respectively.",Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23866042/),[μg] / [ml],0.5,271287,DB00759,Tetracycline
,4071950,recovery,The recovery of OTC in the urine in the 72-h period was in the range of 73% to 96% of the available dose administered.,Pharmacokinetics and renal clearance of oxytetracycline after intravenous and intramuscular administration to dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071950/),%,73,271854,DB00759,Tetracycline
,4071950,recovery,The recovery of OTC in the urine in the 72-h period was in the range of 73% to 96% of the available dose administered.,Pharmacokinetics and renal clearance of oxytetracycline after intravenous and intramuscular administration to dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071950/),%,96,271855,DB00759,Tetracycline
,4071950,renal clearance,The mean OTC renal clearance ranged from 482 to 1050 ml/min and the creatinine clearance from 651 to 1304 ml/min.,Pharmacokinetics and renal clearance of oxytetracycline after intravenous and intramuscular administration to dairy cows. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071950/),[ml] / [min],482 to 1050,271856,DB00759,Tetracycline
up to,4071950,urine flow,The OTC and creatinine clearances were significantly correlated to the urine flow up to 30 ml/min.,Pharmacokinetics and renal clearance of oxytetracycline after intravenous and intramuscular administration to dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4071950/),,30,271857,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),%,70,273125,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),[h·μg] / [ml],19.13,273126,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),[h·μg] / [ml],27.22,273127,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),%,80,273128,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),[h·μg] / [ml],21.88,273129,DB00759,Tetracycline
,6487493,relative bioavailability,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),,26.91,273130,DB00759,Tetracycline
,6487493,lag time,The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.,Comparative bioavailability of tetracycline and lymecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487493/),%,60,273131,DB00759,Tetracycline
